Conditions,Outcome Measures Aggregated
COVID,"Proportion of asymptomatic subjects|Proportion of subjects with recent contact history|Proportion of subjects with recent travel history || Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events || LUS applicability with COVID 19|Radiographic correlation (chest Xray and tomodensitometry)|LUS Mortality prediction|Prediction of Prone position response || Seroconversion of IgM for COVID-19.|Seroconversion of IgG for COVID-19. || measurement of pulmonary function changes either obstructive or restrictive also lung diffusion and if there is remaining interstitial fibrosis|measurement for cardiac function and ejection fraction changes and if there is changes in pulmonary artery pressure|assessment of IGM and IGG level and if there is immunological changes || Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS): Tennant et al., 2007|Self-rated health status: Bombak, 2013|Brief Resilience Scale (BRS): Smith et al., 2008|Intolerance of Uncertainty Scale (IUS-12): Carleton et al., 2007|Positive Affect subscale of the Positive and Negative Affect Scale-X (PANAS-X): Watson & Clark, 1999|UCLA 3 item loneliness scale: Russell, 1996|Multidimensional Scale of Perceived Social Support (MSPSS): Zimet et al., 1988|Subjective Health Complaint Scale (SHC): Eriksen, Ihlebæk, & Ursin, 1999|Leeds Sleep Evaluation Questionnaire (LSEQ): Parrott & Hindmarch, 1980|Self-reported napping: Stone et al., 2018|Work and Social Adjustment Scale (WSAS): Mundt et al., 2002|International Physical Activity Questionnaire -short form (IPAQ-SF): Craig et al., 2003 || SARS-COV-2 RNA detection|Viral contamination of peritoneal cavity and fluid|Viral contamination of peritoneal cavity and fluid in open cases|Viral infection of members of the surgical team || Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.|Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.|Technical success rate of endoscopic procedures during the 30-days study period.|IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.|Adverse events rate of endoscopic procedures during the 30-days || Rate of avoidable Emergency Department presentations per diagnosed COVID-19 case|All cause mortality per diagnosed COVID-19 case All-cause mortality rate at 30 days per diagnosed COVID-19 case|Rate of hospital admission per diagnosed COVID case|Rate of MBS claims for un-referred visits to general practitioners and analogous COVID-19 MBS telehealth items per diagnosed COVID case|Average length of stay (LOS) for admitted patients per diagnosed COVID case|Rate of admission to Intensive Care Unit (ICU) for admitted patients per diagnosed COVID case|Time from presentation to admission to ICU for patients admitted to ICU per diagnosed COVID case|Rate of intubation in admitted patients per diagnosed COVID case|Rate of readmission within 30 days of discharge in admitted patients per diagnosed COVID case|All-cause mortality at 90 days per diagnosed COVID case|Rate of avoidable Emergency Department presentations with COVID-19 diagnosis per 100,000 population, during trial period|Rate of hospital admission with COVID-19 diagnosis per 100,000 population, during trial period|Rate of admission to ICU with COVID-19 diagnosis per 100,000 population during trial period|Rate of mortality with COVID-19 cause of death per 100,000 population, during trial period|Qualitative assessment of TCC-COVID app usability via a subjective feedback questionnaire provided to all patients enrolled in the study.|Cost-effectiveness of TCC-COVID by measuring the incremental cost per death averted, per ICU admission averted and per length of stay in ICU|Rate of hospital bed days with COVID-19 diagnosis per 100,000 population, during trial period|Rate of ICU bed days with COVID-19 diagnosis per 100,000 population, during trial period|Qualitative assessment of KIOLA physician portal usability via a subjective feedback questionnaire || Number of patients in need for hospitalization|Length of hospitalization and ICU admission|The need for mechanical ventilation|Severity of COVID-19 disease || fear among dentist during COVID 19 epidemic|practice modification among dentist during COVID 19 epidemic || Efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement (Clinical improvement: Reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier)|Proportion of patients in each category according to the ordinal scale|Duration of oxygen therapy in both groups|Duration of hospital stay in both groups|Proportion of patients on mechanical ventilation at day 7 in both groups|Mortality in both groups|Duration of Intensive Care Unit stay|Incidence of adverse effects in both groups|Presence of antibodies against SARS-CoV-2 in serum after plasma administration|Change in Cytokines in both groups|Change in acute phase reactants in both groups|Correlation of the titers in COVID-19 convalescent plasma donors with duration of illness, the severity of symptoms, duration of hospital stay, drugs used in therapy, duration between recovery, and donation. || Presence of sHLH as determined by expert chart review by two independent reviewers|Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection|Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin > 10000 μg/L) in Covid 19 viral infection|Characterization and incidence of the hyper-inflammatory state in COVID-19|all cause mortality assesed on day 15|all cause mortality assesed on day 29|immunophenotpye || COVID19 clinical scale|Number of died patients|Oro/nasopharynx virus|Thorax imaging (0=none; 1=unilateral; 2=bilateral; 3=ground-glass opacification; 4=consolidation)|Days in hospital|Venous gas blood analysis || Correlation between serology testing and clinical suspicion of COVID-19|Prevalence of SARS-CoV2 exposure|Correlation of pre-existing risk factors with results of serology testing|Number of asymptomatic participants with positive antibody serology|Proportion of antibody- positive participants who subsequently develop COVID-19|Proportion of participants who are eligible for in plasma donation || Radiographic findings and their temporal changes in COVID-19 positive patient: A Prospective study || we will compare the clinical outcome of the COVID 19 patients with their age and gender|we will compare the effect of different treatments given to the COVID 19 patients at Max Hospital || Mortality due to COVID-19 disease|Hospital admission and ICU admission due to Covid-19, Severity of Covid-19 (mild, moderate or severe), Hospital admission due to other respiratory febrile illness, immunological outcomes in the sub study || To evaluate the safety of a therapeutic Covid-19 vaccine in participants by measuring the severity of local and systemic adverse events and laboratory abnormalities.|To evaluate the immunogenicity of a therapeutic Covid-19 vaccine in participants by measuring CD8+ T cells immune response|Virologic response after vaccination|Clinical outcome and progression after vaccinations || Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion|Change in percent of supplemental oxygen|Number of patients that required change in level of respiratory support|Mortality|Mean length of ICU stay (days)|Mean length of hospital stay (days)|Mean length of ventilation (days)|Number of patients with progression to renal dysfunction and/or multisystem organ failure|IL-6 level|Number of anti-SARS CoV 2 specific T cells|Diversity of circulating T cells|ARS-CoV-2 Antibody Titer|SARS-CoV-2 Neutralizing Titer || Clinical response to COVID-19|Immunological response to COVID-19|Genetic predisposition to COVID-19|Microbiome-related response to COVID-19 || Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents || Hypoxic respiratory failure|Mortality|Sepsis|Circulatory failure|Days in hospital|NAD levels || number of patients with virological cure || Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale|Determined potential predictive factors of critic form in patients with chronic lung diseases|Determined percentage of death|Determined duration of oxygen therapy|Determined duration of hospitalization|Determine mean values of the WHO CoVid-19 infection progression scale measured || effect of Ivermectin on eradication of virus. || Clinical consequences of a Covid-19 infection in the care population|Risk factors at M6|Risk factors at year 1|Risk factors at year 2|Impact of hospital reorganization on medical care at M6|Impact of hospital reorganization on medical care at Year 1|Impact of hospital reorganization on medical care at Year 2 || Change of PCR from positive to negative|Clinical improvement|Adverse events || Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2. || Establishment of a reliable prediction model for the effectiveness of virus control || Positive IgM/IgG tests|Comparison of the point of care test and Elisa|Re-infection rate|IgM/IgG positive participants on follow-up test || Attack rate || Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups. || COVID19 versus H1N1; radiological comparative study || Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge || Adverse effects and Safety|NK transfer Immunogenicity || Arms 1 & 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate|Arms 1 & 2: number of critical and severe COVID-19 infected patients who survive the infection|Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate|Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate || CoV-2 Infection after 21 days|CoV-2 Infection after 14 days|Cases of suspected or confirmed CoV-2 infection|Hospitalisation and death || Clinical characteristics of patients with COVID-19|Prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death|Clinical characteristics of the patients with the worst prognosis|Relationship between the different treatments and the prognosis || Testing for the presence of COVID-19 (SARS-CoV-2 virus) in the semen|Kinetics of SARS-CoV-2 virus presence in the semen || Score of five-item Brief Symptom Rating Scale (BSRS-5) || Coronavirus sequencing|Coronavirus culturing || The percentage of knowledge regarding COVID-19 information || 28 day ventilator free days|90 day all-cause mortality || Number of patients with response to treatment || Evaluation of the rate of SARS-CoV-2 positive cancer patients and health professionals in a comprehensive cancer center or in a cancer setting.|Evaluation of test accuracy|Interleukin-6 quantification|Interleukin-2 quantification|Interleukin-1 quantification|Tumor Necrosis Factor (TNF) quantification|Interferon gamma quantification || Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of ≤ 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs || Participant age|Participant sex|Participant race/ethnicity|Proportion of participants previously hospitalized. || Coagulopathy associated with COVID-19|Markers of dysregulation of coagulation system|Markers of dysregulation of RAS|Markers of Haemolysis/inflammation|Markers of Haemolysis/Inflammation|Markers of Inflammation (bacterial sepsis)|Markers of organ dysregulation - kidney|Markers of dysregulation of cardiovascular system|marker of dysregulation of endocrine system || Rate of Hospitalization|Rate of Transfer to Intensive Care Unit|Rate of Intubation|Rate of Death || Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections|Number of severe COVID-19 cases|Severity of COVID-19 cases|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of viral and bacterial infections|Number of participants with azithromycin-resistant bacterial strains in nasal swabs test || Adverse effects|Immune-score|COVID-19 prevention|Clinical response || liver disease|COVID infection in patients with chronic liver disease|decompensation of cirrhosis|Effect of Antiviral drugs on Covid-19 infection || Impact of a multidisciplinary and personalized rehabilitation program on COVID patients's quality of life|Impact of a multidisciplinary and personalized rehabilitation program in terms of Physical capacities|Impact of a multidisciplinary and personalized rehabilitation program in terms of Respiratory capacities|Impact of a multidisciplinary and personalized rehabilitation program in terms of Functional capacities|Impact of a multidisciplinary and personalized rehabilitation program in terms of Malnutrition prevalence rate using GLIM malnutrition diagnostic criteria|Impact of a multidisciplinary and personalized rehabilitation program in terms of mortality|Impact of a multidisciplinary and personalized rehabilitation program in terms of Quality of life|Impact of a multidisciplinary and personalized rehabilitation program in terms of Anxiety and depression|Impact of a multidisciplinary and personalized rehabilitation program in terms of Healthcare consumption|Impact of a multidisciplinary and personalized rehabilitation program in terms of Medico-economic evaluation|Patient's opinion concerning the rehabilitation program || Development of severe respiratory disease defined as a respiratory rate (RR)>30 and/or an O2 sat<93%|Life threatening respiratory disease|Critical systemic illness, defined as respiratory failure|Death|Combination of secondary outcomes #2 (Life threatening respiratory disease) and/or #3 (Critical systemic illness, defined as respiratory failure) and//or #4 (death)|Duration of oxygen support requirement in patients with covid-19 due to saturation in ambient air <93%. || Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19|Correlation of inflammatory mediators in the bronchoalveolar lavage fluid with extent of lung injury (e.g. based upon oxygen requirement)|Correlation of circulating inflammatory mediators with renal and cardiovascular markers|Assess the role of inflammatory mediators obtained from patients in the development of renal injury using in vitro models (i.e. applying these inflammatory mediators isolated from these clinical samples on kidneys cells in a petri dish) || The primary endpoint is the rate of faecal SARS-CoV-2 virus clearance (rectal swab or stool sample) assessed by RT-PCR in the niclosamide group, compared to the placebo group || Number of patients with mortality or need for mechanical ventilation || The number of patients with mortality|Length of hospital stay|The need for mechanical ventilation || Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events || Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)|Development of COVID || Number of patients with improvement or died || The primary cardiac outcome is the proportion of patients with a diagnosis of myocardial inflammation (myocarditis).|The primary cardio-pulmonary outcome is the proportion of patients with thrombosis|Myocardial injury|Myocardial stress|Systemic inflammation|Vascular injury|Endothelial activation and haemostasis|Fibrin lysis|Coagulation|Platelet count|Renal function|Quantify myocardial perfusion as a measure of coronary microvascular function|Association of the primary outcome according to a prior history of cardiovascular disease or no history of prior cardiovascular disease.|Patient reported outcome measures (PROMS) - health status|PROMS - functional capacity || observation || Virus negativity|Inflammatory Marker|Inflammatory Marker 2 || 7-point ordinal symptom scale|The composite of all-cause mortality and need for mechanical ventilation|The composite of all-cause mortality and hospitalization|All-cause mortality|Need for mechanical ventilation|Need for hospitalization || Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation > 94% on room air for >24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality || Clinical improvement using WHO ordinal scale|Number of ventilator-free days at Day 28 (VFD28)|Number of participants with treatment-related adverse events || Time to virological cure|Safety|Clinical improvement|Clinical symptoms|Biomarkers || Volume of IV fluid infused|Quantity of Blood pressure medication administered|Resuscitation status|FiO2 needs|Days on Oxygen|Number of participants with hospital acquired pneumonia|Number of Patients with Acute Kidney Injury (AKI)|Number of patients with hemodynamic collapse|mortality || Respiratory SOFA.|Need of a high dose of oxygen or mechanical ventilation.|Change in oxygen saturation.|Oxygen desaturation.|Change in Quick SOFA score.|Myocardial infarction.|Stroke.|Acute kidney injury.|Pulmonary thromboembolism.|Combined endpoint (stroke, myocardial infarction, acute kidney injury and pulmonary thromboembolism.|Admission to ICU.|Invasive Mechanical Ventilation.|Hospital Length of Stay.|ICU length of stay.|Death || Stool calprotectin|Stool frequency|Stool consistency|Gastrointestinal symptoms|Duration of Covid-19 disease|Severity of Covid-19 disease|Diarrhea|Stool Zonulin|Microbiome composition || Ventilator-free days at 28 days|change in airway resistance|change in lung compliance|oxygenation (PaO2/FiO2 ratio)|length of stay (ICU and hospital)|rate of barotrauma|mortality. || Number of patients with improvement or mortality || time to be symptoms free|hospitalization|Mechanical ventilation|length of stay|mortality || Negative PCR|Need for mechanical ventilation || ICU admission|Hospitalization|Length of stay at the ICU|Death|CT scan result|C reactive protein|Blood Count|Sodium|Urea|Troponine|Liver function|Coagulation test|Creatinine|Clearance|Potassium|Calcium|Gamma-glutamyl transpeptidase|Bilirubine|Alcaline phosphatase|Prothrombine || Intubation or death || Cohort 1: Proportion of Participants Alive and Free of Mechanical Ventilation at Day 29|Cohort 2: Mortality Rate at Day 29|Cohort 1: Time to 2-point clinical Improvement by Day 29|Cohort 1: Time to return to room air or discharge by Day 29|Cohort 1: Mortality rate at Day 29|Cohort 2: Time to 1-point clinical improvement by Day 29 || laboratory measured vitamin D levels || Dyspnoea|Anxiety and Depression|Sleep Quality|Health Related Quality of Life|Kinesiophobia|Patient Satisfaction|Fatigue || 7-day death|7-day ICU || Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients:|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in IP versus control group patients|NEWS assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in IP versus control group patients|Rate of mechanical ventilation in IP versus control group patients|Duration of mechanical ventilation (if applicable) in IP versus control group patients|Duration of supplemental oxygen in IP versus control group patients|Time to return to room pressure (SpO2 > 94%) on room air|Duration in ICU (if applicable) in IP versus control group patients|Rate of Mortality in IP versus control group patients|Duration of hospitalization in IP versus control group patients|Time to discharge in IP versus control group patients|Effect on the rate of change of partial pressure of oxygen (PaO2) and PaO2/FiO2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in IP versus control group patients || Viral clearance|Symptoms duration|SpO2|SpO2/FiO2 || Primary Outcome|Respiratory infection|Serious Adverse Events || Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Interleukin 6 (IL-6) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Frequency of adverse events and severe adverse events || Monitored versus Non-Monitored in-patient admission|Emergency Department Visits|Length of stay|patient satisfaction|the incidence of mechanical ventilation and ECMO|serious adverse events || Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes || Rate of Completion|Clinical improvement at Day 7|Change in Chitinase 3-like 1(Chi3l1) (ng/mL)|Change in Interleukin-6 (IL-6) (pg/mL)|Change in CCL5 (RANTES) (ng/mL)|Mortality|Time to Discharge|Days on mechanical ventilation || Radiological pattern of initial presentation, disease progress, healing and recovery|Survey of co-morbid lung diseases || treatment efficacy - Change in PaO2/FiO2 ratio|Safety as measured by bleeds|Safety as measured by other (non-bleed related) adverse events|Safety as measured by fibrinogen levels|Changes in lung compliance (defined as tidal volume / (peak inspiratory pressure - PEEP))|Clinical status as determined by a 7 point ordinal scale|Sequential Organ Failure Assessment (SOFA) score|Follow up period - oxygen free days|Follow up period - ventilator free days|Follow up period - intensive care stay|New oxygen via ventilation use - incidence|New oxygen via ventilation use - duration|Incidence of new mechanical ventilation use|Duration of new mechanical ventilation use|In hospital mortality || Evaluation of airtightness (Fit test)|User Comfort|Breathing easiness|Field of view quality|Ease of use || Number of patients with improvement in body temperature, myalgia, arthralgia, total lymphocyte count, D-dimer, fibrinogen and ferritin levels|Progression to severe disease || Detection of nCOVID-19 using a face mask|Independent Patient use of face mask"
COVID 19,"Evaluate the safety|Change in requirement for mechanical ventilatory support || Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events. || Estimate the prevalence of COVID-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.|Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies|Estimate of the prevalence of active infection in Cabarrus County.|Estimate of the prevalence of exposure and potential immunity to COVID-19. || diagnostic of COVID disease composite || Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality || Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )|Mortality rate|Determine viral load in each patient || Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications. || Change in mortality|Change in requirement for mechanical ventilation|Change in the duration of mechanical ventilation|Incidence of Treatment-Emergent Adverse Events || Symptomatic COVID-19|Severity of COVID-19 over the study period|Effectiveness of preventing/reducing SARS-CoV-2 infection || Identifying the metabolomic signature|Identification of the metabolomic profile according to clinical severity. || Prevention of SARS-CoV-2 infection|Presence of any adverse effects related to HCQ|Incidence of COVID-19 related symptoms || Time to clinical recovery|Viral clearance|radiological lung extension|drug adverse events|28 day mortality|intensive care unit (ICU) admission rate|Duration of hospital stay || Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection|Troponin greater than 99th percentile during hospitalization for Covid-19 infection|AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori)|Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori)|AKI KDIGO grade 1 or higher|Association with troponin elevation >99th|Association with elevation of serum creatinine >30%|With the onset of chronic renal failure (eDFG <60 ml / min / 1.73m2)|The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital|The occurrence of death from any cause during hospitalisation and three months after discharge from hospital || Personal protection measures|impact of Covid-19 pandemic on type of face masks used in dental clinic || COVID-19-free survival in experimental arms compared to placebo|Incidence of confirmed SARS-COV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related adverse events || Seroconversion status|The proportion of asymptomatic infections among staff who have seroconverted|The durability of COVID 19 seroconversion in asymptomatic healthcare workers at JHAH|Identification of risk factors for COVID 19 seroconversion in asymptomatic healthcare workers || awareness of Egyptian population || detection of severe acute respiratory syndrome related to coronavirus-2 in brain tissues|quantification of inflammation, necrosis and hemorrhage in different brain areas || Anti-A antibody concentration|Anti-B antibody concentration|Blood group || Number of physician using los flow nasal cannula during COVID 19 pandemia|Number of physician getting sick during Covid 19 pandemic || Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms || Time to complete remission || The PaO2/FiO2 ratio at D11|Changes in Tregs between Baseline and Day 7 (expressed in %)|Number of days alive with oxygen therapy within 28 days|Maximal oxygen rate within 28 days|Number of days alive free of invasive or non-invasive ventilation within 28 days|Number of days alive outside ICU within 28 days|Number of days alive outside hospital within 28 days|Time (in days) from randomization to death|Mortality rate at D28|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Use of antibiotics for respiratory (proved or suspected) infection within 28 days|Number of prone positioning sessions|Changes in Tregs during the different visits between baseline and day 28|Cytokines analysis on plasma samples at Day 0, 7 and 14|Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14|T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline|T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline|Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline. || COVID-19 (SARA-Cov-2) infection|Severity of COVID-19 (SARA-Cov-2) infection|Hospitalization|Disease duration|Death|Oxygen support|Type of oxygen support|Symptoms of COVID-19|Serum Levels of 25-hydroxyvitamin D3|Serum levels of calcium|Serum levels of phosphorus|Serum levels of creatinine|Serum levels of albumin|Serum levels of the blood urea nitrogen (BUN)|Serum levels of the parathyroid hormone (PTH) || Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Association between presence of Liver disease and fear levels|Association between presence of Liver disease and anxiety levels|Association between presence of Liver disease and stress levels|Correlation between Fear and Child-Turcotte-Pugh Score|Correlation between anxiety and Child-Turcotte-Pugh Score|Correlation between stress and Child-Turcotte-Pugh Score|Correlation between fear and Model for End Stage Liver Disease Score|Correlation between anxiety and Model for End Stage Liver Disease Score|Correlation between stress and Model for End Stage Liver Disease Score || Overall survival|Time to all-cause mortality or Artificial Pulmonary Ventilation (APV)|Time to all-cause mortality, nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization|Proportion of patients with severe pneumonia|Proportion of patients with low oxygen saturation value|Proportion of patients with Hb <90 g/l (9.0 g/dl) at any point during hospitalization|Proportion of patients hospitalized or transferred to Intensive Care Unit (ICU)|Time to nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization|Time to pneumonia/recurrent pneumonia|Time to primary or recurrent coronavirus infection disease (COVID-19) || Viral load measured in tracheal aspirate 72 hours after initiation of core warming|PaO2/FiO2 ratio 72 hours after initiation of core warming|Duration of mechanical ventilation || mortality|the mean time with oxygen therapy|the mean time with Non-invasive mechanical ventilation|the mean time of intubation|respiratory function parameters|radiological lung extension|mean duration of hospitalization and ICU use|the requirement of additional organ support|the levels of IL-6|Incidence of adverse events|time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity|the levels of CRP|the levels of procalcitonin (PCT)|levels of D-dimer|levels of ferritin || Inflammation|Oxygenation|Chronic Pulmonary outcomes|Pulmonary artery pressure using transthoracic echocardiography|Exertion|Quality of life assessment || Change from baseline in clinical assessment score COVID 19 (CAS COVID 19)|- Combine endpoint -|C-reactive protein|D-dimer|EuroQol Group. EQ-5D™|EuroQol Group. EQ VAS|HADS|Hospital length of stay || The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days|Time to symptom resolution-Fever,Shortness of Breath,Fatigue|Hospital length of stay|Change in SOFA pre and post transfusion|Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive|Radiological improvement|Adverse events (AE) associated with transfusion|To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion]|Levels of bio-markers pre and post transfusion|Need of Vasopressor use || change from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline|Combine endpoint: Time to death or mechanical ventilation|C-reactive protein|D-dimer|EuroQol Group. EQ-5D™|exposure area on lung CT || Peak oxygen uptake|Oxygen uptake at anaerobic threshold|Borg rating of perceived exertion scale|Walk distance|Borg dyspnea scale|Anxiety score|Depression score || Health care provider safe return to work || Change in SARS-CoV-2 mucosal immune response in the nasopharynx|Change in microbial load in the nasopharynx|Change in Viral Load in the nasopharynx over the course of COVID-19 infection|Symptom assessment|Temperature assessment || Transpulmonary pressure || Biological acquired thrombophilia|Overexpression of interferon type I || Proportion of participants with no symptoms of cough, fever or dyspnea|Improvement in dyspnea|Hospitalization for SARS-CoV-2|Oxygen Use|Mortality|Clinical status|Anxiety|Sleep Disturbance|Visual Analog scale || Number of Cured Patients|Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group || Physical symptoms|Contact History|Travel History|Fever|Headache|Soar Throat|Runny nose|Cough|Shortness of breath|Nausea|Vomiting|Muscle pain|Joint pain|Diarrhoea|Other|Hospitalisation history|Co-morbid conditions || Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative/peers evaluation of the patient|Serious of symptoms at admittance hospital || Hospitalization || overactivity of the renin / aldosterone system || Laboratory Result|Clinical Outcome || Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0|The proportion of subjects undergoing DLT events in each dose cohorts during the DLT observation period|PK parameters-Peak concentration|PK parameters-Time to peak|PK parameters-Areas under the concentration-time curves|PK parameters-Terminal elimination rate constant|PK parameters-Elimination half-life|PK parameters-Clearance (CL)|PK parameters-Volume of distribution|The concentration-time curves of plasma Ang1-10|The concentration-time curves of plasma Ang1-9|The concentration-time curves of plasma Ang1-8|The concentration-time curves of plasma Ang1-7|The concentration-time curves of plasma aldosterone|ADA positive rate|NAb positive rate || Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0|Safety evaluation- proportion of subjects undergoing DLT events|PK parameters-Areas under the concentration-time curves|PK parameters-Maximum measured concentration|PK parameters-Time from dosing to maximum measured concentration|PK parameters-Terminal phase elimination rate constant|PK parameters-Terminal phase elimination half life|PK parameters-Clearance|PK parameters-Volume of distribution during terminal phase and at steady state|PK parameters-Mean residence time|Anti-drug antibody"
COVID-19,"To assess the safety and tolerability of the COVID-19 vaccine following one or two consecutive intramuscular injections in healthy volunteers|To assess induction of SARS-CoV-2 spike protein-binding antibodies upon one or two administrations of the COVID-19 vaccine by means of ELISA up to study day 56|To assess induction of SARS-CoV-2 neutralizing antibodies upon one or two administrations of the COVID-19 vaccine by means of serum neutralization assay up to study day 91|To assess SARS-CoV-2 spike protein-specific, cell-mediated immune responses up to study day 91, induced by one or two doses of vaccine, by means of intracellular staining and flow cytometry.|To assess potential measles virus shedding by means of RT-qPCR of saliva, nasal swab, urine, or blood samples in sentinel groups on day 0 and up to day 42 || To identify the genetic determinants of COVID-19 severity|To identify the genetic determinants of COVID-19 clinical trajectories. || Diagnostic values of anosmia and ageusia for COVID-19|Diagnostic values of CODA || detection of viral infection using serology and viral-RNA detection kits|Temporal trend of antibodies in blood || Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels. || Pulmonary follow-up sequelae in patients after COVID-19|Evaluation of risk factors for adverse Outcome after COVID-19|Compare the functional Pulmonary outcome of COVID-19 disease|Compare the radiological Pulmonary outcome of COVID-19 disease|Quality of Life after COVID-19|Physical performance after COVID-19 using Clinical Frailty Scale|Physical performance after COVID-19 using frailty assessment tests|Microbiota and COVID-19 || Incidence of healthcare workers with SARS-CoV-2|Incidence of ENT patients with SARS-CoV-2|Development of SARS-CoV-2 antibodies among healthcare workers|Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers|SARS CoV-2 and bacterial super infections in upper respiratory airways || Global evaluation of the implication of the Belgian anesthesiologists during COVID-19 pandemic|If any compare our results with other countries || The incidence of COVID-19 cases after two-doses of vaccination|The incidence of severe cases of SARS-CoV-2 pneumonia and deaths accompanied by COVID-19 after two-doses of vaccination|The incidence of any adverse reactions/events|The incidence of serious adverse events (SAE)|The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody|The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody|The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody || SARS-CoV-2 levels of IgG antibodies|SARS-CoV-2 viral load in nasopharyngeal swab of IgG positive subjects|Epidemiology correlations || Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure|Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure|Effects of COVID-19 on General Health Status|Effects of COVID-19 on Access to Healthcare Services|Effects of COVID-19 on Dietary Habits|Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise)|Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise)|Effects of COVID-19 on Weight|Effects of COVID-19 on HbA1c (Glycated Hemoglobin)|Barriers to Type 2 Diabetes Management Due to COVID-19|COVID-19 Screening|COVID-19 Testing|COVID-19 Vaccine Willingness/Hesitancy|Trusted Sources of COVID-19 Information|Effects of COVID-19 on Housing|Effects of COVID-19 on Employment|Effects of COVID-19 on Income|Sources of Stress During COVID-19 || Identification of asymptomatic carriers of SARS-CoV-2|Validation of the ability of the immunoassay kit to detect antibodies to SARS-CoV-2|Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2|Exploration of SARS-CoV-2 epidemiology || Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number || Clinical clearance || Rate of patients with positive anti-COVID19 serology|Rate of patients with symptomatic or severe (hospitalization) form of infection || COVID-19 test positivity|Mortality|Intensive care unit admission rate|Mechanical ventilator application rate|Oxygen apply rate (Nasal prong, Facial Mask, High flow nasal cannula)|Rates of vasopressor and inotrope use || Acute myocarditis|Multi-systemic inflammatory syndrome|Kawasaki disease|Results of SARS-CoV-2 || Viral evolution|Immune response|Disease severity || Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies|Positive or negative Covid-19 test|Positive or negative character of the antibodies test|Biological parameters|medical-economic comparison || Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Immunogenicity|Change in GMT of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein receptor binding domain-specific antibody|Change in GMT of anti-SARS-CoV-2 B cell epitope antibody|Change in IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Adverse events || Patient Prognosis Score|Oxygen Saturation|Laboratory Data|Radiological Features|Hospital Stay|Liver Function|Kidney Function || Invasive respiratory support in patients with COVID-19|Mortality in patients with COVID-19 || Percentage of subjects with COVID-19 disease progression || Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank || Organ transplantation activity during COVID-19 pandemic|Further analysis on organ transplantation with stratification || Recovery|Mortality|ICU admission || Retrospective study on individuals with or without symptoms to verify the reliability of a prognostic/diagnostic test based on IgM/IgG analysis.|ACE2 expression in patients with COVID-19 infection || 7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)|Sequential Organ Failure Assessment (SOFA) scores|Incidence of AE / SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time (in days) from treatment initiation to death|All-cause mortality || Patient Characteristics|Treatment Measures and Intervention strategies|Clinical and survival outcomes || Estimation of severity of patients with COVID-19 in relation to Laboratory findings. || diagnostic value of COVID-19 antibodies testing|Role of COVID -19 Antibodies testing in treatment of Patients|Assement of COVID -19 prevalence among healthcare workers || Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days || Determination of cause of death and contributing factors based on clinical, radiological, microbiological and histopathological data of the deceased patient|Detailed description of the postmortem radiological changes induced by COVID-19|Detailed description of the postmortem histopathological changes induced by COVID-19|Postmortem quantity of viral RNA|Postmortem disease mechanisms at cellular level || Dose-Limiting Toxicities|National Early Warning Score (NEWS)|Time to improvement by one category on a WHO ordinal scale|Time-to-SARS-CoV-2 negativity after infusion of SARS-CoV-2 specific T cells|Duration of persistence of SARS-CoV-2 specific T cells in the recipient's blood circulation|Time-to-normalization of cytokine level, lymphocyte subsets, and gene transcriptome after T cell infusion|Overall survival (OS) at 3 months after infusion of SARS-CoV-2 specific T cells || COVID-19 Seroconversion || Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality || Overall Mortality within 60 days|Length of ICU stay during current admission for COVID || Immune Response description|Evolution of the SARS-CoV2 overtime|Clinical and Immunological Analysis|Comparison of the occurrence of clinical events with other immunological data || improvement of condition|change in organs function with PFS and OS || Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality || Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Immunogenicity|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein receptor binding domain-specific antibody|Change in GMT of anti-SARS-CoV-2 B cell epitope antibody|Change in IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Change in the neutralizing activity against pseudovirus of SARS-CoV-2|Change in binding inhibition of SARS-CoV-2 spike (S) glycoprotein and ACE2|Change in IFN-γ production against SARS-CoV-2 spike (S) glycoprotein by T cells in peripheral blood mononuclear cells|Adverse events || Confirm safety|Suggestion of efficacy|Optimal dose of SARS-CoV-2 antigen and GM-CSF || clinical, biological and radiological characteristics|patients' journey description|Treatments effects || Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.|Differences in gut microbiota composition between COVID-19 patients in relation to mortality.|Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.|Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation. || Deep Venous Disease Incidence|30-days mortality|ICU admission|Anticoagulant treatment || the number of intubations in COVID-19 patients initially hospitalised in wards|the number of intubations in COVID-19 patients initially hospitalised in wards. || Identification of COVID-19 || Household COVID-19 Testing Uptake|COVID-19 Symptoms, Diagnoses, and Testing Scale|COVID-19 Avoidant Behaviors Scale|Seasonal Influenza Vaccine Uptake|COVID-19 Improved Household & Family Mutual Aid|COVID-19 Household Environment Scale || Frequency of solicited local and systemic reactogenicity adverse events (AEs)|Safety Laboratory Values (Serum Chemistry)|Safety Laboratory Values (Hematology)|Frequency of any serious adverse events (SAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of medically attended adverse events (MAAEs)|Frequency of Unsolicited AE and Adverse Events of Special Interest (AESIs)|Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs)|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs)|Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs)|Neutralizing Antibody Activity Expressed as GMTs|Neutralizing Antibody Activity Expressed as GMFRs|Neutralizing Antibody Activity Expressed as SCRs|Assessment of Cell-Mediated (T helper 1 [Th1]/T helper 2 [Th2]) Pathways|Optimal dose of SARS-CoV2 antigen and GM-CSF|Duration of detection IgG and neutralizing antibody againts SARS-CoV-2in blood after vaccination || Prevalence of latent COVID-19 infections at one point in time among residents and staff of all old people's and nursing homes in Solingen.|Prevalence of latent COVID-19 infections over a follow-up period of 6 months among staff of one single nursing home|Analysis of risk factors (previous illnesses, medication...) || Incidence of COVID-19 cases after two-doses immunization schedule|Frequency of adverse events up to seven days after immunization|Incidence of COVID-19 cases after two-doses immunization schedule according to previous exposure|Incidence of COVID-19 cases after 14-days of first immunization|Combined incidence of SARS-CoV-2 infection|Incidence of severe COVID-19 cases after two-doses immunization schedule|Frequency of adverse events up to 28 days after immunization|Frequency of severe COVID-19 cases|Frequency of adverse events of special interest after immunization|Seroconversion rate|Cell-mediated immune profile|Seropositivity rate || Incidence of Treatment-Emergent Adverse Events|Immunogenicity|Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody|Change in the neutralizing activity against pseudovirus of SARS-CoV-2|Change in IFN-gamma production against SARS-CoV-2 spike (S) glycoprotein by T cells in peripheral blood mononuclear cells|IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody|Adverse events|Rate of SARS-CoV-2 positive and incidence rate of COVID-19 after the first vaccination || 30-days survival|Ventilator free survival|6-months survival|Incidence of complications|Days in intensive care units (ICU)|Positivity for Immunoglobulin G to SARS-Cov-2|Clearance of viral load|Sequential Organ Failure Assessment (SOFA) score|Any variation from Standard Therapy Protocol || Rate of care actions identified by nurses|Rate of care actions taken by nurses || Participants with serious adverse events.|Comparison of clinical severity score between patients on the experimental versus control arms;|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms|Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|Mortality of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms || Duration of Viral shedding of SARS-CoV-2 by qRT-PCR|Sars-CoV-2 viral load|Area under the curve of SARS-COV-2 viral load|Time to alleviation of all symptoms Time to alleviation of all symptoms|Number of participants requiring emergency department visits or hospitalizations within 28 days of initiation of treatment || Change in the partial pressure of carbon dioxide (PaCO2)|Change in minute ventilation|Change in respiratory system compliance|Change in driving pressure|Change in ventilator synchrony|Change in mean arterial pressure|Change in the fraction of inspired oxygen percentage of oxygen (FiO2)|Change in the partial pressure of carbon dioxide (PaO2) to the fraction of inspired oxygen percentage of oxygen (FiO2) ratio|Change in hydrogen ion activity (pH)|Change in Bicarbonate (HCO3)|Change in red blood cell count|Change in white blood cell count|Change in white cell differential|Change in hemoglobin levels|Change in hematocrit|Change in mean cell volume|Change in mean cell hemoglobin|Change in mean cell hemoglobin concentration|Change in platelet count|Change in red cell distribution width|Change in blood albumin level|Change in serum alkaline phosphatase level|Change in serum aspartate transaminase level|Change in serum alanine aminotransferase level|Change in blood urea nitrogen levels|Change in serum calcium level|Change in serum chloride level|Change in serum potassium level|Change in serum creatinine level|Date patient is re-intubated or need mechanical ventilation for a second time|Length of intensive care unit stay|The total hospital stay|Disposition at discharge|Change in heart rate|Change in the dosage of vasopressor medication || Deterioration of the condition|Mortality|The information analysis degree, the proportion of signal loss, the proportion of wrong signal, || Viral load during the period of admission to the nasopharyngeal smear.|Clinical indicators on admission and every 48 hours thereafter|Analytical parameters|Mobility|Microbiome analysis in feces || Establishment of a clinical basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.|Establishment of a biological basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.|Dosage of IgM and IgG anti SARS-CoV2|Evaluate the diagnostic performance of the minute test for IgM|Evaluate the quantification of IgG in long term (M12) in the Cancer Centres populations|Evaluate the frequency of reinfections among the persons who have developed IgG|Evaluate the threshold of protective IgG among the subjects who have developed IgG|Evaluate the influence of polymorphisms of receptor of IgG Fc-gamma low-affinity (FcδIIA, FcδIIIa) on the humoral immune response|Evaluate the severity of Covid-19 infection (invisible, visible, prolonged, severe and fatal) by age group|Evaluate the frequency of reinfection by Covid-19 (recurrence of evocative clinical symptoms and positive viral PCR or positive IgM serology) during follow-up|Evaluate the risk factors (clinical and therapeutic) to develop severe forms of Covid-19 infection in patients|Evaluate the changes in health care practice|Evaluate the resources associated with organizational changes|Evaluate the allocated resources|Evaluate the incidence of Covid-19 infections|Evaluate the distribution of risk factors for contamination in patients and in the general population|Evaluate the anxiety state over time|Evaluate the depression over time|Evaluate the post-traumatic developments|Evaluate the change in health care change frequency|Evaluate the number of patients concerned by health care changes|Evaluate the rate of morbidity|Evaluate the rate of mortality || Frequency of local and systemic adverse reactions in the first 7 days after immunization|Seroconversion rates|Frequency of adverse reactions up to 28 days after immunization|Frequency of severe adverse events|Frequency of adverse events of special interest|Cell-mediated immune response|Frequency of detection of antibodies against SARS-CoV-2|Geometric mean titer of neutralizing antibodies || COVID-19 Positive Case || Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19|Protection Indexes of One Vaccine Dose For Symptomatic COVID-19|Protection Indexes of Second Vaccine Dose For Hospitalization, Disease Severity/and Death|Protection Indexes of Two Vaccine Doses For SARS-CoV-2 infection|Safety indexes of adverse reactions in 28 days|Safety indexes of adverse reactions in 7 days|Safety indexes of serious adverse events in 1 year|Immunogenicity parameters (seroconversion rate, seropositivity rate) in 14 days|Immunogenicity parameters (seroconversion rate, seropositivity rate) in 28 days|Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 14 days|Immunogenicity parameters (GMT and GMI of neutralizing antibody and IgG) in 28 days || Incidence of solicited adverse events within 7 days after vaccination.|GMT of neutralizing antibodies against live SARS-CoV-2 virus at Day 14 after the booster vaccination.|Incidence of adverse reactions within 28 days after vaccination.|Incidence of adverse events within 28 days after vaccination.|Incidence of unsolicited AE within 28 days after vaccination.|Incidence of serious adverse events(SAE) from the first dose to the 6 months after completing the last dose of vaccination.|GMT of binding antibodies against SARS-CoV-2 S and RBD protein measured by ELISA at Day 14, Day 28 and Month 6 after the booster vaccination.|Proportion of the participants with at least a four-fold increase of the binding antibodies against SARS-CoV-2 S and RBD protein at Day 14, Day 28 and Month 6 after the booster vaccination.|Fold increase of binding antibodies against SARS-CoV-2 S and RBD protein at Day 14, Day 28 and Month 6 after the booster vaccination.|GMT of neutralizing antibodies against live SARS-CoV-2 virus at Day 28 and Month 6 after the booster vaccination.|Proportion of the participants with at least a four-fold increase of neutralizing antibodies against live SARS-CoV-2 virus at Day 14, Day 28, Month 6 after the booster vaccination.|Fold increase of neutralizing antibodies against live SARS-CoV-2 virus at Day 14, Day 28 and Month 6 after the booster vaccination. || Diagnosis of COVID-19 on lung ultrasound|Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray|Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray|Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19|Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19 || The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate || Number of COVID-19 PCR negative cases || Success rate in production of SARS-CoV-2 specific T cells from convalescent donor || SARS-CoV-2 infection status|Olfactory and gustatory loss|Ability to detect odor|Ability to detect salty taste|Ability to detect sweet taste|Severity of infection according to hospitalization rate || Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device|Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device|Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients|Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3/Th3|Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles|Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy|Phase Angle in COVID-19 Patients: Measured via Multifrequency || SARS-COV-2 infection|Individual factors|Hospital ward level || Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|Prevention of progression assessed by an alternate severity scale|Time to reaching maximal severity score|Proportion of patients in each stage at maximum severity|PaO2/FIO2 or SaO2/FIO2 ratio, measured daily|Length of hospital Stay (death assigned as worst case)|Frequency of Intubation, ECMO, or need to intubate with ""Do Not Resuscitate"" order|Mortality|IL6 level|TNF-alpha level|Fibrinogen level|CRP level|Ferritin Level|D-dimer level || Number of days until complete resolution of symptoms per group|Number of hospital admissions per group|Number of days until a reduction in symptoms per group|Number of adverse events per group || Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme || Proportion of symptomatic patients with immune response (IgM/IgG/IgA)|Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)|Time to IgM|Time to IgG|Time to IgA|Serology kits inter-observer agreement|Proportion of symptomatic patients with immune response (IgM/IgG/IgA)- long term|Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA) -long term || SpO2 at hospital entry|in-hospital mortality|need of intubation|Percentage of hospitalized patients among those with recommendation of hospitalization || Development of data repository to provide a secure, centralized storage location for COVID-19 related specimens || Anti-SARS-COV-2 antibodies|Positive SARS-CoV-2 PCR|Clinical questionnaires and ELISA antibody testing results|Detection of Anti-SARS-CoV-2 antibodies by ELISA Assay Algorithm || Longterm morbidities and sequels of SARS-CoV-2 infections in the general population|Longterm quality of life of SARS-CoV-2 infected individuals recruited from the general population|Longterm health care utilization of SARS-CoV-2 infected individuals recruited from the general population || Identification of prognostic factors for progression to a severe form of COVID-19 infection|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of clinical manifestations|Description of biological manifestations|Description of radiological manifestations|Description of physiological manifestations|Patient-related prognostic factors|Virus-related risk factors|Comparison of the results of different diagnosis tests || Diagnostic accuracy of electronic nose signal in COVID-19 || Time To Response (TTR)|Objective Response Rate (ORR)|All-cause mortality|Duration in days required for hospital discharge|Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours|Number of days without oxygen therapy|Incidence of oxygen use, NIV or high flow oxygen therapy|Duration in days of oxygen prescription, NIV or high flow oxygen therapy|Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample|Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample|Biochemical response: serum viral load of SARS-CoV-2|Biochemical response: C-reactive protein (CRP)|Biochemical response: blood test for lymphocytes (lymphopenia)|Parenchymal involvement (chest CT)|Define the optimal dose of CPZ and its tolerance: rates of serious adverse events|Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects|Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale (GA-VAS)|Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation|Define the optimal dose of CPZ and its tolerance: biological anomalies|Define the optimal dose of CPZ and its tolerance: ECG abnormalities|Define the optimal dose of CPZ and its tolerance: plasma CPK assessment|Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment|Define the optimal dose of CPZ and its tolerance: CPZ dose administered || Hypoxemia via oxygen level, or saturation (SpO2) in percent|Progression to mechanical ventilation, ECLS or death|Oxygen requirements|Days of hospitalization|Time to hospital discharge|Time to resolution of fever|Days of resting respiratory rate|Serious adverse events or patient or worsening condition|Erythrocyte Sedimentation Rate (ESR)|C-Reactive Protein (CRP)|Ferritin|D-Dimer|Creatine Phosphokinase, Total (CK)|Troponin|Lactate Dehydrogenase (LDH)|Procalcitonin (PCT)|B-Type Natriuretic Peptide (BNP)|N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP)|Interleukin-6 (IL-6), High Sensitive ELISA|Complete Blood Count (CBC) with Differential|Comprehensive Metabolic Panel (CMP)|7-Point Ordinal Scale of Clinical Status|Modified Borg Dyspnea Scale (MBS) || Characterize immune response|Immune response and outcome|B- and T-cell arm immune response || TESTING: Proportion tested for COVID-19|TESTING: Time to Test from Symptom Onset|CHANGE IN PROTECTIVE BEHAVIORS Over time - Recommended Practices|PROTECTIVE BEHAVIORS - Days quarantined in the past month|PROTECTIVE BEHAVIORS - Vaccine Acceptance|Cultural Identity and Connectedness|Substance Use|Depression|Anxiety|Demographic || All Cause-death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death || COVID-19 positive case || % of COVID-19 co-infections|% of antibiotic switches following FA results || Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oximetry from baseline|Changes in fever from baseline || Accuracy of non contrast MSCT chest in COVID-19|MSCT chest can be used as an alternative diagnostic tool for COVID-19 cases. || Time to positive COVID-19 disease|Number of COVID-19 test positive cases|Number of COVID-19 serological test positive cases|Severity of COVID-19 disease between each arm|Number of common COVID-19 complications between each arm || Severe COVID-19|Death || Category Changes in the ""7-Ordinal Scale""|Time to category 5, 6 or 7 of the "" 7-Ordinal scale""|Time to an improvement of one category from admission in the ""7-Ordinal scale""|Status at day 30 in the ""11-Ordinal scale""|Status at day 15 and 30 in the ""11-Ordinal scale""|Time to first deterioration|Mean change in the ranking in the ""7-Ordinal scale"" from baseline to days 3,5,8,11,15,29 and 60|Mean change in the ranking in the ""11-Ordinal scale from baseline to days 3,5,8,11,15,29 and 60.|Mortality of any cause at 15 days|Mortality of any cause at 28 days (day 29)|Mortality of any cause at 60 days|Oxygenation free days|Ventilator free days|Duration of hospitalization (days)|Infusion-related adverse events|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load|Incidence of thrombotic arterial events|Incidence of thrombotic venous events|rate of rehospitalizations || For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60 || Disease progression measured by WHO scale|Comparison of maximum WHO score per group|Comparison of decrease of median and maximum WHO score per group|Comparison of time to clinical improvement per group|Comparison of time to reach score of ""6"" or greater on the WHO scale || A composite of either severe COVID-19 or death from any cause through Day 29.|A composite of either death from any cause or hospitalization for COVID-19 complications or sequelae during the 168-day post-dose period (Day 1 to Day 169).|The incidence of participants with respiratory failure, defined as requirement for mechanical ventilation, ECMO, non-invasive ventilation, or high-flow nasal cannula oxygen delivery.|COVID-19 symptom severity assessments based on symptom severity scores over time during the 28-day period from and including the day of the dose of AZD7442 or placebo.|Progression through Day 29 of one or more COVID-19-associated symptoms to a worse status than recorded in the participant-reported symptom diary at study entry, prior to start of AZD7442 or placebo.|Detection (detectable versus undetectable) from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.|Level of SARS-CoV-2 RNA from nasal swabs through Day 29.|Change from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.|Time to return to usual (pre-COVID-19) health through Day 29.|Duration of fever through Day 29.|Incidence of ADA to AZD7442 in serum over time.|Pharmacokinetics - Serum Concentration|Pharmacokinetics - Maximum Serum Concentration|Pharmacokinetics - Time to Maximum Serum Concentration|Pharmacokinetics - Area under the plasma concentration-time curve to the last measurable time point|Pharmacokinetics - Area under the plasma concentration-time curve extrapolated to infinity || Survival time without needs of a ventilator.|Morbidity|Mortality|Length of stay|Effect on viral pharyngeal specimen clearance|Effect on viral blood specimen clearance|Effect on hemostasis disorders|Kinetics of appearance of neutralizing antibodies|Transfusion endotheliopathy effect|Transfusion biological Inflammation effect|Transfusion hemovigilance|Decrease in the consumption of antibiotics || Prior treatment by ACEi|Prior treatment by ARB|Baseline characteristics and comorbidities|Major Clinical Adverse Events || Symptoms consisent with COVID-19|Number of close contacts|Number of participants with positive test for COVID-19|Self-reported health based on the single question: ""In general, would you say your health is..""|Ability to make ends meet based on the single question: ""At the end of the month, are you able to make ends meet?"" || Prevalence of COVID-19 calculated using a questionnaire|Standardized Mortality rate|Morbidity rate || possible risk factors|frequency of positive test results after prescribed protective measures|frequency of positive test results within the family or other social groups|number of COVID-19 tests in the outpatient clinic || To characterize the immunologic mechanisms by which BTK inhibition may ameliorate hyper- inflammatory responses in patients with COVID-19.|1. Characterization of TLR3 and TLR7/8-dependent immunologic phenotypes in COVID-19 patients before and after BTK inhibition.|2. Evaluation of mechanisms of immune cell-specific activation, cytokine production, exhaustion and apoptosis in COVID-19 patients before and after BTK inhibition.|3. Transcriptional, chromatin, and epigenetic profiling of immune cells at the single cell level in COVID-19 patients before and after BTK inhibition.|4. Longitudinal evaluation of TCR and BCR repertoire development in COVID-19 patients before and after BTK inhibition.|5. Characterization of SARS- CoV-2 serological responses in COVID-19 patients with and without BTK inhibition.|6. Characterization of genetic variants that correlate with disease severity and/or response to BTK inhibition treatment.|7. Evaluation of soluble biomarkers as surrogate markers of hyper- inflammation/prognosis and of response to BTK inhibition therapy in COVID-19 patients || Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement || Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection|Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms (to be reported as absolute number and frequency of events)|Time to COVID-19 infection in patients receiving study drug (in days)|Safety and tolerability of study drug (to be reported as absolute number and frequency of events) || Prevalence of contagiousness in asymptomatic individuals by PCR with nasopharyngeal swabs|Ratio of asymptomatic immunized (IgG) population|To validate saliva specimens as a biological sample for COVID-19 testing || To create an immune profile for each COVID19-positive patient during their ICU stay|To correlate patients' immune profile to disease severity and patient's outcome || i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality || The incidence of adverse reaction (AR)|The incidence of Adverse Events of Special Interest (AESI)|The incidence of adverse events (AE)|The incidence of grade 3 adverse events (AE)|The incidence of severe adverse events (SAE)|Geometric mean (GMT) of specific antibody|Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies|The positive conversion rate of S-RBD protein-specific antibody|Geometric mean fold increase (GMI) of S-RBD protein-specific antibody|The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody|Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies || The evaluation of the correlation between the baseline LUS score and mortality rate of patients with severe COVID-19 pneumonia who were followed up in the intensive care unit|The evaluation of the correlation between the baseline CT score and mortality rate of patients with severe COVID-19 pneumonia who were followed up in the intensive care unit || Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality || Prevalence of IGG for COVID-19|Changes in prevalence of IGG for COVID-19 || Number of patients with increased disease severity|Incidence of adverse events and serious adverse events (Safety)|Number of COVID-19 patients discharged from hospital|Number of COVID-19 patients transfer to ICU|Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale|Number of of symptom free patients || Time to reach normal body temperature|Development of COVID-19 symptoms during HCQ preventive therapy in staff|COVID-19 test result at follow-up in patients|Worsening of symptoms in COVID-19 patients || Valid SARS-CoV-2 Test || Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Age|Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Age group|Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Gender|Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Index month|Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Height|Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Weight|Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Body Mass Index (BMI)|Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Treatments|Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Comorbidities|Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Follow-up|Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: History of thrombosis|Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Charlson Comorbidity Index (CCI)|Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: CCI severity|Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Molecular/diagnosis testing|Distribution of the use of treatments for COVID-19: Anticoagulation|Distribution of the use of treatments for COVID-19: Angiotensin-converting enzyme (ACE) inhibitors|Distribution of the use of treatments for COVID-19: Angiotensin II receptor blockers (ARBs)|Distribution of the use of treatments for COVID-19: ARBs combination|Distribution of the use of treatments for COVID-19: Statin|Distribution of the use of treatments for COVID-19: HIV protease inhibitor|Distribution of the use of treatments for COVID-19: Non-pharmacological treatment|Distribution of the use of treatments for COVID-19 symptoms: Anticoagulation|Distribution of the use of treatments for COVID-19 symptoms: Angiotensin-converting enzyme (ACE) inhibitors|Distribution of the use of treatments for COVID-19 symptoms: Angiotensin II receptor blockers (ARBs)|Distribution of the use of treatments for COVID-19 symptoms: ARBs combinations|Distribution of the use of treatments for COVID-19 symptoms: Statin|Distribution of the use of treatments for COVID-19 symptoms: HIV protease inhibitor|Distribution of the use of treatments for COVID-19 symptoms: Non-pharmacological treatment|Distribution of composite outcomes of COVID-19 patients: In-hospital death|Distribution of composite outcomes of COVID-19 patients: Overall survival|Distribution of composite outcomes of COVID-19 patients: Utilization of Extracorporeal membrane oxygenation (ECMO)|Distribution of composite outcomes of COVID-19 patients: Utilization of mechanical ventilation (invasive & noninvasive)|Distribution of composite outcomes of COVID-19 patients: Utilization of oxygen therapy|Distribution of composite outcomes of COVID-19 patients: Intensive care unit/high care unit (ICU/HCU) admission|Distribution of composite outcomes of COVID-19 patients treated with anticoagulant therapy during the follow-up period|Distribution of composite outcomes of COVID-19 patients treated without anticoagulant therapy during the follow-up period || Performance of the LumiraDx Assay versus reference methods with regards to clinical sensitivity and specificity for the detection of the SARS-COV-2 IgG/IgM and viral antigen in patient samples. || Profiles of volatile organic compounds (VOCs) in exhaled air between 2 health conditions|Profiles of volatile organic compounds (VOCs) in exhaled air on 1 health condition|Profiles of volatile organic compounds (VOCs) in exhaled air between 2 periods || Number of patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients || Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy|Adverse events|Dose of plasma needed to clear viremia|Clearance of viremia|Fever and symptoms|Inflammatory parameters|Antibody response to SARS-CoV-2 || Measurement of matrix metalloproteinase-7 ""MMP-7"" serum level (pg/ml) as a biomarker of macrophage activation|Measurement of matrix metalloproteinase-9 ""MMP-9"" serum level (pg/L) as a biomarker of macrophage activation|Measurement of transforming growth factor B ""TGF-B"" serum level ( pg/ml) as a biomarker of macrophage activation|Measurement of platelet derived growth factor ""PDGF"" serum level (ng/ml) as a biomarker of macrophage activation || Determine CD8 T cells that are responsive to SARS-CoV-2. || Percentage of Participants who Experience COVID-19 Related Hospitalization or Death|Proportion of Participants with a COVID-19-related Hospitalization, Defined as up to Days 60 and 90|Proportion of Participants with a COVID-related Emergency Department (ED) Visit Through Days 29, 60, and 90 || Health Outcomes || ECG changes associated with COVID-19 || The incidence of COVID-19 cases after two-doses of vaccination|The incidence of solicited AEs.|The incidence of COVID-19 cases after at least one dose of immunization.|The Geometric Mean Titer (GMT) of neutralizing antibody|The Geometric Mean Titer (GMT) of IgG antibody|The positive rates of neutralizing antibody|The positive rates of IgG antibody|The seroconversion rates of neutralizing antibody|The seroconversion rates of IgG antibody|Specific T cells with ELISPOT assay|The incidence of AEs|The incidence of SAEs|The occurrence of Antibody Dependent Enhancement (ADE)/ Vaccine Enhanced Disease(VED) || Disease progression|Adverse events (AE)|Time ro resolution of fever and symptoms|Clearance of viraemia|Inflammatory parameters|Antibody response to SARS-CoV-2 || Diffusion Capacity for Carbon Monoxide (CO) 3 months after COVID diagnosis|Prevalence of Sleep Disordered Breathing (SDB) 3 months after COVID diagnosis|Prevalence of sleep disorders 3 months after COVID diagnosis|Prevalence of ventilatory muscle function impairments, 3 months after COVID diagnosis|Prevalence of cardiac impairments 3 months after COVID diagnosis|Follow-up of pulmonary diffusion capacity of carbon monoxide|Follow-up of sleep disorders treatment compliance|Follow-up of sleep disorders treatments efficacy|HLA alleles aspect of COVID clinical presentation|KIR loci aspect of COVID clinical presentation|metabolomic aspect of COVID clinical presentation || Cumulative Incidence of Serious Adverse Events (SAEs) at study Day 14|Days to hospital discharge (or discharge equivalent) following first dose of CCP || Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers). || Mortality|Admission to Intensive Care Unit (ICU)|Time of hospitalization|Clinical changes|Radiological changes|Calcidiol changes|Inflammation markers changes (CRP)|Inflammation markers changes (IL-6)|Inflammation markers changes (Leucocytes)|Inflammation markers changes (D-dimer)|General biochemical parameters changes (Creatinine)|General biochemical parameters changes (Ferritin)|General biochemical parameters changes (Bilirubin)|General biochemical parameters changes (Albumin)|General biochemical parameters changes (Haemoglobin)|General biochemical parameters changes (HDL cholesterol)|General biochemical parameters changes (Procalcitonin)|General biochemical parameters changes (Protonin)|General biochemical parameters changes (Calcium)|General biochemical parameters changes (Phosphate)|General biochemical parameters changes (pO2) || Results of SARS-CoV-2 RT- PCR testing, antibody assay, and culture|SARS-CoV-2 culture and RT-PCR results|Symptom checklist and RT-PCR cycle threshold || COVID-19 Contamination Rate.|Number of Participants With Adverse Events|Average Number of Adverse Events|Days Over Which an Adverse Event Was Reported|Other Virus or Bacteria Contamination Rate. || Prevalence (magnitude) of anxiety of general adult population during COVID-19|prevalence (magnitude) of depression and anxiety of general adult population during COVID 19 || 28 Days mortality|Requirement of supplemental oxygen support|Number of days on assisted ventilation|Days to step down|Days to Hospital Discharge|Adverse events during hospital stay|Change in C-Reactive Protein (CRP) levels|Change in neutrophil lymphocyte ratio|Change in Ferritin levels|Change in lactate dehydrogenase (LDH) levels|Change in radiological (X-ray) findings|Days to negative SARS-CoV-2 Polymerase Chain Reaction (PCR) test|Anti-SARS-CoV-2 Antibody|Change in fever|Change in Sodium levels|Change in Potassium levels|Change in Chloride levels|Change in Bicarbonate levels || Mortality|X-ray changes|Disability changes|Ambulation changes|lymphocyte count changes|C-Reactive Protein changes|Ferritin changes|D-Dimer changes || Prevalence of contagiousness in asymptomatic individuals by PCR|Ratio of asymptomatic immunized (IgA/IgM and IgG) population|Description of demographic characteristics || Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.|Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.|Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.|Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation. || Incidence of SARS-CoV-2 infection|Incidence of COVID-19|Incidence of hospitalization due to COVID-19|Level of neutralizing antibodies|Previous SARS-CoV-2 infection || To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.|To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19.|To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19. || Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection || Number of subject acquiring COVID-19 infection|Incidence of Adverse Event and Serious Adverse Event (safety and tolerability)|Number of subject developing Upper Respiratory Tract Infection (URTI) symptoms|Number of subject developing severe COVID-19 infection based on ordinal scale || Cardiac pathological findings from series of 60 patients dying from COVID-19 disease|viral load in cardiac tissues and the extent of damage|Co-localize the SARS-CoV-2 using RNAscope in situ hybridization, with its entry receptor ACE2 and serine protease TMPRSS2 in different cell types found in the heart|Multi-organ involvement obtained from hystological analyses of paraffine blocks from different organs (ie kidney, spleen, bowel,....) || Missing Outcome Measures || decrease in mortality|lymphocytes|PCR levels vs control|PCR levels vs before treatment|AB levels and clinical improvement|Inflammatory cytokines vs controls|Inflammatory cytokines vs before treatment || Rate of viral elimination by Day 10 [pilot stage, dose selection]|Time to viral elimination [pivotal stage]|Time to clinical improvement [pivotal stage]|Rate of viral elimination|Time to normalization of clinical symptoms|Duration of oxygen therapy|Change in the level of lung damage according to CT|Rate of transfer to the intensive care unit|Rate of the use of non-invasive lung ventilation|Rate of the use of mechanical ventilation|Mortality|Peak plasma concentration (Cmax)|Time to peak plasma concentration (Tmax)|Area under the plasma concentration versus time curve (AUC0-t)|Trough plasma concentration (Ctrough) || COVID-19 Detection Rate|Number of outbreaks|Enrollment over time || Hospitalization|Mortality || Duration of symptoms of the COVID-19|Severity of the COVID-19|Evolution of oral and fecal microbiota || Adherence to the Mediterranean diet before and during the COVID-19 confinement|Eating behaviours|Level of physical activity during the COVID-19 confinement|Weight gain during the COVID-19 confinement || Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Viral load of SARS-CoV-2 || The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness|AEs, SAEs, MAAEs, and AESIs through 365 days post dose of IMP|The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP|The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARSCoV- 2 nucleocapsid antibodies|The incidence of COVID-19-related death occurring after dosing with IMP|The incidence of all-cause mortality occurring after dosing with IMP|Serum AZD7442 concentrations, PK parameters if data permit.|Incidence of ADA to AZD7442 in serum || Identification of markers associated with asymptomatic COVID + status (results of the serological test) versus symptomatic COVID + status through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Identification of markers associated with a positive or a negative serology through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Description of the serological status according to the professional risk of exposure to the virus|Description of the clinical manifestations of COVID-19 infection in hospital professionals|Identification of risk factors associated with the loss of anti SARS-CoV-2 immunity through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Identification of markers associated with symptomatic COVID-19 infection during follow-up despite the presence of anti SARS-CoV-2 antibodies through a questionnaire (medical history, work environment, lifestyle) and a biological collection|Correlation between the serology result and the PCR result (swabs) for people who have been tested as part of routine care.|Identification of potential therapeutic targets to avoid developing a symptomatic form|Identification of potential therapeutic targets to promote the maintenance of an anti SARS-CoV2 protective immunity|Creation of COVIDneg and COVID + asymptomatic control groups for other COVID-19 biological collections. || Saliva SARS-CoV-2 RT-PCR test results|Saliva and midturbinate swab SARS-CoV-2 RT-PCR test results || Rates of hospitalization for a COVID-19 related complication (Phase 3)|Time to clinical recovery (TTCR) (Phase 2)|Symptom Severity Score (Phase 2) || Clinical worsening (yes/no) of the patient during hospitalization|D-DIMERS plasma levels in blood|Fibrin monomers plasma levels in blood|Antithrombin plasma levels in blood|Prothrombin Fragment 1 plasma levels in blood|Prothrombin Fragment 2 plasma levels in blood|Thrombin generation test plasma levels in blood|Microvesicles of platelet plasma levels in blood|Cross-linked platelets plasma levels in blood|Willebrand Factor plasma levels in blood|Factor VIII plasma levels in blood || Number of physiotherapy treatments|Type of physiotherapy treatments|Time of the first physiotherapy treatment|First time standing|First time walking|First time sitting out of bed|6 minutes walking test (6MWT)|1 minute sit-to-stand test (1m-STST)|Upper extremity muscles strength|Lower extremity muscles strength|Functional independence in ADL|ICU stay length|Length of hospitalization|Duration of invasive mechanical ventilation (IMV)|Patients returned home|Patients discharged to in-patient rehabilitation|Patients transferred to other hospitals|Exitus || Choice and indication of pharmacological agents for management of Severe COVID-19 || The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness|AEs, SAEs, MAAEs, and AESIs through 365 days post dose of IMP|The incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring after dosing with IMP through Day 366|The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARS-CoV-2 nucleocapsid antibodies|The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP|The incidence of COVID-19-related Emergency Department visits occurring after dosing with IMP|Serum AZD7442 concentrations, PK parameters if data permit.|Incidence of ADA to AZD7442 in serum. || Time to confirmed diagnosis of COVID-19|All-cause mortality|Severity of COVID-19 disease|Incidence of COVID-19 complications || Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19|Immunoglobulin Anti-SARS CoV-2 Levels|Negative Nasal Swab Polymerase Chain Reaction (PCR) SARS CoV-2 Viral Tests|Duration of symptoms|Time to discharge|Rate of medical procedures|Difference in changes in serum/plasma immunoglobulin anti-SARS CoV-2 levels || The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)|The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load || The effect of web-based training on symptom management, medication compliance and quality of life of COVID-19 cases to be monitored and treated at home during and after home isolation will be evaluated with questionnaires. || Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients || Composite endpoint of venous thromboembolism (DVT and/or fatal or non-fatal PE), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause mortality or progression to intubation and invasive ventilation|Development of disseminated intravascular coagulation (DIC) according to the ISTH criteria|Number of days requiring invasive ventilation|Number of days requiring non-invasive ventilation|Improvement on a seven-category ordinal scale recommended by the WHO as clinical improvement scale for patients with respiratory infections || Incidence and severity of adverse events (safety)|Establish optimal dose formulation|Duration of detection of antibodies against SARS-CoV-2 || Medical Sequelae in COVID- 19 Survivors|Risk Factors for Medical Sequelae in COVID-19 Survivors|Antibody and cell-mediated immune responses to SARSCoV-2|Antibody and cell-mediated immune responses to SARSCoV-2 over time|Incidence of reinfection with COVID-19|Incidence of clinical silent infection|Mental health status in COVID-19 survivors and contacts || Behavioral Intentions|Personal Decisions Subscale|Social Expectations Subscale|Voting Behavior Question|Protest Question|Transportation || Measurement of N-terminal pro-B type natriuretic peptide, troponin-I and D-dimer in COVID-19 patients|Cardiac complications in COVID-19 patients associated with more adverse effects || Proportion (%) of patients with virological clearance of SARS-CoV-2 at day 7 post-dose*|Viral load reduction of SARS-CoV-2 at Day 3, 7, 10, and 14 post-dose compared to the baseline|Proportion (%) of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose*|Change in WHO Ordinal Scale for Clinical Improvement at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Change in NEWS score at Day 3, 7, 10, 14, and 28 post-dose from the baseline|Time to achieve normalization of body temperature, post-dose|Time to achieve normalization of respiratory rate, post-dose|Time to achieve normalization of oxygen saturation, post-dose || The proportion of vaccinated volunteers with no laboratory confirmed symptoms caused by SARS-CoV-2, within 6 months post vaccination versus a placebo|The prophylactic efficacy of the vaccine|The proportion of volunteers with increased levels of the immune response in terms of geometric mean titers of specific antibodies|The proportion of volunteers with increased levels of the immune response in terms of specific neutralizing antibody titers|The frequency of severe cases of COVID-19 following a single / double vaccination|Duration of disease|The incidence of asymptomatic COVID-19 following a single / double vaccination || rate of virological cure by Rt -PCR for COVID -19using the triple therapy as compared to standard treatment|resolution of pneumonia BY high resolution Computed tomography || Number of COVID-19 Participants With Notable Differences in the pCLE images in comparison with the pCLE images of non-COVID-19 Participants|Number of Participants With the Correspondence of pCLE Images to High Resolution Computer Tomography and Morphologic Data as a Measure of Specificity and Sensitivity of the Method || The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay || Number of participants completing plasma infusion for COVID-19|Number of participants intubated|Sequential Organ Failure Assessment (SOFA) score change|National Early Warning Score change|Ventilator-free Days|Intensive care unit-free Days|In hospital mortality|Angiopoietin 1&2 blood test|Soluble Tie2 blood test|Soluble Thrombomodulin blood test|Syndecan-1 blood test|Prothrombin time blood test|Partial thromboplastin time blood test|D-dimer blood test|Fibrinogen blood test|Thromboelastography blood test|Von Willebrand Factor Antigen blood test|Factor VIII blood test || To estimate the prevalence of SARS-CoV-2 IgG seropositivity among individuals in communities surrounding selected NIAID clinical research sites|To estimate prevalence of SARS-CoV-2 infection based on results of SARS-CoV-2 RNA testing|To estimate prevalence of SARS-CoV-2 infection by presence versus absence of symptoms consistent with COVID-19|To estimate seroprevalence of SARS-CoV-2|To assess correlation between demographic, clinical and social factors with SARS-CoV-2 infection and seroprevalence|To estimate potential size of populations for referral to COVID-19 prevention and treatment studies|To assess knowledge, attitudes, and behavior about SARS-CoV-2 and COVID-19 through a study questionnaire|To compare performance characteristics of PCR-based and serologic SARS-CoV-2 tests using saliva and/or oral fluid and DBS samples || Assessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE)|Preliminary Efficacy: Recovery from COVID-19 as determined by negative PCR or asymptomatic by the NIH classification for the severity of illness|Mortality|Preliminary Efficacy: To assess prevention of respiratory deterioration associated with COVID-19 by measuring the PaO2/FiO2 ratio|Hospitalization|Life support|Clinical status by the new NIH Patient Classification for the severity of illness|Clinical status by NEWS2|Support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale|Support measurements: improvement of severity rating on a 7-point ordinal scale|Virus Clearance|Exploratory: Serum cytokines/chemokines and immunomodulating factors|Exploratory: complete blood counts|Exploratory: Histone and cell-free DNA levels || Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor-α concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial || ICU outcome|Hospital outcome|Mechanical ventilation|Hospital complications || Nasal epithelial transcriptional response to SARS-CoV2|ACE2-AngII system || Rate of COVID-19 positive conversion|Time-to-first clinical event || sensitivity, specificity and accuracy|repeatability|validation|asymptomatic sensitivity, specificity and accuracy || Change of maximum oxygen uptake (VO2max) over time-points (baseline - 4 weeks - 8 weeks) assessed during cardio-pulmonary exercise testing (CPET)|Change of walking distance during a six minutes walk test (6MWT) over time-points (baseline - 4 weeks - 8 weeks)|Change of numbers over time-points (baseline - 4 weeks - 8 weeks) how often someone can stand up and sit down on a chair within 30 seconds during a 30-seconds sit-to-stand test (30secSTS)|Change of absolute body fat over time-points (baseline - 4 weeks - 8 weeks) via Bioelectrical Impedance Analysis (BiA)|Change of body fat percentage over time-points (baseline - 4 weeks - 8 weeks) via Bioelectrical Impedance Analysis (BiA)|Change of absolute Lean Body Mass (LBM) over time-points (baseline - 4 weeks - 8 weeks) via Bioelectrical Impedance Analysis (BiA)|Change of realtive Lean Body Mass (LBM) over time-points (baseline - 4 weeks - 8 weeks) via Bioelectrical Impedance Analysis (BiA)|Change of generalized anxiety measured over time-points (baseline - 4 weeks - 8 weeks) via Generalized Anxiety Disorder Scale-7 (GAD-7)|Change of depression measured over time-points (baseline - 4 weeks - 8 weeks) via the Patient Health Questionnaire-9 (PHQ-9)|Change of mental stress measured over time-points (baseline - 4 weeks - 8 weeks) via Perceived Stress Scale (PSS-10)|Change of fatigue measured over time-points (baseline - 4 weeks - 8 weeks) via Brief Fatigue Inventory (BFI)|Change of resilience measured over time-points (baseline - 4 weeks - 8 weeks) via Brief Resilience Scale (BRS)|Change and time kinetics of handgrip strength (HGS) over time-points (baseline and before each exercise session) measured via handgrip Dynamometer.|Change and time kinetics of physical and functional limitations of COVID-19 survivors over time-points (baseline and before each exercise session) via Post-Covid-19-Functional Scale (PCFS)|Change of work ability over time-points (baseline, 4 weeks, 8 weeks) via Work Ability Index (WAI) questionnaire.|Change of troponin (TnT) over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of BNP over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of CK-MB over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of HS-CRP over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of IL-6 over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of cholesterol over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of triglycerides over time-points (baseline - 4 weeks - 8 weeks) via blood sample. || Determination of the immunological parameters (Immunoglobins G) of the SARS-CoV-2 infection|Symptoms suggestive of COVID-19|Factors assumed to be related to infection with SARS-CoV-2 and the occurrence of moderate to severe forms of COVID-19 || Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure || Reduction in documented infection with COVID-19 Reduction in infection with COVID-19|Need for hospitalization|Hospital length of stay|Need for ICU admission|ICU length of stay|Need for mechanical ventilation|Duration of mechanical ventilation|Recovery time from COVID-19|Change in any existing comorbidities or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections|Change in lymphocyte subsets (CD4, CD8)|Mortality|Treatment-emergent adverse events|Treatment-emergent changes in vital signs|Treatment-emergent laboratory parameters || Proportion of patients with improvement in clinical status|Time to clinical improvement|Proportion of patients that reach a score of 6, 7 or 8 in the NIAID 8-point ordinal scale|Duration of hospitalization|SARS-CoV-2 PCR negativization rate|Proportion of patients with clinical improvement at day 7|Proportion of patients with immediate adverse events (< 24 hours)|Proportion of patients with late adverse events (1 - 28 days) || Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased (categorical) || Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality || Frequency of Hypercoagulability as measured by thromboelastography measured by TEG and platelet aggregation.|Frequency of High Platelet Reactivity (HPR)|Frequency of thrombo-inflammatory syndrome|Correlation between TEG6s parameters and clinical outcomes|Correlation between HPR and clinical outcomes|Determine response to anticoagulation therapy|Determine level of platelet aggregation|Determine platelet thrombi and fibrin rich platelet thrombus Area Under the Curve|Determine short and long IgG, IgM and IgG antibody levels || Hospitalization Rate|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|Rate of nasopharyngeal swab positivity in donors|Rate of donor titers level|Impact of donor titers level on efficacy|Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months. || negative testing of covid19 || Time to tracheal intubation (TTI)|First pass success rate|Total time of airway manipulation|Number of intubation attempts|Number of Operators needed for intubation|Number of alternative techniques used for intubation|Cormack-Lehane Grade for the first attempt of intubation|Lifting force applied on laryngoscope blade|Laryngeal pressure application|Vocal cord position|Anesthesiologist perception of intubation difficulty|Anesthesiologist perception of contributors to difficulty in intubation, if any|Patient acceptability of the COVID Barrier Box|Patient comfort with the COVID Barrier Box|Patient comments on the COVID Barrier Box || Mortality rate|Change in patients clinical manifestation|Length of hospitalization|C-reactive protein|Lymphocyte count|Serum lactate dehydrogenase|Serum Interleukin-6|Erythrocyte sedimentation rate || Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization || Reactive hyperemia index (RHI)|Percentage of COVID-19 patients with impaired endothelial vasodilator function.|Percentage of non-COVID-19 patients with impaired endothelial vasodilator function. || Composite of death and/or need for mechanical ventilation and/or admission to ICU|Occurrence of a clinical manifest cardiovascular event|Overall mortality and mortality rate|Risk stratification score to predict the primary endpoints || Clinical Outcomes of Patients with COVID-19 using the National Early Warning Score 2 (NEWS2) system|Clinical Outcomes of Patients with COVID-19 using the new NIH Patient Classification of severity of illness|Mortality|Cytokine/Chemokine/Hematopoietic Growth Factors/ Complement and Other Immune Modulators in Patients with COVID-19 || Proportion of participants who test negative for COVID-19|Time taken in days for relief of clinical symptoms|Proportion of participants with mild symptoms of COVID-19 progressing to moderate or severe illness|Proportion of participants who test positive for COVID-19 with Ct value>30 || Activation of platelet NLRP3 inflammasome || Biomarker|Protective factors|SmartWatch compliance|Arrhythmias|QT time changes|Longitudinal risk models || Intra-hospital mortality|composite outcome (worsening during hospitalization)|Pathologies leading to hospitalization|overall mortality at 3 months (90 days)|Potentially avoidable readmission rate|mortality rate by pathology at 3 months|length of stay|rate of transfer to intermediate or intensive care|rate of transfer to rehabilitation care|specific gravity outcomes for patients with pneumonia : CURB 65 scale (Confusion, Urea, Respiratory rate, Blood pressure, Age [>65])|specific gravity outcomes for patients with cardiac Failure : KILLIP class|specific gravity outcomes for patients with cardiac Failure : Weight variation|specific gravity outcomes for patients with cardiac Failure or lung disease|Leukocytes serum level|Polynuclear neutrophils serum level|Lymphocytes serum level|Hemoglobin serum level|Thrombocytes serum level|Quick serum level|INR (International Normalized Ratio)|fibrinogen serum level|PTT serum level (partial Thromboplastin time)|D-Dimers serum level|glucose serum level|glycated hemoglobin serum level (HbA1C)|C-reactive protein serum level (CRP)|sodium serum level|potassium serum level|chlorides serum level|calculated osmolality serum level|Phosphates serum level|corrected calcium serum level|urea serum level|creatinine serum level|eGFR (CKD-EPI) serum level|albumin serum level|prealbumin serum level|cyanocobalamin serum level|folate serum level|25-hydroxy vitamin D (D2 + D3) serum level|proBNP (Brain Natriuretic Peptid) serum level|Ultra sensitive Troponin T serum level|ASAT (aspartate transaminase) serum level|ALAT (alanine aminotransferase) serum level|Alkaline phosphatases serum level|Gamma glutamyl transpeptidase. serum level|Total bilirubin serum level|ferritin serum level|TSH serum level|Arterial pH|Arterial pCO2 (carbon dioxide partial pressure)|Arterial pO2 (oxygen partial pressure)|Arterial lactate|Arterial HCO3 (bicarbonate)|protein serum level|Arterial pressure|cardiac rates|respiratory rates|temperature|oxygen saturation|peak flow|specific scales : VAS of pain|specific scales : FIM|specific scales : SOFA score|specific scales : MNA|specific scales : NRS|serum or urine positive bacteriologic sample|Patient questionnaire || A list of COVID-19 specific TCR sequences|One or more measures from peripheral blood immunophenotyping that is/are associated with COVID-19 outcome|Group of COVID-19 specific TCR sequences that is associated with COVID-19 outcome || Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome|Evaluate the median duration of hospitalization.|Evaluate the evolution of systemic inflammation parameters.|Evaluate COVID-19 mortality rate|Evaluate the proportion of the requirement of mechanical ventilation.|Evaluate ruxolitinib adverse reactions|Evaluate the proportion of secondary infections during the treatment with ruxolitinib || Conversion from negative to positive COVID-19 test || Area under the curve of SARS-COV-2 viral load obtained from nasopharyngeal and /or oropharyngeal swabs.|Assessment of clinical improvement using an Ordinal Severity Scale|Evaluate oxygen saturation|Evaluate oxygen supplementation|Assess respiratory rate|Evaluate the PaO2 / FiO2 ratio (for patients on mechanical mechanisms)|Length of hospital stay|Length of stay in intensive care|Assess the rate of orotracheal intubation|Change in the profile of cytokines/chemokines in both groups|Presence of antibodies against SARS-CoV-2 in serum after convalescent plasma administration|Death rate|Rate of transfusion reactions to convalescent plasma infusion || Time to clinical improvement|Mortality|oxygen saturation by pulse oximetry (SpO2) Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events || The proportion of subjects in the study groups in whom, during the first 7 days after drug administration, one of the following events developed according to the laboratory-instrumental methods or on the basis of a clinical presentation|All-cause mortality|The elimination time of the SARS-CoV-2 virus|The median time to clinical improvement on the WHO Ordinal Scale for Clinical Improvement|The incidence of severe and extremely severe COVID-19 disease|The need for respiratory support|The need for invasive mechanical ventilation of the lungs, ECMO|Time to cancellation of oxygen support|The need to stay at the intensive care unit|Duration of fever (≥ 380C), days|The dynamics of the decrease in points on the NEWS scale|Dynamical CRP, ferritin, D-dimer values|Changes in the degree of lung lesion determined by the CT || Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events || Responses || Mortality|Severe disease || Geometric mean (GMT) of specific antibody|The incidence of adverse reaction (AR)|The incidence of adverse events (AE)|The incidence of severe adverse events (SAE)|The incidence of serious adverse events|Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies|The positive conversion rate of S-RBD protein-specific antibody|Geometric mean fold increase (GMI) of S-RBD protein-specific antibody|The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody|Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies || Severe Covid-19|Severe Covid-19 with pulmonary embolism|CRRT(Continuous Renal Replacement Therapy)|ECMO (Extracorporeal Membrane Oxygenation )|ICU Mortality || Physical functions|Respiratory function|Cognitive function|Depression status|Sensory functions|Heart function || Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Change from pre-dose baseline in RBC count|Change from pre-dose baseline in WBC count|Change from pre-dose baseline in Platelets count|Change from pre-dose baseline in Hemoglobin result|Change from pre-dose baseline in Creatine kinase result|Change from pre-dose baseline in Alanine aminotransferase (ALT) result|Time-weighted average changes in SARSCoV-2 RNA levels in nasopharyngeal swabs from baseline to Day 8|Duration of COVID-19 related symptoms through Day 29 among subjects with mild-moderate COVID-19|Proportion of subjects who have mild-moderate COVID-19 and develop severe COVID-19 after randomization|Assessment of PK parameters: maximum serum concentration observed (Cmax) || Sensitivity || Efficacy Measurs(Time to negative conversion in viral nucleic acid test(by RT-PCR) for diagnostic samples)|Safety Measurements : 90 of participants with treatment-related adverse events as assessed byCTCAE v5.0|PK Measures:AUC0-tau|PK Measures：Cmax|PK Measures：Tmax|PK Measures：t1/2|PK Measures：CL|PK Measures：Vd|Proportions of participants with negative conversion in viral nucleic acid test|Viral load change from baseline|Pulmonary CT（observe by imaging reports to degree of pulmonary inflammation, degree of vitreous fibrosis) || Percent of subjects return to room air (RTRA)|Percent of subjects who have recovered|Improved COVID-19 Clinical Classification|Return To Room Air (RTRA)|Percent of subjects who achieve clinical stability|SARS-CoV-2 RNA undetectable|Clinical Deterioration|Percent of subjects discharged|Death (all cause) || Among asymptomatic residents and caregivers in French nursing homes and geriatric healthcare institutions belonging to the UNIVI Group: prevalence of covid 19|Exposure to SARS Cov-2 Among asymptomatic residents and caregivers in French nursing homes and geriatric healthcare institutions belonging to the UNIVI Group|Recurrence of Covid-19 at 1, 3 and 6 months among residents and caregivers who had at least on positive test at inclusion (RT-PCR test or NB Biotech rapid serological test)|Risk factors for Covid-19 infection in caregivers|Covid-19 symptoms among residents|Prevalence of Covid-19 at 3 months || Change in incidence of laboratory-confirmed COVID-19 infection|Distribution of disease severity|Duration of symptoms in COVID-19 positive participants|Number of participants with COVID-19 positive IgG serology|Number of workday absences due to COVID-19 suspected/confirmed infection|Number of workday absences for any reason|Adverse health events || Eradication of SARS COV-2 from patients' respiratory tract secretions by treatment day 7th.|Comparative decrease of the viral load|Clinical improvement|Pneumonia patients meeting severity criteria.|Number of days with fever || COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications || All-Cause Mortality Rate|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Time to ICU Discharge|Duration of All Oxygen Use|Duration of Mechanical Ventilation|Absolute Value Change from Baseline in Ordinal Scale|Mean Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale || PK Outcome: Area under the plasma concentration-time curve (AUC) of RDV|PK Outcome: Half-life (t1/2) of RDV|PK Outcome: Trough concentration (Ctrough) of GS-441524|Safety Outcome: Maternal renal adverse event (AE) of any grade|Safety Outcome: Maternal hepatic AE of any grade|Safety Outcome: Maternal hematologic AE of any grade|Safety Outcome: Maternal Grade 3 or higher AE|Safety Outcome: Serious AE|Safety Outcome: Maternal Grade 3 or higher AE assessed as related to RDV by the Clinical Management Committee (CMC)|Safety Outcome: Pregnancy loss|Safety Outcome: Congenital anomalies|Safety Outcome: Preterm birth, defined as < 37 weeks|Safety Outcome: Preterm birth, defined as < 34 weeks|Safety Outcome: Small for gestational age, defined as < 10th percentile|Safety Outcome: Newborn birth weight|Safety Outcome: Newborn length|Safety Outcome: Newborn head circumference|PK Outcome: AUC of RDV|PK Outcome: t1/2 of RDV|PK Outcome: Ctrough of GS-441524|Safety Outcome: Renal AE of any grade|Safety Outcome: Hepatic AE of any grade|Safety Outcome: Hematologic AE of any grade|Safety Outcome: Grade 3 or higher AE|Safety Outcome: Grade 3 or higher AE assessed as related to RDV by the CMC || Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death || The safety of the candidate therapies in COVID-19 patients by measuring physiological changes in the circulatory and respiratory system.|The safety of the candidate therapies in COVID-19 patients by recording the number of treatment related adverse events.|Measuring the PK of the proposed trial treatments in COVID-19 patients.|Measure a change in the expression of key coagulation biomarkers in the blood of COVID-19 patients during and after treatment period.|Measure a change in the expression of key cytokines in the blood of COVID-19 patients during and after treatment period.|To evaluate the improvement or deteroriation of patients in each treatment arm.|To evaluate the number of oxygen-free days.|To evaluate incidence of any form of new ventilation use.|To evaluate ventilator-free days|Change in the ratio of the oxygen saturation to fraction of inspired oxygen concentration (SpO2/FiO2)|To evaluate SARS-CoV-2 viral load.|To evaluate time to discharge|To evaluate the use of renal dialysis or haemofiltration for each treatment arm. || Number of contaminated personnel|Number of symptomatic staff by occupational category and service|Number of contaminated personnel with effective protection|comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodies || The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (eucivirus neutralization assays)|The incidence of adverse reaction (AR)|The incidence of adverse events (AE)|The incidence of severe adverse events (SAE)|The Geometric mean titer (GMT) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays)|The Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays)|The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (pseudovirus neutralization assays)|The positive conversion rate of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody|The GMT of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody|The GMI of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody || Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19.|Time to clinical improvement|Frequency and severity of adverse events by CTCAE v5.0, (Key secondary endpoint)|Case fatality rate|Length of hospital stay Length of hospital stay (if applicable)|Length of stay in ICU|Duration of ventilation support / ECMO|Time until negative SARS-CoV-2 PCR (nasopharyngeal sample)|Predictive value of comorbidities|Predictive value of coagulation markers|Predictive value of inflamation|Percentage of former COVID-19 patients willing to donate qualifying for plasma donation.|Amount of Plasma Units that could be collected for the clinical trial|Titer of anti-SARS-CoV-2 in transfused plasma units|Impact of donor characteristics on anti-SARS-CoV-2 humoral response|Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes.|Effect of timing of plasma transfusions || Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma || Time-weighted average change in symptom score|Number of days with symptoms|Proportion of SARS-CoV-2 infected adults seeking non-scheduled care for COVID-19|Time to clearance of SARS-CoV-2 in upper respiratory specimens|Rate of change from the maximal viral load|Proportion of laboratory confirmed infections in SARS-CoV-2 uninfected adult contacts|Time-weighted average change from baseline viral load in SARS-CoV-2 uninfected contacts who become infected|Change in modified ordinal outcome scale|Change in IgM, IgG and neutralizing antibodies from baseline || Clinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale.|Change from baseline in C-reactive protein (CRP) concentration|Change from baseline in d-dimer concentration|Change from baseline in ferritin concentration|Change from baseline in fibrinogen concentration|Change from baseline in lactate dehydrogenase (LDH) concentration|Change from baseline in troponin concentration|Change in alanine aminotransferase (ALT) over time|Change in aspartate aminotransferase (AST) over time|Change in creatinine over time|Change in hemoglobin over time|Change in international normalized ratio (INR) over time|Change in platelets over time|Change in total bilirubin over time|Change in white blood cell (WBC) count with differential over time|Clinical efficacy, as assessed by time to recovery|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of study product administration|Duration of hospitalization|Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Duration of new non-invasive ventilation or high flow oxygen use during the study|Duration of new oxygen use|Duration of non-invasive ventilation/high flow oxygen use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of ventilator/ extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Oxygenation use|Proportion of subjects alive and without respiratory failure|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to death|Ventilator/ extracorporeal membrane oxygenation (ECMO) use || oxygen|adverse events || Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms) || Rate of seeking healthcare visits (including hospitalizations, emergency room visits, or ambulatory or virtual clinician visits) for symptoms or concerns related to COVID-19 or deaths in participants newly diagnosed with COVID-19 (index cases)|Rate of hospitalization/death or emergency room visits related to COVID-19 infection among index cases|Rate of hospitalization/death or emergency room visits related to COVID-19 in index cases with high risk for disease progression (defined as age 50 or older, or age 18-49 with at least one co-morbidity or risk factor)|Self-reported disease severity in index cases|Time to seeking healthcare (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) or death in index cases|ICU admission/ventilation support in index cases|SARS-CoV-2 infection in close household contacts|Time to symptom onset and self-reported disease severity in household contacts|Rate of healthcare visits (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) for symptoms or concerns related to COVID-19 infection or deaths among household contacts who contract COVID-19 || Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures || Sensibility and specificity|Delay between the first symptoms and the positive serological result || Change from pre-COVID-19 condition in ADL independence on the mod. Rankin scale score at the enrolment (T0) assessment, at 3, 6 and 12 months|Change from pre-COVID-19 condition in walking performance on the Walking Handicap scale (WHS) at 3, 6 and 12 months|Patient-reported health-related well-being perception on the 36-Item Short Form Survey - SF-36 at 3, 6 12 months follow-up|Change in global ADL disability on modified Barthel Index (mBI), from the enrolment (T0), at 3, 6 12 months follow-up|Change in walking capacity on Functional Ambulation Category (FAC), from the enrolment (T0) assessment, at 3, 6 12 months follow-up|Change in cognitive abilities on the Montreal Cognitive Assessment (MoCA) from the enrollment (T0) assessment, at 3, 6 12 months follow-up|Change in patient-reported pain on Numerical Rating Scale from the enrollment (T0) assessment, at 3, 6 12 months follow-up|Change in swallow abilities on Dysphagia Outcome Severity Scale (DOSS) from the first functional assessment in acute care, at 3, 6 12 months follow-up|Change in endurance on 6-Minutes Walking Test (6MWT) from the enrolment (T0) assessment, at 3, 6 12 months follow-up|Change in mood status on Beck Depression Inventory (BDI) from the enrolment (T0) assessment, at 3, 6 and 12 month follow-up || Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion|Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients. || Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 days || Symptomatic improvement|Peripheral blood oxygen saturation || 6 minute walk test distance|Patient reported outcomes and quality of life|Free-living physical activity and sleep quality || Descriptive-epidemiological analysis of health conditions|Evaluation of frailty condition|Identification of biomarkers of inflammation|Assessment of functional capacity|Evaluation of drug consumption|Evaluation of inflamma-miRs || Evaluation of clinical improvement of AZVUDINE (FNC) in COVID-19 treatment|Clinical cure outcome rate|Recovery of body temperature|Clinical improvement of diarrhea, myalgia fatigue and other symptoms|Assessment of inflammatory biochemical markers (Reactive C Protein, erythrocyte sedimentation rate, and Procalcitonin)|Assessment of immunological function biochemical markers (IL-6, IgG, IgM, IgA, and complement factor C3 and C4)|Assessment of renal function biochemical markers (serum creatinine and calculated glomerular filtration rate)|Assessment of liver function biochemical markers (AST/TGO, ALT/TGP, ALP, GGT, BIL total, and direct BIL)|Evaluation of time to negative conversion of SARS-CoV-2 viral load by RT-PCR|Evaluation of the number of cycles for the detection of SARS-CoV-2 viral load by RT-PCR and application of the standard curve for calculating viral load|Analysis of the relationship between the calculated viral load and the clinical evolution of the participants in the experimental group (FNC) and the PLACEBO group|Time for improvement of pulmonary condition by imaging exams during treatment|Evaluation of pulmonary condition by imaging exams during treatment|Time for clinical improvement of respiratory signs and symptoms|Assessment of clinical improvement of respiratory signs and symptoms|Time for normalization of O2 saturation|Respiratory rate evaluation|Frequency of supplemental oxygenation or non-invasive ventilation|Frequency of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Proportion of moderate cases that progressed to severe cases|Assessment of hospitalization time|Evaluation of drug interaction events frequency|Evaluation of drug interaction events intensity|Assessment of adverse events frequency|Assessment of adverse events intensity|Assessment of unexpected adverse events frequency|Assessment of unexpected adverse events intensity|Assessment of serious adverse events frequency|Assessment of serious adverse events intensity|Overall mortality rate|Evaluation of the tolerability of azvudine in the 5 mg regimen orally QD up to 14 days|Assessment of adherence of azvudine in the 5 mg regimen orally QD up to 14 days|Time of use of azvudine in the 5 mg regimen orally QD up to 14 days || Proportion of participants who have a post treatment seroresponse to the spike antigens of AZD1222|The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination|The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)|Biochemistry; change from baseline for blood chemistry measures|Haematology; change from baseline for hematology/hemostasis measures|Proportion of participants who have a post treatment|Genometric mean titres and genometric mean fold rise|Proportion of participants who have a post treatment seroresponse to AZD1222 as measured by SARS-CoV-2 nAbs|The incidence of serious adverse events (SAEs) and adverse events of specisl interest (AESIs) collected from Day1 through Day365 || Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate || Time to alleviation of COVID-19-related symptoms by Day 30|Percentage of patients with hospital admission or death by day 30|All-cause mortality by day 30|COVID-19-related mortality by day 30|Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID-19 by day 30|Percentage of patients with alleviation of COVID-19-related symptoms defined as symptom-free for a continuous period of more than 24 hours (ie, later than 3 AM/PM assessments) by day 7, by day 14, and by day 30|Time to hospital admission or death|Change from baseline in oxygen saturation levels|Change from baseline in COVID-19 viral load in nasopharyngeal sample at day 30 || Days alive without respiratory life support (invasive mechanical ventilation) at day 28.|Days alive and out of hospital on day 28 after randomisation.|Days alive at day 28 without life support (vasopressor/inotropic support, invasive mechanical ventilation or renal replacement therapy).|Number of participants with one or more SARs as described in section 6.1 plus incidence of new persistent nerve injury or grade 3 or 4 (full-thickness skin loss or worse) pressure wounds.|28-days all-cause mortality. || In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis || Clinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale.|Change from baseline in C-reactive protein (CRP) concentration|Change from baseline in d-dimer concentration|Change from baseline in ferritin concentration|Change from baseline in fibrinogen concentration|Change from baseline in troponin concentration|Change in alanine aminotransferase (ALT) over time|Change in aspartate aminotransferase (AST) over time|Change in creatinine over time|Change in hemoglobin over time|Change in international normalized ratio (INR) over time|Change in platelets over time|Change in total bilirubin over time|Change in white blood cell (WBC) count with differential over time|Clinical efficacy, as assessed by time to recovery|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of study product administration|Duration of hospitalization|Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Duration of new non-invasive ventilation or high flow oxygen use during the study|Duration of new oxygen use|Duration of non-invasive ventilation/high flow oxygen use|Incidence of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Mean change in the ordinal scale|Oxygenation use|Proportion of subjects alive and without respiratory failure|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to death|Ventilator/ extracorporeal membrane oxygenation (ECMO) use || Time to clinical improvement|Time to recovery|Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status|Proportion of patients with recovery as defined as the subject satisfies one of the following|Change of clinical status assessed by 7-category ordinal scale|Change in National Early Warning Score (NEWS)|Time to National Early Warning Score (NEWS) of ≤ 2 which is maintained|Duration of hospitalization|Duration of non-invasive ventilation or high flow oxygen use|Incidence of non-invasive ventilation or high flow oxygen use|Duration of supplement oxygen use|Incidence of supplement oxygen use|Duration of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|28-Day mortality || Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up. || Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 14 days|Severity of COVID-19 symptoms|ICU admission|Mechanical Ventilation|Mortality || COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score || Time elapsed until clinical improvement or hospital discharge|acute adverse events|Clinical Status|Duration of clinical events|SARS-CoV-2 in nasopharyngeal swab|IgG, IgM and IgA titers for SARS-CoV-2|Neutralizing antibodies || MRI brain abnormalities|Neurological Examination|Autonomic Testing || Measure level of Abs in asymptomatic close contacts of COVID 19 patients. || Post-acute COVID-19 disability from the care provider's perspective, 9 months after hospitalization|Post-acute COVID-19 disability from the care provider's perspective, 18 months after hospitalization|Post-acute COVID-19 disability from the care provider's perspective, 24 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 9 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 18 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 24 months after hospitalization|Type of treatments|Acceptable symptom state (questionnaire self-administered on ComPARe IT dedicated platform)|Health-related quality of life (questionnaire self-administered on ComPARe IT dedicated platform)|Pain (questionnaire self-administered on ComPARe IT dedicated platform)|Impairments, activity limitations and participation restrictions, health-related quality of life Fatigue (questionnaire self-administered on ComPARe IT dedicated platform)|Impairments, activity limitations and participation restrictions, health-related quality of life (questionnaires self-administered on ComPARe IT dedicated platform)|Urinary symptoms, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Female sexual dysfunction, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Erectile dysfunction, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Global activity limitations and participation restrictions (questionnaire self-administered on ComPARe IT dedicated platform)|Work Ability (questionnaire self-administered on ComPARe IT dedicated platform)|Work productivity (questionnaire self-administered on ComPARe IT dedicated platform)|Comorbidities (score completed by the investigator during a face-to-face visit)|Impairments, activity limitations and participation restrictions (checklist completed by the investigator during a face-to-face visit)|Mobility test to assess the consequences of neurological, cardiorespiratory, osteoarticular or respiratory impairments (clinical assessment by the investigator during a face-to-face visit)|Locomotor impairments (clinical assessment by the investigator during a face-to-face visit)|Upper extremities impairments (clinical assessment by the investigator during a face-to-face visit)|Respiratory impairment (clinical assessment by the investigator during a face-to-face visit)|Cognitive impairments (clinical assessment by the investigator during a face-to-face visit)|Muscular impairments (clinical assessment by the investigator during a face-to-face visit)|Respiratory impairments (clinical assessment by the investigator during a face-to-face visit)|Total costs|Costs drivers|Estimated Years lived with Disability|Burden of post-acute COVID-19 on participant's close relative|Resource utilization|Symptoms of anxiety and/or depression of participant's close relative|Symptoms of post-traumatic stress || Proportion x 100 = percent of patients with improved COVID-19 symptoms || To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population || Number of Households with New SARS-CoV-2 Infection by Day 28|Risk Factors Associated with Secondary Household Transmission|Number of Self-Swab Tests vs. NP Swabs at Day 1 with Detectable Viral Load || Time to clinical improvement|Time to viral clearance|Rate of clinical improvement at separate time points|Rate of viral clearance at separate time points|Time to body temperature normalization|Rate of resolution of lung changes on CT|Rate of adverse drug reactions (ADR) and serious ADR|Rate of severe ADR|Rate therapy termination due to ADR || Change in clinical state as assessed by a 6-point ordinal scale|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Time (days) to clinical improvement|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction (PCR) negativity|Percentage of patients with National Early Warning Score 2 of 3 or more || Survival|Length of ICU stay|Length of Hospital stay|Length of ventilator therapy|Adverse events || Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale|The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92%|Rate of non invasive ventilation (NIV) / high flow nasal therapy (HFNT) use|Rate of intubation|Ventilator-free days at day 28|Rate of ICU admission/length of stay/mortality|Severity index measurement || Physical health symptoms|Lack of physical health symptoms|Fever || The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.|The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms.|The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19.|The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms. || Viral shedding in days since initial diagnosis|Rate of adverse events and severe adverse events|Time to clinical recovery|Rate of non-invasive or mechanical ventilation|Length of hospital stay|All-cause mortality|Undetectable COVID-19 virus levels || To reflect the effect of COVID-19 on the burnout, anxiety, depression and stress levels of healthcare professionals during the COVID-19 crisis|To reflect the effect of COVID-19 on the post-trauma stress disorder levels of healthcare professionals following the COVID-19 crisis || Incidence of the AE in all groups|Seroconversion rate of the IgG antibody against SARS-CoV-2|Geomean titers of the IgG antibody against SARS-CoV-2|Seroconversion rate of the neutralizing antibody against SARS-CoV-2|Geomean titers of the neutralizing antibody against SARS-CoV-2|Incidence of Serious adverse events (SAE) in all groups|Cellular immune response by ELISpot|Geomean titers of neutralizing antibody response to Ad5-vector|Cellular immune response by ICS|Geomean titers of the IgA antibody against SARS-CoV-2 || Qualitative and quantitative parameters obtained by in silico modeling of intra-pulmonary vascular remodeling in 3D at 2-4 months.|Specific mechanical parameters of pulmonary parenchymal stiffness/localized compliances obtained by dynamic poromechanical modeling at 2-4 months. || Part A - SARS-CoV-2 viral load|Part B - Occurrence of hospitalizations, emergency room visits or death|Part A - Occurrence of hospitalizations, emergency room visits or death|Part A - Time to sustained clinical recovery|Part A - Serious adverse events (SAEs) and AEs of Special Interest (AESIs)|Part A - Vital Signs: Heart Rate (bpm)|Part A - Vital Signs: Blood Pressure Systolic and Diastolic (mmHg)|Part A - Vital Signs: Body Temperature (°C)|Part A - Vital Signs: Respiratory Rate (breaths per minute)|Part A - Vital Signs: Oxygen Saturation (SpO2)|Part A - Number of Participants with Laboratory Abnormalities|Part A - Free and total ensovibep concentration in serum (mass per volume units)|Part A - Observed maximum concentration (Cmax)|Part A - Time to Cmax (Tmax)|Part A - The area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Part A - The area under the concentration-time curve from time zero extrapolated to infinity time (AUCinf)|Part A - Terminal Elimination Half-Life (T½)|Part A - Terminal Elimination rate constant (λz)|Part A - The apparent volume of distribution during terminal phase associated with λz (Vz)|Part A - Apparent total body clearance of the drug from plasma (CL)|Part B - SARS-CoV-2 viral load|Part B - Time to sustained clinical recovery|Part B - Proportion of patients with treatment-emergent ADAs (TE-ADA)|Part B - SAEs and AESIs|Part B - Vital Signs: Heart Rate (bpm)|Part B - Vital Signs: Blood Pressure Systolic and Diastolic (mmHg)|Part B - Vital Signs: Body Temperature (°C)|Part B - Vital Signs: Respiratory Rate (breaths per minute)|Part B - Vital Signs: Oxygen Saturation (SpO2)|Part B - Number of Participants with Laboratory Abnormalities || Reduction in Participant Symptoms of COVID-19|Incidence of Treatment-Emergent Adverse Events|Rate of Hospitalization|Change in Oxygen Saturation|Change in Body Temperature || Adverse reactions/events rate|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIb|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIb|Serious adverse events|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ib|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ib|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ib|Level of IgG antibodies against SARS-CoV-2 Phase Ib|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIb|Level of IgG antibodies against SARS-CoV-2 Phase IIb || Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9 || Antibody titres to SARS-CoV-2 || Reduction in Respiratory Failure|Reduction in Cardiac/Circulatory Failure|Improvement in Oxygenation|Improved Clinical Outcomes || Blood pressure|Breathing sounds average power|Risk of aspiration|SaO2 level|Montreal Cognitive Assessment (MoCA) || mortality || Incidence of symptomatic rt-PCR-confirmed SARS-CoV-2 infection|incidence of Serology-confirmed infection with SARS-CoV-2|severity of COVID-19 disease|symptomatic respiratory infection|effect of prior adult immunization with other vaccines associated with trained immunity || Severity and death|Adverse events that require study treatment interruption|Time to clinical improvement|Antibodies against SARS-CoV-2|Disease progression 1|Disease progression 2|Time on mechanical ventilation|Number of days with fever|Adverse events attributed to the study intervention || Immune signature on admission : phenotypic profile of blood T-cells|Immune signature on admission : inflammatory cytokines|Dynamics of cellular immunity: CD4 and CD8 T cells|Dynamics of cellular immunity: gd T cells|Dynamics of cellular immunity: T cell transcriptomic analysis|Dynamics of cellular immunity: humoral immunity || Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples || Incidence of Serious Adverse Events (SAEs) post first dose until the study end|Incidence of unsolicited Adverse Events (AEs) for 28 days post each dose|Incidence of local and systemic solicited AEs for 7 days post each dose|Incidence of Adverse events of special interest (AESIs) post first dose until study end|assessment of time course of antibody to Spike protein of one IM dose of AZD1222 followed by one IM dose of rAd26-S|Determination of anti-SARS-CoV-2 neutralising antibody levels in serum following one IM dose of AZD1222 followed by one IM dose of rAd26-S|Proportion of participants who have a post treatment seroresponse || questionnaire to assess strength of correlation between current smoking and SARS-CoV-2 RT-PCR positivity|questionnaire to assess strength of correlation between current alternative nicotine delivery systems and SARS-CoV-2 RT-PCR positivity|questionnaire to assess strength of correlation between former smokers and SARS-CoV-2 RT-PCR positivity|questionnaire to assess strength of correlation between former alternative nicotine delivery systems and SARS-CoV-2 RT-PCR positivity || Development of an AI model to predict clinically relevant outcomes for ward-based patients with COVID-19 monitored for up to 20 days. Metrics to be employed depend on the algorithm used but include, Log-Loss, precision and/or recall and confusion matrix.|Performance of the wearable vital signs sensor as measured by the percentage of possible data capture that is actually obtained|Look for evidence of circadian disruption in the vital signs of the enrolled patients. || Time to confirmed clinical recovery|Number of participants who achieve oxygen-free recovery at Day 29|Number of participants who experience ≥2-point improvement from baseline or assessed as fit-for-discharge on the ordinal scale at Day 29|Incidence of all-cause mortality|Distribution of participants across the 8-point ordinal scale of clinical severity status scores at Day 8, Day 15 and Day 29|Worst post-baseline score on the 8-point ordinal scale of clinical severity status|Number of intensive care unit (ICU) days|Number of invasive mechanical ventilator days|Number of participants who achieve clinical recovery at Day 8, Day 15, and Day 29|Number of participants who achieve sustained clinical recovery at Day 60|Number of participants who experience one or more treatment-emergent adverse events (TEAEs)|Number of participants who experience one or more serious adverse events (SAEs)|Number of participants who experience one or more common terminology criteria for adverse events (CTCAE) grade 3 or higher|Number of participants who experience one or more adverse events (AEs) leading to dose modification|Number of participants who experience one or more adverse events (AEs) leading to discontinuation || Recovery time|Time of disappearance of fever symptoms|The rate of conversion from COVID-19 positive to COVID-19 negative|Time of disappearance of cough|Respiratory rate|Blood oxygen saturation|PaO2|PaCO2|The time of obvious improvement as shown on chest CT scans relative to admission|The rate of obvious improvement as shown on chest CT scans relative to admission|Levels of C-reactive protein|Erythrocyte sedimentation rate|Levels of Procalcitonin|Levels of interleukin-6|Levels of interleukin-10|Levels of tumor necrosis factor-alpha || Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature || Change in stress level as measured by survey|Change wellness as measured by survey || Measure the students' interest in studying anatomy on-line.|Assess the easiness of using technology during studying anatomy online|Assess the student satisfaction regarding the provided study materials || Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg || Oxygen supplementation|28-day and in-hospital mortality rate|Number of participants transferred to the Intensive Care Unit (ICU)|Number of participants intubated|Length of hospital stay in days|Type of respiratory support|C-reactive Protein (CRP)|Lymphocyte count|Length or respiratory support required, in days|Lactate dehydrogenase (LDH)|Ferritin|D-Dimer|White Blood Cell (WBC) Count || COVID-19 symptom occurrence and severity|COVID-19 treatments|Hospitalization || Primary outcome|Secondary outcome || Percentage of Participants with SARS-CoV-2 Viral Load Greater than 5.27|Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death|Change from Baseline to Day 7 in SARS-CoV-2 Viral Load|Percentage of Participants Demonstrating Symptom Resolution|Percentage of Participants Demonstrating Symptom Improvement|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3832479|Pharmacokinetics (PK): Mean Concentration of LY3819253 and VIR-7831 || Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity || Cumulative Incidence of Treatment-Emergent Adverse Events|Incidence of COVID-19 related hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality || Change from Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA|Time to Cessation of SARS-CoV-2 Viral Shedding|Time to Sustained Non-Detectable SARS-CoV-2 Virus RNA|Proportion of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints|Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA|Time to Alleviation or Improvement of COVID-19 Symptoms|Time to Alleviation of COVID-19 Symptoms|Duration of Fever|Frequency of COVID-19 Related Complications|Time to Alleviation of an Individual Symptom|Percentage of Participants with Adverse Events (AEs)|Plasma Concentration of AT-511, AT-551, AT-229 and AT-273 || To calulate the time of intubation|To calculate the time with oxygen therapy|To calculate the time with Non-invasive mechanical ventilation|To evaluate mortality rate|To calculate respiratory function parameters|To evaluate radiological lung extension|To evaluate radiological evolution|To describe the duration of hospitalization and ICU use|To evaluate the requirement of additional organ support|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory markers|To calculate the number of adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To assess time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity|To evaluate the effect of IV tocilizumab on the serum levels of inflammatory|To calculate the number of serious adverse events in patients with COVID-19 pneumonia treated with Tocilizumab|To calculate the number of adverse events of special interest in patients with COVID-19 pneumonia treated with Tocilizumab|To evaluate respiratory function || The proportion of subjects with clinical improvement score measured by an 8-point WHO COVID-19 Clinical Improvement Ordinal Scale as assessed by the odds ratio (OR) at Day 14.|The OR at Days 7, 21, and 28 based on the clinical improvement score (as measured by an 8 point WHO COVID 19 Clinical Improvement Ordinal Scale).|The OR at Days 7, 14, 21, and 28 of a decrease of at least 1, 2, 3, and 4 points in subjects with severe COVID 19.|Time to at least 2 point improvement from baseline on Days 7, 14, 21, and 28 in subjects with severe COVID 19.|Worsening (increase in clinical improvement score) of at least '1' score on Days 7, 14, 21, and 28.|Mortality by Days 7, 14, 21, and 28.|Duration of supplemental oxygen/ventilator support by Days 7, 14, 21, and 28.|Duration of intensive care unit stay by Days 7, 14, 21, and 28.|Duration of hospitalization by Days 7, 14, 21, and 28.|Ventilator free days by Day 14 and Day 28.|Days on ventilation. || Geographical distribution of the interventional studies after 11th of March 2020.|Geographical distribution of the Observational studies after 11th of March 2020.|Monthly Research study completion rate as per geographic distribution of the Research.|Statistical correlation of the interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the observational studies Research with developed, developing and under developed countries.|Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries. || 30-day mortality|Length of Intensive Care Unit (ICU) Stay in Days|Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|Number of major and clinically relevant non-major bleeding events || Incidence of SARS-CoV-2|Severity of disease in confirmed infected participants || Rate of Clinical Status Improvement|Time to Clinical Improvement|Rate of Viral Elimination by Day 10|Time Before the End of Fever|Change in the Level of Lung Damage According to CT|Rate of Transfer to the Intensive Care Unit|Rate of the Use of Non-invasive Lung Ventilation|Rate of the Use of Mechanical Ventilation|Mortality || The evaluation of clinical efficacy of the combination of metabolic cofactor supplementation and hydroxychloroquine|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Chest Tomography|ECG Measurement|Change of complete blood count from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in creatinine levels from baseline|Changes in D-dimer levels from baseline|Changes in ferritin levels from baseline|Changes in triglycerides levels from baseline|Changes in LDH levels from baseline || Evolution to severe progression of COVID-19|Need for admission to ICU.|Mortality rate.|Hospital admission rate|Delay to hospital admission|Average hospital stay|Need for invasive mechanical ventilation|Occurrence of major vascular events|Economic cost of the care derived from the episode for the social and health care system. || Day 28 Mortality|Clinical Status Assessment|Respiratory Failure Assessment|Treatment Survival|Treatment-Emergent Adverse Events || Gender Distribution of the Patients|Age Distribution of the Patients|Percentage of Patients With Accompanying Diseases|Percentage of Patients With Baseline Clinical Symptoms|Body Temperature Means of the Patients|Heart Rate Means of the Patients|Respiratory Rate Means of the Patients|Systolic and Diastolic Pressure Means of the Patients|Number of Participants With Clinical Response|Changes in Oxygen Saturation (SpO2) Values|Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)|Changes in Serum Lymphocyte Counts|Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)|Changes in Serum Ferritin Levels|Changes in Serum D-dimer Levels|Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism|Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Mortality|Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity || Venous thromboembolic events (VTE)|Mechanical ventilation free-survival|Major Adverse Cardiovascular Events (MACE)|Out-of-hospital death not attributed to major injury|Time from randomization to hospitalization|Length of Hospitalization|Hospitalization in Intensive Care Unit|Clinical requirement of mechanical ventilation|Clinical duration of mechanical ventilation|Composite vascular endpoint I|Composite vascular endpoint II|Major Bleeding|Mortality || Impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.|Hospital length of stay|30-Day Mortality|Resolution of Symptoms|Incidence of QTc >500ms after initiation of therapy|Incidence of discontinuation of therapy || intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event || Severity of COVID-19 Infection|Degree of severity of respiratory disease|Septic shock as defined by sepsis-3 criteria || Melatonin|Inflammatory cytokines|C-reactive protein (CRP)|Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route || Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.|Hospitalization status|Duration of hospitalization|NEWS2 Score|Mortality|SARS-CoV-2 nasopharyngeal viral load|Inflammatory markers|DHO Concentration|Brequinar Concentration || TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L) || Time-weighted Average Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation|Composite of All-Cause Medically Attended Visits (MAVs) (Medical Visits Attended in Person by the Participant and a Health Care Professional) or Death by Day 28|Composite of COVID-19 related MAVs or Death by Day 28|Proportion of Participants Hospitalized by Day 28|Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: AUClast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: CLss/F of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: t1/2 of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Vz/F of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Cmax of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Tmax of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Clast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Tlast of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: AUCtau of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: λz of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|PK Parameter: Ctau of RDV and its Metabolites (GS-441524 and GS-704277) in Parts A and B|Change in SARS-CoV-2 Viral Load From Baseline to Day 5|Change in SARS-CoV-2 Viral Load From Baseline to Day 7|Change in SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B|Time to Negative SARS-CoV-2 Polymerase Chain Reaction (PCR)|Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire || The proportion of adverse reactions (AR) up to Day 28 after prime and boost vaccination of the recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.|The proportion of adverse events (AE) within 7 days after each dose of the recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.|The proportion of abnormal markers of hematology, blood chemistry and urine analysis within 3 days after each dose of the recombinant SARS-CoV-2 vaccine (CHO cell) or placebo|The proportion of serious adverse events up to Month 12 after prime and boost vaccination.|The proportion of neutralizing antibody positive conversion rate, positive rate, GMT and GMI at Day 14, Day 21, Day 28, Day 42 after prime vaccination of recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.#Day 0, Day 14 vaccination program#|The proportion of IgG antibody positive rate at Day 14, Day 21, Day 28, Day 42 after prime vaccination of recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.#Day 0, Day 14 vaccination program#|The proportion of neutralizing antibody positive conversion rate, positive rate, GMT and GM at Day 28, Day 35, Day 42, Day 56 after prime vaccination of recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.#Day 0, Day 14 ,Day 28 vaccination program#|The proportion of IgG antibody positive rate at Day 28, Day 35, Day 42, Day 56 after prime vaccination of recombinant SARS-CoV-2 vaccine (CHO cell) or placebo.#Day 0, Day 14 ,Day 28 vaccination program# || Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events || Negative Polymerase Chain Reaction assay at day 0|Polymerase Chain Reaction assay at day 60|Clinical improvement related to COVID-19|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic Use|Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic|COVID-19 symptomatic onset rate || Time to clinical improvement|Rate of virological cure || Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours|Change in organ dysfunction|Lactate clearance|Renal replacement therapy|Extracorporeal Membrane Oxygenation|ICU length of stay|Time on mechanical ventilation|Cumulative catecholamine dose|Overall and ICU mortality|Change of plasma Interleukin-6 (IL6) level|Change of plasma Interleukin-10 (IL10) level|Change of plasma Procalcitonin (PCT) level|Change of HLA-DR level|Change of TNF alpha level after ex-vivo stimulation || Survival Outcome|COVID-19 Testing Methods|COVID-19 Clearance || Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 300ml convP therapy on hospital days|Impact of 300ml convP on weaning from oxygen therapy|Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways|Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer|Safety of convP therapy|Change of the 8-point WHO COVID19 disease severity scale on day 15|Change of the 8-point WHO COVID19 disease severity scale on day 30|Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80.|Impact of plasma therapy on risk of long-term structural lung damage and lung function || Evaluate the effect of RBT-9 versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale|Time to first occurrence of death from any cause or new/worsened organ dysfunction|All-cause survival|Oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio|Fever incidence|Acute kidney injury (AKI) incidence|New or worsening congestive heart failure (HF)|Hospitalization status|Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest|Oxygen-free days|Intensive care unit (ICU) status|Days on ventilator|Time to and duration of vasopressor or inotrope utilization|Dialysis status || Percentage of asymptomatic preoperative COVID-19 positive testing|Percentage of hospitalization per geographic area|Percentage of death per geographic area|ICU census per geographic area|Percentage of asymptomatic preoperative COVID-19 positive testing per geographic area || The primary endpoint is the difference in SARS-CoV-2 infection between the two groups after 1 months and is a combined endpoint consisting of primary outcome components 1, 2 and/or 3:|Positive oropharyngeal/nasal swab (PCR); || Incidence of confirmed COVID-19|Incidence of probable or suspected COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of the COVID-19 pandemic and the societal response on participants' financial status|Incidence of COVID-19 on participant's physical health|Impact of COVID-19 on participants' mental health|Impact of COVID-19 on physical health of offspring born to participants during follow-up || Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0 || Time to Release From Quarantine Time|Time to Hospital Discharge|Number of Health Care Workers Who Developed SARS-COV-2 Infection|Rate of Housemate Infection|Rate of Hospitalization || Incidence of SAEs following the first vaccination and throughout the study duration (Day 180) [Safety and Tolerability].|Incidence of Solicited AEs for 7 following each vaccination [Safety and Tolerability].|SARS-CoV-2 antigen-specific antibody levels|The rate of participants seroconverting from negative to positive SARS-CoV-2 S antigen|The rate of participants seroconverting from negative to positive SARS-CoV-2 N|Quantity of SARS-CoV-2 neutralizing antibodies|Count of peripheral blood mononuclear cells (PBMCs)|Quantity of seasonal coronavirus antigens|Quantity of antibodies to the ChAdOx1vector and the persistence of these antibodies over time || Lenght of hospital stay (days)|Number of Intensive Care Unit admissions|Variation of the Brescia COVID-19 Respiratory Severity Scale after treatment|Occurence of CTCAE 5.0 adverse events|Variation of the chest X-ray radiological findings according to Brixia scoring system || Percent change in C-reactive protein (CRP) levels in patients with serum IL-6 level greater than the upper limit of normal|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale|Proportion of patients who recover|Proportion of deaths|Proportion of patients alive not receiving mechanical ventilation|Proportion of patients alive not requiring extracorporeal membrane oxygenation (ECMO)|Proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale|Time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale|Time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale|Proportion of patients receiving mechanical ventilation|Proportion of patients receiving ECMO|Proportion of patients discharged and alive|Time to recovery|Time to death due to any cause|Number of ventilator free days|Proportion of patients with serious adverse events|Proportion of patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with hypersensitivity reactions|Proportion of patients with infusion reactions|Proportion of patients with gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level || Prevention of COVID-19 Complications or death: During the 30-day treatment period, time to first occurrence of new/worsened organ dysfunction during index hospitalization or death from any cause.|Improving clinical recovery: Hierarchical composite outcome measures including time to death from any cause through Day 30, new/worsened organ dysfunction, clinical status at day 30 and hospital discharge before Day 30 and alive at Day 30:|Time to hospital discharge|Total number of days alive and free from respiratory decompensation requiring initiation of mechanical ventilation (includes invasive or non-invasive ventilation, CPAP, or BiPAP)|Total number of days alive, not in the ICU, and free from respiratory decompensation requiring initiation of mechanical ventilation (includes invasive or non-invasive ventilation, CPAP, or BiPAP)|Time to composite of acute kidney injury or initiation of renal replacement therapy, or death from any cause|Time to death from any cause || Composite Endpoint of Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-cause Death by Day 28.|Proportion of Participants Experiencing Treatment-Emergent Adverse Events|Composite Endpoint of COVID-19 Related MAVs (Medical Visits Attended in Person by the Participant and a Health Care Professional) or All-cause Death by Day 28|All-cause Mortality at Day 28|Rate of Hospitalization by Day 28|Composite Endpoint of COVID-19 Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-cause Death by Day 14|Composite Endpoint of COVID-19 Related MAVs (Medical Visits Attended in Person by the Participant and a Health Care Professional) or All-cause Death by Day 14|Time-weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load from Baseline to Day 7|Time to Alleviation (Mild or Absent) of Baseline Coronavirus Disease 2019 (COVID-19) Symptoms as Reported on the COVID-19-adapted InFLUenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)|Proportion of Participants Progressing to Requiring Oxygen Supplementation by Day 28 || Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19 || Time to improvement in oxygenation|28-day mortality|Assessment of cytokine and inflammatory profile at baseline and at 48 hours after therapy|Qualitative and quantitative toxicity|incidence and duration of supplemental oxygen administration|Incidence and duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula|Incidence and duration of mechanical ventilation|Incidence and duration of vasopressor support|Incidence and duration of extracorporeal membrane oxygenation|Duration of fever|Correlation of cytokine profile to clinical outcomes specified in primary and secondary objectives|Duration of hospitalization|Secondary infections || All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate || Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization || Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis|Demographics and clinical characteristics|Laboratory parameters and radiography image features|Treatment, complications and clinical outcomes || Outcome 30 days after ICU admission || Sensitivity and Specificity || Primary endpoint: Disease Progression|Improvement in Hypoxic Index|Hospital Length of Stay|Days on invasive mechanical ventilation|Inflammatory Markers|Viral clearance|Radiological assessment|Safety of Imatinib || Immune signature|Dosage of cytokines and chemokines in plasma samples|Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity || Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality || Patients free of mechanical ventilation or death|Time of clinical improvement|Rate of change in phosphorylated CCR5|Rate of change in peripheral blood levels of proinflammatory cytokines and chemokines|Change in the trafficking and activation pattern of peripheral leukocytes || Change in Organ failure|Change in Organ Failure|All-cause mortality|Change in Viral load|Organ dysfunction-free days|ICU complications|Ventilator-free days (VFDs|Length of stay (LOS) at ICU|Prognosis Factors || Incidence of symptomatic fever >37.8, dry cough, or shortness of breath (resident/patient report or nurse observation) respiratory infection with confirmed PCR+ result for SARS-CoV-2.|Requirement for admission to acute care hospital and/or ICU admission or death|Asymptomatic PCR+ SARS-CoV-2 test result|Time to clinical recovery (TTCR). || Percentage of participants|Correlation of findings|Proportion of patients || Change in Primary symptom (cough)|Change in Primary symptom (Fever)|Time for Negative COVID-19 Test|Body temperature|white blood cells count|C-reactive protein test|ferritin test|Radiology|Quality of life assessment: || Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization || Clinical status using ordinal scale|Status of alive and not using mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Status of discharged or not requiring supplemental oxygen|Mortality || collecting and analyzing of DiaNose sensors signals from potential VOC markers in the breath samples of all subjects to build and validate a predictive algorithmic model for diagnosing COVID 19. || Acalabrutinib and ACP-5862 plasma PK parameter: AUC12h|Acalabrutinib and ACP-5862 plasma PK parameter: AUClast|Acalabrutinib and ACP-5862 plasma PK parameter: Cmax|Type, frequency, severity, and relationship to study intervention of any treatment-emergent AEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study intervention|Proportion of participants alive and free of respiratory failure at Days 14 and 28|Percent change from baseline in CRP at Days 3, 5, 7, 14, 28|Time to improvement- clinical improvement of ≥ 2 points(from first dose date)on a 9-point category ordinal scale Or live discharge from the hospital Or considered fit for discharge(a score of 0,1,or2 on the ordinal scale)whichever comes first,by Day 28 || Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2|Compliance with study drug administration|Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT) || COVID-19 disease incidence rate (symptomatic infections per month)|COVID-19 related hospitalization rate due to SARS-CoV-2|Case (disease) fatality risk (percent) due to SARS-CoV-2|Proportion asymptomatic infections, by age group|SARS-CoV-2 infection annual attack rate (percent)|SARS-CoV-2 infection fatality risk|Infection fatality of SARS-CoV-2 infection.|Serial interval number of SARS-CoV-2 infection|Reproduction number of SARS-CoV-2 infection|Correlation between anti-coronavirus (endemic coronavirus or SARS-CoV-2) antibody titers and reinfection|Antibody titers against SARS-CoV-2 over time || Population based data on spectrum and recovery from COVID-19 symptoms|Predictors of recovery. || Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge || Kirkpatrick level 3 on a 5-modalities Likert scale || Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS) || Perioperative transmission of SARS-CoV-2 || Time to sustained recovery through Day 29|Proportion of subjects achieving recovery status scores at Day 29|Proportion of subjects that die or develop respiratory failure by Day 29|Subject Clinical status|Proportion of subjects achieving at least one category improvement in clinical status|Proportion of subjects achieving at least two category improvement in clinical status|Time to at least one category improvement in clinical status|Time to at least two category improvement in clinical status|Time to a National Early Warning Score 2 (NEWS2) of </= 2 and maintained for 24 hours|Change from baseline in National Early Warning Score 2 (NEWS2)|Incidence of treatment-emergent adverse events|Incidence of treatment-emergent graded laboratory abnormalities || Time to recovery|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29|Incidence of mortality at Day 29|Incidence of in-hospital mortality|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29|Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29|Duration of mechanical ventilation|Duration of ECMO|Duration of noninvasive ventilation|Duration of ICU stay|Duration of hospital stay|Change in oxygen saturation || Response|Survival || In-hospital mortality|Incidence of renal replacement therapy|Incidece of adverse events || Study 1- Clinical and virological outcome in exposed contacts|Study 1- Transmission of SARS-CoV-2 in exposed contacts|Study 2- Virological outcome in index cases|Study 2- Clinical outcome in index cases || Time to recovery|Time to elimination of COVID-19 related symptoms|Mean number of days with mild COVID-19 related symptoms|Mean number of days with mild overall respiratory symptoms|Time to symptom reduction|Time to elimination of symptoms|Average number of days with mild respiratory symptoms|Oxygen saturation|Hospitalization rate|Mortality || lung injury score|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|d-dimers|Absolute lymphocyte counts|The immune correlates of protection against future exposure to SARS-CoV-2|Immunological profile|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Occurrence of adverse event related to immunoglobulins|IgG, IgA and IgM against COVID-19|ACE2 expression in patients with COVID-19 infection|All cause mortality rate [|Ventilation free days|ICU free days || subprophylactic anticogulation level || Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay || Proportion of patients with persistent COVID-19 symptoms for at least 12-weeks post-randomization in K031-120 or K032-120 study. || FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result. || Change from baseline in C-reactive protein (CRP) after treatment with C21 200 mg daily dose (100 mg b.i.d.)|Change from baseline in Body temperature|Change from baseline in IL-6|Change from baseline in IL-10|Change from baseline in TNF|Change from baseline in CA125|Change from baseline in Ferritin|Number of subjects not in need of oxygen supply|Number of subjects not in need of mechanical invasive or non-invasive ventilation|Time to need of mechanical invasive or non-invasive ventilation|Time on oxygen supply (for those not needing mechanical invasive or non-invasive ventilation)|Adverse events || Hospitalization rates for COVID-19|ICU Admission Rates|Invasive Ventilation Rates|Pneumonia || Overall survival|Clinical improvement|Time of COVID19 PCR negativity|Radiological improvement (day 15 and day 30 assessment)|days required to discharge from hospital || SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation|Clinical status on the seven-category ordinal scale || COVID-19 PCR status at completion of treatment (day 7) from tracheal aspirate || Percentage of Participants With Disease Progression at Day 28|Percentage of Participants With Disease Resolution at Day 28|Percentage of Participants Requiring Invasive Mechanical Ventilation or ExtraCorporeal Membrane Oxygenation (ECMO) or who are not Alive on Day 28|Change From Baseline in Oxygen use|Change From Baseline in Saturation of Oxygen (SpO2) percent (%)|Change From Baseline in Clinical Status Related to COVID-19|Percentage of Participants who Die (Mortality Rate) at Day 28|Percentage of Participants Testing Negative for COVID-19 at Day 28|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters, Electrocardiogram Findings and Physical Examination Findings|Plasma Concentrations of FSD201|Maximum Observed Plasma Concentration (Cmax) of FSD201|Area Under the Concentration-Time Curve (AUC) of FSD201|Elimination Half-Life (t1/2)|Apparent Total Body Clearance (CL/F) of FSD201|Apparent Volume of Distribution (Vz/F) of FSD201|Average Observed Plasma Concentration at Steady State (Cav) of FSD201 || Gather information on patients treated with hyperbaric oxygen therapy|Gather information on adverse events || predicitive value of noncoding RNAs in COVID-19 associated organ dysfunction || In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident ARDS (Adult Respiratory Distress Syndrome) and intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Death from any cause after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident stroke after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident heart failure after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident myocardial infarction after hospital admission with a confirmed COVID-19 diagnosis at follow-up || The seropositive rates of SARS-CoV-2 neutralizing antibody|The seropositive level of SARS-CoV-2 neutralizing antibody|The seropositive rates of SARS-CoV-2 IgG antibody (tested by ELISA)|Incidence of adverse reactions/events|Serious Adverse Events (SAE)|Level of SARS-CoV-2 IgG antibody (tested by ELISA)|The seropositive level of SARS-CoV-2 IgG antibody (tested by ELISA) || Burnout|Emotional Distress|Insomnia|Needs and difficulties in work situations || 10-point Likert scale|Participant adherence to the training dose|Participant adherence to the training intensity|Adverse effects|Rate of perceived exertion|Post COVID-19 Functional scale || PCR negative|Time from randomization to clinical recovery|Evaluate symptoms progression|Evaluate Faviparivirs effect|Evaluate Favipiravir's effect|Evaluate the safety of Favipiravir || Reducing the Time to Sustained Response|Reducing the Rate of Progression || Occurrence of adverse reactions (AR) within 7 days after each dose of the recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.|Occurrence of adverse events (AE) within 7 days after each dose of the recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.|Occurrence of AE up to Day 28 after prime and boost vaccination.|The proportion of SAEs up to Day 28 after prime and boost vaccination.|The proportion of SAEs up to Month 12 after prime and boost vaccination.|The proportion of abnormal markers of hematology, blood chemistry and urine analysis within 7 days before prime vaccination and at Day 3 after each dose of recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.|GMT of anti-RBD specific antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|Four-fold increase in anti-RBD specific antibody titers, at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|GMFI of anti-RBD specific antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|GMT of SARS-CoV-2 neutralizing antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|Four-fold increase in SARS-CoV-2 neutralizing antibody titers, at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.|GMFI of SARS-CoV-2 neutralizing antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after prime and boost vaccination.|Seroconversion rates of IFN-γ stimulated by the overlapping peptide library of S-RBD protein at Day 14, Day 28 after boost vaccination. || Serum IgG antibody levels specific for the SARS-CoV- 2 rS protein antigen(s)|Neutralizing antibodies from microneutralization assay|Blood levels of cytokines: TNF-α, IFN-γ, IL-2, IL-4, IL-5 and IL-6|Adverse events || Accuracy of nCapp COVID-19 risk diagnostic model || How vaccination and other attitudes are affected by COVID || Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function || Clinical|Virological|Symptom remission|Hospitalisation|Mortality|Biological variables || Time to cessation of oxygen therapy DNase I to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy hospitalized patients with COVID-19 and respiratory dysfunction.|28-day mortality|Number of Days alive and without ventilator treatment|Number of Days alive and without high flow nasal oxygen treatment (Optiflow)|Number of Days alive and free of stay in the ICU|Number of Days alive and outside hospital|Number of Days alive and free of a new episode and with oxygen saturation ≤93% after primary endpoint has been met|Number of Days alive and without need of supplemental oxygen|Number of patients with adverse reactions || ICU mortality|Duration of ECMO after start of CytoSorb|Duration of mechanical ventilatory support after start of CytoSorb|Duration of pharmacologic hemodynamic support after start of CytoSorb|Change in serum concentrations of inflammatory biomarkers after start of CytoSorb|Change in Pa02/Fi02 ratio after start of CytoSorb || Hospitalization|Uncontrolled asthma after ≥ 5 days of starting study medication|Pneumonia|Otitis media|Fever resolution time|Time to improve respiratory symptoms|Hospitalization in the Intensive Care Unit|Need for Orotracheal Intubation|Mechanical Ventilation Time|Mortality || Proportion of participants who progress by at least one level higher on the modified WHO ordinal scale by Day 14|Change in room air oxygen saturation (SpO2) from baseline over time|Change in National Early Warning Score (NEWS) 2 symptom score from baseline over time|Change from baseline on the modified WHO ordinal scale at each visit up to Day 28|Time to improvement of at least one level lower on the modified WHO ordinal scale|Time to progression of at least one level higher on the modified WHO ordinal|Number of participants with adverse events and serious adverse events || Hospital discharge - alive / death|Length of mechanical ventilation free days|Length of renal replacement therapy free days|Number of documented venous thromboembolism or arterial thrombosis || Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Proportion of patients with at least one (≥1) COVID-19-related hospitalization or all-cause death|Concentration of REGN10933 in serum over time|Concentration of REGN10987 in serum over time|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by RT-qPCR in saliva samples|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by RT-qPCR in nasal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Time to negative RT-qPCR in nasopharyngeal swabs with no subsequent positive RT-qPCR|Change from baseline in viral load at each visit, as measured by RT-qPCR in nasopharyngeal swabs|Change from baseline in viral load at each visit, as measured by RT-qPCR in saliva samples|Change from baseline in viral load at each visit, as measured by RT-qPCR in nasal swabs|Correlation of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Concordance of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Time-weighted average change from baseline in viral load (log10 copies/mL) from day 1 to post-baseline study days|Proportion of participants with ≥1 COVID-19-related medically-attended visit|Proportion of participants with ≥2 COVID-19-related medically-attended visit|Total number of COVID-19-related medically-attended visits|Proportion of participants admitted to a hospital due to COVID-19|Proportion of participants with ≥1 outpatient or telemedicine visit due to COVID-19|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Immunogenicity as measured by anti-drug (ADA) to REGN10933|Immunogenicity as measured by ADA to REGN10987|Immunogenicity as measured by neutralizing antibodies (NAbs) to REGN10933|Immunogenicity as measured by NAbs to REGN10987|Proportion of participants with high viral load at each visit|Proportion of participants with viral loads below the limit of detection at each visit|Proportion of participants with viral loads below the lower limit of quantitation at each visit|Proportion of participants admitted to an intensive care unit (ICU) due to COVID-19|Proportion of participants requiring mechanical ventilation due to COVID-19|Number of days of hospitalization due to COVID-19|Proportion of participants with all-cause mortality|Time to first onset of symptoms consistent with COVID-19 (asymptomatic cohort only)|Duration of symptoms consistent with COVID-19|Proportion of participants with ≥1 COVID-19-related hospitalization or all-cause death|Time to COVID-19 symptoms resolution|Proportion of participants with ≥1 COVID-19-related hospitalization, emergency room visit, or all-cause death|Proportion of patients with (≥1) COVID-19-related medically-attended visit or all-cause death|Proportion of participants with ≥1 COVID-19-related medically-attended visit by type of visit|Cumulative incidence of patients with ≥1 COVID-19-related hospitalization or all-cause death|Cumulative incidence of patients with ≥1 COVID-19-related hospitalization, emergency room visit, or all-cause death|Cumulative incidence of patients with ≥1 COVID-19-related medically-attended visit or all-cause death|Proportion of participants requiring supplemental oxygen due to COVID-19|Time to all-cause death|All-cause death || Incidence of SARS-CoV-2 clearance|Time to clearance of nasal SARS-CoV-2|Median quantity of SARS-CoV-2|Proportion of days with fever after randomization|Proportion of days with respiratory symptoms after randomization|FLU-PRO© Plus|Serious adverse events|Adverse events resulting in treatment discontinuation|Adverse events considered related to the investigational products|LRTI|Maximum score on WHO Ordinal Scale for Clinical Improvement during study participation|Cumulative incidence of hospitalization|Days of hospitalization|Cumulative incidence of mortality || EuroQol 5 Dimension 5 Level (EQ-5D-5L) visual analog score|WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)|EuroQol 5 Dimension 5 Level (EQ-5D-5L) overall utility index || Increased number of people recovering from COVID-19|Decrease number of patients that require respiratory support ,|Decrease duration of hospital stay || Clinical response|Side effects in the treatment group || occurrence of significant clinical degradation|occurrence of a severe form|occurrence of an orotracheal intubation|occurrence of an Acute Respiratory Distress Syndrom|average length of stay in hospital|mortality|evolution of the imaging parameters || Modified COVID Ordinal Outcomes Scale: Study Day 15|Modified COVID Ordinal Outcome Scale: Study Day 8|Modified COVID Ordinal Outcome Scale: Study Day 29|Proportion of patients hospitalized: Day 1 to 29|Time to hospitalization Day 1 to Day 29|Time to symptom resolution: Day 1 to Day 29|All-cause, all-location mortality: Day 1 to Day 29|Oxygen-free days: Day 1 to Day 29|Fever-free days: Day 1 to Day 29|Ventilator-free days: Day 1 to Day 29|ICU-free days: Day 1 to Day 29|Hospital-free days: Day 1 to Day 29 || Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline || Intubation or death|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE) || death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response || Heart failure|Tamponade|Pericardial Effusion|Myocarditis|Pericarditis|Arrythmias|Troponin I|N-terminal prohormone BNP|Stroke|Myocardial infarction|Shock|Deep venous thrombosis|Discharge disposition|Primary diagnosis|Rate of ICU admission/transfer|Total hospital length of stay|ICU length of stay|Percentage of patients in cohort that had EKG testing or Echocardiography || A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.|Time to clinical improvement|Inpatient mortality|Duration of hospitalization|Duration of intubation for mechanical ventilation.|Time to normalization of temperature.|Maximum severity of COVID19 illness.|A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization. || Rate of virological cure by Rt -PCR for COVID -19 using ivermectin when compared to standard treatment|resolution of pneumonia || Levels of senescent CD16+CD8+ T cells prior to COVID-19 disease and time to COVID-19 disease morbidity (antibody positvity). || Phase II first step: Change in the slope of SARS-COV 2 viral load|Phase II second step: Change in the slope of SARS-COV 2 viral load|Phase III: Number of free days from respiratory support || Time to Recovery|Achievement of Recovery|Overall Survival|Hospital Length of Stay|Clinical Response: Maximum Temperature (Tmax) Response|Clinical Response: Rate of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Duration of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Time to Non-Elective Invasive Mechanical Ventilation|Clinical Response: Rate of Vasopressor/Inotrope Utilization|Clinical Response: Duration of Vasopressor/Inotrope Utilization|Clinical Response: Time to Vasopressor/Inotrope Utilization|Clinical Response: Duration of Increased Supplemental Oxygen from Baseline|Biochemical Response: C-reactive Protein Response Rate|Safety: Rate of Secondary Infection || Proportion of subjects alive and discharged from the hospital.|Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).|Time to discharge from hospital.|Change from Baseline in Interleukin 6 (IL-6).|Incidence of treatment-emergent adverse events. || Safety index-incidence of adverse reactions|Immunogenicity index-seroconversion rates of neutralizing antibody|Safety index-incidence of serious adverse events|Immunogenicity index-seropositive rates of neutralizing antibody|Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody|Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody || 28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement || The relief of main symptoms/ disappearance rate of time|Chest CT absorption|Evaluation standard of comprehensive curative effect|Virus antigen negative conversion rate|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score || Proportion of participants who have died due to any cause|Number of Ventilator free days|Number of ICU free days|Oxygen free days|Vasopressor free days|Hospital free days|Improvement in the COVID-19 ordinal scale|Change in SOFA Score|Number of treatment-related adverse events || Clinical improvement|Mean change in the 7-point ordinal scale|Mortality|Time to resolution of fever|Clinical improvement or fever resolution|Tachyarrhythmias|Mortality or tachyarrhythmias|Time to clinical improvement from admission using the 7-point ordinal scale|Change in NEWS2 score|Duration of hospitalization|PO2/FIO2 || Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function || Measure the effect of COVID-19 pandemic on the academic performance of veterinary medical students|Measure the average studying time|Evaluate on-line education during COVID-19 pandemic lockdown|Evaluate on-line education in practical lessons during COVID-19 pandemic lockdown || Immune responses to components of SARS-Cov-2|Swabs for the presence of SARSCoV-2|Difference between the study groups in anti-SARS-CoV 2 seropositivity status || Knowledge about COVID-19 by questionnaire|Perception about COVID-19 by questionnaire|Attitude towards COVID-19 by questionnaire || Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)|Proportion progressing to respiratory failure or death (SARS-CoV-2 PCR positive)|All cause mortality|Proportion progressing to pneumonia.|Proportion progressing to severe pneumonia|Peak severity of illness|Safety and tolerability || Frequency of occurrence of Neutropenia ≥ grade 3|Frequency of occurrence of Thrombocytopenia ≥ grade 3|Frequency of occurrence of Anemia ≥ grade 3|Frequency of occurrence of Lymphopenia ≥ grade 3|Frequency of occurrence of CPK increase ≥ grade 3|Frequency of occurrence of Increase ALT and / or AST ≥ grade 3|Frequency of occurrence of Increase total bilirubin or direct bilirubin ≥ grade 3|Frequency of occurrence of Neurotoxicity ≥ grade 3|Frequency of occurrence of QT-QTc interval extension ≥ grade 3|Frequency of occurrence of Other adverse events ≥ grade 3|Percentage of patients in whom treatment cannot be completed.|Percentage of patients with adverse events.|Percentage of patients with serious adverse events.|Percentage of patients with ECG abnormalities.|Change in the viral load of SARS-CoV-2|Time to negative PCR test for COVID-19|Mortality|Percentage of patients requiring invasive mechanical ventilation and / or ICU admission|Percentage of patients requiring non-invasive mechanical ventilation|Percentage of patients requiring oxygen therapy || Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events || Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE) || Frequency of Adverse Events|Immune response against SARS-CoV-2 Spike protein|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination|Immunity against SARS-CoV-2 || Clinical improvement|Immune-inflammatory improvement|Mortality || Frequency of seroconversion to SARS-CoV-2|Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion|Hospital admission rate|ICU admission rate|Mortality rate|Incidents of AEs or SAEs related to HCQ upon study termination time || Clinical course on Day 15.|Clinical course on Day 3.|Clinical course on Day 8|Clinical course on Day 11.|Clinical course on Day 29.|Duration of treatment|Sepsis-related Organ Failure Assessment score|Duration without mechanical ventilation|Mortality|cumulative incidence of grade 3 and 4 adverse events (AEs). || Death|Viral load || The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time || Presence of immediate adverse events|Presence of solicited injection site reactions and systemic reactions|Presence of unsolicited adverse events|Presence of medically attended adverse events|Presence of serious adverse events (SAE) and adverse events of special interest (AESI)|Presence of out-of-range biological test results|Neutralizing antibody titer|Fold-rise in neutralizing antibody titer|2-fold and 4-fold rise in neutralizing antibody titer|Occurrence of neutralizing antibody seroconversion|Binding antibody concentration|Binding antibody concentration ratio|Fold-rise in binding antibody concentration (post/pre) ≥ 2 and ≥ 4|Neutralizing antibody titers at Day 91 to Day 387|Fold-rise in neutralizing antibody titer at Day 91 to Day 387|2-fold and 4-fold rise in neutralizing antibody titer at Day 91 to Day 387|Occurrence of neutralizing antibody seroconversion at Day 91 to Day 387|Occurrences of virologically-confirmed COVID-19-like illness|Occurrences of serologically-confirmed SARS-CoV-2 infection|Correlates of risk/protection based on antibody responses to SARS-CoV-2 || Change in Plasma Viscosity|All Cause Mortality|Bleeding and Thromboembolic Complications|Time to Treatment Failure|Duration of ICU Stay|Duration of Hospital Stay|Discharge Disposition|Change in Clinical Status|Change in Body Temperature|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Heart Rate|Change in Respiratory Rate|Change in Ventilator Days|Change in Ventilator Oxygen Percent (FiO2)|Change in Positive End-Expiratory Pressure (PEEP)|Change in Vasopressor Requirements|Change in Need for Treatment from a Registered Respiratory Therapist (RRT)|Change in Sequential Organ Failure Assessment (SOFA) Score|Change in Partial Pressure of Arterial Oxygen (PaO2)/Percentage of Inspired Oxygen (FiO2) Ratio|Change in Ventilatory Ratio|Change in White Blood Count (WBC)|Change in Hemoglobin (Hb)|Change in Hematocrit (Hct)|Change in Platelet Count|Change in Mean Platelet Volume (MVP)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Bilirubin|Change in Total Protein|Change in Albumin|Change in C-reactive Protein (CRP)|Change in Interleukin 6 (IL-6)|Change in Prothrombin Time (PT)|Change in International Normalized Ratio (INR)|Change in Activated Partial Thromboplastin Time (aPTT)|Change in Anti-factor Xa (anti-Xa)|Change in Fibrinogen|Change in D-dimer || Reactogenicity|Adverse events|Serious adverse events|IgG titre|Neutralizing antibody titre || Clinical improvement defined by the improvement of 2 points on a 7-category ordinal scale, at 14 days.|Proportion of patients free of oxygen at day 14 and 28|Proportion of patients discharged alive from hospital at day 14 and 28|Time to discharge for patients alive|Proportion of patients that were hospitalized to ICU or who died at day 14 and 28|14 and 28 day mortality rate|The time until weaning from oxygen therapy|The proportion of patients with clinical degradation of at least 1 point on the ordinal scale to 7 categories on D14 and D28 || IP-10 levels || Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Change from pre-dose baseline in RBC count|Change from pre-dose baseline in WBC count|Change from pre-dose baseline in Platelets count|Change from pre-dose baseline in Hemoglobin result|Change from pre-dose baseline in Creatine kinase result|Change from pre-dose baseline in Alanine aminotransferase (ALT) result|Time-weighted average changes in SARSCoV-2 RNA levels in nasopharyngeal swabs from baseline to Day 8|Duration of COVID-19 related symptoms through Day 29 among subjects with mild-moderate COVID-19|Proportion of subjects who have mild-moderate COVID-19 and develop severe COVID-19 after randomization|Assessment of PK parameters (Group A and B): maximum serum concentration observed (Cmax) || Participants with Solicited Adverse Events (AEs) - Phase 1|Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1|Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1|Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1|Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1|Serum IgG Antibody Levels Expressed as GMTs - Phase 2|Serum IgG Antibody Levels Expressed as GMFRs - Phase 2|Serum IgG Antibody Levels Expressed as SCRs - Phase 2|Participants with Solicited Adverse Events (AEs) - Phase 2|Participants with Unsolicited AEs - Phase 2|Participants with Unsolicited AEs - Phase 1|Participants with Abnormal Vital Signs - Phase 1|Changes from Baseline in Body Temperature - Phase 1|Changes from Baseline in Blood Pressure - Phase 1|Changes from Baseline in Pulse Rate - Phase 1|Participants with MAAEs - Phase 1|Participants with Related MAAEs; Serious Adverse Events (SAEs); and Adverse Events of Special Interest (AESI) - Phase 1|Assessment of Serum IgG Antibody Levels Expressed as GMTs at Multiple Time Points - Phase 1|Assessment of Serum IgG Antibody Levels Expressed as GMFRs at Multiple Time Points - Phase 1|Assessment of Serum IgG Antibody Levels Expressed as SCRs at Multiple Time Points - Phase 1|Assessment of Serum IgG Antibody Levels Expressed by Seroresponse Rates (SRRs) at Multiple Time Points - Phase 1|Angiotensin-Converting Enzyme 2 (ACE2) Receptor Binding Inhibition Assay Expressed as GMTs - Phase 1|ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs - Phase 1|ACE2 Receptor Binding Inhibition Assay Expressed as SCRs - Phase 1|ACE2 Receptor Binding Inhibition Assay Expressed as SRRs - Phase 1|Neutralizing Antibody Activity Expressed as GMTs - Phase 1|Neutralizing Antibody Activity Expressed as GMFRs - Phase 1|Neutralizing Antibody Activity Expressed as SCRs - Phase 1|Neutralizing Antibody Activity Expressed as SRRs - Phase 1|Assessment of Cell-Mediated (T helper 1 [Th1]/T helper 2 [Th2]) Pathways - Phase 1|Assessment of Serum IgG Antibody Levels Expressed as GMTs - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as GMFRs - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as SCRs (≥ 4-fold change) - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as GMTs at Multiple Time Points - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as GMFRs at Multiple Time Points - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as SCRs (≥ 4-fold change) at Multiple Time Points - Phase 2|ACE2 Receptor Binding Inhibition Assay Expressed as GMTs - Phase 2|ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs - Phase 2|ACE2 Receptor Binding Inhibition Assay Expressed as SCRs - Phase 2|Neutralizing Antibody Activity Expressed as GMTs - Phase 2|Neutralizing Antibody Activity Expressed as GMFRs - Phase 2|Neutralizing Antibody Activity Expressed as SCRs (≥ 4-fold change) - Phase 2|Assessment of Serum IgG Antibody Levels Expressed as GMTs - Phase 2 Boost|Assessment of Serum IgG Antibody Levels Expressed as GMFRs - Phase 2 Boost|Participants with MAAEs - Phase 2|Participants with Related MAAEs; SAEs; and AESIs - Phase 2|Participants with Abnormal Vital Signs - Phase 2|Changes from Baseline in Body Temperature - Phase 2|Changes from Baseline in Blood Pressure - Phase 2|Changes from Baseline in Pulse Rate - Phase 2|Participants with SARS-CoV-2 Positivity - Phase 2|Assessment of SARS-CoV-2 by Qualitative PCR - Phase 2|Assessment of Cell-Mediated (Th1/Th2) Pathways - Phase 2 || Dyspnea|Chest expansion|Fatigue severity|Visual Analog Scale for pain|Hospital anxiety and depression scale || Changes on eicosanoid lipid mediators|Changes on plasma levels of a panel of 40 human cytokines and chemokines|Severe clinical outcome || Transfusion-related Serious Adverse Events|All-cause in-hospital mortality|Length of hospital stay|Length of ICU stay|Need of invasive mechanical ventilation|Duration of mechanical ventilation|Clinical Improvement at 14 days || SARS-CoV-2 related hospital admission|the duration of hospital admission due to documented COVID-19|the cumulative incidence of documented SARS-CoV-2 infection|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented SARS-CoV-2 infection|the cumulative incidence of hospital admission for any reason|the cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection || real time reverse transcriptase quantitative PCR|ct values || Time to elimination of SARS-CoV-2 virus|Time to CRP normalization|Time to D-dimer normalization|Time to body temperature normalization|Change in absolute neutrophil count (ANC)|Change in white blood cells (WBC)|Change of CRP|Change of D-dimer|Change in fibrinogen|Change of Quick's value|Change of international normalized ratio (INR)|Changes of lung injury on CT scan|Frequency of clinical status improvement by 2 scores in accordance with the WHO-OSCI or discharge from the hospital|Frequency of deterioration of the patients' status|Frequency of AEs and SAEs || Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause|Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load|Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold|Pharmacokinetics (PK): Area Under the Concentration-time Curve from 0 to Infinity (AUC0-inf) for both LY3819253 and LY3832479|Percentage of Participants who Experience a Serious Adverse Event(s) SAE(s)|Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization|Percentage of Participants Demonstrating Symptom Resolution|Percentage of Participants Demonstrating Symptom Improvement|Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479|PK: Mean Concentration of LY3832479 in the Presence of LY3819253|Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death from Any Cause|Change from Baseline to Day 7 in SARS-CoV-2 Viral Load|Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization or Death from Any Cause|Time to Sustained Symptom Resolution|Time to SARS-CoV-2 Viral Clearance || Incidence of MAAEs and SAEs|Incidence and severity of solicited local reactogenicity AEs|Incidence and severity of solicited systemic reactogenicity AEs|Incidence and severity of unsolicited AEs|Incidence of abnormal changes of laboratory safety examinations|Vital Signs - Fever|Vital Signs - Tachycardia|Vital Signs - Bradycardia|Vital Signs - Hypertension|Vital Signs - Hypotension|Vital Signs - Respiratory Rate|GMFR in IgG titer|GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus|Percentage of subjects who seroconverted|GMFR in neutralizing antibody|GMT|Seroconversion rate of neutralizing antibody|CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein|CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein || Clinical deterioration or death || Registry Data || Need for hospitalization|Duration of hospitalization|Need for ICU/Ventilator Support|Duration of ICU/Ventilator Support|Overall Survival || To determine SARS-CoV-2 viral load and infectivity insaliva that may contribute to asymptomatic transmission || Proportion of patients developing severe ARDS.|All-cause mortality.|Percentage of patients requiring tracheal intubation, use of Non-invasive Ventilation NIV or High Flow Nasal Cannula (HFNC) devices during the study period|Percentage of patients who progress to severe ARDS, death or ICU admission.|Differences in Time to Clinical Improvement|Change in clinical status of subject on a 7-point ordinal scale.|Percentage of patients requiring immunosuppressive/immunomodulatory treatment as a rescue medication.|Proportion of patients developing adverse effects, serious adverse reactions, laboratory or physical examination findings, EKG abnormalities acquired during the trial, death and adverse events leading to early discontinuation of treatment. || Proportion of participants with disease progression from randomization to 28 days post-randomization|Proportion of participants with all-cause mortality|Proportion of participants who transfer to ICU level care by Day 28 (ICU level care is defined as a hospital setting where patient to nurse ratio is < 4);|Proportion of participants with a new onset of neurologic disease (requiring medical intervention), including stroke by Day 28;|Proportion of participants with evidence of new CHF or new MI requiring medical intervention by Day 28;|Proportion of participants with a new onset embolus or thrombus by Day 28;|Proportion of participants who develop a need for renal replacement therapy (defined as need for any type of dialysis including intermittent or continuous peritoneal or hemodialysis) by Day 28;|Proportion of participants with an increase in the WHO Ordinal Scale of Clinical Improvement score at any time during the study;|Length of hospital stay defined as the number of days in hospital from time of randomization to time of discharge or death, whichever occurs first;|Change from baseline in inflammation markers over time. || Tolerability of high dose leflunomide as measured by leflunomide dose modifications|Tolerability of high dose leflunomide as measured by discontinuation of leflunomide|Tolerability of high dose leflunomide as measured by Adverse Events|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol || The proportion of patients with a two-point change using the 8-category ordinal scale|All-Cause mortality|Time to a 2-point clinical change|Hospitalization|Duration of ECMO or invasive mechanical ventilation|Duration of ICU stay|SARS-CoV-2 negative|Negative oropharyngeal or nasopharyngeal swab|Serious adverse events (SAEs)|Discontinuation due to adverse events || Characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)|Characterise prevalence and severity of organ volume change and damage (lung, pancreas and spleen)|Change from Baseline in liver-specific biomarkers: volume, iron corrected T1(cT1), fat content and T2star|Change from Baseline in organ-specific biomarkers characterising organ volume change in the heart and spleen along with organ volume and damage in the kidney, liver and pancreas assessed by volume, iron corrected T1 (cT1) and fat infiltration|Change in patient reported outcome measured by the Dyspnea-12 questionnaire|Change in patient reported outcome measured by the St. George's Respiratory questionnaire (SGRQ)|Change in patient reported outcome measured by the EQ-5D-5L questionnaire|Degree of change in liver MR-derived biomarkers || Proportion of participants developing acute hypoxemic respiratory failure or all-cause death|Time (in days) to recovery|Time (in days) to death or respiratory failure|Proportion of patients who died from any cause, had respiratory failure, or required humidified heated high-flow nasal cannula (HHHFNC) at 15 Lpm|Time (in days) to death or respiratory failure or HHHFNC at 15 Lpm|Subject 28-day all-cause mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Participant's clinical status by ordinal scale|Mean change in the ordinal scale|Time to discharge or to a National Early Warning Score (NEWS)-2 of = 2 and maintained for 24 hours, whichever occurs first|Change in NEWS-2 Score from Day 1 (baseline) to Days 2, 4, 7, 11, 15, and 29|Duration of hospitalization|Number of hospitalizations related to COVID-19|Cumulative incidence of Serious Adverse Events (SAEs)|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Incidence of discontinuation or temporary suspension of study product administrations (for any reason)|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in total bilirubin|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in prothrombin time (PT) || Safety-oxygen, ICU transfer and ventilation|Safety-changes in absolute lymphocyte count|Safety-changes in creatinine clearance|Safety-secondary bacterial infections|Laboratory measurements of safety and antiviral efficacy related to COVID-19-SARS-CoV-2 by measuring the clearance of SARS-CoV-2 from respiratory secretions|Laboratory measurements-D-dimer levels|Laboratory measurements-ferritin|Laboratory measurements- IL-6 || Change in clinical conditions|Change of Clinical symptoms - respiratory rate|Hypoxia|Changes of blood oxygen|Inflammatory parameters|Evolution of Acute Respiratory Syndrome|Hospital discharge|ICU discharge|Rate of mortality || Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive|Rate of patients hospitalized|Percentage of patients reporting each severity rating on a 7-point ordinal scale|Change from enrolment in inflammatory markers in plasma and in immune phenotype and assessment of cell-activation markers in PBMCs|Rate of patients requiring oxygen supplementation|Time to hospitalization|Time to assisted ventilation and oxygen supplementation|Change from baseline in microRNA-124 levels|Change from baseline in CRP, Troponin I & T and D-dimer|SARS-CoV-2 viral load|Number and rates of participants with Treatment Emergent Adverse Event || Length of hospitalization|Mortality|Number of cases admitted to Intensive Care Unit (ICU)|Length of use of mechanic ventilator|Number and severity of symptoms|Inflammatory markers|C-reactive protein|Vitamin D|Creatinine|Calcium|Physical activity || Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence|Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.|Preliminary safety and efficacy evaluation of N-803 by changes in lymphocyte counts|Further evaluate efficacy of N-803 using changes to the National Early Warning Score (NEWS)|Further evaluate the safety of N-803 using change from baseline in hemoglobin|Further evaluate the safety of N-803 using change from baseline in platelets|Further evaluate the safety of N-803 using change from baseline in white blood cell count || Collection of convalescent plasma || Adverse reactions/events rate|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Serious adverse events|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) || Incidence of adverse events|Incidence of laboratory abnormalities|Incidence of anti-drug antibodies|Proportion of patients requiring intubation|Percentage of days requiring supplemental oxygen|Overall survival (OS) || Incidence of adverse reactions/events|Serious Adverse Events (SAE)|Incidence of abnormal indicators of laboratory safety examinations(including blood routine, blood biochemistry, urine routine and coagulation function)|The seropositive rates of SARS-CoV-2 neutralizing antibody|The seropositive level of SARS-CoV-2 neutralizing antibody|The seropositive rates of SARS-CoV-2 IgG antibody(tested by ELISA)|The seropositive level of SARS-CoV-2 IgG antibody(tested by ELISA)|The proportion of IFN-γ positive cells (by ELISpot)|Level of IL-2、IL-4、IL-5、IL-6、TNFα、IFN-γ (by ELISA) || Western blot measurement of ACE2 receptor expression in porcine cells || IL6 concentration|IL6 concentration change from baseline value|Complement parameters|Complement parameters change from baseline values|Inflammatory cytokines baseline concentrations|Inflammatory cytokines change from baseline values|Concentration of markers of macrophage activation|Markers of macrophage activation change from baseline values || Clinical improvement || Length of stay in ICU|Mortality|Complications || Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5. || Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.|All-cause death|Composite outcome of ICU admission or all-cause death|Composite outcome of mechanical ventilation or all-cause death|Major bleeding|Number of participants who received red blood cell transfusion|Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.|Renal replacement therapy|Number of hospital-free days alive up to day 28|Number of ICU-free days alive up to day 28|Number of ventilator-free days alive up to day 28|Number of organ support-free days alive up to day 28|Number of participants with venous thromboembolism|Number of participants with arterial thromboembolism|Number of participants with heparin induced thrombocytopenia|Changes in D-dimer up to day 3 || CRPxN/R ratio change|Clinical deterioration by the WHO definition|PCR Viral Load|CT severity involvement index|LDH change || Time to viral clearance|Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15|Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2)|Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax)|Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin|Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC || Health status (WHO classification)|Incidence of Serious Adverse Events|COVID-19 prevalent symptoms at onset|COVID-19 Prognostic Factors|Incidence of COVID-19 in the RSA cohort|Affective/mood state change from baseline in the "" At home "" cohort|Cognitive function in the ""Dementia"" and ""At home "" cohorts|Daily Life Function in the ""Dementia"" and ""At home "" cohorts|Instrumental Daily Life function in the ""Dementia"" and ""At home "" cohorts|Residual signs and symptoms in the "" Outcomes "" cohort|Incidence of outcomes in the "" Outcomes "" cohort per Frailty Status|Incidence of outcomes in the "" Outcomes "" cohort per Comorbidity burden at baseline || Change of serum creatinine|Number of participants requiring intubation and ventilatory support|Change in number of deceased participants|Number of participants requiring dialysis|Number of participants requiring a vasopressors|Change in blood inflammatory markers|Percent change in supplemental oxygen requirements || Patient Disposition Post treatment|oxygenation|IL-6 levels|Chest Xray radiographic results|Brescia-COVID Respiratory Severity Scale|SMART-COP Score|PSI Score|CRP levels || lung injury score|Serum ferritin|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap || Hospitalization || Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events || Incidence of treatment-emergent adverse events|Incidence of solicited injection site reactions (IM injection only)|Viral load >5 (log10 copies/mL) on Day 7 (+/- 1) based on nasopharyngeal sampling|Incidence of COVID-19 related hospitalizations or all-cause death|Incidence of COVID-19 -related medically attended visits|Incidence of COVID-19 -related emergency room visits, hospitalization, or all cause-death|Incidence of severe/critical COVID-19 or all cause death|Time to sustained recovery defined as sustained improvement or resolution of COVID-19 symptoms|Incidence of all-cause mortality|Change from baseline in SARS-CoV-2 viral load (log10 copies/mL) assessed by RT-qPCR from saliva samples (and NP samples for Day 7)|Duration of SARS-CoV-2 shedding assessed by RT-qPCR from saliva samples|SARS-CoV-2 clearance assessed by RT-qPCR from saliva samples (and NP samples for Day 7)|SARS-CoV-2 viral load assessed by RT-qPCR from saliva samples|Incidence of treatment emergent adverse events|Assessment of PK Parameter: Cmax for ADG20|Assessment of PK Parameter: Time to Cmax (Tmax) for ADG20|Assessment of PK Parameter: Area under the curve for ADG20|Assessment of PK Parameter: Half-life of ADG20|Assessment of PK Parameter: Clearance of ADG20|Assessment of PK Parameter: volume of distribution of ADG20|Incidence of ADA to ADG20 || Laboratory determination of presence of anti-SARS-COV2 antibodies (IgM, IgA, and IgG) || New-onset cardiac arrhythmia|Elevation of NT-proBNP|Left ventricular dysfunction || Frequency of complete symptom resolution after 2 weeks of dietary supplementation|Frequency of complete symptom resolution after 4 weeks of dietary supplementation|Time from diagnosis to complete symptom resolution [days]|Frequency of freedom from fatigue after 2 weeks of dietary supplementation|Frequency of severe COVID-19 (examination in an emergency department / hospitalisation with requirement for oxygen (at least 24 h), intensive care or ventilation / death by COVID-19) || Questionnaire|Physiologic assessment|Surgical follow-up || The 6-month cumulative incidence of acquired COVID infection in the study cohort. || Tolerability of high dose HCQ as measured by HCQ dose modification|Tolerability of high dose HCQ as measured by discontinuation of HCQ|Tolerability of High Dose HCQ as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol || Plasma IL-1Ra levels|Plasma IL-6 levels|Plasma markers|Safety Endpoints related to the Serious adverse reactions of the IMP|Safety Endpoints related to the anaphylactic reactions of the IMP|Safety Endpoints related to neutropenia caused by the IMP|Safety Endpoints related to any severe laboratory abnormalities|Feasibility endpoints related to IMP and deviations|Exploratory Data on Clinical efficacy by time to recovery|Exploratory Data on Clinical efficacy|Exploratory Data on Clinical efficacy of the ordinal scale || In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit || Outcome comparison between different antiviral therapies|Outcome comparisons between ventilation types|Identification of risk factors|Number of days in hospital vs. clinical classification || Time to Recovery || Seroconversion during pregnancy - DSS1|Seroconversion during pregnancy - At delivery|Pregnancy loss|Pregnancy course and perinatal outcome|Vertical transmission|Potential mechanisms for vertical transmission 1) placental barrier, 2) immune response and 3) fetal damage of vertical transmission and mechanism in SARS-CoV-2 infection. || Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: IL-6|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: ferritin|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: c-reactive protein (CRP)|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: D-dimer|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: neutrophil/lymphocyte ratio|Change in biomarkers thought to be associated with progression of COVID-19 compared to baseline: lactate dehydrogenase (LDH)|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Time to each of the individual endpoints of the composite primary outcome measure|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All-cause mortality at day 28|Time to clinical improvement || Percentage of Subjects Dying or Requiring ICU Admission|Percentage of Subjects Who are Dependent on Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Subjects in Each Severity Category of the 7-Point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Subjects who Sustained Normalization of Temperature|Number of Subjects who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression|Mortality Through Day 29 || Proportion of Participants Alive Who Never Received Mechanical Ventilation and/or Extracorporeal Membrane Oxygenation (ECMO)|Proportion of Participants Alive, Discharged Home, and Not on Supplemental Oxygen|Time to Recovery as Based on a Modified 8-Point Ordinal Scale|Days in Intensive Care Unit/Critical Care Unit (ICU/CCU) (Either on or off Mechanical Ventilation and/or ECMO)|Days on Mechanical Ventilation and/or ECMO|Time to Death from Any Cause|Changes in Pressure of Arterial Oxygen to Fractional Inspired Oxygen Concentration (PaO2/FiO2) Ratio, Both as Categorical and Continuous Variables|Change in Resting Peripheral oxygen saturation (SpO2) Adjusted by FiO2|Change in (Non-invasive) Oxygen Supplementation Requirements || Antibody seroconversion rate (≥ 4-fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination.|Incidence of local and systemic solicited AEs for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination).|Incidence of unsolicited AEs, SAEs and AESIs through 29 days post each vaccination (ie, until Day 29 following the first vaccination and Day 57 following the second vaccination).|Incidence of SAEs and AESIs after first vaccination until study end (Day 180).|Antibody seroconversion rate (≥ 4-fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post first vaccination.|Antibody seroconversion rate (≥ 4-fold increase from baseline) against RBD antigen.|GMT and GMFR of immunogenicity against Spike and RBD antigens (MSD serology assay) at the day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).|Antibody seroconversion rate (≥ 4-fold increase from baseline) SARS-CoV-2 neutralising antibodies.|GMT and GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180). || Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Length of Time to Clinical Progression|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS) || Cumulative incidence of SAEs through day 30|Cumulative incidence of grade 3 or 4 AEs through day 30|Incidence of discontinuation of therapy (for any reason)|Severe disease progression composite outcome|Cumulative incidence of events|Hospital length of stay|Days of fever|Days of non-invasive ventilator use|Days of non-rebreather mask oxygen supplementation|Score on Cytokine Release Syndrome (CRS) Grading Scale|Percentage of subjects reporting each severity score on 8 point ordinal scale Day 1 and EOT (End of Treatment - Day 6)|Percentage of subjects with qTC prolongation at EOT|Cumulative Incidence of mortality|Cumulative Incidence of ICU admission|Cumulative Incidence of Invasive mechanical ventilation|Cumulative Incidence of ECMO|Cumulative Incidence of hypotension requiring vasopressor support|SARS-CoV-2 viral eradication from nasopharyngeal specimens at EOT|Change in Alanine Aminotransferase (ALT) levels|Change in Aspartate Aminotransferase (AST) levels|Change in Creatinine levels|Change in Glucose levels|Change in White Blood Cell (WBC) count|Change in Hemoglobin levels|Change in Platelet count|Change in total bilirubin levels|Change in Lactate Dehydrogenase (LDH) levels|Change in C-Reactive Protein (CRP) levels|Change in Interleukin 6 (IL-6) levels || Incidence of adverse events related to treatment (safety)|Change from baseline autonomic response at the end of the treatment|Change from baseline Trial Making Test (TMT) score at the end of the treatment|Change from baseline Digit span score at the end of the treatment|Change from baseline balance parameters at the end of the treatment|Change from baseline gait parameters at the end of the treatment|Change from baseline Functional Status Score for the intensive care unit (FSS-ICU) at the end of the treatment|Change from baseline Functional Reach Test (FRT) distances at the end of the treatment|Change from baseline Beck Depression Inventory-II (BDI-II) score at the end of the treatment|Change from baseline Beck Anxiety Inventory (BAI) score at the end of the treatment || Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation/Fraction of Inspired Oxygen || Number of Participants with a First Occurrence of COVID-19 of Any Severity Starting 14 Days after Second Dose of SCB-2019|Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited AEs|Number of Participants with Serious Adverse Events (SAEs), or Medically Attended AEs (MAAEs), or AEs Leading to Early Termination, or Adverse Events of Special Interest (AESIs)|Number of Participants with a First Occurrence of Moderate-to-Severe COVID-19 Starting 14 Days after Second Dose of SCB-2019|Number of Participants with First Occurrence of Any Laboratory-Confirmed SARS-CoV-2 infection Starting 14 Days after Second Dose of SCB-2019 or Placebo|Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of SCB-2019 or Placebo|Number of Participants with First Occurrence of Any Laboratory-Confirmed Asymptomatic SARS-CoV-2 infection Starting 14 Days after Second Dose of SCB-2019 or Placebo|Burden of Disease Score of COVID-19 or SARS-CoV-2 Infection Cases Starting 14 Days after Second Dose of SCB-2019 or Placebo|Number of Participants with a First Occurrence of COVID-19 of Any Severity, Associated with Hospitalization, Starting 14 Days after Second Dose of SCB-2019 or Placebo|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of SCB-2019 or Placebo, regardless of evidence of prior SARS-CoV-2 Infection|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of SCB-2019 or Placebo, regardless of risk of severe COVID-19|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of SCB-2019 or Placebo|Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb|Number of Participants with Seroconversion for SARS-CoV-2 Specific nAb|Geometric Mean Titer (GMT) of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor|Number of Participants with Seroconversion for of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor|Geometric Mean Titer (GMT) of SCB-2019 binding antibody|Geometric Mean Fold Rise (GMFR) of SCB-2019 binding antibody|Number of Participants with Seroconversion for SCB-2019 binding antibody|Geometric Mean Titer (GMT) of Trimer-Tag binding antibody|Geometric Mean Fold Rise (GMFR) of Trimer-Tag binding antibody || Percentage of Participants Dying or Requiring ICU Admission|Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours|Time to Hospital Discharge|Duration of ICU Stay|Duration of Any Oxygen Use|Duration of Mechanical Ventilation|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Time to Sustained Normalization of Temperature|Percentage of Participants with Normalization of Fever|Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Length of Time to Clinical Progression || Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative Incidence of Intubation|Time to Extubation|Length of Intensive Care Unit (ICU) stay|Number of Patients who Present a Decrease in C-reactive protein (CRP)|Number of Patients with Acute Kidney Injury (AKI)|Number of Patients with a Need for Renal Replacement Therapy (RRT)|Duration of Renal Replacement Therapy (RRT)|Patient Survival|Number of Patients with Hemodialysis|Number of Patients with Continuous Renal Replacement Therapies (CRRT)|Number of Patients with Peritoneal Dialysis || Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA) || Change in respiratory viral clearance (by PCR)|Fecal viral clearance (by PCR)|Reduction (change) in respiratory viral shedding (by PCR)|Reduction (change) in GI viral shedding (by PCR)|Progression to severe COVID-19 Disease|Time to resolution of a fever || Most severe outcome || Clinical recovery|Clinical worsening|Clinical severity|Time to symptoms remission|Medication Use|Hospitalization time|Blood routine test|Heart rate|Blood pressure|Cardiac auscultation|Oxygen saturation|Adverse events || Time to clinical improvement|Time to recovery|Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status|Proportion of patients with recovery as defined as the subject satisfies one of the following|Change of clinical status assessed by 7-category ordinal scale|Change in National Early Warning Score (NEWS)|Time to National Early Warning Score (NEWS) of ≤ 2 which is maintained for 24 hours|Changes on CT scan/X-ray|Change from baseline of CRP|Time to normalize the CRP|Duration of hospitalization|Duration of non-invasive ventilation or high flow oxygen use|Incidence of non-invasive ventilation or high flow oxygen use|Duration of supplement oxygen use|Incidence of supplement oxygen use|Duration of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|28-Day mortality || Time to Recovery|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin Time (PT)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics|Duration of Hospitalization|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use|Percentage of Participants Requiring New Oxygen Use|Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Mean Change in the Ordinal Scale|14-day Participant Mortality|29-day Participant Mortality|Time to an Improvement by at Least One Category Using an Ordinal Scale|Time to an Improvement of at Least Two Categories Using an Ordinal Scale|Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First || Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of solicited local AE signs and symptoms|Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of solicited systemic AE signs and symptoms|Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of unsolicited AE|Assess the safety of GRAd-COV2 by laboratory measures: full blood count; blood Biochemistry (Sodium, Potassium, Albumin, Liver Function Tests; Renal function, lactate dehydrogenases (LDH), alkaline phosphatases (ALP)).|Assess the safety, tolerability and reactogenicity of GRAd-COV2: Occurrence of serious AE|Immunogenicity || Number of Participants Requiring Mechanical Ventilation or Dying|Days to Recovery|Duration of Hospitalization|Incidence of Death|Proportion of Participants Transferred to ICU|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score|Incidence of Grade III-V Adverse Events|Incidence of Secondary Bacterial or Viral Infections|Change in Th1 T Cell Frequency|Change in Th17 T Cell Frequency|Change in Interleukin-2 (IL-2)|Change in Interleukin-2 receptor (IL-2R)|Change in Interleukin-6 (IL-6)|Change in Interleukin-7 (IL-7)|Change in Interleukin-8 (IL-8)|Change in Interleukin-10 (IL-10)|Change in Interferon gamma-induced Protein 10 (IP-10)|Change in Macrophage Inflammatory Protein 1alpha (MIP-1a)|Change in Monocyte Chemoattractant Protein-1 (MCP-1)|Change in Granulocyte Colony-stimulating Factor (G-CSF)|Change in Tumor Necrosis Factor (TNF)-alpha|Change in Vasoactive Intestinal Peptide (VIP)|Change in Gene Expression Profile of Regulatory T Cells (Tregs)|Change in Gene Expression Profile of cluster of differentiation 8 (CD8)+Interferon Gamma (IFNg)+ Granulocyte-macrophage colony-stimulating factor (GM-CSF)+|Change in Gene Expression Profile of CD8+ T cell immunoglobulin and mucin domain-containing protein 3 (Tim3)+ Programmed cell death protein 1 (PD-1)+|Change in Gene Expression Profile of cluster of differentiation 14 (CD14)+ cluster of differentiation (CD16)+ monocytes|Change in SARS-CoV-2 Viremia|Change in Immunoglobulin G (IgG) Antibodies|Change in Immunoglobulin M (IgM) Antibodies|Overall Survival || Composite of All-Cause Mortality or Invasive Mechanical Ventilation (IMV) Through Day 29|All-Cause Mortality Through Day 29|Invasive Mechanical Ventilation Through Day 29|Time to Recovery|Clinical Status Assessed by an 8-Point Ordinal Scale on Day 15|Clinical Status Assessed by an 8-Point Ordinal Scale on Day 29|Renal Replacement Therapy (RRT)-Free Days (Among Those Without End-Stage Kidney Disease [ESKD] at Randomization) Through Day 29|Recovery Through Day 29|Percentage of Participants Experiencing Serious Adverse Events (SAEs)|Percentage of Participants who Permanently Discontinue Investigational Drug due to Adverse Events (AEs) || Decrease incidence of intubation by 30% or greater|Decrease renal injury || Clinical alleviation of symptoms|Hospitalisation|Time to negative viral load|Inflammatory changes|Mortality|Adverse events || Total Leak Volume of Non Invasive Ventilation Mask|Glasgow Coma Scale(GCS)|Respiratory Rate|Heart Rate|Metabolic Data: Blood Gas Measurements|Metabolic Data: Bicarbonate (HC03)|Metabolic Data: Partial Pressure of Carbon Dioxide (PaC02)|Metabolic Data: Partial Pressure of Oxygen (Pa02) || SARS-CoV-2 Infection|Symptomatic vs. Asymptomatic Infection With SARS-CoV-2|Occupational Health Exposure|Impact of Hydroxychloroquine Use on Need for Hospitalization With SARS-CoV-2 Infection|Impact of Hydroxychloroquine Use on Need for ICU Care With SARS-CoV-2 Infection|Adverse Effect Profile of Hydroxychloroquine|Seroconversion Following SARS-CoV-2 Infection|Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates || rate of in-hospital mortality|rate of escalation from non-invasive ventilation to invasive mechanical ventilation || hs-cTnT|NT-proBNP || Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death|Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement|Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement|Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7 || Occurrence of Adverse Events and Serious Adverse Events|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Change from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (SpO2/FiO2)|Time to clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale|Time to SpO2 > 94% on room air|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 || Subject alive and free of respiratory failure|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Chnage from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (PaO2/FiO2)|Occurrence of Adverse Events and Serious Adverse Events|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC) || Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9 || Maximum clinical severity of disease|Incidence of treatment emergent adverse events|Renin angiotensin system peptides|Plasma biomarkers || Proportion of patients with sustained clinical recovery|Proportion of patients reporting each category of 7-Category Ordinal Scale of Clinical Status|Proportion of patients transferred to the ICU|Duration of fever|Duration of hospitalization|Change in ESR|Change in serum CRP level|Change in serum IL-6 level || Changes in inflammatory biomarkers|Changes in proresolving mediators|Changes in fatty acids in the erythrocyte fraction|Changes in cardiac biomarkers|Changes in biomarkers of organ damage|Changes in thrombosis parameters|Changes in coagulation parameters|Changes in markers of infection|Changes in infection load|Changes in clinical parameters|Length of hospital stay|Complications || Rate of entering the critical stage|Trend of White blood cell count|Change of the ""Sequential Organ failure Assessment"" (SOFA)|Rate of biochemical criterion (CK, ALT, ferritin) recovery|Rate of disease remission || Safety and Tolerability of ANA001 as measured by the incidence of treatment emergent adverse events (TEAE's) (Part 1 and Part 2)|Efficacy as measured by median time to hospital discharge (Part 2)|Efficacy as measured by median time to hospital discharge (Part 1)|Pharmacokinetics (PK) of ANA001 as measured by plasma concentrations (Part 1)|Efficacy of ANA001 as measured by mean change from baseline in the National Early Warning Score (NEWS 2) (Part 2)|Efficacy of ANA001 as measured by mean number of days on rescue therapy (Part 2) || Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days || Disease Severity|Clinical improvement|Time to recovery|Time to clinical improvement|Clinical status|Mortality|Mechanical Ventilatory Support|Mechanical Ventilatory Support Duration|Freedom from mechanical ventilation|Adverse events|Additional intervention|Viral titer || Soluble P-selectin level|D-dimer level|VWF level|CRP level|Change in clinical status as assessed by the World Health Organization (WHO) Ordinal Scale for COVID-19 Trials|Time to hospital discharge|Safety of Crizanlizumab as assessed by adverse events || Number of Participants With Early Viral Clearance|Number of Participants With Negative RT-PCR Results|Number of Patients That Progress to More Severe Disease|Number of Patients With Abnormal Radiological Findings|Number of Patients With Abnormal Laboratory Findings || Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase || Oxygen saturation (%)|Respiratory rate per minute|Dyspnea level|Anxiety|Quality of life level || Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs) || serological test|neutralizing Ab|Immuno phenotyping || Number of participants with helminth infections|Number of participants with SARS-CoV-2 antibodies|Number of participants with positive malaria test|Average Differential blood count|Average Hematocrit levels|Number of participants with latent tuberculosis infection|Number of participants with Wuchereria bancrofti infection|Number of participants with Strongyloides stercoralis infection|Number of participants with Ascaris infection|Number of participants with hookworm infection|Number of participants with Strongyloides infection|Number of participants with Trichuris infection || Safety indexes of adverse reactions|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule （day 0,14）|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)|Occurrence of abnormal changes of laboratory safety examinations (hemoglobin,WBCs, platelets, ALT, AST, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte)|Safety indexes of serious adverse events (SAEs）|Immunogenicity indexes of neutralizing-antibody seroconversion rates|Immunogenicity indexes of IgG antibody seropositivity rates|Immunogenicity indexes IgM antibody seropositivity rates|Immunogenicity indexes of GMT of neutralizing-antibody|Immunogenicity indexes of GMR of neutralizing-antibody || Time to recovery|All-cause mortality|Necessity for assisted ventilation|Individual symptoms duration|Vitamin D|Zinc|Interleukin 6 (IL-6)|Angiopoietin-2|sTREM-1|Immunoglobulin M (IgM)|Immunoglobulin (IgG) || Emergency Room Visits and Hospitalizations|Emergency room visit count|Hospitalization admission count|Time to ER Visit|Time to hospitalization|All-cause mortality|Inpatient Length of stay|Time to ICU admission|Time to intubation|Time to other serious COVID-19 complications || Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) || Incidence of death or required mechanical ventilation|Proportion of patients with treatment-emergent Serious Adverse Events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral load as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average change from baseline in viral load as measured by RT-qPCR in NP swab samples|Change from baseline in viral load as measured by RT-qPCR in NP swabs|Time to sustained negative RT-qPCR in NP swab samples|Incidence of deaths due to any cause|Incidence of required mechanical ventilation|Proportion of patients who died or went on mechanical ventilation|Proportion of patients who died|Proportion of patients who went on mechanical ventilation|Time to discharge|Serum concentration of REGN10933 over time|Serum concentration of REGN10987 over time|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10933|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10987|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10933|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10987|Assessment of PK parameter: Observed terminal half-life [t1/2] for REGN10933|Assessment of PK parameter: Observed terminal half-life [t1/2] of REGN10987|Assessment of PK parameter: Clearance (CL) for REGN10933|Assessment of PK parameter: Clearance (CL) of REGN10987|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10933|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10987|Assessment of PK parameter: Mean residence time (MRT) of REGN10933|Assessment of PK parameter: Mean residence time (MRT) of REGN10987|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of anti-drug antibodies (ADA) to REGN10987 || Time to Participant Response|Number of Participants with Treatment Related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)|Number of Participants with Treatment Related Side Effects as Assessed by the General Assessment of Side Effects (GASE)|Hospital Average Length of Stay (ALOS) as Measured by the Mean Participants' Inpatient Days|Overall Survival Defined as the Time From the Start of Treatment until Death due to any Reason || Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures|Thyroid tests at Day0 and Day7|Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)|Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea|Need for ward or intensive care hospitalization || Percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the ""Not hospitalized"" category|Subjects' clinical status distribution based on 5-point clinical status scale during the study|28-day case fatality rates || Incidence of adverse events|Humoral immunity|Level of SARS-CoV-2-specfic neutralizing antibodies|Th1 vs Th2 polarization|SARS-CoV-2- antigen specific T cell responses to the COH04S1 vaccine|Evolution of activated/cycling and memory phenotype markers on the surface of SARS-CoV-2- specific T cells elicited as a result of the COH04S1 vaccination|Comparison of one vaccine injection vs two vaccine injections for immunogenicity|Comparison of one vaccine injection vs two vaccine injections for adverse events || Death|Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO|Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)|Cumulative incidence of grade 3 and 4 adverse events|Number of participants with serious adverse events|Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|Number of participants with laboratory abnormalities in peripheral blood|Duration of laboratory abnormalities in peripheral blood|Number of participants with laboratory abnormalities in plasma|Duration of laboratory abnormalities in plasma || Rate of invasive mechanical ventilation|Severity assessment by ordinal severity scale|Severity assessment by SOFA score|Length of hospital stay|Length of stay in intensive care|Death rate || Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody|Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody|Safety evaluation|SCR of anti-S1-RBD antibody|GMT of SARS-CoV-2 neutralizing antibody|GMT of anti-S1-RBD antibody|Geometric mean fold increase in anti-S1-RBD and SARS-CoV-2 neutralizing antibodies|Evaluation of lot to lot consistency || Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) || Patients alive and free of mechanical ventilation|Patients alive and discharged free of oxygen|Patients with occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation|Time to response|Number of ventilator free days|Mortality || Proportion of Participants Experiencing any Treatment-Emergent Adverse Events|Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities|Plasma Concentrations of Remdesivir (RDV) and Metabolites|Change From Baseline in Oxygenation Use|Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Clinical Improvement on a 7-point Ordinal Scale|Time (days) to Discharge From Hospital|Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result|Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load|Bilirubin Concentrations in < 14-day-old Participants|Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale|Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)|Proportion of Participants With Concomitant Use of Medications other than RDV for Treatment of Coronavirus Disease 2019 (COVID-19) || Health Care Workers absenteeism|the cumulative incidence of documented COVID-19|the cumulative incidence of Hospital Admission due to documented COVID-19|the number of days of unplanned absenteeism, because of documented COVID-19|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented COVID-19|the cumulative incidence of Intensive Care Admission due to documented COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19|the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|the number of days of self-reported fever (≥38 gr C)|the cumulative incidence of self-reported fever (≥38 gr C)|the number of days of self-reported acute respiratory symptoms|the cumulative incidence of self-reported acute respiratory symptoms|the cumulative incidence of death for any reason|the cumulative incidence of Intensive Care Admission for any reason|the cumulative incidence of Hospital Admission for any reason|the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period || Virological cure || Change in mean clinical status score in each treatment arm|Number of adverse events in each treatment arm|Number of patients with an improvement in clinical status score in each treatment arm|Number of patients with a deterioration in clinical status score in each treatment arm|Number of patients with at least 95% oxygen saturation on room air in each treatment arm|Time to patients with at least 95% oxygen saturation on room air in each treatment arm|Number of patients with an improvement in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients with an deterioration in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients requiring Continuous Positive Airway Pressure in each treatment arm|Number of patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to patients requiring Continuous Positive Airway Pressure in each treatment arm|Time to patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to discharge in each treatment arm|Number of deaths in each treatment arm || Adverse Events|Creatinine|Aspartate transaminase|Alanine transaminase|Prothrombin time|Partial Thromboplastin Time|Duration of viral illness|Hospitalization rate|ICU admission|Ventilatory requirement|Lymphocyte count|Neutrophil count|Ferritin|D-Dimer|Lactate Dehydrogenase|C-Reactive Protein|Troponin|Mid-turbinate nasal swabs|Peripheral Blood Mononuclear Cell (PBMC) immune profiling || Primary Analysis|Secondary Between group differences in viral load|AUC comparison|Stratified|Time to viral load drop|Ordinal scale || Symptoms recovery|Hospitalization|Blood white blood cell count (WBC)|Duration of mechanical ventilation|Duration of hospitalization|Intensive care unit (ICU) admission|Duration of ICU stay|Blood C-reactive protein (CRP)|Blood Lymphocyte count|Blood Ferritin|Blood platelet count|Blood interleukin-6 (IL-6)|Blood Tumor Necrosis Factor alpha (TNF) || Interleukin-6|C Reactive protein|Oxygenation|TNF alpha|IL-10|Return to room air (RTRA)|EKG qt interval|Leukocyte differential|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|NK cell surface antigen (CD3-CD54+)|CD4+/CD8+ ratio|Myoglobin|Troponin|Creatinine kinase MB|Serum ferritin|Adverse events|7-point ordinal scale|D-dimer|Chest X-ray|CT scan|PCR test for SARS-CoV-2 || Percent of patient echos that are not interpretable|Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)|Time to acquire images as measured by time stamps|Percent of agreement between AI calculate LVEF and LVEF read by physician || mechanical ventilator free days|Change in oxygenation|Hospital Mortality || WHO Ordinal Scale for Clinical Improvement|Mortality|Duration of hospitalization|Mechanical ventilation|Time to cancellation of oxygen support|Invasive mechanical ventilation|Stay in the intensive care unit|The transition of the disease to an extremely severe course|Fever|The dynamics of the National Early Warning Score (NEWS)|The dynamics of changes in the level of C-reactive protein|The dynamics of residual symptoms|The dynamics of blood biochemical parameters|The dynamics of CT signs || Brainstem dysfunction prevalence|Brainstem dysfunction prevalence after sedation weaning|Link between brainstem dysfunction and clinical dysautonomia|Link between brainstem dysfunction and clinical dysautonomia after sedation weaning|Characterization of brainstem dysfunction in COVID-19 patients: EEG power|Characterization of brainstem dysfunction in COVID-19 patients: EEG power after sedation weaning|Characterization of brainstem dysfunction in COVID-19 patients: EEG functional connectivity|Characterization of brainstem dysfunction in COVID-19 patients: EEG functional connectivity, after sedation weaning|Characterization of brainstem dysfunction in COVID-19 patients: EEG complexity|Characterization of brainstem dysfunction in COVID-19 patients: EEG complexity after sedation weaning|Characterization of brainstem dysfunction in COVID-19 patients: multivariate classification|Characterization of brainstem dysfunction in COVID-19 patients: multivariate classification after sedation weaning|Duration of mechanical ventilation|Mortality|Duration of hospitalisation|Duration of coma, disturbance of consciousness, delirium|Neurological functional evolution with mRankin|Neurological functional evolution with GOSE || The ratio of individuals living in the province of Reggio Emilia who completed the survey|The ratio of individuals who changed the lifestyles during the lock-down|The number and the type of support services used the most by participants || Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0|Proportion of participants with detectable virus || Viral Load || Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients, according to the adapted Berlin criteria|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate || Serum C-reactive protein (CRP) level|Serum ferritin level|Serum Interferon gamma-induced protein 10 (IP10) level|Serum IL-6 level|Serum TNF-related apoptosis-inducing ligand (TRAIL)|Study drug related adverse events|Patient adherence to the study protocol|Ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2) ratio (PaO2/FiO2 ratio) for ventilated patients|Length of ventilation for ventilated patients|Length of stay in the ICU|Survival by day 28|Remission of respiratory symptoms|Documented infections up to discharge|Sequential organ failure assistance (SOFA) score || time to viral clearance|% of mortality|Length of stay|time to be afebrile|need for mechanical ventilation || Composite incidence of: all-cause mortality, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, stroke, or shock|Score on WHO Ordinal Scale|Incidence of acute kidney injury (KDIGO criteria for Acute Kidney Injury (AKI))|Requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Cardiac injury|Hypercoagulability|Disseminated Intravascular Coagulation (DIC) Score|Length of Hospital Stay || Mortality rate of subjects treated with whole lung low-dose radiation|Survival rate of subjects treated with whole lung low-dose radiation|Change in number of Intensive care unit days|Change in number of days using supplemental oxygen|Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated|Quantitation of Lung Involvement using Chest CT|Quantitation of Lung Opacities using Chest CT|SARS-CoV2 viral titers|Incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs|Change in performance status after low dose radiation to lungs || Mechanical ventilation-free survival|Duration of days on a ventilator|Days until pulse oxygen is > 93% on room air|Days until supplemental oxygen is no longer required|Duration of fever >= 38°C|Overall survival|Infusion reactions|Secondary infections|Change in Clinical Status, based on 7-point ordinal scale|Viral load|Radiographic Improvement || Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms || Predictive values of CT criteria|Accuracy of CT composite severity score|Accuracy of deep-learning based score|Predictive values of deep-learning based diagnostic algorithms|Dice similarity coefficient between manual and automated segmentation of lung disease abnormalities || Improvement of respiratory symptoms|Improvement of respiratory signs|ICU admission|Mechanical ventilation || All-cause mortality at Day 29|Disease Severity (8 point scale)|Mortality|P/F ratio|Change of the SOFA score.|Duration (days) of mechanical ventilation|Ventilator free days.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 || Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (including extracorporeal membrane oxygenation [ECMO])|Percentage of Participants with at Least 1-Point Improvement on NIAID-OS or Live Discharge from Hospital|Number of Ventilator-Free Days|Time to Recovery|Overall Improvement on the NIAID-OS|Duration of Hospitalization|Percentage of Participants with a Change in Oxygen Saturation from <94% to ≥94% from Baseline|Mortality|Duration of Stay in the Intensive Care Unit (ICU) in Days|Time to Clinical Deterioration (one-category increase on the NIAID-OS)|Time to Resolution of Fever, in Participants with Fever at Baseline|Mean Change from Baseline on the National Early Warning Score (NEWS)|Time to Definitive Extubation|Time to Independence from Non-Invasive Mechanical Ventilation|Time to Independence from Oxygen Therapy in Days|Number of Days with Supplemental Oxygen Use|Number of Days of Resting Respiratory Rate <24 Breaths per Minute || Mean change in oxygenation|Median change in oxygenation|number of AE's (Adverse Events)|number of SAE's (Serious Adverse Events)|mean change in 6-point ordinal scale change|Time since randomization until improvement in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence of fever (defined as 37.1°C or more) for more than 48h without antipyretic|Number of days with fever|Mean change in CRP levels between day 1 and day 6|Mean change in CRP levels between day 1 and day 15 (or discharge whichever comes first)|Mean change in ferritin levels between day 1 and day 6|Mean change in ferritin levels between day 1 and day 15 (or discharge, whichever comes first)|Incidence of AE's|Incidence of SAE's|Incidence of SUSAR's (Suspected Unexpected Serious Adverse Reaction)|Incidence of SAR's (Serious Adverse Reaction)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change of SOFA score between day 1 and day 6 (or on discharge, whichever is first)|Mean change of SOFA score between day 1 and day 15 or on discharge, whichever is first)|Percentage of patients reporting each severity rating on a 6-point ordinal scale at randomization, day 6 and 15 (or discharge, whichever comes first) and day 28 (phone call)|6-point Ordinal Scale at 6 and 15 days (or discharge whichever comes first) and day 28 (phone call), in relation to serum D-dimers and complement C5a levels at randomization|Incidence of nosocomial bacterial or invasive fungal infection for 28 days (phone call) after enrolment in trial|Time since randomization until first use of high-flow oxygen devices in non-ventilated patients|Time since randomization until first use of non-invasive mechanical ventilation in non-ventilated patients|Time since randomization until first use of invasive mechanical ventilation in non-ventilated patients|Number of ventilator-free days|Duration of invasive and non-invasive mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial on invasive or non-invasive mechanical ventilation for less than 24h prior to or after randomization|Time since randomization to progression to ARDS (Acute Respiratory Distress Syndrome)|Time to progression to ARDS in ventilated patients according to D-dimers at randomization|Time to progression to ARDS in ventilated patients according to complement C5a at randomization|All-cause mortality rate (excluding group that entered during ventilation)|All-cause mortality rate (including group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities at follow up|Incidence of lung fibrosis on chest CT scan at follow up|All cause mortality for the entire study population || Phase II: Time-weighted change from baseline in viral shedding over 8 days in site collected nasopharyngeal (NP) swabs by Quantitative Reverse Transcription Polymerase chain reaction (RT-qPCR), defined as a change from baseline in log10 viral load|Phase III: Hospitalization or death from any cause by Day 29|Phase II: Time-weighted change from baseline in viral shedding in NP swabs by RT-qPCR over 29 days|Phase II: Loss of detection of Severe acute respiratory syndrome coronavirus 2 ribonucleic acid (SARS-CoV-2 RNA) by site collected NP swab at Day 4, 8, 15, 22 and 29|Phase III: Time to death over 29 days|Phase III: Hospitalization by Day 29|Phase III: Hypoxia or hospitalization or death from any cause by Day 29|Phase III: Hypoxia by Day 29|Phase III: Time to clinical improvement over 29 days, defined as the time to either an improvement of two points on the 11-point WHO Clinical Progression Scale or a score of 0 on the Clinical Progression Scale, whichever comes first|Phase III: Time to loss of detection of SARS-CoV-2 RNA by site collected NP swabs over 29 days || Incidence of mortality|Incidence of subjects who are alive and not on mechanical ventilation|Number of ventilator-free days|Time to hospital discharge || Change in respiratory status|Length of time participant spends in the prone position|Length of time participant spends in the supine position|Length of time participant spends lying on side|Length of time participant spends sitting up|Length of time participant spends standing or walking|Dyspnea or difficult/labored breathing|Discomfort with proning|Length of hospital stay|Invasive mechanical ventilation|Loss of IV access as a consequence of turning in bed|Acute respiratory distress syndrome (ARDS) diagnosis|Hospital mortality || Mortality|Disease severity || Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event || Number of Participants with Treatment Emergent Adverse Events Graded as Assessed by CTCAE Version 4.0|Time to Improvement (2 points) in Clinical Status Assessment Using the World Health Organization 7-Point Ordinal Scale (WHO 7OS)|Time to Resolution of Fever for at least 48 hours Without Antipyretics for Patients with Documented Fever (>=37.2 degree celsius [oral], or >=37.8 degree celsius [rectal], or >=38.0 degree celsius [tympanic])|Time to Improvement in Oxygenation for at least 48 hours|Change from Baseline in the World Health Organization (WHO)-7 Point Ordinal Scale|Time to Discharge from Clinic or Hospital or to National Early Warning Score 2 (NEWS2) of <=2 and maintained for 24 hours|Percentage of Patients Alive and not Using Supplemental Oxygen at Time of Discharge from Hospital/Clinic or Day 30|Number of Days of Resting Respiratory Rate of more than 24 breath/min|Number of Days with Hypoxemia|Number of Days of Supplemental Oxygen use|Number of Ventilator-free Days|Number of Days in Intensive Care Unit (ICU)|Number of Days of Hospitalization for Survivors|Number of Participants with all cause deaths|Percent change from baseline in Proinflammatory Cytokines|Incidence of Drug-related Serious Adverse Events (SAEs) || convalescence/death|length of stay in the intensive care unit|length of stay in hospital || Hospitalization for cardiovascular/pulmonary events || Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs)|Number of Participants With AEs Leading to Study Discontinuation|Number of Participants With Serious Adverse Events (SAEs)|Proportion of Participants With Disease Progression|Median Time to Disease Resolution|Proportion of Participants Who Achieve Disease Resolution|Mean Gates Medical Research Institute Ordinal Scale Score|Change From Baseline in Gates Medical Research Institute Ordinal Scale Score|Mean World Health Organization Ordinal Scale Score|Change From Baseline in World Health Organization Ordinal Scale Score|Incidence of Hospitalization|Number of Days of Hospitalization || research database of EHR records from COVID-19 patients processed using NLP tools for named entity recognition and linking adapted to CUH EMR data to identify variables of interest|A set of annotation guidelines to produce human-expert (gold) labelled data for a subset of the EHR|A comparison of the NLP output to terms in the structured problem list to identify missing terms in the structured problem list || Number of participants with treatment-TOMEKA® usage as assessed by Education|Change From Baseline in nutraceuticals usage on the care of the Covid-19 at 9 months || All-Cause Mortality Rate Through Day 29|Time to Actual ICU Discharge|Duration of Mechanical Ventilation|Time to Actual Hospital Discharge|Duration of Any Oxygen Use|Mean Change from Baseline in Ordinal Scale|Absolute Value Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale|Overall Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)|Number of Participants who Develop ARDS Distributed by Severity|Change from Baseline in Sequential Organ Failure Assessment (SOFA) Score|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours || Incidence of intubation|Maximum oxygen requirement|Length of Stay|Ventilator-free days|Treatment failure of prone positioning due to worsening SpO2 status while prone|Mortality || Modified WHO Ordinal Scale|FIO2 || Death|Mechanical ventilation || Change in pulmonary status|Change in ferritin levels|Change in C-reactive protein levels|Change in d-dimer levels|Change in white blood cell count|Incidence of serious adverse events|Overall survival|Length of hospitalization|Duration of ventilation|Ventilator free days|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2) || change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease || Rate of transition to ARDS || Disease Progression|Changes in viral load from baseline to end of treatment - Mean viral load|Changes in viral load from baseline to end of treatment - Area under the viral load vs. time profiles|Changes in viral load from baseline to end of treatment - Time profile of viral load|Changes in viral load from baseline to end of treatment - Percentage of patients that are viral negative|Disease Recovery|Change in WHO Clinical Progression Scale score|Incidence of all-cause mortality|Progression to supplementary oxygen requirement|Incidence of mechanical ventilation|Incidence of ICU admission|Time to hospital discharge|Changes in serum C reactive protein levels (CRP)|Changes in D-dimer levels|Changes in soluble low-density lipoprotein receptor (sLDLR) expression and proprotein convertase subtilisin/kexin type 9 (PCSK9) and soluble angiotensin converting enzyme 2 (sACE2) levels|Changes in LDL-cholesterol|Changes in creatinine|Changes in liver enzymes || Evaluation of food intake at 1 month after discharge from hospital for COVID|Weight variation during the infection|Clinical signs limiting food intake|Factors limiting food intake|Implemented nutritional strategy|Pre-existing chronic disorders|Covid-19 repercussions || Composite outcome: New requirement for mechanical ventilation or death|Mortality|New requirement for mechanical ventilation or death from respiratory failure|New requirement for mechanical ventilation or death from non-respiratory failure|Mortality due to respiratory failure|Mortality due to non-respiratory failure|In hospital - Composite outcome|In hospital - Mortality|Composite outcome (New requirement for mechanical ventilation or death) evaluated in Non-intubated population|Mortality evaluated in Non-intubated population|Mean WHO descriptive score of COVID-19 during hospitalization|Highest WHO descriptive score of COVID-19 during hospitalization || Left Ventricular ejection fraction|Global longitudinal strain|Cardiac output|Peripheral blood oxygen saturation|Venous blood oxygen saturation|Urine creatinine clearance || Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine || Medical Research Council sum score (MRC- SS).|The Functional Status Score for the ICU (FSS-ICU)|Age|Sex|Body Mass Index|Baseline mobility|APACHE II score|Length of stay in ICU|Number of days on mechanical ventilation|Polyneuropathy diagnosis|Number of days on Neuromuscular Blockers|Episodes of prone positioning|Length of stay in hospital|Continuation of care || Proportion of poor outcomes (in index cases)|Secondary household attack rate (in household contacts)|Subjective disease severity (in index cases)|Rate of acute respiratory distress syndrome (in index cases)|Severity of radiological lung pathology (in index cases)|Objective disease severity (in index cases)|Safety: Unintended toxic HCQ accumulation (in index cases)|Safety: Adverse events (in index cases)|Social distancing knowledge, attitudes and practices amongst index cases and household contacts || Change in Clinical status of subject on a 7-point ordinal scale|PCR test|Supplemental Oxygen|Mechanical Ventilation|Incidence of Treatment-Emergent Adverse Events|Laboratory Assessments|C-reactive protein (CRP)|Interleukin 6 (IL-6)|D-dimer || Clinical deterioration || Hospital Admission|Death|Bleeding (as defined by ISTH criteria)|Diagnosis of VTE || Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice || Clinical Improvement|Patient status upgraded to ICU level [Clinical decline]|Oxygen supplementation|Days with fever|Days to discharge|SAEs || Dietary intake|Diet quality|Eating habits || Change (reduction) in viral load from baseline|proportion of subjects change from mild or moderate type to severe type|proportion of subjects change from severe type to critical type|novel coronavirus nucleic acid conversion rate|Novel coronavirus nucleic acid negative conversion time|The time and proportion of improvement in pulmonary imaging|Time and proportion of temperature return to normal|time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.)|time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms|Changes of blood oxygen detection index|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of adverse events || Disease Progression at Day 28|Survival Rate|Time to Fever Resolution|Time to Disease Progression|Resolution of Viral Shedding|Rate of Adverse Events and Serious Adverse Events|Cumulative Rate of Grade 3 and 4 Adverse Events|Rate of Discontinuation|Change in Laboratory Parameter - Platelet Count|Change in Laboratory Parameter - Potassium Level|Change in Laboratory Parameter - Aspartate Aminotransferase (AST)|Change in Laboratory Parameter - Alanine Aminotransferase (ALT)|Change in Laboratory Parameter - Alkaline Phosphatase (ALP)|Change in Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)|Change in Laboratory Parameter - Albumin|Change in Laboratory Parameter - Bilirubin|Change in Vital Signs - Heart Rate|Change in Vital Signs - Blood Pressure|Change in Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2) || Time from randomization to clinical recovery|Negativity in RT-PCR nucleic acid test|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Incidence of deterioration/aggravation of pneumonia|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy or non-invasive ventilation|ICU admission rate within 28 days of randomization|All-cause mortality within 28 days of randomization. || Qualitative assessment of the feasibility of the Hexoskin Platform and Virtual Recruitment Process via three subjective feedback questionnaires provided to all patients enrolled in the study.|Ensure the collection of high-quality data during wake and sleep activities, registered as overall > 90% good quality cardiac data and overall > 90% good quality respiratory data per recording.|Ensure adequate patient compliance, qualified as > 75% of total recording hours completed, and > 75% of daily questionnaires completed.|Investigate the predictive power of Hexoskin physiological data, patient information and symptoms information to correctly classify patient disease progression quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.70). || Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient || Occurrence of adverse reactions|Anti SARS-CoV-2 S IgG antibody response(ELISA)|Neutralizing antibody response to SARS-CoV-2|Occurrence of adverse events|Occurrence of serious adverse reaction|Neutralizing antibody response to Ad5-vector|IFN-γ ELISpot responses to SARS-CoV-2 spike protein || Clinical failure at Day 28|Clinical Improvement, defined as a decrease of at least 2 points on the World Health Organization (WHO) ordinal scale|Rate of overall survival (OS) at Day 28 and Day 60|Incidence and severity of adverse events according to NCI CTCAE v5.0 || Viral clearance at day 6|Viral shedding duration|Symptoms clearance time || Mortality|Need for mechanical ventilation|Days on invasive mechanical ventilation || Progression of respiratory failure or death || The efficacy of Ampion compared to placebo on mortality|The safety and tolerability of Ampion compared to placebo on incidence and severity of adverse events || occurrence of severe cardiac arrhythmia: torsade de pointes and cardiac arrest or sudden death|assessment of QTc interval prolongation during the treatment period compared to baseline ECG || Composite endpoint with disease progression defined as a NEWS2score ≥ 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.|Side effects || Clinical severity status on a 7-point ordinal scale|Time from randomization to discharge from hospital|Time to discharge from hospital or to score of ≤2 maintained for 24 hours in NEWS2, whichever occurs first|Time to resolution of fever, defined as ≤36.6°C (axilla), ≤37.2°C (oral) or ≤37.8°C (rectal or tympanic) for at least 24 hours without antipyretics for 24 hours|Time to SpO2 >94% on room air maintained for 24 hours|Clinical severity status over the hospital period calculated as AUC from the 7-point ordinal scale at Days 3, 5, 8, 11, 15 and 30 || Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation or All-cause Death by Day 28 || Changes from baseline in the clinical improvement score on an 8-point scale at Day 21|Changes from baseline in the clinical improvement score on an 8-point scale at Day 7, Day 14, and Day 28|Time to discontinuation of oxygen therapy after investigational product administration|Time to recovery* after investigational product administration (days)|Changes from baseline in PaO2/FiO2 at Day 7, Day 14, Day 21, and Day 28|Changes from baseline in the NEWS 2 score at Day 7, Day 14, Day 21, and Day 28|Mortality at Day 28 and Day 60 after investigational product administration || number and proportion of participants, per randomized group, with a loss of one or two grades of National Early Warning Score (NEWS2) score at day-7 compared to baseline|the 28-day survival rate|the rate of intensive care unit admission|the rate of nasopharyngeal swab negativation at D7, D14 and D28 || Low blood pressure|dizziness|Incidence of hospitalization, ICU admission, intubation, dialysis and death || Incidence and severity of adverse events || Oxygen Saturation by Pulse Oximetry|Respiratory Rate|Heart Rate|Blood Pressure|Count of Participants With Subjective Work of Breathing || Clinical failure rate at Day 28|Changes from baseline in the clinical improvement score on an 8-point scale at Day 7, Day 14, and Day 28|Time to discontinuation of oxygen therapy after investigational product administration|Time to recovery* after investigational product administration (days)|Time to Clinical Improvement from randomization to clinical improvement (2 points decreased from the baseline score) (days)|Changes from baseline in PaO2/FiO2 at Day 7, Day 14, Day 21, and Day 28|Changes from baseline in the NEWS 2 score at Day 7, Day 14, Day 21, and Day 28 || Incidence of events supposedly attributed to vaccines and immunizations after Sputnik V || Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention|Duration of fever || Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)|Delta (peak minus baseline) troponin level|Delta (baseline to peak) brain natriuretic peptide (BNP) level|Change in left ventricular ejection fraction (LVEF) on echocardiography|Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level|Delta (peak minus baseline) D-Dimer inflammatory biomarker level|Time (days) to primary endpoint|Number of participants requiring mechanical ventilation|Number of participants requiring mechanical circulatory support (MCS)|Re-hospitalization at 90 days|All-cause mortality || Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation || RECAP Early warning score || Number of participants with clinical infection with COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events || VTE events and complications || Assess safety of UNI911 INHALATION in healthy volunteers: AE frequency || Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days || Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation || Time to sustained clinical improvement|Response rate|Mortality|Proportion of subjects alive and discharged without supplemental oxygen|Proportion of subjects alive and discharge without supplemental oxygen|Weight in kilogram|Blood pressure in mmHg|saturation in percentage|Temperature in ℃|12-lead electrocardiograms (ECGs)|Virologic load|Antidrug antibody (ADA) titers|Adverse events (AEs) of special interest|Time to sustained recovery || Proportion of patients who are alive and free from advanced respiratory support measures at day 28.|Proportion of patients who require escalation in care|Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)|Proportion of patients surviving to hospital discharge|Drug safety profile|Duration of advanced respiratory support|Duration of hospital stay|Time from treatment initiation to death|Time to resolution of fever|Proportion of patients who require initiation of off-label therapies || Composite of mortality or need for ICU admission or ventilator use || Incidence of solicited adverse events(AEs)|Incidence of unsolicited AEs|Incidence of serious adverse events(SAEs)|Incidence of adverse events of special interest(AESIs)|Seroconversion rate(SCR) of neutralization antibody using wild type SARS-CoV-2|Geometric mean titer(GMT) of neutralization antibody using wild type SARS-CoV-2|GMT of S protein specific antibody|Index of T cell response || Prevalence of subsequent and co-infections|In-hospital mortality|Hospital length of stay (LOS) || Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration-time Curve (AUC) of LY3819253|Pharmacodynamics (PD): Change from Baseline to Day 29 in Viral Load || Proportions (active vs. placebo) of subjects with progressive respiratory insufficiency.|Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events|Time to clinical recovery|Proportions (active vs. placebo) of subjects with respiratory failure or death || Incidence of adverse events (AEs) || Number patients developing severe infection or death || sustained improvement (>48h) of one point on the WHO Scale|Time to improvement on WHO Scale|Mean change in the ranking on an ordinal scale from baseline|time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first|change from baseline in National Early Warning Score (NEWS)|Oxygenation free days|Incidence of new oxygen use during the trial|duration of oxygen use during the trial|Ventilator free days until day 29|Incidence of new mechanical ventilation use during the trial|duration of mechanical ventilation use during the trial|Viral load/viral clearance|Duration of Hospitalization|Mortality|Obesity - mortality|Obesity - duration of hospitalization|Obesity - ICU admission|Obesity - new oxygen use|Drug-drug interactions with lopinavir/ritonavir|Renin Angiotensin System (RAS) fingerprint|SpO2/FiO2 ratio|paO/FiO2 ratio|modified Sequential Organ Failure Assessment|C-reactive protein|Interleukin-6|procalcitonin|IgM Concentrations|IgA Concentrations|differential blood counts || Incidence of COVID-19 cases|Incidence of SAE|Incidence of severe COVID-19 cases|Incidence of solicited adverse reactions|Incidence of unsolicited adverse events|Immunogencity of S-RBD IgG antibody (ELISA method)|Immunogencity of neutralizing antibody|Cell-mediated immune profile || Clear chest CT-scan|PCR test|Physical statues of patient || Corrected QT (QTc) interval measurement || Dyspnea|long of hospitalization|Radiological Treatment Response|Mortality|Allergic drug|Laboratory Treatment Response|O2 saturation without supplemental oxygen|drug reactions Adverse || Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative incidence of intubation|Time to extubation|Length of ICU stay|Number of patients who present a decrease in C-reactive protein|Patient Survival || Pulmonary Function|Chest CT|Changes in hematology|Changes in immune and inflammatory states|St. George's Respiratory Questionnaire(SGRQ) || Patients requiring mechanical ventilation or death|Clinical status of subject at day 15 and day 30 (on a 10-point ""WHO progression"" ordinal scale) || Time to Resolution of Symptoms|SAEs within 24 hours of plasma infusion|Decrease in Inflammatory Markers|Hospitalization within 28 days || PCR test|Laboratory Treatment Response|drug reactions Adverse|Allergic drug|Radiological Treatment Response || Mortality || Measure frequency of people suffered from unusual flu-like symptoms before December 2019|Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible || The number of subjects with serious Adverse Events|Proportion of subjects withe serious Adverse Events|Number of subjects with severe COVID-19|Proportion of subjects with severe COVID-19 || Frequency by grade of solicited local reactogenicity adverse events (AEs)|Frequency by grade of solicited systemic reactogenicity adverse events (AEs)|Frequency by grade of unsolicited adverse events (AEs)|Frequency of Adverse Events of Special Interest (AESIs)|Frequency of clinical safety laboratory adverse events by severity grade|Frequency of Serious Adverse Events (SAEs)|Geometric mean fold rise from baseline in titer measured by a SARS-CoV-2 neutralization assay, for wild-type virus and emergent viral strains|Geometric mean fold rise from baseline in titer of receptor-binding domain (RBD) specific Immunoglobulin G (IgG)|Geometric mean fold rise from baseline in titer of Spike-specific Immunoglobulin G (IgG)|Geometric mean titer measured by a SARS-CoV-2 neutralization assay, for wild-type virus and emergent viral strains|Geometric mean titer of receptor-binding domain (RBD) specific Immunoglobulin G (IgG)|Geometric mean titer of Spike-specific Immunoglobulin G (IgG)|Percent of cells expressing a cytokine by cell type (CD4+ or CD8+), cytokine set (Th1 or Th2 cytokine for CD4+ and CD8+ cytokine for CD8+ or other combinations of interest) and peptide pool (covering spike and T cell epitope regions)|Percentage of subjects who seroconverted, for RBD from wild-type virus and emergent viral strains|Percentage of subjects who seroconverted, for spike protein from wild-type virus and emergent viral strains|Percentage of subjects who seroconverted, for wild-type virus and emergent viral strains|Rate of spot-forming cell per million cells by peptide pool (covering spike and T cell epitope regions)|Responder status, derived from the intracellular cytokine staining (ICS) cell counts for each set of applicable cytokines and each peptide pool|Responder status, determined by interferon (IFN) gamma Enzyme Linked Immunospot Assay (ELISpot) for each peptide pool|Th1/Th2 cytokine balance of T cell response || Need for mechanical ventilation|Death || Time to recovery for patients with baseline ordinal score 4, 5, and 6|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in C-reactive protein (CRP)|Change from baseline in creatinine|Change from baseline in d-dimer concentration|Change from baseline in hemoglobin|Change from baseline in international normalized ratio (INR)|Change from baseline in platelets|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of invasive mechanical ventilation|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of non invasive ventilation or high flow oxygen use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of study product administration|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change from baseline in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale for patients with baseline ordinal score 4 and 5|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Time to recovery for patients with a baseline ordinal score of 4 and 5 || Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Change from baseline in C-reactive protein (CRP)|Change from baseline in d-dimer concentration || Availability of convalescent plasma|Amount of Plasma|Demographics of recipients|Co-morbidity of recipient|Donor status|Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy|Hospital and ICU length of stay|Disposition of patients including survival || Incidence of solicited adverse events (AEs) after vaccination|Incidence of unsolicited AEs after vaccination|Immunogenicity(Anti-SCB-2019 Antibody Titers)|Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs)|Immunogenicity( serum anti SARS-CoV-2 neutralizing antibody titers (ACE2 receptor-based) )|Immunogenicity(serum anti SARS-CoV-2 neutralizing antibody titers (cell based) )|Immunogenicity(serum anti SARS-CoV-2 whole virus antibody titers)|Antibody kinetics of each SCB 2019 vaccine formulation after first and second doses || The proportion of subjects not meeting criteria for one of the following two ordinal scale categories at any time: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in C-reactive protein (CRP)|Change from baseline in creatinine|Change from baseline in d-dimer concentration|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Days of invasive mechanical ventilation/ extracorporeal membrane oxygenation (ECMO) (if applicable)|Days of non-invasive ventilation/high flow oxygen (if applicable)|Days of supplemental oxygen (if applicable)|Desirability of Outcome Ranking (DOOR)|Duration of hospitalization|Incidence of discontinuation or temporary suspension of study product administration|Subject 14-day mortality|Subject 28-day mortality|Subject clinical status|The proportion of subjects meeting criteria for one of the 8 ordinal scale categories|Time to an improvement of one category from baseline using an ordinal scale|Time to an improvement of two categories from baseline using an ordinal scale|Time to recovery || Phase I|Phase IIa|Change in percentages from baseline in circulating white blood cell subpopulations|Change in Plerixafor concentration (ng/ml) from baseline in blood|Change in Tacrolimus concentration (ng/ml) from baseline in blood|Change from baseline in ALT, AST|Change in percentages from baseline in circulating stem cells and immune cells|Change from baseline in platelets|Change from baseline in total Bilirubin|Change from baseline in LDH|Change from baseline in blood urea nitrogen (BUN)|Change from baseline in glomerular filtration rate (GFR)|Change from baseline in hemoglobin || Time-weighted average daily change from baseline in viral load (log10 copies/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average daily change from baseline in viral load (log10 copies/mL)|Time-weighted average daily change from baseline in viral load (log10 copies/mL) in patients with high viral load at baseline|Proportion of patients with high viral load|Proportion of patients with viral loads below the limit of detection|Proportion of patients with viral loads below the lower limit of quantification|Change from baseline in viral load (log10 copies/mL) as measured by RT-qPCR in NP samples|Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions (grade ≥2)|Proportion of patients with injection-site reactions (grade ≥3)|Proportion of patients with hypersensitivity reactions (grade ≥2)|Concentrations of REGN10933 in serum|Concentrations of REGN10987 in serum|Immunogenicity as measured by anti-drug antibodies (ADAs) to REGN10933|Immunogenicity as measured by neutralizing anti-drug antibody (NAb) to REGN10933|Immunogenicity as measured by anti-drug antibodies (ADAs) to REGN10987|Immunogenicity as measured by neutralizing anti-drug antibody (NAb) to REGN10987 || RAND 36|Endothelial dysfunction|6-min walk test|30/60 min chair stand|EQ-5D || The solicited adverse events (SoAEs)|Incidence of abnormal laboratory tests results|Safety of AdimrSC-2f vaccine: AE|Immunogenicity || SarsCoV2 viral copy number|b. Disease progression will be measured on a 7-point scale at 28 days. A 2-point change will be considered disease progression. || Bleeding events and complications || Safety of MVC-COV1901|Immunogenicity (neutralizing antibody titers and antigen specific binding antibody titers)|Immunogenicity (antigen specific cellular immune responses) || Safety indexes of adverse reactions|Safety indexes of adverse events|Safety indexes of SAE|Safety indexes of lab measures|Immunogencity indexes of GMT(ELISA)|Immunogencity indexes of GMT(pseudoviral neutralization test method)|Immunogencity indexes of seropositivity rates(ELISA)|Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|Immunogencity indexes of GMI(ELISA)|Immunogencity indexes of GMI(pseudoviral neutralization test method)|Immunogencity indexes of GMC(Ad5 vector)|Immunogencity indexes of GMI(Ad5 vector)|Immunogencity indexes of cellular immune || Number of participants with adverse events (AEs) and serious AEs|Observed maximum concentration (Cmax) (IV infusion)|Time to reach maximum concentration (Tmax) (IV infusion)|Terminal elimination half life, estimated as (ln2)/λz (t½λz) (IV infusion)|Area under the concentration curve from time zero to the time of last quantifiable concentration (AUClast) (IV infusion)|Area under the concentration time curve from time zero extrapolated to infinity (AUCinf) (IV infusion)|Volume of distribution at steady state (Vss) (IV infusion)|Volume of distribution at terminal phase (Vz) (IV infusion)|Systemic clearance (CL) (IV infusion)|Cmax (IM injection)|Tmax (IM injection)|t½λz (IM injection)|AUClast (IM injection)|AUCinf (IM injection)|Extravascular systemic clearance (CL/F) (IM injection)|Bioavailability (F) (IM injection)|Extravascular terminal-phase volume of distribution (Vz/F) (IM injection)|Number and percentage of participants who are ADA positive || Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event || Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes || Upper respiratory tract viral load at Day 5|Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy|Proportion of participants with undetectable stool viral load after 7 days of therapy and 14 days post-randomisation|Rate of decrease in upper respiratory tract viral load during 7 days of therapy|Duration of fever following commencement of medication|Proportion of participants with hepatotoxicity after 7 days of therapy and 14 days post-randomisation|Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation|Proportion of participants admitted to hospital with COVID-19 related illness|Proportion of participants admitted to ICU with COVID-19 related illness|Proportion of participants who have died with COVID-19 related illness|Pharmacokinetics of favipiravir as measured by Clearance (CL)|Pharmacokinetics of favipiravir as measured by Volume of distribution (V)|Pharmacokinetics of favipiravir as measured by Absorption rate constant (Ka)|Pharmacokinetics of favipiravir as measured by Maximum concentration (Cmax)|Pharmacokinetics of favipiravir as measured by Time to maximum concentration (Tmax)|Pharmacokinetics of favipiravir as measured by Elimination rate constant (Ke)|Pharmacokinetics of favipiravir as measured by Area Under the Curve extrapolated to infinity (AUC (0-inf)|Pharmacodynamics of favipiravir as measured by Rate of viral load decline (delta)|Pharmacodynamics of favipiravir as measured by Maximum increase in viral load under drug treatment (Emax)|Pharmacodynamics of favipiravir as measured by Concentration to achieve half the maximum possible effect (EC50)|Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2 by Day 7 of treatment || Completion of 1-minute test|Completion of 24-hour test || Proportion of patients without any need* for INV until end-of-study (EoS)|Duration of ICU treatment until EoS|28-day all-cause mortality|Time to clinical improvement|Duration of hospitalization|Proportion of patients both for all patients and surviving patients free of renal-replacement therapy (RRT)* until EoS|Proportion of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)* until EoS|Proportion of patients free of INV until Days 6 and 14*|Proportion of patients free of RRT until Days 6 and 14*|Proportion of patients free ECMO until Days 6 and 14*|Proportion of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Proportion of patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28|Proportion of patients with clinical recovery: Axillary temperature ≤36.6 ℃, or oral temperature ≤37.2 ℃, or rectal or tympanic temperature ≤37.8 ℃;|Proportion of patients with clinical recovery: Respiratory frequency ≤24 times/min without oxygen inhalation; and|Proportion of patients with clinical recovery: Oxygen saturation ≥98% without oxygen inhalation|Proportion of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first|Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Duration of INV|Duration of ECMO|Duration of RRT|Duration of auxiliary oxygen therapy (including all types of oxygen therapy)|Duration of hospitalization for survivors|The rate of ICU* admission on Days 6, 14, and 28|Hospital-free days|Time from IMP treatment initiation to death|Time to first prescription of INV|Time to first prescription of RRT|Time to first prescription of ECMO|Time to first prescription of INV, RRT, and ECMO|Time to ICU admission|Cumulative dose of vasoactive therapies and days with vasoactive therapies (daily until Day 14)|Time to clinical recovery|Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28|Correlation of trough levels (quartiles) to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Adverse events (AEs) and serious AEs|Vital signs: height|Vital signs: weight|Vital signs: body temperature (ºC)|Vital signs: pulse rates,|Vital signs: systolic and diastolic blood pressures|Clinical laboratory parameters: blood chemistry|Clinical laboratory parameters: hematology|Clinical laboratory parameters: urinalysis|12-lead electrocardiogram: heart rate|12-lead electrocardiogram: PQ-interval|12-lead electrocardiogram: QRS-interval|12-lead electrocardiogram: QT interval|12-lead electrocardiogram: the heart rate-corrected QTc interval (according to Bazett's formula)|Temperature|D-dimer|Lactate dehydrogenase (LDH)|C-reactive protein|Troponin I|Procalcitonin|Correlation of disease markers to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Decrease of SARS-CoV-2 viral load|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Time course of SARS-CoV-2 viral load|Qualitative virologic clearance in spontaneous sputum and nasopharyngeal swab samples (= 2 consecutive negative SARS-CoV-2 reverse transcriptase polymerase chain reaction tests at least 24 hours apart)|Rate of conversion to a negative SARS-CoV-2 (qualitative) test on Days 6, 14 and 28|Time to conversion to a negative SARS-CoV-2 (qualitative) test|Interleukin (IL)-17|Interleukin (IL)-1ß|Interleukin (IL)-6|interferon gamma (IFNγ)|tumor necrosis factor alpha|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: • Time to appearance of IgA and/or IgG antibodies|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: • Proportion of patients with IgA and/or IgG antibodies on Days 6, 14, and 28 || Safety of UB-612 vaccine|Safety|Immunogenicity || Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results || 2-rank improvement on a 7-point ordinal scale|Changes in alveolar-arterial oxygen partial pressure gradient (A-aDO)|Number of days until discharge from baseline|Proportion of subjects whose category has shifted to Category 1 or 2 || performance of healthcare workers || Incidence of Adverse Reactions (AR)|Incidence of Serious Adverse Events (SAE)|Incidence of Adverse Events/Reactions (AE/AR)|Changes in laboratory test indicators|GMT, seroconversion rate and GMI of Covid-19 S protein RBD specific antibody|GMT, seroconversion rate, GMI of neutralizing antibody (pseudovirus) against Covid-19|GMT and seroconversion rate of neutralizing antibody against Covid-19|Cellular immune response by ELISpot || Feasibility and use of Auscul-X for listening to heart and lung sounds will be assessed by ICU clinicians to determine Auscul-X is at least equivalent to a digital stethoscope using a Likert scale for comparison.|The measurement for acoustic quality in high risk settings determined as clarity and loudness by means of a Likert scale for comparison of Auscul-X and digital stethoscopes by clinicians. || Safety indexes of adverse reactions|Immunogencity indexes of GMT|Immunogencity indexes of neutralizing antibody|Safety indexes of adverse events|Safety indexes of Hematological examination measures（Hemoglobin, WBC）|Safety indexes of Blood routine measures(ALT, AST)|Safety indexes of SAE|Immunogencity indexes of cellular immune || Participants with a disease control status defined as no disease progression to severe. || Duration of viral shedding|Evaluation of Fatality Rate|Evaluation of Clinical Response|Evaluation of Length of Hospital Stay || Time to clinical status downgrade or discharge. || Clinical recovery time || Sensitivity， spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform || lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap || Lung injury|Overall survival|Adverse reactions to plasma || Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Mean of change from pre-dose baseline in ECG readings|Mean of change from pre-dose baseline in WBC count.|Mean of change from pre-dose baseline in RBC count|Mean of change from pre-dose baseline in Platelets count|Mean of change from pre-dose baseline in Hemoglobin result|Serum Concentration of BRII-196 and BRII-198 || Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Serum Concentration of BRII-198 || Incidence of adverse events (AEs) by CTCAE v5.0|Proportion of subjects with SAEs|Proportion of subjects with infusion-related reactions|Proportion of subjects with hypersensitivity reactions|Serum Concentration of BRII-196 || Hierarchical Composite Endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation|AUC SOFA || Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung || Exercise Capacity || Solicited adverse events|Anti-S IgG|SARS-CoV-2 neutralizing titers|Participants achieving ≥4-fold rise of Anti-S IgG|Cellular immune response (IFNγ)|Cellular immune response (T CD4)|Cellular immune response (T CD8)|Serious adverse events|Unsolicited adverse events || Incidence of the Solicited AE in all groups|Incidence of Unsolicited AE in all groups|Incidence of Serious adverse events (SAE) in all groups|Geometric mean titer (GMT) of the IgG antibody against SARS-CoV-2 (ELISA method);|Seroconversion rate of the IgG antibody against SARS-CoV-2(ELISA method )|Geometric Mean Increase Ratio (GMI) of the specific antibody against SARS-CoV-2(ELISA method);|Geometric mean titer (GMT) of the neutralizing antibody against SARS-CoV-2(Pseudo-viral neutralization assay)|Seroconversion rate of the neutralizing antibody against SARS-CoV-2(Pseudo-viral neutralization assay)|Geometric mean increase ratio (GMI) of neutralizing antibody against SARS-CoV-2 (Pseudo-viral neutralization assay)|Geometric Mean Titer (GMT) of the neutralizing antibody against adenovirus type 5 vector|Geometric mean increase ratio (GMI) of the neutralizing antibody against adenovirus type 5 vector|cellular immune response by ELISpot|cellular immune response by ICS || Incidence of AEs|Maximum blood concentration|Time to reach maximum blood concentration|Area under the blood concentration-time curve || Viral nucleic acid test negative conversion rate|Clinical cure rate || Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time || Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen"
COVID-19 Infection,"Qualitative method validation (yes/ no)|Quantitative method validation (antibody concentrations)|Immune cell repertoire sequencing || Invasive ventilation or death|Ventilation|Death|Secondary infections|Digestive tract hemorrhage|Change in 7 points scale || Number of patients admitted with confirmed COVID19 infection|Mortality (ICU)|Mortality (60-day)|Duration of hospitalization in the ICU|Proportion of patients requiring invasive mechanical ventilation|Proportion of patients developing infections during ICU stay|Proportion of patients developing thromboembolic events during ICU stay|Proportion of patients requiring tracheotomy during ICU stay || Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants || Change in severity of COVID-19 infection|Number of days with any symptom of anosmia|Maximal intensity attained in overall assessment of symptoms of COVID-19 infection as measured on Visual Analogue Scale (VAS).|Number of days where rescue medication is required || Seroconversion against SARS-CoV2 in children|Measure of Ab antiN and Ab anti-S1/2|Neutralization activity|Positive qPCR in children|correlation between different Ab and qPCR and neutralization activity|Protective immunity|duration of viral carriage in stool, saliva and or nasopharynx|correlation between antibody profile and viral clearance|Ab profile and memory of immunity|saliva biofluid characteristics of COVID-19 infected|Presence of the virus|Reinfection|Transmission of the virus to the family|Immune response|Mucosal immunity|seroconversion against SARS-CoV2 in parents|Measure of Ab antiN and Ab anti-S1 and neutralization activity|Positive qPCR in parents|correlation between different Ab and qPCR || Survival|Clinical improvement ie percentage of patients not fulfilling the criteria for severe disease || COVID-19 infection || Patient medical files || Factors that predict disease prognosis and outcomes in COVID-19 patients - Hospitalization|Factors that predict disease prognosis and outcomes in COVID-19 patients - ICU|The demographic and clinical characteristics of COVID-19 patients|The demographic and clinical characteristics of COVID-19 patients-Age at diagnosis|The demographic and clinical characteristics of COVID-19 patients -Percentage of patients in each age range|The demographic and clinical characteristics of COVID-19 patients with available PCR (Polymerase Chain Reaction) results|The demographic and clinical characteristics of COVID-19 patientsTime since first symptom until diagnosis|The demographic and clinical characteristics of COVID-19 patients - Physical examination|The demographic and clinical characteristics of COVID-19 patients - Physical examination of patients who are pregnant|The demographic and clinical characteristics of COVID-19 patients - Physical examination Temperature|The demographic and clinical characteristics of COVID-19 patients - Physical examination Heart rate (bmp)|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Hemoglobin|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Hemoglobin II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Red Blood Cells|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology, Red Blood Cells II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology: Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology: Platelet, Leukocyte, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology- INR (International Normalized Ratio)|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Hematology- INR II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Glucose, Cholesterol, Triglycerides|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Glucose, Cholesterol, Triglycerides II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Bilirubin|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Biochemistry: Bilirubin II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Creatinine, Glucose|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Creatinine, Glucose II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other Values: Procalcitonin|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH (Potential Hydrogen), O2 Saturation, FIO2 (Fractional Inspired Oxigen), PAFI [Blood pressure of oxygen / inspired fraction of oxygen (PaO2/FiO2)]|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: PH II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: O2 saturation, FIO2, PAFI|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: O2 saturation, FIO2, PAFI II|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: pCO2 (partial pressure of carbon dioxide), pO2 (partial pressure of oxygen)|The demographic and clinical characteristics of COVID-19 patients - Laboratory values: Other test: pCO2, pO2 II|The demographic and clinical characteristics of COVID-19 patients- Comorbidities, Medication, Symptoms|The patient management (treatment and procedures) in the target population|The outcomes of COVID-19 (discharge, hospitalization, transfer to ICU/ mechanical medical ventilation, in-hospital death) in correlation to patients' clinical and demographic characteristics, and treatment received || Change in participation|Change in patient quality of life|Presence of MRI abnormalities|Neurological symptoms|Deficits in cognition|Deficits in memory|Deficits in visual attention & task switching|Deficits in selective attention, cognitive flexibility & processing speed|Deficits in working memory, attention & executive function|Change in subjective cognitive complaints|Change in depression/anxiety|Change in post-traumatic stress symptoms|Change in family burden|Change in family quality of life|MRI abnormalities (specific) || Characterization of the dynamic changes of innate and adaptive immune responses during SARS CoV 2 infection and convalescence.|Identification of genetic variants that are associated with either severe/lethal COVID-19 or resistance to SARS CoV 2 infection.|Measurement of proinflammatory/anti inflammatory cytokines produced during SARS CoV 2 infection and convalescence, including the IFN signature response.|Survey of other potential blood proteomic biomarkers of disease.|Characterization of serological responses against SARS CoV 2, other viruses or microbiota, and host antigens.|Characterization of intrapatient SARS-CoV-2 genetic variation andevolution during infection and convalescence. || Time to onset of change in the patient's clinical condition|Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE|Length of in-hospital stay|Survival rate|Intubation rate|Proinflammatory markers levels || To compare the efficacy of zavegepant (BHV-3500) to placebo in subjects hospitalized with COVID-19 infection requiring supplemental oxygen, using a six-point rating scale at Day 15. .|Proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at Day 29.|Proportion of subjects who have a 6-point severity rating of 2 or 3, or use any ventilation or high-flow nasal cannula as procedures, on any day through Day 29.|Proportion of subjects admitted into an ICU on any day through Day 29 from AE eCRFs.|Proportion of subjects who have a 6-point severity rating of 3, 4, 5, or 6, are alive, and do not use invasive mechanical ventilation as a procedure at Day 15. The analogous definition is applied to Day 29.|Proportion of subjects who have a 6-point severity rating of 4, 5 or 6, or use a low- or high-flow nasal, are alive, and do not use any ventilation at Day 15. The analogous definition is applied to Day 29.|Difference between treatment groups in the mean 6-point severity rating at Day 29|Number of days from baseline to the first day through Day 29 with any 6-point severity rating greater than baseline.|Number of days from baseline to the first of any 2 consecutive days through Day 29 with all SpO2/FiO2 ratios > 400 on both days.|Number of days from baseline to the first day through Day 29 with ≥ 1-point decrease in any NEWS2 score from baseline.|Number of days from baseline to the first day through Day 29 with all NEWS2 scores < 2 on that day.|Mean change from baseline in NEWS2 score at Days 15 and 29 for subjects who are alive at these time points|Proportion of subjects who have a 6-point severity rating of 5 or 6, are alive, and do not use supplemental oxygen as a procedure at Day 15.|Proportion of subjects who are discharged from the hospital, have a 6-point severity rating of 6 on any day after discharge, and use supplemental oxygen on any day after discharge.|Mean number of days with respiratory rate > 24 breaths/minute through Day 29 for subjects who are alive at Day 29 and do not use invasive mechanical ventilation.|Mean number of days with supplemental oxygen use through Day 29 for subjects who are alive at Day 29. A day in which any 6-point severity rating is 2, 3, or 4, or supplemental oxygen is used as a procedure counts.|Number of days from baseline to the first day through Day 29 on which any SpO2 ≥ 90%, any 6-point severity rating is 5 or 6, and no supplemental oxygen is used as a procedure.|Mean number of ventilator-free days through Day 29 for subjects who are alive at Day 29.|Mean SOFA total scores at ICU admission and Day 29 (if still in ICU), from SOFA and AE eCRFs.|Mean number of days of hospitalization through Day 29 for subjects who are alive on Day 29. All days on study on or before hospitalization discharge are days of hospitalization, from 6-point severity rating scale eCRFs|Number of days from baseline to the first of any 2 consecutive days through Day 29 in which all temperatures show lack of fever on both days and no antipyretics are used on either day.|Number of subjects with deaths, SAEs, severe AEs, and Grade 3 or 4 laboratory test abnormalities at any time on study.|Number and percentage of subjects with severe or life-threatening bacterial, invasive fungal, or opportunistic infections at any time through Day 29 from AE/SAE eCRFs.|Number and percentage of subjects with intranasal administration reactions at any time through Day 29 from AE/SAE eCRFs.|Proportion of subjects with ≥ 50% reduction in eGFR from baseline at any time on study from laboratory test eCRFs. || The percentage of patients who achieve complete recovery|Changes in Chest Imaging|Clinical Status|Time to clinical recovery|Percentages of patients requiring different types of oxygen therapy || SARS-CoV-2 viral load|Rates of AEs and SAEs including laboratory assessments|Viral shedding duration|Hospital Admission || Safety of inhaled rhDNase1 in non-ventilated COVID-19 patients by reporting of adverse events|Time to first study participant enrolment|Enrolment rate|Eligible patient consent rate|Completeness of drug delivery|Completeness of study-specific tests or procedures|Completeness of data collection|Hypoxia rate|Supplemental oxygen requirement type|Progression to mechanical ventilation rate|Duration of mechanical ventilation|Radiological progression|Renal dysfunction rate|Renal dysfunction extent|Secondary bacterial infections rate|Duration of ICU admission|Time to hospital discharge or in-hospital mortality || Change of adherence of the intervention|Change of physical performances || Efficacy of Enzalutamide|Disease progression|Tollerability of Enzalutamide || Change in psychosocial outcomes|Change in stress-related outcomes|Demographic and occupational factors associated psychological and stress-related outcomes || Primary Endpoint|Requirement for mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO)|Infusion-related reactions during 24 hours from the time of infusion|Patient survival at 28 days|Patient survival at 60 days|Requirement for open-label clazakizumab|Time in the intensive care unit (ICU)|Time in the hospital|Time to mechanical ventilation|Clinical status improvement assessed by the World Health Organization (WHO) Clinical Progression Scale at day 14|Clinical status improvement assessed by World Health Organization (WHO) Clinical Progression Scale at day 28|Change in Radiologic Assessment of Lung Edema (RALE) at day 14|Change in Radiologic Assessment of Lung Edema (RALE) at day 28 || Study recruitment|Acceptability of study|Adherence to the practice|Change in resilience|Perceive stress and psychological impact|Breath holding time || Sensitivity of diagnostic test|Specificity of diagnostic test|Concordance of the novel point-of-care diagnostic test|Positive predictive value (PPV) of the novel point-of-care diagnostic test|Negative predictive value (NPV) of the novel point-of-care diagnostic test|Viral load metrics|Disease progression || Imaging data at Baseline|Imagine data at Follow-up || Number of participants who require hospital admission and require supplemental oxygen.|Rate of COVID-19 related hospital admission in patients with SARS-CoV-2 infection.|Number of supplementary oxygen-free days at 28 days (from randomisation).|Number of ventilator-free days at 28 days (from randomisation).|To evaluate overall mortality.|Time to worst point on the scale or deterioration of two points or more (from randomisation) on a 9-point category ordinal scale. || Platelet activation intensity with the occurrence of clinical thrombotic complications || Baseline IgG Assay Information|Change in IgG Assay Information|Compare seroprevalence of anti-SARS-CoV-2 IgG antibodies between groups|Impact of COVID-19 Pandemic on Perceived Wellness and Job Satisfaction"
COVID-19 Pneumonia,"Mean hospitalization time|Mean Oxigenation index evolution|Rate of severe ARDS|Rate and time to dead|Mean time with invasive mechanical ventilation|Time to Viral PCR Negativization || Rate of patients achieving improvement in clinical condition at day 14 after recruitment|Mortality at day 28|Rate of patients achieving improvement in clinical condition at day 28 after recruitment|Rate of patients achieving improvement in clinical condition at day 7 after recruitment|Time to clinical improvement or hospital discharge|Number of ventilator-free days at 28 days|Hospital length of stay|Time to a 2-fold decrease in ferritin|Time to a 2-fold decrease in C-protein reactive|Time to a 2-fold decrease in Dimer-D|Time to a 2-fold decrease in Lactate Dehydrogenase|Time to a 2-fold decrease in Neutrophils to Lymphocytes ratio || time to clinical improvement|Safety of treatments|Tolerability of treatments || Lung diffusing capacity for nitric oxide (DLNO)|Lung diffusing capacity for carbon monoxide (DLco) || Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses || Leg Blood Flow|Clinical evaluations|Clinical characteristics|Presence of device|Therapy|Biochemical evaluations - ProBNP|Biochemical evaluations - D-dimer|Biochemical evaluations - PCR|Functional evaluations - 1-Minute Sit To Stand|Functional evaluations - 6-Minute Walking Test|Functional evaluations - Biceps' muscle strength with dynamometer|Functional evaluations - Quadriceps' muscle strength with dynamometer || Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count || Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion || Change in 6 Minute Walking Test|Respiratory evaluations|Respiratory muscle strength|Functional evaluations - 1 Minute Sit To Stand|Functional capacity with Short Physical Performance Battery (SPPB)|Clinical symptoms with Barthel Dyspnea Index|Fatigue Severity Scale|SF-12 || Evolution of patient status|Assessment of Clinical improvement|Additional visit to the Emergency room|Need for hospitalization|Occurrence of adverse events || residual plasma concentration|The number of days without artificial ventilation|The length of hospital stay in intensive care|Survival|Viral replication in the control bronchoalveolar lavage fluid on Day 7|Viral replication in the control bronchoalveolar lavage fluid on Day 14 || Overall mortality|Clinical outcome assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Time to negative SARS-CoV-2 test || Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline|28-day all-cause mortality rate|Percentage of patients who progress to critical severe|Percentage of subjects achieving recovery in SpO2|Mean change of PaO2/FiO2|Mechanical ventilation time|Time of oxygen therapy|Change in inflammation indicators (CRP or IL-6 etc.) from baseline|Improvement in body temperature|Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&D Blueprint during treatment period|Improvement at D3, 7, 11 & D14 based on ordinal scale recommended by the WHO R&D Blueprint during treatment period|Time to get categories 1 to 4 in the 8-points ordinal scale|Time to attain an improvement of 1 point on the ordinal scale || Lethality rate two weeks after registration|Lethality rate one month after registration|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms || Mortality at day 30|Ventilated Subjects - Ventilator Free Days|Ventilated Subjects - Improvement in Ventilator Settings|High-Flow O2 Support Subjects - Step-Down O2 Therapy|High Flow O2 Support Subjects - Respiration Rate|Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days|Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement|Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score || Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection || Clinical improvement|improvement of laboratory and imaging parameters || Short Physical Performance Battery (SPPB) Score|Functional Independence Measure (FIM) Scale Score|Fatigue Severity Scale Score|Muscle Strength|Two Step Test Length|Six Minutes Walking Test Distance|Muscle Thickness || Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Time to Recovery|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ || Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)|Quality of Life (QoL) as Reported by the Short Form 36 Question Health Survey Version 2 (SF-36v2)|QoL as Reported by the Euro-QoL-5D-5-L (EQ-5D-5L) Instrument|QoL as Reported by Living with Idiopathic Pulmonary Fibrosis Symptoms Questionnaire-Modified (L-IPF-M)|QoL as Reported by the Montreal Cognitive Assessment (MoCA)|Lung Texture as Measured by High-Resolution Computed Tomography (HRCT) Scan of Chest|Prevalence and Incidence of COVID-19 Antibodies || The time from randomization to clinical improvement || Change in Clinical Condition|Rate of mortality within 10-days|Change of Clinical symptoms - respiratory rate|Hypoxia|PaO2 / FiO2 ratio|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group|Complete blood count, cardiac, hepatic and renal profiles; || Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio.|Changes in length of hospital stay|Changes in mortality rate|Changes of С-reactive protein (CRP, mg/L)|Evaluation of Pneumonia Improvement|Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.)|Peripheral blood count recovery time || Number of Participants with Treatment emergent adverse events (TEAEs)|Pharmacokinetic (PK) Plasma Concentrations of Lanadelumab|Percentage Change from Baseline in Plasma Kallikrein Activity (pKal)|Percentage Change from Baseline in Cleaved High Molecular Weight Kininogen (cHMWK)|Percentage Change from Baseline in Functional C1-Inhibitor (C1-INH) || Time to Recovery, Defined as the Time to a Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First)|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Hospital Discharge or ""Ready for Discharge""|Duration of Supplemental Oxygen|Percentage of Participants Alive and Free of Respiratory Failure|Clinical Status, Assessed Using a 7-Category Ordinal Scale|Incidence of Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)|Ventilator-Free Days|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)|Mortality Rate at Days 14 and 28|Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of ≤2 Maintained for 24 hours|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)|Change from Baseline in Respiratory Rate|Change from Baseline in Pulse Rate|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Body Temperature|Change from Baseline in Oxygen Saturation|Change from Baseline in RR, QRS, PR, QT, and QTcF Intervals, as Measured by Electrocardiogram (ECG)|Change from Baseline in Heart Rate, as Measured by Electrocardiogram (ECG)|Number of Participants with Clinical Laboratory Test Abnormalities in Hematology Parameters|Number of Participants with Clinical Laboratory Test Abnormalities in Blood Chemistry Parameters|Serum Concentration of UTTR1147A at Specified Timepoints|Serum Concentration of MSTT1041A at Specified Timepoints|Prevalence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study || Time from randomization to hospital discharge or ""ready for discharge"" up to Day 28|Time to mechanical ventilation or death up to Day 28, defined as the time from randomization to the first occurrence of mechanical ventilation or death (whichever occurs first)|Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status up to Day 28|Clinical status as assessed by the investigator using a 7-category ordinal scale of clinical status on Days 7, 14, 21, 28, and 60|Proportion of participants requiring initiation of mechanical ventilation post-baseline up to Day 28 and Day 60 (participants who do not require mechanical ventilation at baseline)|Proportion of participants who are alive and free of respiratory failure at (participants requiring mechanical ventilation at baseline) at Day 28 and Day 60|Duration of mechanical ventilation (participants requiring mechanical ventilation at baseline) up to Day 28|Time to death up to Days 28 and 60|Mortality on Days 14, 28, and 60 (proportions at specified timepoints)|Time to recovery up to Day 28, defined as the time from randomization to the time when a category of 2 on the 7-category ordinal scale (non-ICU hospital ward or ""ready for hospital ward"" not requiring supplemental oxygen) or better is observed|Proportion of participants who are discharged or ""ready for discharge"" up to Day 28|Proportion of participants who require initiation of mechanical ventilation post-baseline or die up to Day 28 || Change in pulmonary diffusion. || Time to clinical improvement|Rate of patients with Clinical improvement at day 14|Rate of patients with Clinical improvement at day 28|Time to a 2-fold decrease of C-protein reactive from baseline|Time to a 2-fold decrease of ferritin from baseline|Time to a 2-fold decrease of Lactate Dehydrogenase from baseline|Time to a 2-fold decrease of D-dimer from baseline || Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases || Changes of oxygenation index (PaO2/FiO2) ,blood gas test|Detection of TNF-α levels, IL-10 levels|Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).|Changes of c-reactive protein and calcitonin"
COVID-19|SARS-CoV-2,"Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples|Prevalence of anti-SARS-CoV-2 antibodies in blood samples || The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19|The safety and tolerability of 2 IM doses of AZD1222 compared to saline placebo|The reactogenicity of 2 IM doses of AZD1222 compared to saline placebo (Substudy only)|The efficacy of 2 IM doses of AZD1222 compared tosaline placebo for the prevention of SARS-CoV-2 infection|The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of symptomatic COVID-19 using CDC criteria|The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of University of Oxford defined symptomatic COVID-19|The efficacy of 2 IM doses of AZD12222 compared to saline placebo for the prevention of severe or critical symptomatic COVID-19.|The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19-related Emergency Department visits|Antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or saline placebo (Substudy and Illness Visits only)|Anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or saline placebo (Substudy and Illness Visits only)|The efficacy of 2 IM doses of AZD1222 compared to saline placebo in the prevention of COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection|The efficacy of AZD1222 compared to saline placebo for the prevention of COVID-19 following the first dose || Control of Outbreak|Mortality (Residents)|COVID-19 Infection (Residents)|COVID-19 Infection (Staff)|Hospitalization (Residents)|Medication Discontinuation (Residents)|Medication Discontinuation (Staff)|COVID-19 in new LTCH Units (a)|COVID-19 in new LTCH Units (b)|COVID-19 in new LTCH Units (c) || Clinical course of COVID-19|Analysis of development of antibodies to SARS-CoV-2|Estimation of viral load|Detection of viral coinfections|Measurement of cytokine and chemokine response|Characterisation of virus-host-interaction|Identification of disease patterns in proteome|Analysis of change in lymphocyte subtypes|Analysis of histological changes in severe lung disease|Detection of bacterial coinfections || Platelet aggregation analyzed by Multiplate-ADP|Platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.|Platelet aggregation for COVID-19 versus patients hospitalized for respiratory symptoms but negative for Influenza and COVID-19 research.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for influenza or COVID-19 research.|Platelet aggregation in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Platelet aggregation versus time (days) of total hospitalization and in the ICU|Reticulated platelet fraction versus time (days) of total hospitalization and in the ICU|Platelet aggregation versus WHO ordinal scale of outcomes for COVID-19 || epidemiology|Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.|phylogenetic map|interactions between the virus and host cells || Time to first event|Number of in-hospital rate of BARC 3 or 5|Number of participants with Myocardial infarction|Number of participants with Deep Vein Thrombosis|Number of participants requiring Ventilation|Number of All Death|Cause of Death|Number of participants with Stroke|Number of participants with Pulmonary Emboli|Number of participants with Systemic Thromboembolism || Safe and tolerable dose of NT-I7 (Phase I only)|Percent change in absolute lymphocyte count (ALC)|Change in SARS-CoV-2 viral load|COVID-19 Symptom severity as measured by WHO Ordinal Scale for clinical improvement|Time to resolution of COVID-19 symptoms|Incidence of treatment-emergent adverse events|Number of participants by PCR result status (positive or negative) || Proportion of SARS-CoV-2 positive patients for the two different sampling types (saliva vs nasopharyngeal) and two methods (RDT vs PCR) .|Viral loads of SARS-CoV-2 by PCR on saliva and nasopharyngeal swabs || Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only] || Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale|Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5|Toxicity of Study Drug Assessed by Incidence of Adverse Events || Proportion of participants who experience COVID-19 related hospitalization (defined as at least 24 hours of acute care) or death (all cause) up to Day 29.|Time to sustained resolution of all COVID-19-related symptoms|- Change in symptom score (total of ratings)|Time to symptom improvement;|Proportion of participants admitted to hospital due to COVID-19|Proportion of participants with ≥1 COVID-19 related hospitalization|Proportion of participants with ≥2 COVID-19 related hospitalizations|Total number of COVID-19 related hospitalization|Proportion of participants who experience COVID-19 related emergency room (ER) visit|Proportion of participants with ≥1 ER visit due to COVID-19|Proportion of participants with ≥2 ER visits due to COVID-19 through Day 29|Proportion of participants admitted to an intensive care unit (ICU) due to COVID-19|Proportion of patients with all-cause mortality|Proportion of participants with O2 requirement|Proportion of participants with ventilation requirements|Proportion of participants that achieve SARS-CoV-2 clearance in nasopharyngeal (NP) or oropharyngeal (OP) samples|Change from baseline (Day 1) to Day 8 or Day 15 in SARS-CoV-2 viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in NP or OP samples for SARS-CoV-2 test.|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 1, 2, 3 and 4 adverse events (AEs)|Discontinuation or temporary suspension of infusions (for any reason)|Number and proportion of patients with ADE|Mean concentration-time profiles of SCTA01|Incidence and titers (if applicable) of anti-drug antibodies (ADA) to SCTA01 || Proportion of participants with composite end point of mechanical ventilation or death prior to or on Day 28|Change from baseline in the Ordinal 8-point Outcome Scale on Day 28|All-cause mortality on Day 28|Proportion of participants alive and free of respiratory failure on Day 28|Proportion of participants returned to room air by Day 28|Proportion of participants alive and discharged home by Day 28|Proportion of participants with Serious Adverse Events (SAEs)|Proportion of participants with serious infections || Self-reported CAT-score (COPD Assessment Test)|Hospital admissions|Use of antibiotics || Day 14 Binary Assessment of Symptoms|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)|Death|Hospitalization || Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events || Comparaison of the performance of the diagnostic performance (sensitivity, sensibility) of RT-LAMP test using the RT-PCR test as a reference.|Compare the diagnostic performances of RT-LAMP to clinical diagnosis. || Hospitalized patient rates|Emergency room visit rates of patients|Time to emergency room visit|Time to hospitalization|Inpatient length of stay|Time to ICU admission|Time to intubation|Mortality rate|Family members rates with PCR positive test results|Number/characteristics of AEs and SAEs|Changes in blood pressure from baseline|Changes in pulse from baseline|Changes in respiratory rate from baseline|Changes in fever from baseline|Changes in oxygen saturation from baseline || Proportion of patients who are clinically recovered|Time to full clinical recovery or progression to pneumonia or hypoxia|Normalization of chest radiograph|Rate of complications|Death || Critical condition or death|IL-6"
COVID19,"Determine the prevalence of maternal fetal transmission of COVID19|Describe the outcomes of COVID19 positive pregnancies|Understand the placental impact of COVID19 in pregnancy at various gestational ages || Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality || Rate of recovery/ ICU admission/ need for mechanical ventilation|Time to improvement || Efficacy of COVID19 hyper immunoglobulins for patients|Efficacy of COVID19 hyper immunoglobulins for high risk groups|Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events || Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-α|Evaluation of the rate of progression of White Blood Cell (WBC) fraction || clinical characteristics || Percentage of patients with COVID-19 positive samples/biopsies || Missing Outcome Measures || Proportion of asymptomatic children or children with mild respiratory symptoms|Cov2-SARS cases by age|Cov2-SARS cases by symptoms|Viral load|Presence of anti-SARS-CoV-2 antibodies (IgM and IgG) by the rapid serological test || Time to diagnosis of COVID-19 by RT-PCR in subjects|Compliance to complete the study|Sensitivity and specificity of Biovitals® Sentinel|Cross infection rate within the family cluster|Length of hospital stay of positive subjects|Length of ICU stay of positive patients|National Early Warning Score 2 rating of positive patients|Viral load of positive patients|Worsening of comorbidities|Mortality || Comparison of inflammatory/immunological biomarkers <72 hours after development of oxygen requirement|Overall survival at 30 and 100 days after development of oxygen requirement|Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression|Proportion of patients requiring mechanical ventilation|Incidence of secondary HLH (as defined by HS score) || Duration of hospitalization/Recovery status || Proportion of COVID-19 positive cases following intervention|Adverse events || National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers || Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit || Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia|Prevalence odds ratios|Immune response dynamics || Kessler Psychological Distress Scale (K10)|Perceived Stress Scale (PSS-10)|Pittsburgh Sleep Quality Index (PSQI)|Self-compassion scale (SCS)|UCLA Loneliness Scale (UCLA LS)|Uptake of existing mental health services (MHS)|Mood and meaning|Acceptability || Number of subjects for which the prototype swab and the control swab provide the same COVID-19 PCR result || Percentage of SARS-CoV-2 positive subjects|Highest mean WHO descriptive score of COVID-19 in the active treatment group compared to the placebo group.|Highest mean WHO score up to day 60 for the active treatment group as compared to placebo among subjects with a positive test received at any moment during the study after the first visit|Total cholesterol, LDL, HDL, triglycerides (mg/dL) at baseline and at day 60|Ultrasensitive C-reactive Protein (mg/dL) at baseline and at day 60|Difference in hospital length of stay between groups|Difference in duration of mechanical ventilation in both groups|Rate of hospital admissions due to SARS (Severe Acute Respiratory Syndrome) in patients who were negative for SARS CoV-2 upon admission|Mean highest WHO descriptive score in active treatment versus placebo groups up to day 60 among hospitalized patients (WHO grades 3 or more) without serum evidence / PCR detecting SARS-CoV-2 infection|Rate of total events, non-fatal myocardial infarction or non-fatal stroke or death (initial and subsequent), up to day 60 || Change in Inflammatory Marker-CRP|Change in Inflammatory Marker-D Dimer|Change in Inflammatory Marker-LDH|Rates of mechanical ventilation|Rates of clinical thrombotic events|Change in inflammatory-thrombotic response|To compare the incidence of acute kidney injury|Mortality at day 28 || To highlight the perceptions, representations and experiences of septic isolation of patients hospitalized for COVID-19 infection|to identify key elements to improve the medical discourse on septic isolation among patients || The percentage of subjects who develop laboratory-confirmed COVID-19: - with protocol-defined progressive symptoms OR - are hospitalized OR - die|The percentage of subjects who develop symptomatic laboratory-confirmed COVID-19 infection|Mortality rate in subjects who develop laboratory-confirmed COVID19|Percent of subjects who are hospitalized due to having one or more predefined COVID-19 symptoms and laboratory-confirmed SARS-CoV-2|Percent of subjects who require mechanical ventilation, noninvasive ventilation, high flow nasal canula oxygen delivery or ICU admission during the hospitalization for COVID19|Safety and tolerability will be assessed by report of AE/SAEs || Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg|Collection of samples for research|Psycho-social evaluation || Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support || lung injury score|Absolute lymphocyte counts (CD4,CD8 and CD25+FOXP3+ Regulatory T)|Serum levels of IL-6,TNF,TLR3,CRP, ESR and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme II (ACE2) changes over time|Frequency of adverse events and severe adverse events|Angiotensin II (Ang II) changes over time|Sequential organ failure assessment score(SOFA score) over time|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Thrombin time (TT)|IgA antibodies|Melanoma differentiation-associated protein-5, retinoic acid inducible gene-1 (RIG-1) || Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality || Evaluate the safety of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement|Patient survival at 28 days|Patient survival at 60 days|Number of patients requiring the dose of open-label clazakizumab|Reduced duration of intensive care unit stay|Reduced duration of hospital stay|Reduced need for ventilation || Presence of disease || Recruitment Feasibility|Recourse utilization|Safety as reflected on the number and severity of adverse events and serious adverse events|Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.|Effect of basic inflammatory regulation || Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All cause mortality at day 28|Time to clinical improvement || Documented cumulative incidence of SARS-CoV-2 infection|Documented sick leave for SARS-CoV-2|days off work due to the quarantine|Quarantine imposed by close contact outside the center with SARS-CoV-2 positive|Fever|Cumulative incidence of self-reported acute respiratory symptoms|Number of days of self-reported acute respiratory symptoms|Incidence of pneumonia|Cumulative incidence of death from documented SARS-CoV-2 infection|Incidence of admission to ICU|Days in IUC|Incidence of mechanical ventilation|Incidence of hospital admissions|Days of hospitalization|Levels of IgG|Levels of IgM|Levels of SARS-CoV-2 antibodies at the end of the study period || Time-to-clinical improvement|Responders|Critical or dead patients|pO2/FiO2 ratio|SOFA score over time|Hospitalization|Mechanical ventilation|Mechanical ventilation duration|Cardiovascular disease || Percentage of Patients with Clinical Respiratory Aggravation|Percentage of patients hospitalized|Percentage of patients requiring ventilatory assistance|Positive SARS-CoV-2 PCR Test|Duration of symptoms|Duration of hospitalization|Hospitalization intensive care or reanimation|Duration of mechanical ventilatory assistance|Percentage of deaths related to SARS-CoV-2|AE / SAE in both arms || Development of phobias || Occurence|Mortality || Ventilation|Death || Admission to Intensive Care Unit || Primary Safety Measure|Primary Efficacy Measure|Geometric Mean Viral Load|Viral Load Reduction|Time to Clearance of Viral Infection|Proportion of Subjects Demonstrating Clearance of Viral Infection|Median Time to Alleviation of Symptoms || Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment|Time to recover gas exchange to a PaO2/FiO2 ≥300 for at least 24 hours.|Time to reach peripheral capillary oxygen saturation (Sp02) >94% for at least 24 hours. || Adverse Events|Mortality || Clinical improvement.|1. Mortality rate|Rate os serious adverse events .|Clinical improvement by WHO|Clinical improvement by NEWS2 scales|Biologic response|Radiological response|Collection and storage of biological samples || blood sampling for biobank || Clinical Improvement|Viral shedding || Participants who enroll in the ABC Registry"
Corona Virus Infection,"Evaluation of immunological Abbott Architect SARS-CoV-2 IgG Assay|Evaluation of immunological of EUROIMMUN SARS-CoV-2(IgA) ELISA, EUROIMMUN SARS-CoV-2 (IgG) ELISA, WANTAI SARS-CoV-2 Ab ELISA, WANTAI SARS-CoV-2 IgM ELISA, Diasorin LIAISON SARS CoV-2 S1/S2 IgG, Roche ECL anti-SARS-Cov-2 (combined IgG IgA) || Number of subjects who contract COVID-19 while hospitalized for elective outpatient procedures|Patient perception of the effect of pre and post procedure COVID-19 testing on risk of contracting COVID-19 while hospitalized for an elective outpatient procedure. || Percentage of patient who had persistent symptoms after recovery of acute covid19|Type of persistent symptom after acute covid19|Risk factors for persistent symptoms after recovery of acute covid19 || Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation || Differential gene expression profile.|Differential miRNA expression profile.|Multiplex Cytokine assay || Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events|Proportion of subjects with disease worsening event|Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers|Proportion of subjects with a natural antibody response to SARS-CoV-2 infection || Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms|Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2 || Pregnancy Outcome || Serological test evaluation|Population seroprevalence || Cumulative incidence of Grade 3 and Grade 4 adverse events|Cumulative incidence of serious adverse events|Proportion of participants with disease worsening event.|Serum concentration at baseline, Day 7, Day 14, and Day 28 for anti-SARS-CoV-2 antibodies|Percentage of participants with a natural antibody response to SARS-CoV-2 infection || Cohort 1: Days to clinical improvement from study enrolment|Cohort 2: Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Cohort 1: Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Cohort 1: Day 30 mortality|Cohort 1: Change in NEW(2) score from baseline to day 30|Cohort 1: Admission to ICU|Cohort 1: Use of invasive mechanical ventilation or ECMO|Cohort 1: Duration of supplemental oxygen (days)|Cohort 1+2: Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30|Cohort 2: Number participant-reported secondary infection of housemates|Cohort 2: Time to hospital admission related to COVID-19 infection || Number of participants hospitalized and/or requiring repeat emergency room visits|Number of participants admitted to the Intensive care unit (ICU)|Number of participants on a ventilator|All-cause mortality|Time to resolution of COVID-19 symptoms|Severity of symptoms || Safety as assessed by the incidence of Treatment Emergent Adverse Events and Serious Adverse Events|Safety as assessed by the incidence of adverse events of special interest:|Tolerability as assessed by changes in vital signs from baseline (Day 1)|Tolerability as assessed by changes in clinical symptoms from baseline (Day 1)|Tolerability as assessed by changes in clinical laboratory tests from baseline (Day 1)|Time to viral load undetectability;|Proportion of patients with SARS-CoV-2 viral load below the level of detectability;|Mean change in SARS-CoV-2 viral load;|The time to clinical resolution;|Zotatifin plasma concentrations || Mortality rate in COVID-19 patients after high-dose methylprednisolone bolus administration versus mortality rate intermediate-dose dexamethasone pattern (RECOVERY trial)|Admission in Intensive Unit Care (ICU)|Evaluation of respiratory support requirements|Days in hospital|Evaluation of presence of adverse events related with use of high dose of glucocorticoids.|Evaluation of other immunosuppressors requirements.|Status according to the World Health Organization (WHO) 10-category scale. || Psychiatric well-being, level of anxiety, symptoms of depression and coping strategies questionnaire|Prevalence and types of Psychiatric disturbances in patients with COVID-19 infection || Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status|Change in C-reactive protein concentrations|Change in alanine aminotransferase concentrations|Change in aspartate aminotransferase concentrations|Change in bilirubin concentrations|Change in estimated glomerular filtration rate|Change in cardiac troponin concentrations|Change in natriuretic peptide concentrations || Evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to the S protein|Numbers of T lymphocytes producing IFN in response to other CoV-2-SARS viral|Anti-SARS-CoV-2 IgG and IgM levels|SARS-CoV-2 viral load in nasopharyngeal swab || Safety and efficacy assessment of infusion associated adverse events|Chest Radiograph or Chest CT Scan|COVID-19 Quantitative Real Time PCR|Sequential Organ Failure Assessment (SOFA) Score|Rate of mortality|Clinical Respiratory Changes || Positive for SARS-CoV-2|Hospital admissions|Intensive care unit admissions|Intubation and mechanical ventilation|ICU length of stay|Hospital length of stay|Mortality|Incidence of adverse events || Survival|WHO progression scale COVID 19 || Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST) || The survey that was taken by telephone calls || Number of participants who die or require transfer to Intesive care unit|Number of participants who die || Viral load of SARS-CoV-2 in the oral mucosa, oropharynx and saliva of hospitalized patients already considered positive for the virus || Adherence: Number of Days patient exercises independently at least 1 time a day|Recruitment , Implementation and Retention: number of patients contacted, enrolled and completed study|Safety: Number of adverse health events|Activity Measure for Post-Acute Care (AM-PAC).|St George's Respiratory function questionnaire|Short Physical Performance Battery (SPPB )|The Picture Memory Impairment Screen|The Paper Match Stimuli.|The Beck Depression Inventory (BDI).|Discharge Destination || In hospital Mortality|Admission to an intensive care unit (ICU)|Use of invasive mechanical ventilation (IMV)|Presence of thromboembolic disease (deep vein thrombosis, pulmonary embolism or both)|Acute kidney injury (AKI)|Renal replacement therapy (RRT). || Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale|Percent of patients alive at Day 29|Proportion of patients with one point improvement from baseline in clinical status assessment at days 4, 7, 15, 21, 29 using the 7-point ordinal scale|Mean change in the 7-point ordinal scale from baseline to Days 4, 7, 15, 21, and 29 (or until discharge)|Time to resolution of fever|Time to resolution of fever and improvement in oxygenation|Days with fever|Time to change in NEWS2 from baseline|Time to NEWS2 of <2 and maintained for 24 hours|Mean change from baseline to days 4, 7, 15, 21, and 29 in NEWS2|Time-to-improvement in oxygenation|Alive off supplemental oxygen at day 29|Days of hypoxemia|Days of supplemental oxygen use|Days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Ventilator free days in the first 28 days (to day 29)|The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Proportion of patients requiring rescue medication during the 28-day period|The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Days of hospitalization among survivors|Incidence of serious adverse events|The incidence of major or opportunistic bacterial or fungal infections|The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities || Proportion of patients with any TEAEs during the treatment period|Proportion of patients with any AEs, SAEs and drug-related AEs during the study|Proportion of patients with clinically significant abnormality in clinical laboratory tests and ECG during the study|Change from Baseline to Day 7 and Day 14 in PaO2/FiO2 ratio|Time to improvement of oxygenation defined as oxygen saturation (pulse oximetry) >93% and increased ≥1% from Baseline breathing only room air in the 48 hours preceding the measurement during the study|Number of days without oxygen use during the study|Proportion of patients with clinical improvement defined as a reduction of 2 points in the WHO ordinal scale during the study|Number of days hospitalized during the study|Proportion of patients free of respiratory failure during the study|All-cause mortality rate during the study|Change from Baseline to Day 7 and to Day 14 in plasma CRP level|Time to reach 50% reduction from Baseline in plasma CRP level during the treatment period|Number of the patients to reach 50% reduction from Baseline in plasma CRP level during the treatment period|Change from Baseline to Day 7 and Day 14 in serum cytokine levels|Change from Baseline to Day 7 and Day 14 in plasma pRIP1 and pMLKL levels|Change from Baseline to Day 7 and Day 14 in urine NGAL and KIM-1 levels|Plasma drug levels || ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen|Oxygen demand|Duration of hospital stay || Partial pressure of Oxygen in arterial blood to fraction of inspired Oxygen (P/F ratio)|Hospital stay || Relative change from baseline in CRP level|Time to 50% decrease from baseline in CRP level|Time to improvement of oxygenation|Change from baseline in SPO2/FiO2 ratio|Number of Days without need for oxygen support and alive|Numbers of Ventilator-free days and alive|Change from baseline in markers of inflammation: white blood cell count and differential blood lymphocytes|Change from baseline in marker of inflammation: neutrophil to lymphocyte ratio|Change from baseline in marker of inflammation: interleukin 6 (IL-6)|Change from baseline in D-Dimer|Incidence of Deaths|Percentage of participants receiving thrombolytic treatment|Percentage of participants receiving vasopressor treatment|Incidence of serious adverse events (SAEs), adverse events of special interest (AESI) and treatment-emergent adverse events (TEAEs) leading to treatment discontinuation|Incidence of TEAEs leading to study discontinuation (primary reason)|Numbers of Respiratory Failure-Free Days (RFFD) and alive || Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge || Response to treatment: absence of moderate to severe oxygenation impairment (Berlin criteria)|Response to treatment: survival|To quantify the rate of each of: moderate or severe oxygenation impairment within 8 days|To quantify the rate of each of: moderate or severe oxygenation impairment within 15 days|Mortality|Peripheral capillary oxygen saturation (SpO2)|Partial pressure of oxygen/fraction inspired oxygen (PaO2/FiO2)|To assess the rate of patients admitted to the intensive care unit|To measure the length of hospital stay|28-day mortality|To quantify the rate of re-admission within 28 days|To quantify the cumulative incidence and severity of adverse events|Interleukin (IL)-1; IL-2; IL-10; IL-6; IL-8; IL-17; IL-2 receptor levels;|TNFalpha; vascular endothelial growth factor (VEGF); interferon gamma (IFNgamma) levels|Viral load analyses || Survival without needs of ventilator utilization at day 14|WHO progression scale ≤ 5|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge || the number confirmed COVID-19 cases|The person with COVID-19 like symptoms|The improving rate of COVID-19 like symptoms|The satisfaction% to taking JGF || Occurrence of DLTs in all patients during the study treatment, until 21 days after cell infusion and the MTD || Relationship between severity of disease and values of erythrocyte indices|Sensitivity of haemoglobin concentration on severity of the disease || Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge"
Coronavirus,"ICU and hospital mortality of COVID-19 patients|30 days mortality || Prevalence of COVID-19 testing, pneumococcal and influenza vaccinations Using Test History Self-Report|Percentage of Participants Achieving Decreased Levels of COVID-19 Risk Using the NIH Toolbox Surveys on COVID-19|Percentage of Participants Achieving Decreased Levels of COVID-19 Mistrust and Barriers Using the NIH Toolbox Surveys on COVID-19 || Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery || Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality) || Percentage of Participants Achieving Improvement of Health Conditions Using the Severity of Medical Chronic Conditions Surveys|Percentage of Participants Achieving Target Levels of Knowledge, Attitude, and Behaviors with NIH Toolbox Surveys|Prevalence of COVID-19 testing using Participant COVID-19 Test History Survey|Prevalence of pneumococcal and influenza vaccinations using Participant Immunization History Survey || rate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M) among employees working in a GHT Haute Bretagne health establishment.|a) Validation of the Biotech NG test:|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgG|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgM.|b) Risk of presence of anti SARS-CoV-2 antibodies in function:|c) Risk of presence of anti SARS-CoV-2 antibodies in function:|d) Description of the experience and behavioral changes related to the epidemic,|e) Evolution of seroprevalence over time: || Clinical evaluation || Rate of COVID-19 infection || Accuracy of machine learning to be able to predict outcome of coronavirus (COVID-19) infection|Accuracy of machine learning to be able to predict prognosis of coronavirus (COVID-19) infection|Accuracy of machine learning to be able to predict cardiac involvement of coronavirus (COVID-19) infection|Accuracy of machine learning vs human assessment to diagnose coronavirus (COVID-19) infection || Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation || Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by hospital admissions|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by ICU admissions|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by COVID-19 related deaths|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 || Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, Neuron-Specific Enolase, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment || Number of deaths of any cause in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19|Clinical severity score of COVID19 in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19 || Testing Immunity to SARS-CoV-2 over time|Testing the virus over time || Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older.|Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited local reactogenicity signs and symptoms for 7 days following|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of unsolicited adverse events (AEs) for 28 days following vaccination|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 through standard blood tests (full blood count, liver and kidney function tests)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: hospital admissions|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: number of deaths|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring incidence of Covid-19|Assess humoral immunogenicity of ChAdOx1 nCoV-19: antibody quantification|Assess humoral immunogenicity of ChAdOx1 nCoV-19: seroconversion|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays (groups 1, 2, 7 and 8 only)|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1, 2, 7 and 8 only): local reactogenicity|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): systemic reactogenicity|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only)|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) through standard blood tests (full blood count, liver and kidney function tests)|Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) via seroconversion || Proportion of subjects with SARS-CoV-2 positive serology at day 30 following the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Factors associated with a SARS-CoV-2 positive serology at day 30 (+/-7);|Time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology. || Time to SARS-CoV-2 nasopharyngeal excretion, from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Time to apparition of any symptom suggestive of SARS-CoV-2 from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Factors associated with the time to SARS-CoV-2 nasopharyngeal excretion|Factors associated with the time to apparition of any symptom suggestive of SARS-CoV-2 infection|Proportion of contact subjects with apparition of any symptom suggestive of SARS-CoV-2 infection|Proportion of contact subjects with positive serology defined as the presence of SARS-CoV-2 IgM or IgG at day 30 (+/-7) following last contact|Host genetic variants|The time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology. || Validate iAMP testing kit || RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support || Covid-19 vaccine confidence (survey to be developed by study team)|Covid-19 vaccine messaging (messages to be developed by study team & focus group participants)|Covid-19 vaccine uptake (survey to be developed by study team)|Covid-19 vaccine trust (survey to be developed by study team)|Covid-19 vaccine recommendation practices (survey to be developed by study team) || Deterioration resulting in healthcare review|Hospitalisation|Participant anxiety|Participant depression || Impact of plasma exchange || Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the World Health Organisation (WHO) Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) Reverse Transcriptase (RT) - Polymerase Chain Reaction (PCR) on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older || Proportion of subjects who have recovered at Day 28.|Proportion of subjects deceased or requiring mechanical ventilation at Day 28.|Proportion of subjects deceased at Day 28. || Knowledge Beliefs and Practices related to COVID-19|Video Ratings || Missing Outcome Measures || Positive rate of 2019 Novel Coronavirus RNA|Survival rate || The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 || Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]|To compare time to clinical recovery in CX-4945 treatment group evaluated from randomization through Day 28 as compared to the control arm.|To compare changes in clinical status of patients enrolled to CX-4945 treatment arm as compared to the control arm at Day 14 and Day 28.|To evaluate preliminary evidence of anti-viral activity of CX-4945 as compared to the control arm.|Number of Days Hospitalized|To evaluate changes in IL-6 level|To evaluate changes in CRP|To evaluate changes in LDH|To evaluate changes in CPK|To evaluate changes in Ferritin|To evaluate changes in D-dimer|Number of Days of Supplemental Oxygen Use|All-cause Mortality Status|Number of days of on-invasive ventilation/high flow oxygen|Number of days of invasive mechanical ventilation/ECMO|Number of patients returned to room air|Change in pulse oxygen saturation|Number of thrombosis events|Changes in EQ-D5-5L || Assess the incidence of adverse events (intervention-related and intervention-unrelated) in HIV-negative adults aged 18-65 year receiving candidate ChAdOx1 nCoV-19 vaccine or placebo (safety)|Determine if there is a reduction of severe and non-severe COVID-19 disease in HIV-negative adults who receive candidate vaccine ChAdOx1 nCoV-19 compared to placebo recipients (efficacy)|Assess the incidence of adverse events (intervention-related and intervention-unrelated) in HIV-positive adults aged 18-65 year receiving candidate ChAdOx1 nCoV-19 vaccine or placebo (safety)|Assess cellular Immunogenicity of ChAdOx1 nCoV-19 in people living with HIV (immunogenicity)|Assess humoral immunogenicity of ChAdOx1 nCoV-19 in people living with HIV|Assess humoral Immunogenicity of ChAdOx1 nCoV-19 in HIV-negative adults (immunogenicity)|Assess cellular Immunogenicity of ChAdOx1 nCoV-19 in HIV-negative adults (immunogenicity) || Change in viral load|Change in bacterial load|Ventilated associated pneumonia|Days to extubation|Days to discharge|Change in C-reactive protein|7-point clinical outcome|Catheter tip assessment || Evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against COVID-19 disease confirmed with PCR|Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination|Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of serious adverse events|Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of episodes; intensified disease|Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: hospitalization for COVID-19 disease confirmed by PCR|Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: COVID-19 serious disease confirmed by PCR|Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: death associated with COVID-19 disease|Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates)|Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: antibodies against the SARS-CoV-2 spike protein (serum conversion rates)|Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: virus neutralizing antibodies (NAb) against live and/or pseudotyped SARS-CoV-2 virus|Assess the cellular immunogenicity of ChAdOx1 nCoV-19 candidate vaccine || Survival rate|Chest computed tomography|Recovery Time|Depression evaluation || Number of death of any cause, during the 14 days following the inclusion and intervention.|Number of death of any cause, during the 28 days following the inclusion and intervention.|Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19|Rate of patients with at least one severe adverse event at day 28, according to the regulations|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at baseline|Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 28 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 14 days following the inclusion and intervention, compared to mortality data in French hospital geriatric units from the current national survey by the French Society of Geriatrics and Gerontology || Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older || Number of participants with an unplanned hospital admissions|Number of participants with planned hospital admissions that are found to be necessary|Number of participants with an emergency department visits not resulting in hospital admission|Number of planned hospital admissions which are found to be unnecessary || Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication. || Changes in gut microbiome|Changes in fecal bacteria metabolites|Change in plasma cytokines including IL-6, IL-IB, TNF-a and CXCL-10|Trend in symptom score|Change in Quality of life measured by EQ-5D-5L|Change in Quality of life measured by SF-12|Duration of gastrointestinal symptoms|Adverse event assessment || clinical improvement || Complement Activation|Leukotrienes Measure|Coagulation Measure|Hyperinflammation Measure|Cell Count|Cytokines and Chemokine Measure|Endothelial dysfunction measures: || Duration of viral shedding|Incidence of comorbidities|Treatment response as assessed by survival|Mortality of COVID-19|Change in lung ultrasound score|Change in immunoglobulin M (IgM) antibody levels in serum|Change in immunoglobulin G (IgG) antibody levels in serum|Change in immunoglobulin A (IgA) antibody levels in serum || Investigate the safety and tolerability of intranasal administration of ChAdOx1 nCov-19 in healthy adult volunteers: Occurrence of solicited signs and symptoms|Investigate the safety and tolerability of intranasal administration of ChAdOx1 nCov-19 in healthy adult volunteers: Occurrence of unsolicited signs and symptoms|Investigate the safety and tolerability of intranasal administration of ChAdOx1 nCov-19 in healthy adult volunteers: Occurrence of adverse events as identified by change in baseline safety laboratory measures|Investigate the safety and tolerability of intranasal administration of ChAdOx1 nCov-19 in healthy adult volunteers: Occurrence of serious adverse events (SAEs)|Assess the mucosal immune response to intranasal administration of one or two doses of ChAdOx1 nCov-19 in healthy adult volunteers || Demographic information || Safety and Tolerability of Single Ascending Dose (SAD) of EIDD-2801 (Part 1): Adverse Events|Safety and Tolerability of Multiple Ascending Dose (MAD) of EIDD-2801 (Part 3): Adverse Events|Pharmacokinetics (PK) of EIDD-2801 when given as Single Doses (Part 2): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Single Ascending Dose (SAD) (Part 1): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Multiple Ascending Dose (MAD) (Part 3): Maximum observed concentration Cmax|Safety and Tolerability of Single Doses of EIDD-2801 (Part 2): Adverse Events || The number of adverse events after intramuscular injection|Immunogenic end point || Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality"
Coronavirus Infection,"Study the prevalence of Covid-19 infection, coronavirus (SARS coronavirus-2) in territorial agents in the 3 structures : CCTVL, Loire Valley Region Centre, Orleans Metropolitan city|Determine if there is a relationship between the profession carried out by the agents of the territorial community of Orleans metropolitan city, the Loire Valley Region, the CCTVL and contamination by covid-19 || estimation of inflammatory changes in Covid 19 pneumonia by using MVP/PLT ratio || To produce whole genome sequences for the SARS-CoV-2 virus from viral RNA samples|To develop a phylogenetic map of the SARS-CoV-2 virus || Early all-cause mortality|Time in days for SARS-CoV-2 RT-PCR negatives|The serum anti-SARS-CoV-2 antibody titres|Detection of serum antibodies || Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Viral load variation in the nasopharyngeal swab.|Proportion of patients with undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Proportion of patients with clinical improvement. || Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days || Changing of antibody levels against the SARS-CoV-2 glycoprotein S in 42 days|Number of Participants With Adverse Events|Changing of of virus neutralizing antibody titer|Changing of antigen-specific cellular immunity level || Time to negatively RT-PCR|Virologic assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 || Measure of the proportion of contact persons who have developed anti-SARS-CoV-2 antibodies (secondary transmission rate) within the same household of a subject who had a COVID-19 disease assessed by a rapid diagnostic-oriented test || Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions || Emergency department attendance of hospitalisation related to COVID-19|Body temperature|Blood oxygen saturation level|Symptoms as assessed by common cold questionnaire|Symptoms as assessed by FluPro questionnaire|Nasal/throat swab SARS-CoV-2 viral load || COVID-PSL Cohort || Hospitalisation|Death|Transfer to Intensive Care Unit|Oxygen treatment during hospitalisation || To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) || Correlation of surfactant protein genetic variants with severity of COVID-19 infection || Assessment of the presence of the SARS-COV-2 virus at T4|Assessment of the presence of the SARS-COV-2 virus at T1|Assessment of the presence of the SARS-COV-2 virus in the peritoneal effusion at T2 or T4|Assessment of the presence of the SARS-COV-2 virus at T3|Assessment of the presence of the SARS-COV-2 virus at T5 || Percentage of Participants who test positive for SARS-CoV-2 antibodies at first visit|Percentage of Participants who test positive for SARS-CoV-2 antibodies at second visit|Percentage of Participants who test positive for SARS-CoV-2 antibodies at third visit || Voice anaysis || Time to improvement by two points on a seven-category ordinal scale|Clinical status on a seven-category ordinal scale (Day 7)|Clinical status on a seven-category ordinal scale (Day 14)|Overall survival|Time to improvement by two points on the NEWS score|Time to improvement by two points on the NEWS element score for temperature|Time to improvement by two points on the NEWS element score for heartrate|Time to improvement by two points on the NEWS element score for respiratory rate|Time to improvement by two points on the NEWS element score for oxygen saturation.|Admission to intensive care|Requirement for mechanical ventilation|Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|Incidence of bacterial or fungal infection|Incidence of adverse events not directly caused by COVID-19 infection. || Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days). || Time to receipt of SARS CoV-2 testing results|Acceptance of SARS CoV-2 viral testing assessed by proportion of participants who complete a survey|Uptake of SARS CoV-2 testing as assessed by proportion of participants who complete testing|Time to completion of SARS CoV-2 testing|Time from SARS CoV-2 testing to receipt of results || Proportion of patients with clinical worsening|Maximal severity of COVID-19 after treatment|All-cause mortality || 28-Day Mortality|60-Day Mortality|90-Day Mortality || Health workers that require hospitalization || Describe medications used prior to admission associated with worse infection in COVID-19 patients in France.|Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France.|Describe other patient characteristics with worse infection in COVID-19 patients in France.|Quantify other patient characteristics with worse infection in COVID-19 patients in France. || mean change in SARS-Cov-2 viral load in breast milk || Identify antibodies|Determine antibody sensitivity|IgM determination|IgG determination || Percentage of patients who develop severe respiratory failure.|Length of ICU stay.|Length of hospital stay|Survival rate at 6 months|Survival rate at 12 months|Survival rate at 28 days|Percentage of patients with each AE by grade|Percentage of patients who discontinued due to AEs || Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged from Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants ≤ 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Changes from Baseline in Blood Plasma Cytokines Levels|Number of Participants with Adverse Events (AE) || Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged From Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants ≤ 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Number of Participants with Adverse Events (AE) || Mechanical ventilation requirement || Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events || Improvement of the patient's clinical condition based on the WHO ordinal outcomes score|Duration of hospitalization|In-hospital mortality|Temperature (fever)|Need of oxygen therapy|Tolerance as defined by the Incidence of Adverse Events (AE)|Tolerance as defined by the incident of Serious Adverse Events (SAE)|Compliance using the pill count|Blood test || Patient reported main complaint|Conduct qualitative analyses of data || Impact of multi-denominational prayer on clinical outcomes of critically ill COVID-19 patients in the Intensive Care Unit on mortality.|Difference in patient outcomes - Acute Physiology and Chronic Health Enquiry. APACHE II score.|Difference in patient outcomes - Sequential Organ Failure Assessment - SOFA Score|Difference in patient outcomes - Length of stay in ICU.|Difference in patient outcomes - Length of ventilator support|Difference in patient outcomes - length of vasopressor support || Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide || COVID-19 App-based platform|COVID-19 infection || Percentage of Patients requiring supplemental oxygen beyond 8L nasal cannula|Percentage of patients who will require mechanical ventillation|Hospital length of stay|Mortality|Maximum CRP|Maximum troponin elevation || Mortality assessment at D28|Assessment of clinical course in both groups (arms)|Measurement of evolution of respiratory symptoms in both groups (arms)|Assessment of patient satisfaction towards the treatment|Comparison betwween D1 and D28 of patient quality of life evolution between randomization groups (arms)|Comparison betwween D1 and D28 of adverse events and adverse effects between randomization groups (arms) || Proportion of patients in both arms fulfilling the criteria for treatment failure|ICU admission|ICU refusal|Occurrence of complications|lactate dehydrogenase (LDH)|C Reactive Protein (CRP)|ferritin|D-dimer|leukocyte counts || Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.|Incidence of Venous thromboembolism|Incidence of acute myocardial infarction|Incidence of stroke|Number of days using oxygen therapy|Peak of troponin|Peak of D-dimer|Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria || the composite rate of adverse outcomes|The rate of hospitalization || Change in viral load in the oral and nasopharyngeal cavity|Symptom severity in primary participants and co-residents || PCR test|respiratory rate|patients PaO2|serum IL1β|serum TNF-α|Mortality rate || Time to improvement on a 7-point ordinal scale as compared to baseline|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough|Reduction from baseline of NRS for nausea|Time to normalization of fever for at least 48 hours|Time to improvement in oxygenation for at least 48 hours || Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Administration (Injection) Site Reactions|Percentage of Participants with Adverse Events of Special Interest (AESIs)|Change from Baseline in SARS-CoV-2 Spike Glycoprotein Antigen-Specific Binding Antibody Titers|Change from Baseline in Antigen-Specific Cellular Immune Response || Characteristics of lung|Respiratory muscle strength || Hours to recovery|Time fever resolution || The safety of the revised HOME-CoV score strategy for home treatment|The efficacy of the revised HOME-CoV score strategy for home treatment|The applicability of the revised HOME-CoV score strategy for home treatment|The reliability of the revised HOME-CoV score strategy for home treatment|The predictive performances of the revised HOME-CoV score of evolution towards a COVID-19 with a WHO-OSCI≥5.|The predictive performances of the revised HOME-CoV score of evolution towards a COVID-19 with a WHO-OSCI≥6|The predictive performances of the revised HOME-CoV score of evolution towards a fatal COVID-19|Subgroup analysis in patients with confirmed COVID-19 (positive SARS-CoV2 RT-PCR) of the predictive performances of the revised HOME-CoV score|The predictive performances of the revised HOME-CoV score as compared to those of other prognostic scores for COVID-19|Venous thrombo-embolism in COVID-19 patients (ancillary study) || Clearance of viral load|Safety of the treatment || COVID-19 rate"
Coronavirus Infections,"Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients || To better characterize arrhythmic manifestations, employed treatment strategies and long- term outcomes in hospitalized COVID-19 patients in the US through a multicenter retrospective chart review. || Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response || Health status in the 2 years after CoViD-19 diagnosis || Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome || Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-α|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization || Ordinal scale for measuring clinical improvement by the World Health Organization (WHO)|Clinical symptoms improvement, determined with interview and examination|Pain as side effects of the drugs, measured by Visual Analog Scale|Allergic reaction severity in mild, moderate, or severe|Laboratory outcome of leucocyte count|Laboratory outcome of lymphocyte count|Laboratory outcome of neutrophil count|Laboratory outcome of neutrophil to lymphocyte ratio, in scale|Laboratory outcome of D-dimer|Laboratory outcome of TNF-alpha|Laboratory outcome of CRP value|Laboratory outcome of IL-6|Laboratory outcome of ferritin|Laboratory outcome of procalcitonin|chest radiology outcome, measured as improvement of infiltrate based on expert assessment || Clinical|Virological|Microbiological || Proportion of participants in whom there was a positivity for SARS-CoV-2.|Participants who developed mild, moderate, or severe forms of COVID-19.|Measurement of the QT interval.|Widening of the corrected QT interval or with changes in heart rate on the ECG.|Comparison of hematological and biochemical parameters.|Occurrence of adverse events.|Assessment of COVID-19 symptom severity.|Proportion of participants who discontinue study intervention.|Proportion of participants who required hospital care.|Proportion of participants who required mechanical ventilation. || Measurement of the oxygen requirement|Measurement of the reduction in oxygen requirement.|Eliminating supplemental oxygen|Elimination of fever|Time to negative swabs for SARS-CoV-2 by PCR post treatment|Time to negative swabs for SARS-CoV-2 by PCR at Day 14|Intubation and mechanical ventilation requirements|Evaluation of the time to mechanical ventilation|Evaluation the proportion of patients, with at least one measurement of fever at baseline who are afebrile at Day 14|Evaluation of mortality 30 days post-baseline || Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days || Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function || Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Rate of improvement of oxygen-support status|The change of areas of pulmonary lesions shown on chest radiological imaging (chest CT or X-ray)|Blood lymphocyte counts|Level of CRP|Level of hs-CRP|All-cause mortality|Discharge rate || Disease severity|Time to clinical improvement|Proportion of participants alive and not having required invasive or non-invasive ventilation|Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of <300mmHg) || Agreement between the new camera based method and reference standard to estimate body temperature|Agreement between the new camera based method and reference standard to estimate heart rate|Agreement between the new camera based method and reference standard to estimate blood oxygen saturation|Agreement between the new camera based method and reference standard to estimate systolic blood pressure|Agreement between the new camera based method and reference standard to estimate diastolic blood pressure|Agreement between the new camera based method and reference standard to estimate respiratory rate|Prediction of hospital admission using vital signs estimated using reference standard methods|Prediction of death using vital signs estimated using reference standard methods|Prediction of hospital admission using vital signs estimated using the new camera based method|Prediction of death using vital signs estimated using the new camera based method|Prediction of hospital admission using raw camera data|Prediction of death using raw camera data || Measure the time to weaning from high-flow nasal cannula|Measure the time to breathing ambient (room) air|Measure change in lymphocyte count|Measure change in C-reactive protein || positive serologies || Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants"
Covid-19,"SARS-CoV-2 infection || clinical description of covid 19 ambulatory cases.|Biological and radiological description of ambulatory cases|Prevalence of positive cases (PCR and/or serological positive) || IgG anti-COVID-19|IgM anti-COVID-19|IgA anti-COVID-19|Time of onset symptoms|COVID-19 PCR results|Radiological studies || extend of lung involvement|oxygen saturation on admission || Number of Confirmed cases of Covid-19 || Time to clinical improvement|Time to SARS-CoV-2 negativity|Clinical status on day 14|Proportion of participants with SARS-CoV-2 PCR negative result at Day 7|Proportion of participants with SARS-CoV-2 PCR negative result at Day 28|28 Day mortality|Duration of hospitalization in survivors|Time from treatment initiation to death || 1. Analysis of the rate of RT-PCR SARS-CoV-2 positive at 1 month of COVID infection|2. Assess quantitative evaluation of a nasopharyngeal swab SARS-CoV-2 RT-PCR test|Assessment of late stool SARS-CoV-2 RT-PCR, serological status and associated factors with death and RT-PCR results 1 month after the date of first symptom onset || Proportion of patients remaining free of need for mechanical ventilation in both groups|Mortality rate in both groups|Improvement in Pa02/Fi02 ratio in both groups|Duration of hospital stay in both group.|Duration of Intensive Care Unit stay in both groups|Days free of dialysis in both groups|C-reactive proteins|WBC Count || Vital status|Patient requiring more than 3 liters of oxygen to maintain a saturation >95% (intensive care unit or resuscitation department)|Percentage of lung affected on CT|Percentage of lung affected by ground glass opacity on scan|Percentage of lung affected by condensation on scan|Length of hospitalization|rehospitalization|Duration of intubation|Software operating time|C-reactive protein levels|lactate dehydrogenase|lymphocytemia|D Dimers level|Time until onset of symptoms|Time between RT-PCR positive results and first scan|Age|BMI> 30|Medical history of cardiovascular disease|Diabetes|Medical history of respiratory disease|Medical history of immunosuppressed condition|Current or previous history of smoking|Calculate a prognostic score from clinical, biological and CT parameters|Calculate a prognostic score from clinical and biological parameters only|Compare receiver operating curves of prognostic scores with and without CT parameters || The number of patients treated with non-invasive ventilation devices.|Incidence of patients requiring mechanical ventilation|Incidence of organ failure|Duration of hospitalization|Clinical outcome at hospital discharge || INCIDENCE OF CRITICAL PNEUMONIA|MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS|INCIDENCE OF MECHANICAL VENTILATION|DAYS OF MECHANICAL VENTILATION || Serum IgM and IgG antibodies levels in response to vaccine|Sars-Cov2 infection in vaccinated subjects|Covid-19 disease in vaccinated subjects || NETOSIS AND MORTALITY|NETOSIS AND DCOVID-19 SEVERITY|NETOSIS AND INFLAMMATION|NETOSIS AND VENOUS THROMBOSIS || Cross-sectional descriptive study: Egyptian Doctors Stresses, Knowledge and Attitude during COVID-19 Pandemic || COVID-19 Seroconversion rate|Admission for Covid-19 || Change is clinical status|Transfusion related events|SOFA score at days 0, 7, 14, 21, 28|Length of Hospital Stay|Supplemental oxygen|Mechanical Ventilation|Change in mechanical ventilation status|Mortality|Change in inflammatory markers || A retrospective review of the medical records of pregnant women with COVID-19 at the University Hospitals of Strasbourg || Participants with serious adverse events.|Time to clinical improvement.|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006..|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. || Neuroradiological analysis of patients brain MRI || Time to clinical improvement|Time to SARS-CoV-2 negativity|Difference in SARS-CoV-2 AUC|Time to symptoms resolution|Clinical status as assessed with the seven-category ordinal scale on days 7 and 14|Duration of hospitalization in survivors|Day 28 mortality|Time from treatment initiation to death|Proportion with viral RNA detection over time || 14 Day Patient Satisfaction Questionnaire|Emergency Department Visits|14 Day EQ-5D-5L Scores || Death (all-cause mortality) or discharge from ICU (limit of 4 months) || Contacts to the general practitioner|Hospitalizations|Diagnoses|Prescribed drugs || Clinical improve to estrogen therapy in non-severe COVID-19 patients Clinical improve to estrogen therapy in non-severe COVID-19 patients|Clinical improve to estrogen therapy in non-severe COVID-19 patients|Symptomatic improve to estrogen therapy in non-severe COVID-19 patients|Biochemical improve to estrogen therapy in non-severe COVID-19 patients || Assessment of the Pattern and Risk Factors of Covid-19 between infected Healthcare Workers || number of participants with considerable dyspnea: Medical Research Council (MRC, 0-4, lower score better outcome)|number of participants with fatigue|number of participants with anxiety|number of participants with depression|level of independence in B-ADL|level of participation in social|description of qualitative data about patients' experience || Confirmed COVID-19 diagnosis|Hospital admission|Mechanical ventilation|Emergency department revisits|Hospital re-admissions|30 day mortality|Clinical recovery|Patient quality of life || To characterize the changes in brain metabolism in 18F-FDG PET-CT in patients enrolled in Neurocog-Study in the hospital of Nancy|To compare the sensitivity of detection of cerebral abnormalities in MRI and 18F-FDG PET-CT in patients included in Neurocog-Covid study at the hospital of Nancy|To correlate the brain functions impacted on the neuropsychological assessment to the brain metabolism in 18F-FDG PET-CT in patients included in the Neurocog-Covid study at the Nancy Hospital|Correlating brain metabolism to the volume of damage to the lung sequelae of Covid-19. || Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy (after day 2) at day 14|The rate of use of secondary antibiotic therapy (after day 2) at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14 || Development of antibodies || Cohort 1 Index Case: Percentage of patients with COVID-19 associated mild disease/moderate pneumonia progressing to severe pneumonia [Time frame 14 days]|Cohort 1 Household contacts: Percentage of HH members that get infected with SARS-CoV-2 [Time frame 14 days]|Cohort 2: Percentage of COVID-19 associated severe pneumonia patients worsening their condition [Time frame at discharge or day 28 (whichever is first)]|Cohort1 Index cases: Days from recruitment to virological clearance [Time frame 28 days]|Days from recruitment until clinical recovery|- IgG geometric mean titre (GMT) at day 14 and 28 after recruitment [Time frame 14 days and 28 days]|Household contacts IgG geometric mean titre (GMT) at day 14 after recruitment [Time frame 14 days]|Percentage of HH members infected that develop COVID19 symptoms [Time frame 14 days]|Cohort 2 - Hours from recruitment to hospital discharge [Time frame at discharge]|- Hours of duration on oxygen supplementation [Time frame at discharge or day 28 (whichever is first)]|- Death ratio during hospitalization [Time frame at time of death]|- Death ratio at 28 days after enrolment [Time frame 28 days]|- Death ratio at 90 days after enrolment [Time frame 90 days]|- Occurrence of clinical thrombotic and embolic events (myocardial infarction, pulmonary embolus, deep venous thrombosis, cerebrovascular accidents). [Time frame 90 days]|- Occurrence of clinical episodes of gastrointestinal bleeding [Time frame 90 days]|- Change in CRP and D-Dimer levels between baseline (enrolment) and day 3-5 [Time frame 5 days]|- Persisting breathlessness at 28 days and 90 days after enrolment [Time frame 28 days/90 days ]|- Self-reported health at 28 days and 90 days [Time frame 28 days/ 90 days] || Change in COVID-19 severity status || Incidence of SARS CoV-2 infection in healthcare workers|Incidence of hospital admissions caused by SARS-CoV-2 infection|Incidence of ICU admissions caused by SARS-CoV-2 infection|Incidence of pneumonia caused by SARS-CoV-2 infection|Incidence of oxygen support requirement caused by SARS-CoV-2 infection|Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection|Days with body's temperature > 37.5 ºC|Days with cough|Days with fatigue|Medical treatment || adverse events|biomarkers of inflammation and oxidative stress. || SARS-CoV-2-RNA detectability in Swab and Salivette samples || Clinical confirmation of Covid-19 || Retrospective study on the relationship between social status and use of healthcare services during the confinement period linked to the COVID-19 epidemic in Bas-Rhin, France || Retrospective evaluation of the clinical evolution and becoming of adult patients infected with Covid-19 hospitalized at the University Hospitals of Strasbourg from the Emergency Structure || Number of persons in each group who Complain of any suspected Symptoms|Number of persons in each group who are diagnosed as COVID-19 patients || Phenotype/genotype correlation research modulating the severity of Covid-19 disease|Phenotype/transcriptomic correlation research modulating the severity of Covid-19 disease|Phenotype/biomarker correlation research modulating the severity of Covid-19 disease|Development of clinical-biological scores in the severity of Covid-19 disease|Development of predictive imaging scores in the severity of Covid-19 disease|Identification of pathophysiological pathways to susceptibility to Covid-19 disease|Identification of genetic markers for treatment response|Identification of transcriptomic markers for treatment response|Identification of proteomic for treatment response || days of stay at hospital after treatment and discharge|serum zinc before and after treatment|questionnaire including parameters like BMI,,smoking , underling diseases, immunological treatment ,|day of negative conversion for nasopharyngeal swab for rt-PCR FOR covid-19 || Measure level of polymorphisms of interleukin (IL)-12 receptor B1 (IL-12RB1) and TNF- α alpha on COVID-19 related severe acute respiratory syndrome (SARS-CoV-2). || The handheld basic spirometry|PRO scores|Borg Category-Ratio 0-10 Scale|Lung Function Questionnaire with 6-min walk-test|the World Health Organization Quality of Life Brief Assessment [WHOQOL-BREF (HK)]|Body constitution questionnaires || Laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Acute respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Febrile respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of hospitalization for COVID-19 and non-COVID-19 related indications in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Length of hospital stay in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Adverse events and serious adverse events in control arm (Vitamin C)|Drug discontinuation due to adverse events in control arm (Vitamin C) || recover ratio|Time to 2-point improvement|Duration of hospitalization|Time to virological clearance || Arm A: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement|Arm B: number of patients who are discharged from the hospital due to clinical improvement || Clinical complications and Mortality|Neutrophil-Lymphocyte and Lymphocyte-Platelet ratio || Cumulative incidence of symptom resolution|Relative change of symptoms|Assessment of Serious Adverse Events|Clinical improvement|Improvement in peripheral oxygen saturation|Mortality|Comparative proportions of hospitalized patients|Change in systemic inflammation || Acceptance of telemedicine|Patient satisfaction || Determine and compare the seroprevalence for SARS-CoV2 among patients with respiratory pathologies monitored in Pneumology at the Strasbourg University Hospital, in the cluster zone of the Grand Est. || Incidence of changes in specific clinical events in patients with covid-19. || Retrospective description of effect of the ECMO-VV or ECMO-VA in the management of severe ARDS refractory in patients of the Strasbourg and Louvain centres with covid-19 || Biological criteria|Duration of oxygen therapy (days)|Number of intensive care units admissions|Number of days in intensive care units|Mortality rate|Total number of days in hospital|Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score)|Number of bacterial and/or fungal sepsis || Hospitalization or death|All-cause mortality|Time to hospitalization|Length of hospitalization|Admission to intensive care|Adverse events|Serious adverse events || Proportion of patients that worsen|Mortality from any cause at day 28|Proportion of subjects that requires admission to the ICU|Proportion of subjects requiring non-invasive mechanical ventilation|Proportion of subjects requiring invasive mechanical ventilation.|Proportion of subjects with some organ failure|Proportion of patients who have modified their oxygen therapy requirements between treatment assessment visit and baseline|Proportion of subjects with pathological angioTAC|Proportion of subjects with improvement in chest radiography|Proportion and median hospital discharge between patients in both groups.|Titration score|Ferritin score|D-dimer modification score|Adverse events (total and serious).|Related adverse events (total and serious).|Clinically relevant major and non major hemorrhages. || Retrospective analysis of demographic and clinical characteristics of patients with suspected or already confirmed SARS-Cov2 infection with anosmia and / or ageusia || Incidence of adverse events (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of serious adverse events (safety)|All-cause mortality at 29 and 60 days|Incidence of dose-limiting toxicities (safety)|Incidence of laboratory abnormalities (safety)|SARS-CoV-2 viral load as assessed using various sample types|Time to hospitalization, treatment, ICU admission, and discharge from ICU and/or hospital|Anti-drug antibodies|Cytokine levels|AUC of COVI-GUARD (PK)|Cmax of COVI-GUARD (PK)|t½ of COVI-GUARD (PK)|Tmax of COVI-GUARD (PK) || Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|Duration of hospitalisation (days)|Death|Time to become afebrile (days)|Time to non-invasive mechanical ventilation (days)|Time to invasive mechanical ventilation (days)|Time to independence from supplementary oxygen therapy (days)|Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation || Number of Participants Who Achieved Clinical Response by Day 15|Number of Participants Who Achieved Viral Clearance|Number of Participants Discharged or Ready for Discharge|Time to Return to Pre-morbid Supplemental Oxygen Requirement in Participants Receiving Hydrochloroquine or Hydrochloroquine Plus Azithromycin Relative to Placebo || Days alive and out of hospital within 14 days after recruitment|Key-secondary composite endpoint: Occurrence of worsening of COVID-19|Occurrence and time to occurrence of each of the components of the key-secondary composite endpoint|Kidney function assessed by plasma creatinine|Duration of index hospitalisation|30-day mortality|Number of days alive during the intervention period|Number of participants not yet discharged at day 30|Number of readmissions after 30 days.|Kidney function as assessed by eGFR || Proportion of subjects alive and free of respiratory failure at Day 28|Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656)|Proportion of subjects alive and free of respiratory failure at Day 60|Change in clinical status|Discharge from ICU|Time to respiratory failure or death|Change in CRP|Change from baseline in oxygenation index|All-cause mortality at Day 60 and Day 90|Number of days alive and free of respiratory failure at Day 28|Number of days with respiratory failure up to Day 28|Number of days hospitalized up to Day 28|Number of days in ICU (length of stay) up to Day 90|Number of days alive outside of hospital up to Day 28|Number of days alive outside of hospital up to Day 90 || Physical Health|Psychological Health|Coping with distress|Self-Help || Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection || To compare the proportion of participants alive and respiratory failure free of CPI-006 plus SOC versus placebo plus SOC|To compare the time to recovery of CPI-006 plus SOC versus placebo plus SOC|To compare the time to clinical improvement of CPI-006 plus SOC versus placebo plus SOC|To compare the mortality rate due to any cause of CPI-006 plus SOC versus placebo plus SOC || Sensitivity|Specificity|Area under the ROC curve || Pregnancy outcomes|Birth outcomes || Time to recovery|Mortality|Number of Days on mechanical ventilation|Number of days of supplemental oxygen use|Number of patients requiring initiation of mechanical ventilation|Time to improvement in oxygenation for at least 48 hours|Mean change in the 8-point ordinal scale|Proportion of patients on level e-h on the 8-point ordinal scale at day 15|Time to improvement in one category from baseline using the 8-point ordinal scale|Mean change in Sequential organ failure assessment score (SOFA)|Time to resolution of fever for at least 48 hours by clinical severity|Time to improvement of three points from baseline in National Early Warning Score 2 (NEWS2) scoring system|Time to score of <2 maintained for 24 hours in NEWS2 scoring system (National Early Warning Score)|Mean change in NEWS2 scoring system (National Early Warning Score)|Number of days with fever.|Number of days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Cumulative dose of steroids; equivalent to betamethasone dosage (mg)|Cumulative dose of steroids during the study; equivalent to betamethasone dosage (mg)|Incidence of serious adverse events|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Number of ventilator free days in the first 28 days|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients requiring Extracorporeal membrane oxygenation (ECMO)|Number of patients that have been admitted into an intensive care unit (ICU)|Number of patients that have been admitted into a High Dependency Unit (""Intermediärvårdsavdelning"")|Number of days admitted into a High Dependency Unit (""Intermediärvårdsavdelning"") or intensive care unit (ICU) [|Number of days of hospitalization in survivors|Number of patients discharged to institution other than normal domicile.|Number of deaths due to any cause || Test characteristics || Outcome || Adverse events|Change in oxygen saturation || Intraoral viral load|Salivary cytokine profile || Change in pulmonary function (St George's Respiratory questionnaire: SGRQ)|Change in physical function (Activity Measure for Post-Acute Care: AM-PAC)|Change in pulmonary function (Sabrasez single breath count)|Change in pulmonary function (Peak flow tests)|Change in physical function (5 times site to stand test)|Health events (emergency room visits and hospitalizations)|Change in psychological measures (Beck Anxiety Inventory: BAI)|Change in psychological measures (Center for Epidemiologic Studies Depression Scale: CES-D)|Feasibility (Adherence)|Feasibility (Acceptability) || Clinical complete response criteria|Clinical Partial Response criteria|Secondary response criteria || Time to Disease-Aggravation|Complications|Resources|Blood-test || Improvement in the clinical status|Changes in IL-6 concentrations|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation or ECMO|Number of days with high flow oxygen therapy|Changes in other inflammatory markers (C-reactive protein, IL-6) from randomization|Changes in severity markers (D-dimer, lymphocytes, and ferritin) from randomization|Changes in myocardial damage and stress markers (hsTnT and NT-proBNP) from randomization.|Time until reaching a virus negative status by RT-PCR assay|Length of hospital stay|Number of days in the intensive care unit|Mortality by causes || Percentage of children screened with a positive PCR result or a positive Rapid Antigenic Diagnostic (RAD) test|Percentage of PCR-Sars-CoV-2 positive in the sick child in the presence of a Covid contagion in the family environment or not|Percentage of RAD-Sars-CoV-2 positive in the sick child in the presence of a Covid contagion in the family environment or not || Duration of hospitalization|Duration of disease|Hospital-aquired pneumonia|ICU stay duration|Oxygene therapy duration|Mechanical ventilatory support duration || overall response rate in reversal of hyperinflammation || Death|Myocardial infarction|Congestive cardiac failure|Severe cardiac arrythmia|Myocarditis|Respiratory failure including ARDS|Viral pneumonitis|Acute renal failure|Sepsis|Stroke|Gastrointestinal bleeding|Receipt of non invasive or mechanical ventilation|Ability to self care at hospital discharge || Opportunistic fungal co-infections.|Median time|Time between diagnosis and targeted treatment|Preventive strategies || Time to normalize the oxygen requirement (oxygeno-dependence)|Days of hospitalization between the HBO group and the control group.|Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.|Days on invasive mechanical ventilation|Mortality || Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity || Stabilization or Improvement in Clinical Status|Descriptive Clinical Status Analysis|Clinical Status Assessment|Time to death|Mechanical Ventilation Initiation|Mechanical Ventilation Duration|SARS-CoV-2 Test Result|Incidence of all AEs|Incidence of AEs considered related to the IMP|Incidence of serious adverse events (SAEs)|Radiological findings (chest CT/chest X-ray)|Blood glucose|Blood calcium|Sodium|Potassium|Carbon dioxide|Chloride|Albumin|Total protein|Alkaline phosphatase|Alanine transaminase|Aspartate aminotransferase|Bilirubin|Blood urea nitrogen|D-dimer|Fibrinogen|PT|PTT|INR|hsCRP|Ferritin|LDH|IgG|IgM|IgA|IFE|Troponin|Red blood cell count|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|White blood cell count|White blood cell differential|Platelet count|Mean platelet volume|Platelet distribution width|SpO2|A-a gradient|Blood Pressure|Pulse|Respiration Rate|Body Temperature || Adverse events assessment|Blood oxygen saturation|Intensive care unit-free days|Clinical symptoms|Respiratory efficacy|Biomarkers concentrations in plasma || Analyzing the effect of consultation via whatsapp to lenght of stay the patients in emergency medicine department.|Comparing the effect of bedside consultation and consultation via whatsapp on patient discharge or hospitalisation and readmission. || nutritional evaluation|muscle strenght|food intake|biological nutritional status|anosmia || time to exhaustion|Mask comfort/discomfort|heart rate|oxygen saturation|respiratory frequency || Study of the evolution of pregnancies in the first trimester following MAR management during a COVD-19 pandemic period"
Covid19,"Evaluate the diagnostic performance of the ID Now ™ COVID-19 test carried out by nurses in an emergency department in comparison with the reference PCR test: Simplexa ™ COVID-19 Direct || Correlation between Volatile Organic Compounds pattern and COVID-19 detection status.|Correlation between Volatile Organic Compounds pattern and time from COVID-19 detection.|Correlation between the set of Volatile Organic Compounds found in breath biopsy and disease intensity. || Development of a tool to measure frailty|A ""proxy"" variable of the fragility index can be built on the basis of regional administrative databases only.|Give elements to focus the screening policies for COVID19.|Give the prevention of contagion at the elderly population level. || Maternal COVID-19 serology (IgG and IgM)|Maternal/neonatal IgG and IgM concordance|Maternal COVID serology time/profile following vaccination|Breastmilk Serology|Cytokine|Neonatal cytokine|COVID disease vs vaccination immune response|COVID vaccine in pregnant vs nonpregnant || Association between breath VOCs and IgG in blood following second vaccination dose.|Association between VOCs profile and participants' clinical or demographic characteristics || Self-reported Version of the Leeds Assessment of Neuropathic Symptoms and Signs|PainDETEC|EuroQol-5D|The Hospital Anxiety and Depression Scale || immune responses|Duration and breadth of B- and T cell responses|Immune responses in healthy people and patient groups at risk || Correlation between Volatile Organic Compounds pattern in-breath biopsy and COVID-19 detection.|Correlation between Volatile Organic Compounds pattern and the course of the disease || Incidence of COVID-19 cases after two-doses immunization schedule in clusters in the first quarter of study|Incidence of COVID-19 cases after two-doses immunization schedule in clusters up to one year of study|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization status|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to pre-existing SARS-CoV-2 antibodies|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization coverage|Incidence of hospitalization and death due to COVID-19 after two-doses immunization schedule in clusters|Change in average number of reported COVID-19 cases in the study area in comparison to other neighboring cities|Medically-attended adverse reactions to the study vaccine|Frequency of severe COVID-19 cases|Frequency of adverse events of special interest after immunization|Acceptability of the study vaccine|Adherence to vaccination schedule || Incidence of adverse events after receiving the Adsorbed COVID-19 (inactivated) Vaccine|Reactogenicity of Adsorbed COVID-19 (inactivated) Vaccine|Safety of Adsorbed COVID-19 (inactivated) Vaccine|safety of Adsorbed COVID-19 (inactivated) Vaccine || Safety (SAE)|Rate of intubation|Number of participants initiating systemic corticosteroids|Hospital stay|Mortality|ICU stay|Ventilator days|Severity of respiratory failure|Viral load|Antibody measurements|Thrombotic complication|The rate of participants presenting with coagulopathy disorders|Number of participants with laboratory change|Adverse effects|Convalescent plasma efficacy|Convalescent plasma high vs low titer efficacy|Convalescent plasma efficacy according to donor status || Number of participants with severe post-COVID-19 complications|Factors related to the severity of post-COVID-19 complications || to evaluate the role of Ivermectin as a line of treatment for COVID 19|To asses the rate of viral clearance in comparison to other treatment protocols. || Percent Agreement between SOC test and Spartan COVID-19 test || COVID-19 Severity|Overall survival of the hospitalized population || Presence of Volatile Organic Compounds indicating carriers of COVID-19.|Association of exhaled biomarkers with participants' characteristics (age, gender, symptoms-severity, etc.).|sensitivity level of biomarkers' algorithm. || SARS CoV 2 IgG antibodies || Prevalence of COVID-19 amongst county emergency personnel|Correlation of common COVID-19 symptoms with result of COVID-19 test|Co-existence of influenza and COVID-19 positive test results || COVID-19 vaccine effectiveness|COVID-19 PCR confirmation|Vaccine effectiveness by age|Vaccine effectiveness by co-morbidities || Sensitivity and specificity of the COVID-19 antibody testing kit || Neutralizing antibodies|T CD8 lymphocytes|Inflammatory markers|Metabolic markers || Intent to be vaccinated against COVID-19.|Predictors of intent to be vaccinated against COVID-19. || General prevalence of COVID-19|Number of asymptomatic healthcare workers|Number of symptomatic healthcare workers|Number of healthcare workers with a severe form of COVID-19 which led to an hospitalization|Number of healthcare workers infected with COVID-19 and hospitalized in a critical care unit|Influencing factors of the prevalence of the COVID-19 among healthcare workers || Vocal biomarker performance in COVID-19 positive vs. healthy controls|Vocal biomarker vs. symptom burden correlation in COVID-19 positive|Vocal biomarker performance in COVID-19 positive vs. COVID-19 negative symptomatic || prevalence of COVID-19 exposure|correlation between the test results with the presence or lack of COVID-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms || Incidence of COVID-19 infection in the cohort|Link the presence of COVID-19 infection to COVID-19 antibody formation (seroconversion) from quantitative and qualitative testing|Incidence of COVID-19 reinfection|Presence of antibodies in cases of reinfection || Change of the levels of Trace Element at baseline and discharge|Change of Physical Activity Level at baseline and discharge|Change of the levels of Homocystein at baseline and discharge|Change of the levels of Oxidative Stress Parameters at baseline and discharge|Change of the levels of Routine Blood Samples (Hemogram) at baseline and discharge|Change of the levels of Routine Blood Samples (vitamin D, Troponin T, D-Dimer, iron and ferritin) at baseline and discharge|Change of the levels of Routine Blood Samples (C-reactive protein (CRP) and procalcitonin) at baseline and discharge|Change of the levels of Routine Blood Samples (uric acid, chlorine, blood urea nitrogen (BUN) creatine, albumin and bilirubin) at baseline and discharge || Nasal T cell responses|Systemic T cell responses|Systemic and nasal antibody responses || Sensitivity of the COVID-19 diagnostic using the Vocus PTR-TOF process. || COVID-19 Infection|Symptoms|Clinical Observations || Number of Participants with Moderate COVID-19:|Rate of Positive COVID-19 nucleic acid:|Concentration of Active Ingredient:|Rate of Negative COVID-19 nucleic acid || reading of LD and ULD acquisitions || Adoption of lung ultrasound by hospitalists caring for patients with COVID|Percentage of patients with COVID who receive a lung ultrasound|Chest x-ray utilization|Adequacy of Lung ultrasound images, interpretation and clinical decision-making as measured by a lung ultrasound expert|Inpatient mortality || Asses the % agreement between predicate results and Spartan COVID-19 results. || SARS-CoV-2 RNA|breast milk immune|breast milk microbiota|breast milk metabolite|infant microbiota|infant growth and development || Sensitivity of POC testing as compared to core lab testing|Incidence in which decision making would have been altered by POC testing || Seroprevalence estimates in health care professionals || Feasibility of Wearing Fitbit Watch|Feasibility of Wearing TempTraq Patch|Survey Completion Rate || Validate the interest of VOCs analyzed by electronic noses and / or mass spectrometry for the diagnosis of a COVID-19 infection|Identify the nature of VOCs associated with infection by SARS-CoV-2 by mass spectrometry in exhaled air and in sweat|Assessment of the specificity and sensitivity of canine olfactory detection of COVs associated with infection by SARS-CoV-2 (COVID-19) || COVID-19 related mortality within 28 days|COVID-19 related mortality within 60 days|Requirement of invasive ventilation or Pao2/FiO2 ≤ 70 for ≥ 12 hours in the case of patients not eligible for intensive care|Adverse events|Dose of plasma needed to clear viremia|Time to clearance of viremia || The accuracy of the different commercial SARS-CoV-2 antibody immunoassays || Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test on a sample collected by healthcare professionals.|Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test on self-collected sample. || being positive or negative on COVID-19 swab fluid test || antibody synthesis induced after Covid-19 vaccination (positive or negative)|Lack of immunogenicity|COVID-19 incidence|Death during follow up|measure antibody response to vaccines in patient subgroup (diabetic patients, patients with auto-immune disease, patients with cancer, patients with an history of solid organ transplantation)|Longevity of the antibody synthesis induced after Covid-19 vaccination|antibody synthesis induced after one injection of Covid-19 vaccine || pediatric cancer care pattern during COVID 19 pandemic || The effect of Covid 19 pandemic stress on sex ratio at birth || WHO clinical progression scale|lung X-ray|Concomitant medication assessment|Hematimetry|Activated partial thromboplastin time|Fibrinogen level|Fragment D-dimer assessment|Glomerular Filtration Rate assessment|Ferritin blood assessment|C-reactive protein assessment|Lactate Dehydrogenase (LDH) assessment|Troponin I assessment|Procalcitonin assessment|Interleukin-6 assessment|partial pressure of oxygen (pO2) assessment|Quantitative determination of antibodies|SARS-Cov-2 viral quantification in a nasopharyngeal specimen|Time to negativization of RT-PCR|Pneumonia Severity Index (PSI) score|Percentage of patients requiring admission to intensive care units.|Mortality rate at 15 days|Mortality rate at 30 days|Length of stay || rising titre of IGg antibodies || Blood apelins-13/12, -17/16, -36|Blood angiotensin II|Blood Clara cell protein (CC16)|Blood interleukine-6 (IL-6)|Blood surfactant protein D (SP-D)|Plasma apelins degradation speed measurement by UPLC|Plasma ACE2 activity measurement by fluorometry|Plasma kallikrein activity measurement by fluorometry|Plasma neprilysin activity measurement by fluorometry|Plasma ras activity measurement by fluorometry|APACHEII|Oxygenation index|Mechanical ventilation|Pulmonary compliance (Dynamic, real-time, on ventilator device: Tidal volume / Plateau pressure - PEEP|Length of hospital stay|SOFA || Identification of the genetic determinants of COVID-19 severity.|Identification of genetic factors affecting risk of SARS-Cov-2 infection.|Identification of polymorphic variants or mutations affecting treatment response in severe COVID-19 patients. || Measure the phenomenon of vaccine hesitancy among rheumatic diseases patients|Identify factors associated with COVID-19 vaccine hesitancy among rheumatic diseases patients || Evaluate the short- and long-term end-organ complications post-COVID-19 in relation to the severity of the acute COVID-19 infection.|Establish a post-COVID-19 biobank.|The development of any end-organ complication that can plausibly be related to COVID-19. We will evaluate the following end-organ systems: neurological, cardiovascular, pulmopnary, renal, endocrine and metabolic, gastro-intestinal (GI). || Death occurrence within one year of follow up|deaths related to COVID during the one-year follow-up || To evaluate the efficacy and safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins (""S"" and ""M"").|To evaluate safety of two formulations of equine anti-SARS-CoV-2 immunoglobulins (""S"" and ""M"").|Viral load|Mortality|Hospital stay|ventilatory support|blood levels of immunoglobulins against SARS-CoV-2|inflammatory markers|thrombotic marker levels|negativization period of RT-PCR on nasopharyngeal swabbing (Reverse transcription polymerase chain reaction)|SpFI (Partial saturation Oxigen/inspired fraction of Oxigen) gain|Lung Ultrasound|Adverse events || Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 days || case of COVID 19 || Incidence of serious adverse events|Quick SOFA (qSOFA) score|Cardiopulmonary arrest|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Dialysis-free days|Vasopressor-free days|ICU-free days|28-day mortality|Anti-SARS-CoV-2 antibody titers|SARS-CoV-2 RNA by RT-PCR || Mortality of the COVID-19 patients || The dynamics of humoral and cellular immunity || Survival without needs of ventilator utilization or use of immunomodulatory drugs|WHO progression scale ≥6|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs || Prevention of COVID-19 disease|Prevention of hospitalisations due to COVID-19|Incidence of sick-leave episodes || Overall mortality|Mechanical ventilation || Obstetric outcomes|Neonatal outcomes|Infant weight|Infant developmental milestones|Infant COVID-19 diagnosis|Infant height || Death|time to extubation|length of intensive care unit stay|length of hospitalization|immune response|viral load || percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose|the severity of the clinical course of COVID-19|Changing of antibody levels against the SARS-CoV-2 glycoprotein S|Incidence of adverse events in trial subjects|Severity of adverse events in trial subjects || Seroprevelence of SARS-CoV-2 Antibodies among Adults in Kingman AZ|Retention of SARS-CoV-2 Antibodies among Adults in Kingman AZ || Genetic Predisposition to severe forms of COVID-19|Genetic Predisposition to thymic enlargement observed during COVID-19 infection|Genetic Predisposition to enhanced thymic function during COVID-19 infection|Genetic Predisposition to severity of COVID-19 pathology|Basal thymic function in COVID patients|Thymic function in COVID patients|Immune response in COVID patients|Inflammatory response in COVID patients || Prevalence of IgG and IgM anti-SARS CoV2 antibodies || Comparison of the percentage of T cells expressing the HLA-G receptor ILT2 (CD3+CD4+ILT2+ T cells, and CD3+CD8+ILT2+ T cells) between the 3 groups of patients.|Comparison of the expression of circulating soluble HLA-G, between the groups of patients.|1 month survival|Assessment of the severity of the disease according to the isoform of HLA-G|Comparison of the expression of one of the cell receptors of the SARS-CoV-2 virus, called BSG (Basigin), whose expression is modified by the interaction between HLA-G. || Incidence density of moderate and severe clinical cases of COVID-19|Incidence density of moderate and severe clinical cases of COVID-19 after first dose|Incidence density of moderate and severe clinical cases of COVID-19 after second dose|Incidence density of severe clinical cases of COVID-19 after second dose|Median of clinical progression scores between moderate and severe cases|Incidence density of clinical cases virologically confirmed as COVID-19|Mortality confirmed as COVID-19|Incidence density of hospitalizations for any cause|Mortality from any cause|Adverse events|Humoral and cell-mediated immune response|Detection of antibodies against SARS-CoV-2 in samples || Level of serum vitamin D in SLE infected with COVID-19|Vitamin D level with COVID-19 severity || Change in Physical activity (PA) patterns (steps/day) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (time spent in moderate-to-vigorous PA) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (time spent in moderate-to-vigorous PA, in bouts of 10 minutes) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (Mean duration of bouts of moderate-to-vigorous PA) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (total time in sedentary behaviour -lying or sitting-) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in Physical activity (PA) patterns (mean duration of a sedentary bout) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in functional capacity (six-minutes walking test) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in functional capacity (one-minute sit-to-stand test) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in isometric quadriceps strength from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in handgrip force from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in maximal inspiratory and expiratory pressures from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in health-related quality of life from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in dyspnea symptom from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in fatigue symptom from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Change in anxiety and depression symptoms from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Forced expiratory volume in the first second (FEV1) assessed using spirometry at baseline (at hospital discharge or patient's home)|Forced vital capacity (FVC) assessed using spirometry at baseline (at hospital discharge or patient's home)|Ratio between Forced expiratory volume in the first second and Forced vital capacity (FEV1/FVC) assessed using spirometry at baseline (at hospital discharge or patient's home)|Sociodemographics (age) at baseline (at hospital discharge or patient's home)|Sociodemographics (sex) at baseline (at hospital discharge or patient's home)|Anthropometrics (height) at baseline (at hospital discharge or patient's home)|Change in anthropometrics (weight) from baseline (at hospital discharge or patient's home) at 12 weeks and 6 months|Relevant clinical history (diagnosis with lung or cardiovascular disease) at baseline || Titer of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma || Cardiopulmonary exercise test (CPET)|Chalder Fatigue Questionnaire (CFQ)|International Physical Activity Questionnaire (IPAQ)|Generalized Anxiety Disorder (GAD-7)|Patient Health Questionnaire (PHQ-9)|Bergen Insomnia Scale (BIS)|Client Satisfaction Questionnaire (CSQ-8)|Work and Social Adjustment Scale (WSAS)|The Brief Illness Perception Questionnaire (BIPQ)|Modified Medical Research Council Dyspnea Scale (mMRC)|Dyspnea-12|Stair Climbing Test (SCT)|30 second sit to stand test (30STST)|Spirometry, plethysmography and maximal voluntary ventilation|Bioimpedance measurement || anti-SARS-CoV-2 neutralizing antibody titers || Satisfactory outcome || Length of stay|Duration of oxygenation|Duration of ventilation|PCR conversion|Inflammatory biomarkers 1|Inflammatory biomarkers 2|Inflammatory biomarkers 3|Percentage of improvement of subjects' clinical status|X-Ray || Test compliance || Solicited Administration site reactions|Solicited systemic events|Unsolicited Adverse Events and medically attended adverse events|Serious Adverse Events, Medically Attended Adverse Events and New Onset Chronic Diseae|Vaccine ELISA and neutralizing antibody titers for each treatment group|Seroconversion rates || Test Macrophage Migration Inhibitory Factor (MMIF) || MRI with gadolinium|Extra-cellular volume (ECV)|Manganese MRI|CTCA|Cardiac biomarkers|Electrocardiogram || Effect on CBC as per CTCAE v4.0|Effect on biochemistry parameters as per CTCAE v4.0|Lack of adverse events as per CTCAE v4.0 || Prevalence of cardiac abnormality|Demographic variables || Adverse reactions/events|Binding antibody response on ELISA|Neutralizing antibody response on PRNA|T cell response on flow cytometry|Vaccine breakthrough|Adverse events|Binding anti-N antibody response on ELISA|Anti-N and anti-M T cell response on flow cytometry|Th2 cell response on flow cytometry || Design of PAC19QoL Measure (Phase One)|Completion of PAC19QoL Measure monthly for 12 months (Phase Two) || Incidence of venous thromboembolism detected by imaging|In hospital major complications|Number of deep venous thrombosis events|Sequential organ failure assessment|C-reactive protein|Interleukin-6|D-dimer|hs-troponin levels|Acute Respiratory Distress Syndrome|Hospital stay|Right ventricular function|Number of pulmonary embolism events || Serological tests to know the level of antibodies against SARS CoV-2 || COVID-19 disease incidence|SARS-CoV-2 pneumonia|Critical care admission duration with SARS-CoV-2|Oxygen therapy with SARS-CoV-2 || Diagnosing COVID-19 || Network contact test uptake|Network contact test uptake, end of study|Number of contacts tested at 8 weeks|Number of contacts tested|Number of positive contacts at 8 weeks|Number of positive contacts|Test positivity rate per index participant|Proportion of first-time test takers || Acute adverse events (AEs)|Solicited local and systemic adverse events (AEs)|Unsolicited local and systemic adverse events (AEs)|Specific antibody (IgG) response|Neutralizing antibody response|Cellular immune response (IL-4)|Cellular immune response (IFN-γ) || Efficacy - determining hospitalization rates|Safety - documenting adverse events after infusion || The adequacy of nursing care to the needs of the patient|Intervention effectiveness || community pharmacists facing covid-19 || Seroconversion rate|Incidence and severity of adverse events|Virus-neutralizing antibody levels against the SARS-CoV-2|Antibody levels against the SARS-CoV-2 glycoprotein|Percentage of trial subjects with coronavirus disease 2019 (COVID-19) || COVID-19 infection|IgG antibodies seropositivity against SARS-CoV-2 || Identifying different co-morbidities and complications of covid-19 infection. || Evaluate the performance in terms of sensitivity and specificity of the technique by spectral analysis combined with artificial intelligence for the SARS-CoV-2 virus versus to the reference technique by RT-qPCR|Evaluate the detection limit of the technique by spectral analysis combined with artificial intelligence || Crude Mortality in COVID-19 patients|Mechanical ventilation assistance (MVA)|Hospital stay|Inflammatory markers IL6|Inflammatory markers CRP|Inflammatory markers Procalcitonin|Inflammatory markers Ferritin|Thrombotic markers PTT|Thrombotic markers PT|Thrombotic markers D Dimer|Thrombotic markers Fibrinogen|SpO2/FIO2 ratio|Changes in viral load|Modified Sequential Organ Failure Assessment (mSOFA)|WHO 8 point ordinal scale|Anti SARS-CoV-2 antibodies|Adverse events || Covid-19 positive || describe cancer patients with COVID-19 and their clinical course || IgG SARS CoV2 || Levels of IgG in the serum of recovered COVID-19 patients|Factors related to IgG level || Rate of adverse events related to the infusion of anti-SARS-CoV-2 immunoglobulin through CTCAE v4.0.|Clearence of viral RNA evaluated by RT-PCR|Reduction of viral load evaluated by area under the curve of RT-PCR values|Length of hospital stay|Orotracheal Intubation Rate|Infusional reaction rate|Mortality rate|Assessment of adverse events|Evaluation of clinical status|Modulation of serum and cellular inflammatory marker || Mortality|Number of confirmed COVID-19 cases in Siaya || Incidence rate of positive SARS-Cov-2 RT-PCR in Bamako hospital departments during the study|Number of Cepheid Xpert® Xpress SARS-Cov-2 cartridges available for 19.8 USD/number required for the project|Percentage of positive serological tests among the caregivers of the hospital departments of Bamako.|Percentage of caregivers asymptomatic but immunized to SARS-CoV-2|Percentage of caregivers immunized and re-infected with SARS-CoV-2|Number of SARS-CoV-2 mutations/variants detected during the study|Percentage of SARS-CoV-2 mutations/variants detected during the study || Difference in Days Alive and Out of Hospital || Mortality || A SARS antibody semi-quantitative test for the Covid Spike and Neutralizing antibody will be paired with ongoing surveys to measure the response people with blood cancer have to the COVID-19 virus.|A SARS antibody semi-quantitative test for the Covid Spike and Neutralizing antibody will be paired with ongoing surveys to measure the response people with blood cancer have to the COVID-19 virus vaccination. || PCR of SARS-Cov2 RNA || Estimate clinical symptoms by days of follow-up in patients with COVID-19 under treatment with Azithromycin/Ivermectin/Ribaroxaban/Paracetamol vs. Azithromycin/Ribaroxaban/Paracetamol followed by video call for 14 days from U.M.F 13 and U.M.F 20|To assess adverse drug reactions by days of follow-up in patients with COVID-19 under treatment with Azithromycin/Ivermectin/Ribaroxaban /Paracetamol vs. Azithromycin /Ribaroxaban/Paracetamol followed by video call for 14 days from U.M.F 13 and U.M.F 20 || Body Temperature|COVID-19 Symptoms || Collect breath samples from Covid-19 positive patients at time of diagnosis and post recovery || Clinical deterioration|Relief of symptoms|Mortality|Complications at follow up|Cost || Microbial infections and antimicrobial resistance (AMR) patterns associated with hospitalized patients with 2019 novel coronavirus disease (COVID 19) || Length of stay|Post-discharge destination|Readmission rate 30 days after discharge|Change in patient prognosis|Change in functional capacity (lower limb function)|Change in functional capacity (handgrip strength) || Cumulative incidence of serious adverse events related to the treatment intervention.|Mortality at Day 28 post-hospital admission.|Length of hospital stay|Length of supplemental oxygen requirement.|Length of mechanical ventilation requirement.|Length of ICU stay || Post-COVID-19 Functional Status Scale (Turkish version)|Dyspnea assessment|Evaluation of daily living activities|Assessment of the structural validity of the Post-COVID-19 Functional Status Scale || Comparison of the performance of the Biosynex Covid-19 Ag BSS rapid antigenic test against the RT-PCR Covid-19 reference test with the AllplexTM 2019-nCoV kit (Seegene, South Korea) in children with symptoms consistent with Covid19 infection|Sensitivity of the Biosynex Covid-19 Ag BSS rapid antigenic test compared to the RT-PCR Covid-19 reference test performed with the AllplexTM 2019-nCoV kit in children.|Comparison of the time it takes to report results between the two methods || Description of clinical manifestations|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of biological manifestations|Patient-related prognostic factors|Virus-related prognostic factors|Vocal biomarker of Covid-19 related respiratory complications || Demonstrate clinical agreement between an EUA RT-PCR methodology and the Nanomix eLab® COVID-19 Rapid Antigen Panel || decreasing the number of cases infected with covid 19|Measurement of the emergence of clincal symptoms of COVID 19|the seroprevalence of SARS- CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving DOXY compared to those receiving placebo. || Change in plasma IL-6 levels|COVID-19 disease progression by Week 2|Change in dyspnea|Change in diarrhea|Change in fever|Change in neutrophil count|Change in lymphocyte count|Change in neutrophil/lymphocyte ratio|Change in platelet count|Change in C-reactive protein|Change in ferritin|Change in D-dimer|Change in AST|Change in ALT|Time to worsening clinical status || Fatigue Severity Scale|COVID Diagnosis|Fatigue evolution|Sleep hygiene || The first co-objective of this experimental study is to determine if VOCs analyzed by electronic noses are of interest for the diagnosis of an infection by SARS-CoV-2 (COVID-19) infection.|The second co-objective of this experimental study is to determine if VOCs analyzed by mass spectrometry is of interest for the diagnosis of an infection by SARS-CoV-2 (COVID-19) infection.|Identify the nature of VOCs associated with infection by SARS-CoV-2 by mass spectrometry in exhaled air and in sweat|Assessment of the specificity and sensitivity of canine olfactory detection of COVs associated with infection by SARS-CoV-2 (COVID-19) || Case fatality || Assess clinical diagnostic performance of the KnowNow SARS-CoV-2 Rapid Antigen Test|Efficacy to assess the test compared to the reference test method|Usability Questionnaire to evaluate the use of the test with 2 saliva collection methods || routine biomarkers and blood cell count are discriminant to diagnose COVID-19|Probability of COVID-19 and CRP|Probability of COVID-19 and PCT|Probability of COVID-19 and Ddimers|Probability of COVID-19 and NTproBNP|Probability of COVID-19 and cTnT-HS|Probability of COVID-19 and blood cell counts|performance of combined routine biomarkers|Assess usual biomarkers and blood cell count || The main objective of the study is to demonstrate the presence of SARS-COV-2 in the exsufflated gas at the end of laparoscopy.|The secondary objective of the study is to demonstrate the presence of SARS-COV-2 in the peritoneal fluid during laparoscopy || Comparison of participant clinical status between treatment arms|Time to an improvement of one category from admission using 7-point ordinal scale.|Participant clinical status on 7-point ordinal scale|Mean change in the 7-point ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of ≤ 2 and maintained for 24 hours, whichever occurs first.|Change from baseline of National Early Warning Score (NEWS)|Number of oxygen therapy free days|Incidence and duration of new oxygen therapy use during the trial|Number of mechanical ventilator free days|Incidence and duration of new mechanical ventilation use during the trial.|Duration of hospitalisation (days).|28-day mortality|Cumulative incidence of Serious Adverse Events (SAEs)|Discontinuation or temporary suspension of treatment|Changes in white cell count (x10^9/L) over time (hospitalised participants only)|Changes in haemoglobin (g/L) over time (hospitalised participants only)|Changes in platelets (x10^9/L) over time (hospitalised participants only)|Changes in creatinine (umol/L) over time (hospitalised participants only)|Changes in total bilirubin (umol/L) over time (hospitalised participants only)|Changes in Alanine Aminotransferase (U/L) over time (hospitalised participants only)|Changes in Aspartate Aminotransferase U/L over time (hospitalised participants only)|Adverse events of special interest- hyperkeratosis, infections and dental complications || Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) within the CX-4945 Treatment Group assessed by CTCAE v5.0|Clinical Recovery associated with COVID-19 within the CX-4945 Treatment Group|Anti-Viral Activity of CX-4945|Maximum Plasma Concentration [Cmax] of CX-4945|Clinical Benefit of CX-4945 i.e. All-Cause Mortality|Clinical Benefit of CX-4945 i.e. Number of Respiratory Failures|Clinical Benefit of CX-4945 i.e. Number of Hospitalized Days|Clinical Benefit of CX-4945 i.e. Changes in Pulse Oxygen Saturation|Clinical Benefit of CX-4945 i.e. Changes in Clinical Status|Clinical Benefit of CX-4945 i.e. Self-Reported Quality of Life|CX-4945 Inflammatory Marker Outcomes i.e. Plasma IL-6|CX-4945 Inflammatory Marker Outcomes i.e. Plasma CRP|CX-4945 Inflammatory Marker Outcomes i.e. Plasma LDH|CX-4945 Inflammatory Marker Outcomes i.e. Plasma CPK|CX-4945 Inflammatory Marker Outcomes i.e. Plasma Ferritin|CX-4945 Inflammatory Marker Outcomes i.e. Plasma D-Dimer || Hospital free survival.|All-cause mortality|Hospital readmission after discharge from index hospital admission|Suspected Serious Adverse Reactions|FACIT-Fatigue|Modified MRC Dyspnoea Scale|COVID-19 core outcome measure for recovery|Patient Health Questionnaire-2 (PHQ-2)|Generalized Anxiety Disorder-2 (GAD-2)|PTSD Checklist (PCL-2)|Quality of life using the EQ5D-5L|Intervention tolerability using the FACT-GP5|Additional disease specific systemic symptoms || Clinical parameter of acute lung disease|Death|Biochemical parameter of acute lung disease || Quality of life assessment of a survivor of severe COVID-19 infection 6 months after hospital discharge;|Quality of life questionnaire EQ-5D|Evaluation of dyspnea by the Modified Medical Research Council Scale (mMRC)|The Hospital Anxiety and Depression Scale|Baseline and Transition Dyspnea Indexes (BDI-TDI)|Clinical frailty scale measured after discharge from the ICU,|Lawton-Brody Instrumental Activities of Daily Living (iADL) scale|Muscle strength according to the Medical Research Council (MRC) scale|Maximum inspiratory pressure, diaphragmatic mobility and diaphragm thickness|Sit-to-stand test in 1 minute|Cognitive dysfunction measured using the Montreal Cognitive Assessment (MoCA) test|Pulmonary function test with Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurements|Hemoglobin, hematocrit, creatinine and Fasting plasma glucose (FPG)|Quantitative computerized tomography scan|Maximum VO2 during Cardiopulmonary exercise testing|Return to work|Occurrence of thromboembolic events after|Occurrence of falls|Need for readmission|Mortality || Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals || Evaluation of post-traumatic stress symptoms (Post traumatic Stress Disorder (PTSD) scale) at M3 for patients and caregivers|Evaluation of post-traumatic stress symptoms (PTSD scale) at M12 and M24 for patients and caregivers|Change from M3 in the score of the mental (MCS), physical (PCS) components and the scores of the individual domains of the questionnaire SF36 to M12 and M24 for the entire study population|% of patients presenting a positive result by ELISA serology (= without distinction of IgG, IgM and IgA)|Comparison of M0 chest CT results at each follow-up for the entire study population || Improvement of COVID-19 disease status|Proportion of patients who died or had respiratory failure.|Disease progression of COVID-19|All cause of death|Proportion of clinical relapse|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of high flow oxygen therapy|Absolute lymphocyte count|Change of D-dimers || The proportion of participants who require COVID-19 related hospitalization, are hospitalized for COVID-19 related medical support, or are deceased within 28-days following randomization.|Time to substantial alleviation of COVID-19 symptoms. || Assessment of seroconversion, defined as development of immunoglobulin G (IgG) antibodies against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) after vaccination of 2 doses in seronegative individuals.|Assessment of any Adverse Events (AE) of the given vaccine [Safety and tolerability].|Frequency of SARS-CoV-2 infection documented by positive polymerase chain reaction (PCR) test.|Assessment of humoral and cellular immune responses in blood and saliva.|Assessment of escape mutations of sequencing SARS-CoV-2 at breakthrough infection.|Assessment of graft versus host disease in allogenic stem cell transplanted persons after given vaccine.|Assessment of biopsy verified rejection in solid organ transplanted persons after given vaccine.|Assessment of viremia, defined as HIV ribonucleic acid (RNA) > 50 copies/milliliter after vaccination in HIV infected persons.|Assessment of HIV deoxyribonucleic acid (DNA) levels after given vaccine in HIV infected persons.|Assessment of oral and gut microbiota in immunosuppressed and controls, in relation to immune response to vaccination. || Total number of tests among network members referred for COVID testing (network tested) || Probability of Participants for Hospitalisation or Fatal Outcome|Probability of Participants for Intensive Care Unit Admission|Probability of Participants for Fatal Outcome|Prediction of persisting health impairment by using standardized questionnaires|Detection of symptoms, vital parameters and comorbidities predicting clinical course|Influence of size of training data set|Influence of viral load on the course of disease/ clinical outcome|Influence of different virus variants on the course of disease/ clinical outcome|Influence of SARS-CoV2 vaccination (yes/no) on the course of disease/ clinical outcome|Evaluation of parameters (symptoms, vital parameters, comorbidities) according to their potential of clinical course predictions|Probability of Participants for hospitalisation|Influence of different SARS-CoV2 vaccines on the course of disease/ clinical outcome || Antibody seroconversion rate (≥ 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post second vaccination|Incidence of local and systemic solicited Adverse Events (AEs) for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination)|Incidence of unsolicited AEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) through 29 days post each vaccination|Incidence of SAEs and AESIs after first vaccination until study end (Day 180)|Antibody seroconversion rate (≥ 4 fold increase from baseline) against SARS-CoV-2 Spike protein 29 days post first vaccination|Antibody seroconversion rate (≥ 4 fold increase from baseline) against Receptor Binding Domain (RBD) antigen|Geometric Mean Titre (GMT) and Geometric Mean Fold Rise (GMFR) of immunogenicity against Spike and RBD antigens at the day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).|Antibody seroconversion rate (≥ 4 fold increase from baseline) SARS-CoV-2 neutralising antibodies|GMT and GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180) || Sensitivity of CoV-SCAN daily testing regimen|Specificity of CoV-SCAN daily testing regimen|Time from CoV-SCAN positive to PCR positive result || Mortality|Hypoxemia Resolution|Days from admission to intensive care unit and administration of ANALOG PGE1|ICU stay|Days with high flow oxygen|Days of invasive mechanical ventilation prior to administration of PGE1 ANALOG|Evolution time of the disease || Genetic variants with vs without COVID-19|Cognitive function at baseline|Change in cognitive function at 1 month|Genetic analysis || Change in SARS-CoV-2 positivity in the saliva|Change in the SAR-CoV-2 viral load in the saliva|Change in Wisconsin Upper Respiratory Symptom Survey (WURSS-44)|Change Sino nasal Outcome Test (SNOT-22)|Change in clinical condition || Data collection of patient affected by COVID-19|Application of Machine Learning algorithm on data of patients affected by COVID-19 || To predict and monitor the transmission of SARS-CoV-2 in a rural Sub Saharan setting.|To inform intervention strategies targeted at limiting the spread of COVID-19 in a rural Sub Saharan setting.|To create social contact matrices that can be used to parameterise dynamic transmission models. || Forced vital capacity (FVC)|Lung diffusion capacity for carbon monoxide (DLCO)|6-minute walk test distance|Short-form 36 questionnaire (SF-36)|Oxygen uptake at peak exercise|Minute-ventilation/carbon dioxide output during exercise|Dyspnea during exercise|Thoracic CT findings|Forced expiratory volume in 1 second|FEV1/FVC ratio|Forced vital capacity %predicted (FVC%)|Signs and symptoms|Time to hospital discharge|ICU discharge|Weaning from intubation|Weaning from supplemental oxygen|Weaning from noninvasive mechanical ventilation|Mortality || number of persons at risk of infection up to date with their mandatory and recommended vaccinations during COVID19 pandemic|Number of persons at risk of infection accepting COVID19 vaccination || Change from baseline reactive to non-reactive on COVID 19 RT PCR in 7 days|Change of time to clinical recovery from baseline within 7 days || Training, testing and validation of an AI platform for predicting Italian first wave Covid-19 patients prognosis.|Validation of the developed AI platform on italian second wave of Covid-19 patients || Reduction of COVID-19 symptoms after 1 week of treatment with metformin and LDN|Reduction of COVID-19 symptoms after 2 weeks of treatment with metformin and LDN|Reduction in recovery time from COVID-19|Reduction in hospitalizations|Reduction in requirement of additional treatment due to COVID-19|Reduction in mortality || SARS COV 2 Viral clearance|World Health Organization COVID-19 ordinal improvement score|Clinical recovery|Spectrum and severity of adverse events|Maximum Plasma concentration|Minimum Plasma concentration|Area Under the Curve || What measures have been implemented to avoid SARS-COV2 transmission when taking care of patients, during the COVID-19 pandemic.|Professionals SARS-COV2 infection rates.|Professional financial impact. || CT evidence of peculiar patterns in Covid-19 pneumonia || Detection of antibodies to SARS-CoV-2 in human serum and plasma || Histopathological and ultra-structural findings|Molecular characterization|Hidden pulmonary superinfections|Histopathological / ultra-structural findings and clinical / biological expression correlation || To evaluate the time to sustained clinical resolution of symptoms of COVID-19|Time to Complete Clinical Resolution|Change from Baseline in Coronavirus Disease of 2019 (COVID-19) Symptom Severity Score|Scoring of World Health Organization (WHO) Clinical Outcome Scale (9-point Scale)|Rate of Hospitalization Through Day 28|Rate of Progression to Oxygen Therapy Through Day 28|Duration of Hospitalization|Mortality Rate|Time to Viral Clearance Based on polymerase chain reaction (PCR) Test for Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2)|Change from Baseline in log10 Viral Load || Decreased admission rate to the hospital secondary to respiratory illness related to COVID-19|Decrease in total duration of symptoms secondary to respiratory illness related to COVID-19|Assessment of White Blood Cell Count|Assessment of Hemoglobin level|Assessment of Hematocrit level|Assessment of Platelet Count|Assessment of Sodium level|Assessment of Potassium level|Assessment of Chloride level|Assessment of Carbon Dioxide level|Assessment of Blood Urea Nitrogen level|Assessment of Creatinine level|Assessment of Calcium level|Assessment of Glucose level|Assessment of Total Bilirubin level|Assessment of Total Protein level|Assessment of Albumin level|Assessment of Aspartate Aminotransferase level|Assessment of Alanine Aminotransferase level|Assessment of Alkaline Phosphatase level|Assessment of Ferritin|Assessment of D-dimer|Assessment of Creatine Phosphokinase|Assessment of C-Reactive Protein|Assessment of Prothrombin Time and International Normalized Ratio|Assessment of activated Partial Thromboplastin Time|Assessment of Fibrinogen Activity|Assessment of Interleukin 6 level|Assessment of Interleukin 6 receptor level|Assessment of Tumor Necrosis Factor Alpha level|Assessment of Tumor Necrosis Factor Alpha Receptor level|Mortality|Measurement of Participants with Medication Side Effects|Measurement of Participants with new onset Shortness of Breath or Changes in Shortness of Breath Severity|Measurement of Participants Pulse Oximetry readings on room air|Measurement of Participants with new onset Red Eyes or Changes in Red Eyes Severity|Measurement of Participants with new onset Chills or Changes in Chills Severity|Measurement of Participants with new onset Runny Nose or Changes in Runny Nose Severity|Measurement of Participants with new onset Sore Throat or Changes in Sore Throat Severity|Measurement of Participants with new onset Loss of Smell or Changes in Severity of in Loss of Smell|Measurement of Participants with new onset Loss of Taste or Changes in Severity of Loss of Taste|Measurement of Participants with new onset Body Aches or Body Pains or Changes in Body Aches or Body Pains Severity|Measurement of Participants with new onset Diarrhea or Changes in Diarrhea Severity|Measurement of Participants with new onset Headaches or Changes in Headaches Severity|Measurement of Participants with new onset Anxiety or Changes in Anxiety Severity|Measurement of Participants with new onset Fatigue or Changes in Fatigue Severity|Measurement of Participants with new onset Trouble Concentrating or Changes in Trouble Concentrating Severity|Measurement of Participants with new onset Cough or Changes in Cough Severity|Measurement of Participants with new onset Vomiting or Changes in Vomiting Severity|Measurement of Participants with new onset Nausea or Changes in Nausea Severity|Measurement of Participants with new onset Feelings of Hopelessness or Changes in Feelings of Hopelessness severity|Measurement of Participants with new onset feelings of Depression or Changes in feelings of Depression severity|Measurement of Participants with new onset Fever or Changes in Fever Severity|Measurement of Participants with new onset Moving Slowly or Changes in the Severity of Moving Slowly|Measurement of Participants with new onset Speaking Slowly or Changes in the Severity of Speaking Slowly|Measurement of Participants with new onset Feelings of Restlessness or Changes in the Severity of Feelings of Restlessness|Measurement of Participants with new onset Thoughts of Better Off Being Dead or Changes in the Severity of Thoughts of Better Off Being Dead|Measurement of Participants with new onset Thoughts of Hurting Yourself or Changes in the Severity of Thoughts of Hurting Yourself|Measurement of Participants with new onset Loss of Interest in Doing Things or Changes in the Severity of Loss of Interest in Doing Things|Measurement of Participants with new onset Loss of Pleasure in Doing Things or Changes in the Severity of Loss of Pleasure in Doing Things|Measurement of Participants with new onset Trouble Falling Asleep or Changes in the Severity of Trouble Falling Asleep|Measurement of Participants with new onset Trouble Staying Asleep or Changes in the Severity of Trouble Staying Asleep|Measurement of Participants with new onset Unmentioned Negative Impacts of COVID 19 infection or Changes in the Severity of these Negative Impacts of COVID 19 infection || Proportion Enrolled|Participant Age|Participant Sex|Participant Race/Ethnicity|Participant Income|Participant Education|Test Completion || Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by VDP.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FEV1.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FVC.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by TLC.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FRC.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by RV.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FOT.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by LCI.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FeNO.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by exercise capacity.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by baseline dyspnea index questionnaire|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by (mMRC) dyspnea scale questionnaire.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by CAT.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by SGRQ.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by IPAQ.|Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by eosinophil count.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by VDP.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FEV1.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FVC.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by TLC.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FRC.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by RV.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FOT.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by LCI.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FeNO.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by exercise capacity.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by the baseline dyspnea index questionnaire.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by the mMRC dyspnea scale questionnaire.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by CAT.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by SGRQ.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by IPAQ.|Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by eosinophil count..|Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by sex.|Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by age.|Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by smoking history measured in pack-years. || Seroprevalence and duration of protective immunity || Accuracy of Covid19 Detection || The proportion of vaccinated volunteers with no laboratory confirmed symptoms caused by SARS-CoV-2 within 9 months post vaccination|The proportion of volunteers with increased levels of the immune response in terms of geometric mean titers of specific antibodies in ELISA following the vaccination compared with a placebo.|The proportion of volunteers with increased levels of the immune response in terms of specific neutralizing antibody titers in ELISA following the vaccination, compared with a placebo|The proportion of volunteers with an ex vivo cellular immune response following the vaccination, compared with a placebo|Incidence and type of adverse events during the study|Incidence of serious adverse events during the study|Cases of early termination of the study due to the development of adverse events / sever adverse events || Hospital admission or death in the first 2 weeks after randomization|Hospitalization at 30 days|Mortality at 30 days|Serious adverse events at 30 days|Death at week 12|Duration of symptoms || Satisfactory service regarding hospital response to COVID-19|Feelings of apprehension regarding hospital visits|Medical staff wearing of facial masks and hand hygiene|Cleanliness and sterilization of hospital facilities|Convenience and accessibility of hand sanitizers|Helpfulness and readability of posters and stand-up banners|Satisfaction with hospital safety measures for COVID-19|Recommendation of hospital to friends and family || respiratory complications|Hypotension|need for vasoactive drugs|Number of participants with acute new cardiovascular disorder|Number of participants with organ failure|Number of participants with overall survival up to 8 weeks || Disease progression, defined as WHO Clinical Progression Scale score of ≥ 6, at any time from day 1 to day 28|Disease recovery, defined as WHO Progression Scale score of ≤ 2, at day 28 || SARS-CoV-2 infection rate || Physical activity level|Psychosocial status|Sleep quality|Health related quality of life|Activities of daily living || Collecting vitamin D results in patients from the South-East London area together with age, sex, ethnicity and BMI and other relevant laboratory results.|Collecting Covid-19 screening results together with age, sex, ethnicity and BMI and other relevant laboratory results. || Incidence of adverse events after administration of IMP in the phase II/III|Percentage of patients requiring escalation of oxygen therapy in non-invasive and invasive methods in phase III|Mortality during hospitalization, up to 14, 30, 60 and 100 days of observation in the study and control groups,|The number of complications secondary to COVID-19 (bacterial, fungal infections, sepsis, septic shock, multi-organ failure) by the 30th day of observation;|COVID-19 Performance Status score during hospitalization from randomization to discharge from hospital or death, and to day 14 and 30 of observation in the study and control groups|The maximum degree of COVID-19 disease severity assessed in the COVID-19 Performance Status scale during hospitalization (until discharge from hospital or death)|NEWS (National Early Warning Score) 2 scores during hospitalization from randomization to discharge from hospital or death in the study and control groups|Assessment of the number of patients who were not able to take all capsules despite the lack of swallowing disorders in the initial evaluation,|The number of days with fever (temperature above 38.0°C) up to the 30th day of observation in the study and control groups,|Number of hospitalization days up to the 30th day of observation in the study and control groups|Number of days of stay in the intensive care unit until the 30th day of observation in the study and control groups|Number of days of mechanical ventilation in convalescents up to the 30th day of observation in the study and control groups (if applicable)|The number of days of non-invasive ventilation in convalescents up to the 30th day of observation in the study and control groups (if applicable)|Number of days of passive oxygen therapy in convalescents up to the 30th day of observation in the study and control groups (if applicable)|Safety of treatment up to day 100 of follow-up in the study and control and pilot groups (type, frequency, severity of adverse events [AE]) || Determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19).|Determine the immunologic effects of convalescent plasma infusion|Absolute lymphocyte count (10*3/uL)|reatinine kinase (mg/dL)|C-reactive protein (mg/dl)|D-Dimer (ng/ml FEU)|Interleukin-6 (pg/ml)|Ferritin (ng/mL) || Evaluation of the incidence of arrhythmia and conduction block in COVID-19 patients using Holter|Detection of myocardial injury in COVID-19 patients using CMR. || Number of Patients With Early Clinical Improvement|Number of Participants With Late Clinical Recovery|Number of Patients Having Clinical Deterioration.|Number of Patients Remain Persistently Positive for RT-PCR of Covid-19 || The rate of adverse event of special interest (bleeding and hypotension) || Time to COVID-19 symptoms relief|Prevention of severe stage of Covid19|Side effect/ adverse events|COVID-19 severity worsening|Time to negative saliva || DNA damage|The investigators will consider further DNA damage parameter|The investigators will consider oxidative stress marker|The investigators will consider inflammatory marker|The investigators will consider the phenotypic age marker|The investigators will consider RDA and DNA gene expression|The investigators will consider clinical biochemistry marker || SARS-CoV-2 seroprevalence ITM staff|SARS-CoV-2 seroprevalence in ITM staff, stratified by variables || hospital care|days of hospital care|days of need suplemental oxigen|serum level of d-dimmer|serum level of creatinine|thromboembolic event|need for mechanical ventilation || Hosptialized patient data|Trends in COVID 19 exacerbation || Identify the factors associated with the worsening of the COVID19|Describe the clinical care pathway of patients from Day 0 to Day 14|Describe the health status at Day 30|Describe the quality of life during the disease || Composite endpoint (death, initiation of mechanical ventilation, ICU admission and thrombotic event)|Death|Mechanical ventilation|ICU admission|Thrombotic event || diagnose of COVID19 disease|Progression to a more severe disease state, defined as need for oxygen therapy.|lasting of disease|Incidence of COVID-19 disease onset in the first week after treatment || Positivity of the rapid diagnostic test || Sensitivity|Specificity|Sensitivity and specificity in relation to the cycle threshold value of the reference RT-PCR|Sensitivity and specificity in relation to the time since symptom onset|Specificity in asymptomatic participants|Frequency of nosebleed or unbearable pain during or immediately after specimen collection || Detection of IgG and IgM antibodies for Sars-Cov-2 in children aged between 4 and 16 y.o. cohabiting with at least a subject with a previous diagnosis of COVID-19.|Detection of IgG and IgM antibodies for Sars-Cov-2 in adults with a previous diagnosis of COVID-19 cohabiting with at least a child aged between 4 and 16 y.o. || Primary endpoint|Secondary endpoint|Safety endpoints || To compare the reasons for consultation between patients with a history of Covid 19 and those who have not been infected with SARS-CoV-2.|To Assess the presence of somatoform disorders between COVID-19 and non-COVID-19 patients.|To compare the quality of life of COVID-19 patients with that of non-COVID-19 patients. || SARS-CoV-2 genomic RNA in patient sperm|SARS-CoV-2 location in patient sperm || Sex differences in platelet and immune function and COVID19 severity|Gut microbiome and COVID19 severity || Number of patients that recovered from COVID-19|Change in number of patients hospitalized on invasive mechanical ventilation|number of patients that improved clinically|Number of patient deaths|Number of patients with decreased supplemental oxygenation needed|Change in number of patients needing non-invasive ventilation/ high flow oxygen|Number of days patients are in the hospital|Number of SAEs and AEs of grade 3 and 4|Number of patients with changes in abnormal WBC counts || Peak increase in COVID-19 Sign and Symptom score|Nadir Oxygen Saturation|Peak Heart Rate|Time to COVID-19 Sign and Symptom score resolution|Time to WHO 7-point ordinal scale score of 3 or higher || Measure of seroprevalence of COVID-19 infection assessed by the level of anti-Covid-19 IgG antibodies in the population of people living with HIV monitored at the Pitié-Salpêtrière hospital || Expression of receptors and activating proteases|Prevalencen of olymorphisms of the HSD3B1|Association of polymorphisms of the HSD3B1 || Immunological changes during and after COVID-19 infection || adherence level to coronavirus disease 19 preventive measures among nursing students during written exams.|number of students who develop possible covid-19 symptoms during written exams|Eye,nose,mouth,Face and mask touch frequency during written exams|nursing students knowledge level of COVID 19|COVID 19 risk perception level among nursing students undergoing written exams || Improvement of inflammatory cells and marker|Recovery rate|Duration of seroconversion || Cumulative time on oxygen|Need for advanced airway intervention or death due to COVID19;|Rate of decrease of respiratory rate;|Increase of PaO2 /FiO2 ratio during treatment|Time to discharge from hospital || Composite clinical outcome with oxygen therapy dependency time or hospitalization time|Percentage of participants with adverse events during the use of propolis|Rate and severity of acute kidney injury during the study|Renal replacement therapy.|Rate of need for vasopressor use|Need for intensive care unit (ICU)|Intensive care unit (ICU) readmission|Invasive oxygenation time|Variation of plasma c-reactive protein || Mortality|Transfer to the Intensive Care Unit (ICU)|Thromboembolic complications|Major bleeding complications || Predictors of post COVID-19 complications and predictors of hospitalization|Health symptom score|Vital signs SpO2 score|Vital signs BMI score of 40 kg/m2|Chronic Illness score|Mental health assessment high score >11 on PHQ9 Depression score|Mental health assessment high score >11 on GAD 7 Anxiety score|Evaluate a treatment strategy with ECL-19 || SARS-CoV-2 IgG antibody level|Risk factors for COVID-19 || Inpatient Mortality|Requirement for mechanical ventilation|Transfer to ICU|ICU Mortality|ICU Length of Stay (LOS)|Hospital Mortality|Hospital Length of Stay (LOS) || Time to resolution of symptoms|Severity of Symptoms|Time to Resolution of Individual Symptoms|Incidence of Hospitalization|Incidence of Intensive Care Unit (ICU) Admission|Incidence of Death || Development of Covid Decompensation Index|Feasibility || Determine if there is an inverse correlation with risk of poor outcome including admission to intensive care; mechanical ventilation and 28-day mortality.|Differences in cycle threshold (Ct) levels amongst patients with community acquired SARS-CoV-2 || Progression of COVID-19 from ""moderate"" classification to ""severe/critical""|Total duration of hospitalization|Total duration of hospitalization (from first dose of study drug to discharge)|Composite in-hospital mortality|Total duration of ICU Admission|Total duration of intubation|Total duration of time spent on HFNC or NIPPV from first dose of study drug to discharge|Total duration of time above baseline oxygen requirements from first dose of study drug to discharge|In hospital days with a fever >/= 38 degrees Celsius (00:00 to 23:59:59) from first dose of study drug to discharge (or anticipated first dose if in standard of care arm)|Incidence of adverse events associated with the study drug|Incidence of significant adverse outcomes associated with/attributable to COVID-19|Cumulative dose of corticosteroids received in ED/Hospital|Cumulative dose of remdesivir received in ED/Hospital|Discharge Anticoagulation Needs|Continuous lab results - B-Type Natriuretic Peptide|Continuous lab results - C-Reactive Protein|Continuous lab results - D-Dimer|Continuous lab results - Ferritin|Continuous lab results - Procalcitonin|Continuous lab results - Serum Creatinine|Continuous lab results - Troponin|Continuous lab results - Hepatic Function Panel (ALT/AST/Alkaline Phosphotase)|Continuous lab results - Hepatic Function Panel (Bilirubin)|Continuous lab results - Hepatic Function Panel (Protein/Albumin)|Continuous lab results - Complete Blood Count with Differential Part 1|Continuous lab results - Complete Blood Count with Differential Part 2|Continuous lab results - Complete Blood Count with Differential Part 3 || Phase 2B: Reduction of SARS-CoV2 viral load assessed by Ct PCR at day-4 adjusted on Ct PCR SARS-CoV2 viral load at baseline (ANCOVA)|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-4 with Ct > or = 28|Phase 2B/3: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Phase 3: Symptoms score|Phase 3: Proportion of secondary hospitalization|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-7 with Ct > or = 28 || Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease || Influence of the COVID-19 pandemic on cancer patient's daily life || Assessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE)|Preliminary Efficacy: Recovery from COVID-19 as determined by negative PCR or asymptomatic by the NIH classification for the severity of illness|Mortality|Preliminary Efficacy: To assess prevention of respiratory deterioration associated with COVID-19 by measuring the PaO2/FiO2 ratio|Hospitalization|Life support|Clinical status by the new NIH Patient Classification for the severity of illness|Clinical status by NEWS2|Support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale|Support measurements: improvement of severity rating on a 7-point ordinal scale|Virus Clearance|Exploratory: Serum cytokines/chemokines and immunomodulating factors|Exploratory: complete blood counts|Exploratory: Histone and cell-free DNA levels || Positive control for technical validation|Evaluation of test performance || Identification of host genetic markers associated with the evolution of COVID-19|Analysis of bioethical aspects related to in-hospital management of the health crisis|Analysis of the spectrum of mutants of SARS-CoV-2 and its possible association with the clinical evolution of COVID-19 || Patients' short-term outcome|Patients' long-term outcome|Intensity of care || Number of patients that a short cycle of steroids administered together with colchicine reduces mortality from COVID-19|Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment|Percentage of patients who stop medication due to adverse events.|Severity of symptoms by COVID-19 in the two treatment arms || Time to viral clearance (RT-PCR negativity)|Time to symptom resolution|Time to severe/critical disease|Number of participants reporting an adverse event as evidenced by clinical manifestations || Evaluate the effect of DAADs on covid -19 || Cytokine levels of patients || number of participants with improvement of clinical condition (symptoms and signs)|Reduction of recovery time, hospital stay days and mortality rate|improvement of laboratory investigations and 2 consecutive negative PCR tests taken at least 48 hours apart. || Symptoms of Central Sensitisation|Pressure pain thresholds|Temporal summation|Descending nociceptive inhibition|Functionality and disability || Prevalence of antibodies to SARS-CoV-2 || interleuken- 6 gene (174G/C) single nucleotide polymorphism|interleukin 6 level || Heart rate variability|Electrodermal activity|Respiration rate|Blood volume pulse|Functionality and disability || Identification and characterization of a new COVID-19 salivary signature through Raman spectroscopy|Evaluation of the spectral differences between the experimental groups|Determination of the classification model through multivariate analysis|Correlation with the clinical data|Test of the methodology|Portable Raman as point of care || COVID 19 Detection || Taste and smell acuity|Experienced symptoms, changes in appetite and food-related quality of life || Detection of SARS-CoV-2 on nasopharyngeal samples (gold standard)|Detection of SARS-CoV-2 on a saliva samples by mass spectrometry|Detection of SARS-CoV-2 on saliva samples via RT-PCR || D-dimer trends|Thrombosis|All-cause mortality|Orotracheal intubation || mortality rate|need for intensive care unit rate|length stay in hospital || Medical history and co-morbidities|The physical examination data, and reports of relevant investigations data provided by the physician and the family during hospitalization|Electrocardiography QT Interval|Number of different therapeutic classes|Comprehensive Geriatric Assessment (CGA)|Biological parameters|Medical imaging results|Diagnosis of COVID-19|Length of hospitalization|Number of death from any cause|Reports of relevant investigations data provided by the physician and the family during the two-month telephone follow-up || Levels of serum trace elements parameters|Physical Activity Level|Levels of Routine Blood Samples || Primary criteria of data evaluation || prevalence of SARS-CoV-2 infection || progression|mortality || identify risk factors associated with severe forms of COVID-19|link between the composition of the gut microbiota and admission to intensive care|predictive performance of semi-quantitative culture and rapid metagenomic evaluation || To assess the efficacy of BCG vaccination compared to placebo in reducing severe Covid-19 disease among elderly residents of skilled nursing facilities.|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases)|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases), continued|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of episodes)|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of days) || BAB permeability assessed|4 month follow-up PET/CT scan || Clinical status of subjects as expressed on the WHO-8-Category ordinal scale:|Cycle threshold of SARS-CoV-2 PCR·|multiplex viral examination|supplemental oxygen requirement|modified 10 point BORG scale || Rate of peripheral and central nervous affection|Rate of psychiatric disorders at 6-months follow-up|Rate of psychiatric disorders at 12-months follow-up|Neuropsychological function at 6-months follow up|Neuropsychological function at 12-months follow up and change in function from 6 to 12 months.|Rate of stroke at 6-months follow up|Rate of stroke at 12-months follow up|Rate of death at 6-months follow-up|Rate of death at 12-months follow-up|Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography at 6-months follow-up|Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography at 12-months follow-up|Rate of myopathy at 6-months follow-up|Rate of myopathy at 12-months follow-up|Rate of brain MRI pathology at 6-months follow-up|Rate of brain MRI pathology at 12-months follow-up|Levels of serum neurofilaments at 6-months follow-up|Levels of serum neurofilaments at 12-months follow-up|Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 6-months follow-up|Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 12-months follow-up|Duration of hospital and rehabilitation stay || Incidence of adverse events by type, frequency, severity, and causality (safety)|Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety)|Incidence of serious adverse events by type, frequency, severity, and causality (safety)|Incidence of dose-limiting toxicities (safety)|Incidence of clinically meaningful laboratory abnormalities (safety)|Viral load as assessed using plasma and salivary samples at various timepoints|Time from onset of COVID-19 symptoms to treatment (Day 1)|Presence and levels of anti-drug antibodies directed to COVI-AMG|Cytokine levels post-treatment|AUC of COVI-AMG (PK)|Cmax of COVI-AMG (PK)|Tmax of COVI-AMG (PK)|t½ of COVI-AMG (PK) || Lung function|Radiological alterations|Quality of life alterations || Mortality predictors in patients with Respiratory Failure who require oxygen therapy in the Intensive Care Unit or ventilatory support.|Molecular profile of cell populations present in the BAL at early timepoint during SARS-CoV2 infection to predict severity of disease progression.|Type of possible complications such as AKI (Acute Kidney Injury) , infection, shock|SARS-CoV2 mechanisms of infection in alveolar macrophages|SARS-CoV2 genotypes in a cohort of patients representative of the Lombardy population|Number of successful respiratory weaning || frequency of GIT symptoms among patients with COVID-19 infection || World Health Organization ordinal scale at day 28|Ventilator-free days|28-day mortality || Immunologic impact of 5 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines (e.g, interleukin 6, interleukin 1-beta, etc.).|Virologic impact of 5 days of disulfiram, as measured by the fold-change in copies of SARS-CoV-2 virus per million cells between Baseline and Day 31.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Change in COVID-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score (SSS-8) || Hospitalization for COVID-19 deterioration or death without hospitalization|Adverse events|Serious adverse events|Investigational medication discontinuation|Hospitalization for COVID-19 deterioration or death without hospitalization, evaluated by independent adjudication comittee|Clinical improvement using the Word Health Organization (WHO) COVID-19 scale|Need for intensive care|Duration of hospitalization|Need for invasive mechanical ventilation for severe COVID-19|Need for oxygen therapy for COVID-19|Overall survival|Duration of symptoms|SARS-CoV-2 virological assessment|SARS-CoV-2 serological assessment|Peripheral blood lymphocyte phenotyping|Acute kidney failure|Renal function|Concentration of urea in blood|Concentration of potassium in blood|Liver function|Liver function (2) || Symptomatic SARS-CoV2 infection|SARS-CoV2 infection|Observed prevalence of proper mask wearing|Respiratory infection prevalence || Decrease length of stay|Overall mortality|Incidence of adverse events related to Convalescent Plasma transfusion|Ordinal scale|Improvement in Laboratory Parameters: Serum Ferritin|Improvement in Laboratory Parameters: Procalcitonin|Improvement in Laboratory Parameters: C-Reactive Protein|Improvement in Laboratory Parameters: D-Dimer|Improvement in Laboratory Parameters: Complete Blood count|Chest X-Ray findings || Changes in cytokine levels of Interleukin (IL) 6, IL-8 and Tumor Necrosis Factor-α (pg/mL)|Changes in inflammatory markers; C-Reactive Protein (CRP) (mg/L)|Changes in thrombocyte counts (10^3 counts/microL)|Changes in the coagulation marker Fibrinogen (g/L)|ICU length of stay after admission (days)|Changes in Neutrophil-to-Lymphocyte Ratio|Changes in the coagulation marker D-Dimers (ng/mL)|Changes in the Activation Clotting Time (seconds). || Relation of changes in ultrasound and progression to respiratory failure|Impact of ultrasonographic pneumonia signs on the day of admission on severity of COVID-19 infection|Sensitivity of ultrasonographic pneumonia signs in detecting respiratory failure|Sensitivity of ultrasound in detecting interstitial changes in the lungs|Impact change in severity of ultrasonographic pneumonia signs on severity of COVID-19 infection || Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places reported by the participants in the online questionnaire|Proportion of cases infected in family environment by SARS-CoV-2 reported by participants in the phone interview|Proportion of cases infected in family environment by SARS-CoV-2 reported by participants in the online questionnaire|Proportion of cases infected in professional environment by SARS-CoV-2 reported by participants in the phone interview|Proportion of cases infected in professional environment by SARS-CoV-2 reported by participants in the online questionnaire|Level of adherence to mask-wearing reported in the phone interview|Level of adherence to mask-wearing reported in the online questionnaire|Level of adherence to hand-washing in the phone interview|Level of adherence to hand-washing in the online questionnaire|Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places reported by the participants in the phone interview || oral ulcer|hyposalivation || Ventilation Defect Percentage || complete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio|PT, APTT and D-dimer || Validation|RT- PCR (Saliva)|LAMP|POOL PCR|POOL LAMP || Time to Clinical Improvement (TTCI)|Time to symptomatic recovery.|Mortality Rate|Duration of ICU Stay.|Total hospital stay.|Time to clinical failure or death.|Time to Viral clearance / COVID-19 recovery. || Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by self-reports of symptom questionnaire.|Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by COVID-19 and influenza test result.|Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by hospital admission questionnaire.|Accuracy comparison of symptom-only model to sensor-only model to symptom + sensor model to predict Covid-19 symptoms. || Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450|Change in 7 point-ordinal scale|Change in oxygen saturation-normalization|Need for advanced respiratory care|All-cause mortality|Percentage of adverse events (AEs)|Percentage of serious adverse events (SAEs)|Proportion of participants with normalization of fever for 24 hours|Number of participants who develop new bacterial infection|Number of participants who develop new fungal infection|Incidence of Adult Respiratory distress Syndrome (ARDS2)|Change in serum cytokine Interleukin (IL)-6|Change in serum cytokine IL-8|Change in serum cytokines IL-1β|Change in serum cytokine Tumor Necrosis Factor (TNF-α) || COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) Period until the COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) becomes negative || Proportion of participants who have progression of COVID-19 through Day 29|Occurence of of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of adverse events of special interest (AESI)|Incidence and titers (if applicable) of serum ADA to VIR-7831|Cmax|Clast|Tmax|Tlast|AUCinf|AUClast|%AUCextrap|t1/2|Vz|Vss|CL|Proportion of participants who have progression of COVID-19 through Day 29 as defined by visit to a hospital emergency room for management or illness, or hospitalization for acute management of illness or death|Mean change in FLU PRO Plus total score comparing Vir 7831 vs Placebo (AUC through Day 7) and time to symptom alleviation using the FLU-Pro Plus|Change from baseline in viral load in nasal secretions by qRT-PCR at Day 8|Proportion of participants who progress to develop severe and/or critical respiratory COVID-19 as manifest by requirement for and method of supplemental oxygen at Day 8, Day 15, Day 22 or Day 29|29-day, 60-day, and 90-day all-cause mortality || Feasibility of recruitment|Safety of device: AE|Protocol Adherence|Mortality|Morbidity || The clinical evaluation of saliva as specimen for COVID-19 molecular test || SARS-CoV-2 positivity rate (%)|COVID-19 related mortality rate (%) || exploratory change in viral load|number of patients who have decrease in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCR|number of patients with adverse events during 5 days study duration || Minimize and/or eliminate the number of patients with mild to moderate COVID-19 who are at high risk for progressing to severe COVID-19 and/or hospitalization. || post-intensive care syndrome (PICS)|Evaluate the 3-month mortality of patients released alive from intensive care|Describe the overall state of health and the main organ sequelae of these patients|functional respiratory sequelae || Length of hospitalization || Change in percentage of high barrier uptake on 129Xe MRI predicts outcomes as measured by FVC|Change in percentage of low RBC transfer on 129Xe MRI predicts outcomes as measured by DLCO || T cell immune response|B cell immune response|Platelet immune response|Immune response and chronic forms || Time to recovery || Proportion of subjects who are alive and free of respiratory failure at Day 29|Viral load reduction|Time to sustained clinical improvement|Proportion of subjects with clinical improvement|All-cause mortality at Day 29 || Proportion of subjects who have remained out of the hospital or emergency room through Day 29|Viral load reduction from baseline to Day 8, 15, 29, 43, and 70|Proportion of subjects who have remained out of the hospital or emergency room through Day 43 and 70|Proportion of subjects who have 50%, 70%, and 90% reduction in PRO instrument score|Time to resolution of fever || Changes in model discrimination (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model discrimination (Model 2: mortality in patients receiving MV)|Changes in model discrimination (Model 3: length of stay in the ICU)|Changes in model calibration (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model calibration (Model 2: mortality in patients receiving MV)|Changes in model calibration (Model 3: length of stay in the ICU)|Changes in net benefit (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in net benefit (Model 2: mortality in patients receiving MV)|Changes in net benefit (Model 3: length of stay in the ICU)|Changes in model discrimination in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model discrimination in external database after updating (Model 2: mortality in patients receiving MV)|Changes in model discrimination in external database after updating (Model 3: length of stay in the ICU)|Changes in model calibration in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model calibration in external database after updating (Model 2: mortality in patients receiving MV)|Changes in model calibration in external database after updating (Model 3: length of stay in the ICU)|Changes in net benefit in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in net benefit in external database after updating (Model 2: mortality in patients receiving MV)|Changes in net benefit in external database after updating (Model 3: length of stay in the ICU)|Stakeholder perceptions, beliefs and opinions on COVID prediction models || To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 years|To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population|To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population|To assess the incidence of treatment-emergent of AEs and SAEs in subjects assigned to RTB101 as compared to placebo|To determine the percentage of subjects treated with RTB101 as compared to placebo who develop symptomatic laboratory-confirmed COVID-19 from first dose through Day 14|To determine the percentage of subjects treated with RTB101 as compared to placebo who die from any cause from first dose of study drug through Day 14 and 21|To determine the percentage of subjects treated with RTB101 as compared to placebo who develop laboratory-confirmed COVID-19 from first dose through Day 14 and are subsequently hospitalized for any reason through Day 21|To determine the percent of subjects treated with RTB101 or placebo who have laboratory-confirmed SARS-CoV-2 infection regardless of symptoms from first dose of study drug through Days 7, 14, 21. || Hospitalization|Recovery|ICU Admission|Death || Time to clinical recovery after treatment || Demographic data|Comorbidities|Cumulative Illness Rating Scale-Geriatric (CIRS-G)|Treatments|Signs and symptoms|Fever|Hypoxemia|Tachycardia|Hypotension|Gasometry|Infectious data|Blood count|Ionogram|Liver function|Coagulation|Renal function|Albumin|CRP|Fibrinogen|D-dimers at hospital admission or first recorded|NTproBNP|CK|Troponin|Ferritin|Procalcitonin|Biology - highest rate|Biology - lowest rate|Percentage of pulmonary involvement on chest CT scan|Number of pulmonary lobes affected|Type of lesions|Need for oxygenotherapy|Means of ventilation|Treatment received|Length of ICU Stay|Status at hospital exit|Mortality || Proportion of patients who demonstrate progression of COVID-19 disease || 7-level COVID Ordinal Outcome Scale|Length of hospital stay|Days with oxygen supplementation|Daily oxygen flow values required to obtain saturation values ≥90%,|ICU admission|ICU length of stay|Days on invasive mechanical ventilation or high flow oxygenation|Major arterial and venous thrombotic events|Sleep quality|Fatigue|Mortality|Incidence of any adverse events related to HBOT || composite outcome|death (COVID-19)|death (other disease)|hospital admission (COVID-19)|hospital admission (other disease) || Duration of hospital stay (Days)|Time to Clinical Improvement (TTCI)|All causes mortality|Duration (days) of mechanical ventilation|Duration (days) of supplemental oxygenation|Time to 2019-nCoV RT-PCR negativity in Nasopharyngeal Swab|Frequency of serious adverse drug events || Respiratory muscle strength|FEV1|FVC|FEV1/FVC|PEF|FEF2575|Fat mass|Fat mass percent|Fat-free mass|Body mass index|Predicted muscle mass|Symptom severity perceptions|Performance situations perceptions || Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Patient reported outcomes as assessed by COVID-19 assessment tool|Number of participants that experience death during the study.|Number of participants the experience a related serious adverse event as assessed by CTCAE v5.0.|Number of participants that experiences a Grade 3 and 4 adverse event as assessed by CTCAE v5.0|Number of participants with a discontinuation or temporary suspension of study drug|Each participant will be tested for SARS-CoV-2 viral eradication via a sample from the nasopharynx and the sample will be tested via RT- PCR.|Each participant will perform a 6 minute walk test (6MWD) for distance (400-700m) walked.|Each participant will be assessed for COVID-19 severity via an 8-point ordinal scale|Each participant will be tested for anti-SARS-CoV-2 neutralizing antibodies via standard histogram, 2D plots, tSNE, and viSNE analysis.|Each participant will be tested for anti-SARS-CoV-2 quantitative antibodies via cytokine test panel.|Each participant will be assessed for resolution of COVID19 symptoms via performance of hematology and biochemistry labs, SARS-COV-2 nasopharyngeal swab and tested via RT-PCR and immunology testing for cytokines and cell populations. || Sensitivity and Specificity of the patient's aggravation with a logistic regression model|Sensitivity and Specificity of the patient's aggravation with a cluster model|Study the evolution of daily patient parameters without aggravation over time|Subjective assessment of the connected devices || Treatment and Prevention of COVID-19 Pandemic. || Effect of 5 different mouthwashes on the SARS-Cov2 viral load. || The Lymphocyte/neutrophil ratio || Time until cessation of shedding of SARS-CoV-2 virus|Clinical worsening of COVID-19 disease in symptomatic patients|Development of antibodies to SARS-CoV-2|Time until resolution of symptoms|Time until progression of symptoms|Drug level on day five, one hour after a dose taken on an empty stomach || Concordance between buccal cavity swab and contemporary nasal swab. || The measurements of retinal features in patients with previous diagnosis of COVID19, using optical coherence tomography angiography. || Antithrombin Levels|aPPT Levels|PT Levels|Quick Levels|INR Levels|D-dimer Levels|Fibrinogen Levels|Haemoglobin Levels|Platelet Levels|Thromboembolic complications and bleeding events between groups|Comparison of the duration of requirement for oxygen therapy, and invasive ventilation support or ECMO between groups|Hospital length of stay|Number of days in ICU|Number of days requiring oxygenation|Discharge disposition|Mortality || Determine sensitivity and specificity of MWR diagnostics of pneumonia in patients with COVID-19. (diagnosed by PCR and CT) || Evaluation of the netosis process|Evaluation of the netosis process at day 3|Link between this marker (DNA-MPO) and the clinical course of patients || Ventilation-perfusion (V/Q) mismatch|Regional ventilation|regional perfusion|The Global Inhomogeneity (GI) index|PF raio || Subject´s Responder status (score on the 7-point ordinal scale on Day 15)|Evaluation of change in clinical condition based on the 7-point ordinal scale|Evaluation of change in clinical condition based on the 7-point ordinal scale and Responder Status|Hospital resource utilization comparison || Number of Participants with solicited local and systemic adverse events|Number of Participants with unsolicited adverse events after each dose|Number of Participants with serious adverse events|Number of Participants with changes in clinical laboratory tests of white blood cell count baseline|Number of Participants with adverse events,serious adverse events, and adverse events of special interest|Number of Participants with changes in clinical laboratory tests and vital signs from baseline|Geometric mean titers(GMT)|Seroconversion rates|Geometric mean fold increase|IFN-γ|Levels of other T cell biomarkers || Number of patients with improvement or mortality || Serum IgG for SARS CoV 2 will be monitored || Safety of CAP-1002|Efficacy of CAP-1002 on Cytokine|Efficacy of CAP-1002 on Laboratory Biomarker || Comparison of the expression of ACE2 and TMPRSS2 in the subcutaneous and visceral adipose tissue of obese patients. Determination of cells expressing ACE2 and TMPRSS2 in whole human adipose tissue.|Demonstration of entry and replication of SARS-CoV-2 in human adipose tissue|Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.|Effect of SARS-CoV-2 infection of adipose tissue / adipocytes from thin and obese subjects on endoplasmic reticulum (ER) homeostasis.|Target endoplasmic reticulum stress to reduce spread of SARS-CoV-2 from adipose tissue || Normalization of oxygen|Mortality|Days free of invasive mechanical ventilation || Feasibility of recruitment|Participation Rate|Side Effects and Safety Profile|Rate of hospitalization or death|Symptom Severity Score|Study agent compliance|Symptom monitoring compliance|COVID-19 testing compliance|Hospital-free days|Adverse Events|Grade 3 and 4 adverse events|Viral load || Positivity rate of rtPCR-SARS-CoV-2 (qualitative analysis)|World Health Organization (WHO) Clinical Progression Scale [0 to 10; 0 = uninfected; 10 = death]|World Health Organization (WHO) COVID=19 Ordinal Scale for Clinical Improvement [1 to 8; 1 = not hospitalized, no limitation on activities; 8 = death]|Time-to-recovery|SARS-CoV-2 viral load|Duration of fatigue|Duration of anosmia|Overall duration of clinical manifestations|Proportion of subjects needing additional drugs or interventions|Proportion of subjects needing oxygen use|Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation|Proportion of hospitalizations|Proportion of mechanical ventilation use|Proportion of vasopressors use|Proportion of deaths|Duration of new oxygen use|Duration of hospitalization|Duration of mechanical ventilation|Proportion of increased ultrasensitive C-reactive protein (usCRP) (defined as usRCP > 7 mg/L)|Proportion of decrease in erythrocyte sedimentation rate (ESR) (defined as ESR decrease > 50% compared to baseline (Day 0))|Proportion of increase in eosinophils (defined as eosinophils increase > 50% compared to baseline (Day 0))|Proportion of increased d-dimer (defined as d-dimer > 500 mg/dL)|Variation in oxygen saturation compared to baseline (Day 0)|Disease duration|Change in viral load from baseline to Day 5|Proportion of post-COVID mental symptoms|Proportion of post-COVID physical symptoms|Proportion of post-COVID overall symptoms || Oxygen Saturation|Roth´s test || In-hospital mortality|Mortality up to 3 months from admission|Admission to Intensive care unit (ICU)|Complications occurred during the hospital course|Correlation between admission to ICU and in-hospital mortality || Number of participants RT-PCR positive for Covid-19|Number of sick participants who condition deteriorated|Number of sick participants who died || Efficacy for COVID infection prevention|Efficacy for treatment of severe COVID disease|Time to resolution of illness|Cardiovascular events incidence|Change in metabolic factors || Alive and Free from Hospitalization|All-location mortality at 90 days|All-location mortality at 28 days|All-cause mortality at 28 days|All-cause mortality at 90 days|Organ-support free days at day 28|SARS-CoV-2 nasopharyngeal viral loads|SARS-CoV-2 plasma viral loads|SARS-CoV-2 antibody titers|SARS-CoV-2 antibody neutralization|SARS-CoV-2 immune responses|Detection of SARS-CoV-2 variants through next-generation sequencing|Duration of SAR-CoV-2 infectivity|Non-culture surrogates for SARS-CoV-2 infectivity || Fungus detection || NEWS Score|7-point ordinal scale|Rate of progression on NEWS score|Rate of progression on 7 point ordinal score|Time to COVID-19 nucleic acid testing|ICU admissions|survival rate|mechanical ventilation|Assessmentofcomorbidcondition|worsening comorbid condition || Safety of COVID-19-specific CTLs: Infusion Reactions|Safety of COVID-19-specific CTLs: Grade 4 AEs|Safety of COVID-19-specific CTLs: GVHD|Safety of COVID-19-specific CTLs: Marrow Aplasia|Safety of COVID-19-specific CTLs: Neurotoxicty|Safety of COVID-19-specific CTLs: CRS || prevalence of thrombosis|correlation to immunity|Assessment of late complications || T cell subtype ratios|Monocyte ratio || Incidence of subjects with COVID-19|Severity of COVID-19|Seroconversion to SARS-CoV-2|Subjects with symptoms|Hospital admission due to COVID-19|Admission to an intensive care unit due to COVID-19|Elapsed time until hospitalization|Elapsed time until admission into an care unit for COVID-19|Elapsed time until death not related to COVID-19 || The number of participiants who was infected with Covid-19. normalization process of Covid-19 pandemic|The time of seen covid 19 infection after the endoscopic procedures in participiants.|The characteristics of patients with Covid-19 infection. || Satisfaction with online learning|Knowledge about COVID-19 crisis|Perception of COVID-19 crisis || The prognostic capacity of the Radiographic Assessment of Lung Edema (RALE) score of the first CXR under invasive ventilation in patients with severe COVID-19.|The prognostic capacity of changes in the RALE score of consecutive CXRs under invasive ventilation in patients with severe COVID-19|Number of ventilator-free day and alive at day 28 (VFD) || Covid (Coronavirus Disease-19) Ordinal Scale|Mortality|Supplemental Oxygen|Invasive-ventilator|ICU stay|Hospital stay|Inflammatory markers|Thromboembolic complications|COVID ordinal scale || Phase 1 Safety: Incidence of MAAEs and SAEs|Phase 1 Safety: Incidence and severity of solicited local reactogenicity AEs|Phase 1 Safety: Incidence and severity of solicited systemic reactogenicity AEs|Phase 1 Safety: Incidence and severity of unsolicited AEs|Phase 1 Safety: Incidence of changes of laboratory safety examinations|Phase 1 Safety: Vital Sign - Temperature|Phase 1 Safety: Vital Sign - Heart Rate|Phase 1 Safety: Vital Sign - Blood Pressure|Phase 1 Safety: Vital Sign - Respiratory Rate|Phase 2 Efficacy: Percent of subjects that show an increase in N-reactive T cells|Phase 1 Humoral Immunogenicity: GMT of S-specific and N-specific antibodies|Phase 1 Humoral Immunogenicity: GMT of neutralizing antibody|Phase 1 Mucosal Immunogenicity: GMT of IgA antibody levels|Phase 1 Cellular Immunogenicity: T cell activity|Phase 2 Efficacy: Incidence and severity of COVID-19 ≥14 days after vaccination|Phase 2 Efficacy: Mean SARS-CoV-2 viral load|Phase 2 Efficacy: Humoral Immunogenicity - GMT of S-specific and N-specific antibodies|Phase 2 Efficacy: Humoral Immunogenicity - GMT of neutralizing antibody|Phase 2 Efficacy: Mucosal Immunogenicity - GMT of IgA antibody levels|Phase 2 Efficacy: Cellular Immunogenicity - T cell activity|Phase 2 Safety: Incidence of MAAEs and SAEs|Phase 2 Safety: Incidence and severity of solicited local reactogenicity AEs|Phase 2 Safety: Incidence and severity of solicited systemic reactogenicity AEs|Phase 2 Safety: Incidence and severity of unsolicited AEs|Phase 2 Safety: Incidence of changes of laboratory safety examinations|Phase 2 Safety: Vital Sign - Temperature|Phase 2 Safety: Vital Sign - Heart rate|Phase 2 Safety: Vital Sign - Blood Pressure|Phase 2 Safety: Vital Sign - Respiratory rate || Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity || Cytokine level in context with clinical parameters || Decreased Mortality in Participants|Hospital & ICU stay in days || Time to recovery|Incidence of mortality at Day 29|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of participants requiring mechanical ventilation or ECMO, or dying, through Day 29|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29 || SARS-CoV-2 viral load|SARS-CoV-2 viral cultures|SARS-CoV-2 PCR days to negativity|Observed maximum concentration (Cmax)|Terminal Elimination Half-Life (T½)|Time to Cmax (Tmax)|The area under the concentration-time curve from time zero extrapolated to infinity time (AUCinf)|The area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Apparent total body clearance of the drug from plasma (CL)|Apparent volume of distribution at steady state (Vss)|14 Common Covid-19 Related Symptoms score|Treatment-emergent (serious) adverse events ((S)AEs) and AEs of Special Interest (AESIs) including Infusion-related reactions (IRRs)|Concomitant medication|Vital Signs: Heart Rate (bpm)|Vital Signs: Blood Pressure Systolic and Diastolic (mmHg)|Vital Signs: Respiratory Rate (breaths per minute)|Vital Signs: Body Temperature (°C)|Vital Signs: Oxygen Saturation (SpO2)|Clinical laboratory tests (hematology and blood chemistry)|Physical examinations (symptom directed)|Local tolerability at injection site || EVENT IMPACT SCALE - REVISED || A microbiological diagnosis of COVID infection. || lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Frequency of adverse events and severe adverse events|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Thrombin time (TT) || Sensitivity and specificity precision of dogs to detect people with COVID-19 by their odour.|Identification of the volatile profile that is specific to asymptomatic or mild symptomatic participants with SARS-CoV-2 compared with uninfected individuals. || hematological findings|clinical presentations || sensoneural hearing level - PTA|vestibular function || progression of covid 19 clinical picture || Time to develop clinical deterioration, defined as the time from randomization to a deterioration of two points (from the status at randomization) on a Seven-category ordinal scale.|Length of hospital stay|Number of participant requiring increased amount of supplemental oxygen|Number of participants requiring mechanical ventilation|Number of participants who die || clinical improvements in mild cases|clinical improvements in moderate cases|Clinical deterioration in mild & moderate cases|Radiological improvement in moderate cases|28 days mortality in mold & moderate cases|symptomatic improvement or worsening in mild & moderate cases|compare change in SARS-CoV-2 viral load in nasopharyngeal swab in mild & moderate cases|Length of stay in hospital beyond 10 days in mild & moderate cases || changes of semen volume in (ML)by covid-19 from normal values.|changes of sperm concentration in (million/ml) by covid-19 from normal values.|changes of sperm morphology in (percentage of normal forms) by covid-19 from normal values.|changes of sperm motility in percentage of (A+B) by covid-19 from normal values.|changes of semen volume in (ML) by covid-19 from from the first sample|changes of sperm concentration in (million /ML) by covid-19 from from the first sample|changes of sperm morphology in percentage of normal form by covid-19 from from the first sample|changes of sperm motility in percentage of (A+B) by covid-19 from from the first sample || Proportion of subjects discharged from hospital|Incidence of adverse events (safety)|Time to hospital admission, treatment, and discharge|Number of days hospitalized|Change in clinical status as assessed using a 0-8 ordinal scale|Change in RT-PCR test results|Change in C-reactive protein levels|AUC of STI-5656 (PK)|Cmax of STI-5656 (PK)|t½ of STI-5656 (PK)|Change in cytokine levels|Tmax of STI-5656 (PK) || Determination of key protective cellular immune parameters|Determination of public T-cell receptor response to SARS-CoV-2 || SARS-CoV-2 specific antibodies|Maintenance of SARS-CoV-2 seroconversion in seropositive individuals|Duration of COVID-19 symptoms measured by a weekly symptom questionnaire|Severity of COVID-19 symptoms measured by Ordinal Scale for Clinical Improvement|Secretory IgA (sIgA) antibodies|Blood group A antigen antibodies|Blood group B antigen antibodies|Tn antigen antibodies|Innate immune system activation|Cytokines|Total antibodies|T cell activation|B cell activation|Intestinal inflammation|Intestinal barrier function|Indirect marker of intestinal permeability || Diagnostic Performance of AI model || Number of participants with treatment-related adverse events|Number of Participants With Vital Sign Findings Reported as TEAEs|Number of Participants With Clinically Significant Findings in Physical Examinations|Number of Participants With Clinically Significant Changes From Baseline in ECG Data|Number of participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters|Number of Participants with Presence of Serum anti-SARS-CoV-2 IgY || Flavor perception|Flavor perception intensity || Infection rate|Hospitalization|Death || Duration of symptoms of Long COVID:|Number of participants clinically recovered|Length of home stay/ sick listed|Severity of the Long COVID symptoms|Hypercoagulation marker|Immune response marker|Inflammatory marker|Physical activity|Cognitive performance score|Severity of anxiety and depression|Severity of anxiety || SARS-CoV-2 viral load || Number of patients with disease progression|Worst severity rating on the WHO COVID Ordinal Scale for Clinical Improvement during the 30 days following randomization|Time to disease progression|Number of Hospital-free days during the 30 days following randomization|All-cause mortality || Surgery code|Urgency|Type of anesthesia|Delay between surgery and first symptoms|Surgery duration|Hospital stay (in days)|Intensive care unit stay (in days)|Post-op complications|Covid status before surgery|Covid status post-surgery|COVID19 Diagnosis by CT scan|COVID19 Diagnosis by swab test|COVID 19 Diagnosis by antibody test|COVID19 symptoms - dry cough|COVID19 symptoms - fever|COVID19 symptoms - myalgia|COVID19 symptoms - anosmia|COVID19 symptoms -respiratory distress|Treatment for COVID19 - Plaquenil|Treatment for COVID19 - Antivirals|Need for intubation|Death|Age|Gender|Ethnicity|BMI|Comorbidities || Time to clinical improvement|Find the prediction factors associated with good outcome of patients on CP therapy|Time to negative PCR|Mortality rate|Hospital stay time|Adverse effect of plasma therapy || The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale.|SARS-CoV-2 RNA viral load measurements change.|Proportion of patients with qualitative serum IgM / IgG.|Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change. || Determine the safety of KDS-1000 given at low and high doses compared to placebo by collecting the rate and severity of adverse events (AE)|Determine the efficacy KDS-1000 given at low and high doses compared to placebo by COVID-19 specific questionnaire.|Determine the efficacy KDS-1000 given at low and high doses compared to placebo by measurement of SARS-CoV-2 clearance.|Determine the safety of KDS-1000 given at low and high doses compared to placebo by collecting the rate and severity of AE. || Rate of hospitalization|Physical symptoms assessed through daily checklist|Rate of intubation|Rate of death|Depressive symptoms assessed weekly|Post traumatic stress disorder symptoms assessed weekly|Anxiety symptoms assessed weekly|Suicidality assessed daily || Evaluate secondary transmission/prevalence of SARS-CoV-2 in Kindergarten through 12th grade schools in the Surveillance Cohort.|Evaluate secondary transmission/prevalence of SARS-CoV-2 in Kindergarten through 12th grade schools in the Exposure Cohort.|Describe return to school outcomes in Kindergarten through 12th grade schools in Surveillance Cohort.|Describe return to school outcomes in Kindergarten through 12th grade schools in Exposure Cohort. || Endotracheal intubation|Mortality|Tracheostomy|Length of Respiratory Intensive Care Unit stay|Length of Hospital stay || Mortality|Sequential Organ Failure Assessment (SOFA) Score and its changes over time|Need for catecholamines|Need for renal replacement therapy|Need for mechanical ventilation|Changes of partial pressure of oxygen in arterial blood (PaO2) / fraction of inspired oxygen (FiO2) during treatment in ICU|Changes in D-dimer|Changes in blood lactate levels|Changes C reactive protein (CRP)|Changes in procalcitonin levels|Changes in creatinine levels || Any incidence of admission to hospital for >24 hours in the 28 days following first positive test for SARS-CoV2.|Any incidence of admission to hospital for >24 hours following first positive test for SARS-CoV2.|Mortality following first positive test for SARS-CoV2.|Health-related quality of life assessment.|Hospitalization by age and comorbidities.|Incidence and types of adverse reactions including anaphylaxis.|Recruitment rate.|Overall satisfaction with participation in research.|Type and frequency of viral variants in patients receiving bamlanivimab. || Feasibility of Recruitment|Tolerability of Low dose Radiotherapy|Withdrawal|Adverse events|Feasibility of biochemical analysis || Symptoms|Wellbeing - HRQL || The cumulative incidence of reactogenicity for all the subjects received at least 1 dose of investigational medicinal product (IMP), regardless of whether the subject withdrew early, delayed/missed the second dose or received any antipyretic.|The seroconversion rate for serum RBD-specific binding antibodies for all the subjects received 2 doses of IMP, excluding subjects who missed the second dose, received any COVID-19 vaccine other than the IMPs or had a post-dose COVID-19 infection. || Incidence of adverse events by type, frequency, severity, and causality (safety)|Changes in viral shedding from Baseline to Day 15|Changes in viral shedding from Baseline to Day 8, 29, 43, and 70|Time to viral RNA negativity|Time to resolution of symptoms || Reverse transcriptase-PCR|Fluorescence immunohistochemistry (IHC)|Single molecule fluorescence in situ hybridization (smFISH)|Viral culture || COVID-19 antibodies || Time specific disease severity|Progression to severe disease|Need for respiratory support (high flow nasal oxygen, non-invasive ventilation, or intubation) in those admitted to hospital because of disease progression.|In-hospital and 30- and 60-day all-cause mortality. available).|Time-specific viral load as measured by RT-PCR using NP swabs and sputum (where available).|Cough aerosol sampling positivity || Mortality|Mechanical Ventilation|Mechanical Circulatory Support|Time (days) to the primary end point|Peak and delta (change from baseline) troponin level|Baseline BNP level|Inflammatory biomarkers|Hospital length of stay|Need for re-hospitalization || time to fever control|PCR conversion || Mortality at 28 days|Systemic Therapeutic Response|Respiratory Response|Legnth of ICU Stay|Legnth of Hospital Stay|Pulmonary Function || Grade 2 and higher adverse events 4 weeks after administration.|Grade 3 and higher adverse events 4 weeks after administration.|Related Serious adverse events (SAEs) throughout the study period|Elimination half-life (t1/2) of C135-LS and C144-LS|Clearance rate of C135-LS and C144-LS|Area under the curve of C135-LS and C144-LS|Investigational product (IP)-related adverse events during study follow up.|Anti-C144-LS and anti-C135-LS antibodies in all study groups.|Serum neutralizing activity against SARS-CoV-2 || World Health Organization (WHO) Clinical Progression Scale [0 to 10; 0 = uninfected; 10 = death]|World Health Organization (WHO) COVID=19 Ordinal Scale for Clinical Improvement [1 to 8; 1 = not hospitalized, no limitation on activities; 8 = death] [Time Frame: Day 7]|Time-to-recovery|Viral load|Positivity rate of rtPCR-SARS-CoV-2 (qualitative analysis)|Duration of fatigue|Duration of anosmia|Overall duration of clinical manifestations|Proportion of subjects needing additional drugs or interventions|Proportion of subjects needing oxygen use|Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation|Proportion of hospitalizations|Proportion of mechanical ventilation use|Proportion of pressors use|Proportion of deaths|Proportion of post-COVID mental symptoms|Proportion of post-COVID physical symptoms|Proportion of post-COVID overall symptoms|Duration of new oxygen use|Duration of hospitalization|Duration of mechanical ventilation|Proportion of increased ultrasensitive C-reactive protein (usCRP) (defined as usRCP > 7 mg/L)|Proportion of decrease in erythrocyte sedimentation rate (ESR) (defined as ESR decrease > 50% compared to Day 1)|Proportion of increase in eosinophils (defined as eosinophils increase > 50% compared to Day 1)|Proportion of increased d-dimer (defined as d-dimer > 500 mg/dL)|Disease duration|Change in viral load from baseline to Day 5 || Prevalence of test positivity|Correlation of the positive result of the test with the manifestations of the signs|Development of COVID|Analysis of genomic sequences of the virus|Evaluation of the test relevance|Evaluation of predictive biomolecular markers|The trend over time of the antibody response in subjects positive|The frequency of re-infection|Evaluation of the mode of transmission relatively anamnestic data|The relation between mode of transmission and the available clinical documentation|Evaluation of the mode of transmission for the use of barriers || Change from Baseline Muscle Strength at 1st week, 3rd week and 12th week.|Change from Baseline '5 Times Sit to Stand Test' at 1st week, 3rd week and 12th week.|Change from Baseline Modified Borg Scale at 1st week, 3rd week and 12th week.|Change from Baseline Barthel Index for Activities of Daily Living at 1st week, 3rd week and 12th week.|Change from Baseline Visual Analog Scale at 1st week, 3rd week and 12th week. || Improvement or maintenance of the oxygenation level measured by PaO2|Improvement or maintenance of the oxygenation level measured by O2 Saturation|Improvement or maintenance of adequate levels of carbon dioxide measured by PaCO2|Improvement or maintenance of adequate levels of HCO3|Improvement or maintenance of adequate levels of excess base.|Improvement or maintenance of adequate levels of blood pH|Improvement or maintenance of PaO2/FiO2|Improvement or maintenance of SatO2/FiO2|Uninterrupted and faultless operation in the period of use of the ventilator|Inspiratory peak pressure> 35 cm H2O that does not have a clinical explanation other than the ventilator (such as a mucus plug)|Plateau airway pressure> 30 cm H2O that does not have a clinical explanation other than the ventilator|VT> 8 cc / kg of ideal weight that does not have a clinical explanation other than the ventilator|Decrease or increase in respiratory rate, tidal volume, PEEP, peak inspiratory pressure, FiO2, not due to a clinician order (changes not ordered by the clinical team but due to the ventilator variability)|Pneumothorax (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Pneumomediastinum (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Subcutaneous emphysema (not having an explanation other than ventilatory support, such as the insertion of a central catheter)|Hemodynamic deterioration in the hour following the start of the Unisabana-Herons ventilator that requires a 100% increase in the dose of vasopressors and that does not have a clinical explanation other than the ventilator|Cardiac arrest without a clinical explanation other than the ventilator|Death without a clinical explanation other than the ventilator|Elevation of creatinine that does not have a clinical explanation other than the ventilator|Elevation of BUN that does not have a clinical explanation other than the ventilator|Digestive bleeding without a clinical explanation other than ventilator|Stress ulcers (upper gastrointestinal tract) without a clinical explanation other than ventilator|Pneumonia associated with ventilator.|Tracheobronchitis associated with ventilator.|Critical care polyneuropathy that does not have a different explanation for the use of the ventilator and / or muscle relaxants necessary for mechanical ventilation|Critical care myopathy that does not have a different explanation for the use of the ventilator and / or muscle relaxants necessary for mechanical ventilation || The time to basic clinical improvement and to recovery defined as the following|14-day Participant Mortality|29-day Participant Mortality|Percentage of Participants in Each Clinical Status Category as Assessed by a 9-Point Ordinal Scale on Day 14|Time to an improvement of one category from admission on 9-Point Ordinal Scale|Time to an improvement of two categories from admission on 9-Point Ordinal Scale|Percentage of Participants in Each Clinical Status Category as Assessed by a 9-Point Ordinal Scale on Day at days 3, 5, 8, 11,14 and 29|Mean change in the ranking on 9-Point Ordinal Scale from baseline to days 3, 5, 8, 11, 14 and 29|Duration of conventional oxygen therapy Use|Duration of new conventional oxygen therapy Use|Duration of Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of Mechanical Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Oxygen Use|Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use|Percentage of Participants Requiring Ventilator or ECMO Use|Incidents of post-COVID-19 related symptoms at Day 29|Incidents of post-COVID-19 related symptoms at Day 60|Percentage of participants with post-COVID-19 related symptoms at Day 29|Percentage of participants with post-COVID-19 related symptoms at Day 60|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Percentage of Participants Discontinued or Temporarily Suspended From Investigational dietary supplements|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Total Bilirubin|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Lymphocytes || Clinical changes in COVID-19 symptoms|Pharmacokinetics evaluation of INM005|Time to progression of disease|Disease progression|Discharge|Intensive care unit (ICU) hospitalization|Mechanical ventilation assistance (MVA)|Mortality|Changes in viral load || Incidence of 60-Day Patient Mortality|Time to Mechanical Ventilation|Number of Patients with Ongoing Clinical Symptoms|Number of Participants Displaying Presence of Any Pulmonary Function Abnormality || Ordinal scale outcome|Viral negative|Change in NEWS|mortality || Time to clinical recovery|Proportion of patient with negative conversion in nasopharyngeal swab|Clinical Outcome || Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events || Number of Participants Reporting Treatment-emergent Adverse Events|Number of Participants Reporting Local and Systemic Adverse Events|Number of Participants Reporting Serious Events|Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific Neutralizing Antibody|Seroconversion Rates of SARS-CoV-2 Specific Neutralizing Antibody|GMT of anti-IgG Antibody|GMFR of anti-IgG Antibody|Seroconversion Rates of anti-IgG Antibody|Pharmacokinetic Parameter of Maximum (Peak) Observed Plasma Concentration (Cmax) Following Intramuscular Injection of DS-5670a|Pharmacokinetic Parameter of Time to Reach Maximum Concentration (Tmax) Following Intramuscular Injection of DS-5670a|Pharmacokinetic Parameter of Area Under the Concentration-time Curve Following Intramuscular Injection of DS-5670a|Pharmacokinetic Parameter of Apparent Total Body Clearance (CL/F) Following Intramuscular Injection of DS-5670a|Pharmacokinetic Parameter of Terminal Elimination Half-life (t1/2) Following Intramuscular Injection of DS-5670a|Pharmacokinetic Parameter of Apparent Volume of Distribution (Vz/F) Following Intramuscular Injection of DS-5670a || Placental histological evaluation|Cellular analysis on maternal blood and cord blood: phenotyping from PBMCs and NFS with the characterization of lymphocyte populations by the CytodiffTM technique|Cellular analysis on maternal blood and cord blood: functional activities from PBMCs and NFS with the characterization of lymphocyte populations by the CytodiffTM technique|Number of cytokines in maternal blood and cord blood|Number of immunoglobulins in maternal and fetal blood|Maternal clinical evaluation then neonatal on medical file and telephone questionnaire 1 month after childbirth. Comparison of results between groups.|Foetal clinical evaluation then neonatal on medical file and telephone questionnaire 1 month after childbirth. Comparison of results between groups. || Clinical improvement (efficacy)|ventilation|WHO (World Health Organization) scale|SOFA (Sequential Organ Failure Assessment) score|naso-pharyngeal swab|SARS-CoV2|P/F|thrombosis|curarization|complication kidney|complication lung|Leucocytes|Lymphocytes|C-reactive protein|D-dimer|Troponin I (TnI)|PCTI (Procalcitonin) (ng/mL)|Ferritin|Albumin|LDH|Lung Ultrasound Score (LUS)|ecmo|death|hospitalization|Lung Function tests|High resolution computed tomography (HRCT)|Improvement mortality || Change on cognitive Impairment: Vigilance (RASS)|Change on cognitive Impairment: Cooperation|Change on cognitive Impairment: Communication|Change on cognitive Impairment: Agitation|Change on cognitive Impairment: Delirium|Change on cognitive Impairment : Introduction of neuroleptic|Change on cognitive Impairment: temporo-spatial disorientation|Change on physical Impairment : dyspnea|Change on physical Impairment: Modified Borg scale dyspnea score.|Change on physical Impairment : cough|Change on physical Impairment : respiratory rate|Change on physical Impairment : ventilation mode|Change on physical Impairment : Peripheral capillary oxygen saturation (SpO2) at rest|Change on physical Impairment : respiratory rate on activity|Change on physical Impairment : Peripheral capillary oxygen saturation (SpO2) on activity|Change on physical Impairment : orthostatic hypotension|Change on physical Impairment : electrocardiogram at rest|Change on physical impairment : numeric verbal scales of fatigue|Change on physical Impairment: numeric verbal scales of pain|Change on physical Impairment : stiffness or pain involving joints|Change on physical Impairment : stability of the trunk in siting|Change on physical Impairment : autonomy for bed-chair transfers|Change on physical Impairment autonomy for walking|Change on physical Impairment : sores|Change on Imagery cerebral|Change on physical Impairment neurologic exam|Change on physical Impairment Medical Research Council (MRC-SS MRC Sum score)|Change on physical Impairment five times sit to stand test|Change on cognitive Impairment The Montreal Cognitive Assessment (MoCA)|Cognitive Impairment Frontal Assessment Battery (FAB)|Change on psychological Impairment : sadness|Change on psychological Impairment : anxiety|Change on psychological Impairment: Insomnia|Change on psychological Impairment : Apathy|Change on psychological Impairment : sideration|Change on psychological Impairment : Despair|Change on psychological Impairment : Culpability|Change on psychological Impairment : Conduit addictive|Change on psychological Impairment : psychiatric or psychologic care|assess type of psychiatric treatment|Change on psychological Impairment : Hospital Anxiety and Depression Scale (HADS)|Change on psychological Impairment : Posttraumatic Stress Disorder Checklist Scale (PCL-S)|assess psychological Impairment|asses demographics information|assess comorbidities|assess past and current medications|assess related symptoms nature of COVID-19|assess characteristics of ongoing hospitalization|assess medical complications in intensive care|Descriptive data of the rehabilitation care pathway after stay in intensive care until return home|Number of new medical qualifying events since last contact|Social status|Activities of Daily Living (ADL) scale|Quality of life Medical outcome study short form 12 items (MOS-SF-12 ) questionnaire|Gait analysis 6-minute walk test (6MWT)|Balance and Gait analysis || Demographics of recipients|Co-morbidity of recipient|Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy|Hospital and ICU length of stay|Disposition of patients including survival || Lung function measured with spirometry|Diffusion capacity measured with the single breath method|Bone mineral density by dual-energy X-ray (DEXA)-scan|Lean mass by dual-energy X-ray (DEXA)-scan|Fat free mass by dual-energy X-ray (DEXA)-scan|Fat mass by dual-energy X-ray (DEXA)-scan|Vertebral fracture assessment by dual-energy X-ray (DEXA-scan)|Weight will be measured on a weighing scale|Height will be measured using a stadiometer|Body mass index (BMI) will be calculated from the weight and height|Fasted resting energy expenditure by indirect calorimetry (ventilated hood)|Resting blood pressure|Waist circumference|Fasting glucose levels|Fasted lipid profile|Six minute walking test to determine exercise capacity|Peak work rate by cardiopulmonary cycling exercise test (CPET)|Peak O2-consumption and CO2-production by cardiopulmonary cycling exercise test (CPET)|Maximal heart rate during cardiopulmonary cycling exercise test (CPET)|Respiratory muscle strength by mouth pressure|Upper extremity muscle strength by measuring handgrip strength|Lower extremity muscle strength by measuring isometric muscle strength|Mobility using the short physical performance battery (SPPB)|Physical activity level by accelerometry|Cognitive function by Montreal Cognitive Assessment (MOCA)|Dietary intake by a food diary|Smell by the Sniffing Sticks treshold test|Taste using the taste strips 'filter paper disc method' test|Taste and smell function using the taste and smell function questionnaire|The hospital anxiety and depression scale (HADS) to determine anxiety and depression levels|The Perceived stress scale (PSS) to determine stress levels|Perceived social support using the multidimensional scale of perceived social support (MSPSS)|Loneliness using the loneliness scale (LS)|Subjective multidimensional health status by euroqol-5 dimensions|Dyspnea using the modified medical research council (mMRC)|Fatigue using the Checklist Individual Strength (CIS)|Sleep quality using the Pittsburgh Sleep Quality Index (PSQI)|General pain using the Visual Analogue Scale (VAS)|Medical history|Treatments/therapies after SARS-CoV-2 infection|Vaccination for COVID-19|Re-infection with COVID-19|Medication use|Muscle and adipose tissue cross sectional area (CSA) on chest-CT scan|Persistent lung damage on chest-CT scan || The mean scores anxiety and depression among pregnant women during COVID-19 pandemic || Number of Infected Subjects|Adverse Events Other Than Those Resulting From Contagion or Disease Progression || Structural Change in Lung|Carbon monoxide diffusion capacity (DLCO)|Exercise Capacity|Short Form Health Survey Score (SF-16) || Clinical Improvement || Time to sustained clinical recovery|Time to Patient Reported Global Daily impression|Proportion of patients showing sustained resolution of Symptoms|Time to improvement in symptoms|Proportion of patients that progress to severe COVID-19|Reduction in Death Related to COVID-19|Reduction in Patient Hospitalization|Reduction in incidence of hospitalization for respiratory distress or O2 saturation|Time to sustained clinical recovery among SARS-CoV-2 IgG-negative subjects at enrollment from start of study treatment|Time to sustained clinical recovery among subjects with ≤3 days of COVID-19 symptoms at enrollment from start of study treatment|Time to negative conversion of detectable SARS-CoV-2 viral RNA in RT-PCR assays of saliva|Proportion of patients showing negative conversion of detectable SARS-CoV-2 viral RNA in saliva || Provide an adequate sample and compare the signals given from the two groups. || Phase I and II - The number, grade and percentage of study participants who experience any study injection-associated AEs or SAEs.|Phase II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 per group at 28 days following last vaccination (in relation to Day 0-baseline).|Phase I and II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 at baseline (day 0) and throughout the study|Phase I and II - IIBR-100 immunogenicity as determined by GMT, GMFR, Seroconversion rates of the binding antibody titers to SARS-CoV-2 at baseline (day 0) and throughout the study|Phase I and II - Cellular immunity as assessed by ELISPOT and ELISA. || Vitamin D serum concentration|Clinical improvement|Hospital length of stay.|Intensive care unit length of stay.|Supplemental oxygen, non-invasive or invasive ventilation or organ support|Duration of supplemental oxygen, non-invasive or invasive ventilation or organ support|Absence of fever|Time until negative laboratory SARS-CoV-2 test.|Mortality all causes.|Mortality related to Covid-19.|Biological markers || lung injury score|Transe membrane protease ,serine II (TMPRSS2) changes over time|Testosterone levels changes over time|Dihydrotestosterone(DHT) levels changes over time|Cholesterol levels changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Time to first negative SARS-CoV-2 PCR in NP swap|All cause mortality rate|Ventilation free days|ICU free days || Fever|Shortness of Breath|Cough|Sore Throat|Headache|Muscle/ Joint Pain|Diarrhoea|Vomiting/ Nausea|Runny Nose|Loss of Smell/Taste|Other symptoms || Test Result || Time spent on medications used to increase blood pressure|Time spent on mechanical ventilation|Time spent in the intensive care unit (ICU)|Time spent in the hospital|Time spent on dialysis|Mortality || Change in the quality of life|Change in lung volume parameters (spirometry)|Change in respiratory flow parameters (spirometry)|Change in lung diffusing capacity|Change in Body Mass Index (BMI)|Change in the body composition (bioelectrical impedance analysis)|Change in C-reactive protein (CRP) values (blood sample)|Change in D-Dimer values (blood sample)|Change in white blood cell (WBC) values (blood sample)|Change in gasometry (blood sample)|Change in the percentage of opacity (chest computed tomography) || Missing Outcome Measures || Ordinal scale of seven World Health Organization (WHO) categories of IL-17 inhibitor versus low dose IL-2 versus indirect IL-6 inhibitor (colchicine) versus standard treatment in the treatment of severe COVID-19|Time until independence from oxygen therapy in days|Ventilator free days (in days)|Assessment of worsening pulmonary involvement, defined as the presence of one of these criteria (absence or presence)|In patients who needed mechanical ventilation, time to indicate mechanical ventilation|Duration of hospitalization, in survivors|Analysis of in-hospital mortality|Analysis of general mortality || Distance walked in the 6-min walk test (6 MWT).|Number of repetitions performed in a 1-min Sit-to-Stand (STS) test|Dyspnea evaluated by the modified Medical Research Council (mMRC)|Fatigue evaluated by the Multidimensional Fatigue Inventory (MFI-20)|Anxiety and Depression evaluated by the Hospital Anxiety and Depression Scale (HADS) || SARS-CoV-2 infection|Exposure based on behavior || Fatigue || The number of participants with knowledge of COVID related symptoms and transmission as assessed by a questionnaire we've developed specifically relevant to the intervention videos we are using for the project.|Behavioral outcome 1: Number of participants who report behavior change related to messages provided in the intervention videos; measured via a specific questionnaire instrument we've developed to correspond to the intervention.|Behavioral outcome 2: Willingness to pay (WTP) for masks|Behavioral outcome 3: Number of people who click on links for additional information on the covid-19 behaviors|Behavioral outcome 4: The amount of money donated to a COVID-19 relief fund. || improved || Clinical Improvement|Need for invasive mechanical ventilation|Length of ICU stay|Length of hospital Stay|Length of need of mechanical ventilation|All cause mortality|Occurrence of side effects || Therapeutic success (cured)|28 days in hospital mortality|Percentage of clinical failure of treatments|Length of hospital stay|Incidence of side effects || Percentage of Hospitalization of medical cause in patients with COVID-19 in each arm|Time to hospitalization|Percentage of Use of invasive mechanical ventilation support in each arm|Time to invasive mechanical ventilation support|Percentage of dialysis in each arm|All-cause mortality|Negative of the swab at 3±1 days and 12±2 days after entering the study|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) || Salvia samples have equal or higher sensibility than nasal swaps in children for detection of SARS-CoV-2|Parental home testing of saliva and feces is feasible in children || Functional Capacity|Functional Capacity (SPBB) short performance physical battery test|The Short Form Health Survey SF-12|The Short Form Health Survey SF-12 Quality of Live|European Quality of Life-5 Dimensions EQ-5D|Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)|Cost-effectiveness of the telerehabilitation intervention || Comparison of disease-specific TCR signatures in patients and controls|Identify the immunodominant antigens that elicit a T-cell response to COVID-19|Risk Stratification based on an individual's immune signature|Determine whether an immune signature can be detected in individuals exposed to SARS-CoV-2 earlier than currently available tests|Explore whether additional research assays could potential identify and/or confirm antigenic binding || Clinical status at day 28|Time to clinical improvement|Time to decline of at least 2 categories|Incidence of mechanical and/or non-invasive ventilation|Number of ventilator-free days to day 28|Organ failure free days to day 28|Incidence of ICU stay|Duration of ICU stay|Time to clinical failure|SAPS II|CCI|APACHE II|SOFA 6|Mortality rate|Time to hospital discharge or ""ready for discharge""|Duration of supplemental oxygen || Safety / Tolerability|Immunogenicity || Number of surgical operations performed whether elective or emergency || Solicited adverse events (AEs)|Unsolicited AEs|Serious adverse events (SAEs)|Medically attended adverse events (MAEs)|Change in serum neutralizing antibody titers against vaccine-encoded SARS-CoV-2 S protein|Change in serum binding antibody concentrations against vaccine-encoded SARS-CoV-2 S protein|Potential vaccine virus shedding: frequency|Potential vaccine virus shedding: magnitude|Potential vaccine virus shedding: duration || PaO2/FiO2 ratio|Viral Load Measurement|Duration of mechanical ventilation|Mortality || Baseline levels of serum vitamin D in COVID-19 patients|Correlation between D-dimer and vitamin D serum levels in COVID-19 patients|Correlation between transferrin and vitamin D serum levels in COVID-19 patients|Correlation between ferritin and vitamin D serum levels in COVID-19 patients|Effects of vitamin D3 supplementation on COVID-19 patients || Number of participants with treatment-TOMEKA® usage|Change From Baseline in herbs Vernonia amygdalina usage || Perception and knowledge towards the vaccine || Physician's judgment on clinical recovery from the time of admission|Clinical improvement in NEWS2|Improvement in serum biomarkers|Requirement for indotracheal intubation|Occurrence of Macrophage Activation Syndrome(MAS)|Occurrence of Coagulopathy || Viral Load Outcome|Clinical Symptoms Outcome || Comparison with Naso-pharyngeal swab|Mask out over time|mask as a screening tool in asymptomatic people || SARS-CoV-2 related volatile organic compounds (VOC)|To compare the SARS-CoV-2 specific VOC with the clinical symptoms of COVID-19 and diagnostic findings || Change from baseline to Day 8 in SARS-CoV-2 viral shedding as measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swab samples|Time-weighted average change in viral shedding as measured by RT-qPCR in nasopharyngeal swab samples|Change from baseline to Day 15 in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasopharyngeal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Number of participants requiring hospitalization due to worsened COVID-19|Time to resolution of all COVID-19-related symptoms|All-cause mortality rate at Day 29|Number of participants experiencing Adverse Events (AEs)|Number of participants experiencing Serious Adverse Events (SAEs) || Comparison of the distribution of frequencies of each score of a 5-scale patient state evaluated from the 11-point WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatment|Absolute change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS)|Relative change of the measure of the 11-point of WHO Clinical Progression ordinal Scale (CPS)|Absolute change of the SOFA score|Relative change of the SOFA score|Time until hospital discharge|Time until discharge from the intensive care unit|Comparison of the rate of serious and non-serious adverse events between the two arms of treatment|Relative changes of circulating concentrations of suPAR (μg/liter), D-dimers (μg/liter), ferritin (μg/liter), and Interleukin-6 (μg/liter) by Day 7 from baseline Day 1|Relative changes of circulating concentrations of C-reactive protein (mg/liter) by Day 7 from baseline Day 1|Relative changes of circulating concentrations of suPAR (μg/liter),D-dimers (μg/liter), ferritin (μg/liter), and Interleukin-6 (μg/liter) by Day 4 from baseline Day 1|Relative changes of circulating concentrations of C-reactive protein (mg/liter) by Day 4 from baseline Day 1|Absolute change of the viral load by Day 7 from baseline Day 1|Relative change of the viral load by Day 7 from baseline Day 1|Absolute change of the viral load by Day 4 from baseline Day 1|relative change of the viral load by Day 4 from baseline Day 1|Transcriptomic analysis|Proteomic analysis || Proportion of patients with clinical improvement|Hospital and ICU length of stay;|Duration of invasive mechanical ventilation|Duration of vasopressor use|Renal failure by AKIN criteria|Incidence of cardiovascular complications|Incidence of venous thromboembolism|Mortality || Assessment of treatment emergent adverse events (AEs) - Safety|Incidence of dose-limiting toxicities (DLTs) - Tolerability|Establish Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) - Tolerability || SOP ""Analgesia, sedation, delirium and pain therapy""|SOP ""Treatment of acute respiratory distress syndrome (ARDS)""|SOP ""Infectious treatment""|SOP ""Weaning""|SOP ""Nutrition""|SOP ""Sepsis"" || Cytokine (or chemokine) production in response to heterologous stimuli|Neutralization assay || Survival|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0 || Inflammation of the lungs - O2|Inflammation of the lungs - CRP|Inflammation of the lungs - IL6 || Performance Evaluation || Clinical improvement|Time to discharge of patients|The rate of patients entering intensive care|Patients' rate of needing mechanical ventilation|Change in SpO2 (measured by pulse oximetry)|Normalization in body temperature|Dyspnea Scale (Modified Borg Dyspnea Scale (MBS)|6-minute walking test (14th day and 28th day)|The time it takes for patients to improvement of their symptoms (cough, shortness of breath)|The time it takes for the PCR to become negative|Sequelae and recovery rates in control thorax computed tomography at the end of month 1 and 6 months|Need for re-hospitalization|Normalization in laboratory results of blood parameters (PT, aPTT, D-dimer, Ferritin, Lymphocyte Count, CRP)|Normalization in laboratory results of biochemistry parameters (Glucose, ALT, AST, LDH, Total Bilirubin, Total Protein, Albumin, Alkaline Phosphatase, GGT, Sodium, Potassium, Calcium, Phosphor, CPK, Magnesium, eGFR, BUN, Uric Acid, Creatinine Clearance)|Mortality rate|Normalization in Blood Pressure|Normalization in Respiration Rate/Minute|Normalization in SpO2 || Level of Inflammatory Markers|Score on St. George's Shortness of Breath Questionnaire (SGSQ)|Score on Short Form Zarit Burden Interview (ZBI-12) || Preterm delivery|Preeclampsia|Eclampsia|Hemolysis Elevated Liver enzymes Low Platelets Syndrome (HELLP)|Number of participants with Cesarean delivery (CD)|Percentage of participants with Cesarean delivery (CD)|Deep venous thrombosis|Pulmonary embolism|Pregnancy loss at less than 24 weeks' gestation|Intrauterine Fetal Demise (IUFD)|Maternal death|Low birth weight|Number of participants with Neonatal intensive care unit (NICU) admission|Percentage of participants with Neonatal intensive care unit (NICU) admission|Number of participants with APGAR score (Activity, Pulse, Grimace, Appearance, Respiration score) at 5 minutes < 7:|Percentage of participants with APGAR score (Activity, Pulse, Grimace, Appearance, Respiration score) at 5 minutes < 7:|Number of participants with Respiratory distress at birth|Percentage of participants with Respiratory distress at birth|Neonatal death|Number of participants with Delivery < 32 weeks|Percentage of participants with Delivery < 32 weeks|Number of participants with Spontaneous delivery < 37 weeks|Percentage of participants with Spontaneous delivery < 37 weeks|Number of participants with Fetal distress|Percentage of participants with Fetal distress|Number of participants with Unscheduled cesarean delivery|Percentage of participants with Unscheduled cesarean delivery|Postpartum hemorrhage|Number of participants with Intraventricular hemorrhage|Percentage of participants with Intraventricular hemorrhage|Umbilical cord pH|Small for gestational age (SGA)|Large for gestational age (LGA) || In hospital days|14 day mortality|D-dimers|C-reactive protein|Oxygen saturation|TNF alpha|IL-6|Ferritin|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 || Clinical Course Binary Outcome|Serious Adverse Events|Time to symptomatic recovery|SCL18 (self-check list of 18 symptoms of COVID-19)|Patient's Global Impression of Change|Adverse Events|Day-60 Follow-up || The Maximum Tolerable Dose (MTD)|Number of participants with treatment-related adverse events as assessed by CTCAE V4.0|Pharmacokinetic parameters(Cmax)|Pharmacokinetic parameters(AUC) || Plasma desmosine levels|Plasma dp-ucMGP levels|Safety|Serum PIVKA-II levels || respiratory degradation event 1|respiratory degradation event 2|New Early Warning Score (NEWS) evaluation|Assessment of caregiver feelings|Intensive Care Unit tansfer || Primary Efficacy Endpoint: Time to resolution of hypoxia (Stage I)|Time to alleviation of symptoms (Stage I)|Percentage of patients with score of 0 = absent or mild = 1 (Stage I)|Time to improvement in each of the symptoms (Stage I)|Percentage of patients reporting a 'clinical relapse' (Stage I)|Time to negative conversion of detectable SARS-CoV 2 (Stage I)|Percentage of patients showing negative conversion of detectable SARS-CoV 2 (Stage I)|Changes over time in patient's clinical status on the 10-point ordinal scale of clinical status (Stage I)|Changes over time in patient's clinical status on the 8-point ordinal scale of clinical status (Stage I)|Changes over time in findings on chest X-ray (Stage I)|Changes over time in the National Early Warning Score-2 (Stage I)|Percentage of patients requiring ICU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Time (no. of days) from randomization to ICU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Duration (no. of days) the patient requires CU management, high flow nasal oxygen and mechanical ventilation (Stage I)|Percentage of Patients dying (all cause and due to COVID-19) (Stage I)|Percentage of 'clinical relapse' (Stage I + Stage II)|Incidence of treatment emergent adverse events (Stage I + Stage II) || For Viral Domain: Change in Viral Shedding|For Clinical Domain: Time-to-sustained-resolution|Time to viral cessation|Time to first resolution|Time to full resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2 || For the Viral Domain: Change in Viral Shedding|For Clinical Domain: Time-to-sustained-resolution|Time to viral cessation|Time to first resolution|Time to full resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2|Indicator participant has a negative SARS-CoV2 RT-PCR test || What's your work or study system nowadays?|Habits before the Covid-19 pandemic|Habits in the Covid-19 pandemic|Personal Covid-19 exposure and disease|Positive Covid-19: tests, diagnosis, symptoms and quarantine|Negative Covid-19: tests and quarantine|Expectations|Date of birth|Sex|Height|Weight|Blood type|Pathologic history|Region of residence|City of residence|Rural or urban environment|Cohabitants in the family unit || Survey: Epidemic-Pandemic Impacts Inventory (EPII) || Retrospective analysis of the neurological disorder after severe SARS-CoV-2 infection || Daily calls to the Emergency System|Daily count of Emergency Department visits|Daily average boarding time|Outcome at ED discharge|Mortality || Changes in dyspnea level|Changes in respiratory rate|Changes in heart rate|Changes in pulsed oxygen saturation (SpO2)|Number of sit-to-stand repetition || comparing % of change in cytokine's clearances of pro et anti -inflammatory types|Evaluation of the impact upon the survival rate at 28 and 90 days.|Chemokine kinetics|Cytokine kinetics|Complement pathway kinetics|PaO2/FiO2 ratio || Master Protocol: Dose-finding/Phase I|Master Protocol: Efficacy evaluation/Phase II - Severe patients (Group A)|Master Protocol: Efficacy evaluation/Phase II - Mild to moderate patients (Group B)|CST-2 Phase I: To determine the safety and tolerability of multiple ascending doses of EIDD-2801 to recommend dose for phase II.|CST-2 Phase II: To determine the ability of EIDD-2801 to reduce serious complications of COVID-19 including hospitalization, reduction in SAO2<92%, or death.|Master Protocol: Safety assessed by rate of adverse events|Master Protocol: To evaluate clinical improvement|Master Protocol: To evaluate clinical improvement using WHO clinical progression scale|Master Protocol: To evaluate clinical improvement using SpO2/FiO2|Master Protocol: To evaluate discharge|Master Protocol: To evaluate admission to ICU|Master Protocol: To evaluate safety further (WCC)|Master Protocol: To evaluate safety further (Hg)|Master Protocol: To evaluate safety further (platelets)|Master Protocol: To evaluate safety further (creatinine)|Master Protocol: To evaluate safety further (ALT)|Master Protocol: To evaluate overall mortality|Master Protocol: To evaluate the number of oxygen-free days|Master Protocol: To evaluate ventilator-free days|Master Protocol: To evaluate incidence of new mechanical ventilation use|Master Protocol: To evaluate National Early Warning Score (NEWS)2/qSOFA|Master Protocol: To evaluate translational outcomes (Viral Load)|Master Protocol: To evaluate translational outcomes (Baseline SARS-COV-2)|CST-2 Additional: Pharmacokinetic Objective: To define PK of EIDD-2801 and EIDD-1931 in plasma following multiple doses administered to patients with COVID-19.|CST-2 Additional: Virologic Objective: To assess the difference in viral clearance (time to negative PCR) between EIDD-2801 and control.|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (FLU-PRO)|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (WHO Scale).|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (NEWS2)|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (mortality)|CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (death) || antibiotic misuse || Health related Quality of life (general well-being) questionnaire|Revalidation & Reintegration|Depression and/or anxiety|Post traumatic stress syndrome || Clinical description of asthenia|Clinical description of dyspnea|Clinical description of thoracic disorders|Clinical description of neurological disorders|Clinical description of anosmia || Fatal or non-fatal venous thromboembolism (VTE)|Fatal or non-fatal cardiovascular events, encompassing stroke and myocardial infarction|All-cause death|Prevalence of cardiovascular risk factors|Length of hospitalization|Prevalent use of in-hospital thromboprophylaxis|In-hospital course of D-dimer (μg/mL)|In-hospital course of Troponin (ng/ml) || PaO2|FiO2|General Anxiety Disorder-7 Score || Determination of peripheral blood RNA microarray assay|Determination of nasopharunx Microbiota analysis|Determination of in vitro cytokines production|Determination of peripheral blood cytometry|Relation between study parameters || Highest disease status|Percentage of deaths|Percentage of hospital admissions|Percentage of ICU admissions|Disease duration in days of symptoms|Age and clinical frailty score || Immunogenicity index-geometric mean titer(GMT) of neutralizing antibody|Immunogenicity index-Seroconversion rate of the neutralizing antibody|Immunogenicity index-Seropositive rate of the neutralizing antibody|Safety index-Incidence of adverse reactions|Safety index-Incidence of serious adverse events || Clinical improvement|6-point ordinal scale proportion at 14 days|6-point ordinal scale proportion at 28 days|Overall mortality|Days alive and free of respiratory support (DAFOR28)|Mechanical ventilation|PaO2/FiO2 ratio|Hospital stay|Lactate Dehydrogenase|Troponin I|C Reactive Protein|D-Dimers|Fibrinogen|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (APTT)|Tumor Necrosis Factor Alfa (TNF-Alfa)|Interleukin-6 (IL-6)|RT-PCR|Sequential Organ Failure Assessment (SOFA) score|National Early Warning Score 2 (NEWS) 2|Safety and Adverse Events || Rate of clinical deterioration|Rate of recovery|Hospital discharge rate|Mortality rate|Duration of hospitalization|Adverse events || Proportion of participants who have died or progressed to respiratory failure|Proportion of participants experiencing treatment-emergent adverse events|Survival|Viral load|Clinical worsening on a 9-point ordinal scale|Clinical improvement|Time to extubation|Time to discharge from hospital intensive care unit|Incidence of supplemental oxygen administration|Duration of supplemental oxygen administration|Duration of noninvasive ventilation by nonrebreather mask or high-flow nasal cannula|Incidence of noninvasive ventilation by nonrebreather mask or high-flow nasal cannula|Duration of mechanical ventilation plus additional organ support using vasopressors, and/or renal replacement therapy and/or ECMO|Incidence of mechanical ventilation plus additional organ support using vasopressors, and/or renal replacement therapy and/or ECMO|Daily ratio of oxygen saturation (SpO2) to fractional inspired O2 (SpO2/FiO2)|Time to discharge from the hospital|Time to re-hospitalization|Proportion of participants requiring intensive care unit admission || Clinical symptoms duration || Functional Independence measure (FIM) at the admission|Functional Independence measure (FIM) 1-month hospitalization|Functional Independence measure (FIM) at the discharge|weight at admission|weight at the discharge|age|Estimated functional independence measure score before Covid-19|Estimated dyspnea symptoms before Covid-19|Length of stay in ICU unit|Length of stay in acute care|Length of stay in rehabilitation centers|Length of Invasive mechanical ventilation|Presence of pressure ulcers|Risk of bedsore|Joint limitation|Dominant side|Presence of psychic disorders|Muscle strength at the admission|Muscle strength at the discharge|Dyspnea symptoms at the admission|Dyspnea symptoms at the discharge|Functional exercise capacity|Destination of patients at discharge|Oxygen saturation of the blood at the admission|Oxygen saturation of the blood at the discharge|Presence of Hoffman signs|Presence of Babinski signs|Sex|Neurological examination at the admission|Neurological examination at the discharge || Impact Event Scale-Revised (IES-R)|Generalised Anxiety Disorder-7 (GAD-7)|Patient Health Questionnaire-9 (PHQ-9)|Insomnia severity index (ISI)|Demographic data|Hospitalization duration|ICU stay|Medical history|Alcohol consumption|Tobacco consumption || Incidence of Death|Time to Clinical Improvement|Incidence of Mechanical Ventilation|Duration of Mechanical Ventilation|Duration of Hospitalization|Number of adverse events and serious adverse events || Incidence of MAAEs and SAEs|Incidence and severity of solicited local reactogenicity AEs|Incidence and severity of solicited systemic reactogenicity AEs|Incidence and severity of unsolicited AEs|Incidence of changes of laboratory safety examinations|Vital Sign - Temperature|Vital Sign - Heart rate|Vital Sign - Blood Pressure|Vital Sign - Respiratory Rate|GMFR in IgG titer|GMT of S-specific, RBD-specific, and N-specific antibodies|Percentage of subjects who seroconverted|GMFR in neutralizing antibody|GMT of neutralizing antibody|Seroconversion rate of neutralizing antibody|CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein|CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein || Length from the vestibulum nasi to the posterior wall of the nasopharynx.|Length from the vestibulum nasi to the mid-turbinate. || Death or respiratory failure until Day 28|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale of disease severity at Day 14|Status of alive and not on mechanical ventilation or ECMO at Day 14 and 28 NIAID ordinal scale of disease severity at Day 14|Status of requiring supplemental oxygen at Day 28|Status of being alive and not hospitalized at Day 14 and 28|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale of disease severity at Day 14 NIAID ordinal scale of disease severity at Day 28|Number of patients with cure|Number of patients at the ICU or on ventilatory support at Day 28|Number of days free from mechanical ventilation at 28 days|Number of days in hospital|Number of days in ICU|Death or respiratory failure at Day 28 || Virologic clearance|Hospital Stay|Clinically relevant adverse effects|Laboratory tests || Clinical detoriation rate|28-day all-cause mortality rate|Clinical deterioration rate|28-days all-cause mortality rate on day 29|Time to clinical deterioration|Time to Mortality|Proportion of subjects in each of the 9-categories of the ordinal scale|Time to clinical improvement|Proportion of subjects with score ≤2|Days on IMV|Days without oxygen supply|Time to discontinuation from any form of oxygen supply|Proportion of subjects without any form of oxygen supply|Hospital-free-days|SARS-CoV-2 status|Adverse events (AEs), treatment-emergent AEs (TEAEs), AEs of special interest, infusional TEAEs|TEAEs|SAEs|Dose modifications|Time to recovery|Change over time in ECG parameters|Change over time in vital signs || Part A - Determination of the safety and tolerability of two dose levels and selection of an upamostat dose for part B|Part B - Comparison between upamostat and placebo in time to sustained recovery from symptomatic illness. Sustained recovery is recovery, per below definition, maintained for at least 28 days or through end of study, whichever comes first.|Part B - Proportion of patients who are PCR-negative at various time points during the study.|Part B - Time to resolution of individual disease-related symptoms present at baseline|Part B - Development of new disease-related symptoms on study|Part B - Incidence of pneumonia during study among patients without baseline pneumonia|Part B - Changes in laboratory markers of disease severity|Part B - Hospitalization|Part B - Mortality|Part B - Adverse events || Correlation between data captured using Amazon Alexa compared to manual (human) collected data. || Proportion of participants with clinical improvement as defined by an improvement of categories on the WHO Ordinal Scale of clinical status until Days 28.|Time to clinical improvement was defined as time from randomization to an improvement of categories on the WHO Ordinal Scale of clinical status.|Changes in the WHO Ordinal Scale for Clinical Improvement until Days 28 compared to Baseline.|Changes in National Early Warning Score (NEWS) until Days 28 compared to Baseline.|Proportion of participants with negative for COVID-19 as determined by real-time RT-PCR test until Days 14.|Changes in viral load until Days 14 compared to Baseline.|The time to body temperature normalization after the administration of investigational Product (IP).|The time to respiratory rate normalization after the administration of IP.|The time to oxygen saturation (SpO2) normalization after the administration of IP.|Mortality rate at Day 28.|Duration of hospitalization (Day 1 to Day 28).|The incidence of adverse events (AEs).|The incidence of serious adverse events (SAEs). || Mortality rate|Rate of progression disease|Time to recovery || To compare the slope of cycle threshold(Ct) values of nasopharyngeal swabs in people receiving Triazavirin versus placebo|To assess the proportion of patients who progress to severe COVID-19 and the proportion who need ICU or die.|To determine the proportion of patients who develop grade 3 or grade 4 adverse events on treatment|To determine the proportion of patients who stop taking either placebo/Triazavirin || Occurrence of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of adverse events of special interest (AESIs)|Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) readings|Occurrence of disease progression events (not classified as AEs)|Cmax|Clast|Tmax|Tlast|AUCD0-28|AUCinf|AUClast|%AUCexp|t1/2|Vz|Vss|CL|Occurrence of SAEs|Occurrence of AESIs|Occurrence of clinically significant abnormalities on 12-lead ECG readings || Incidence rate, characteristics, and severity of adverse reactions|Shift from baseline of vital sign|Shift from baseline of physical examination|Shift from baseline of hematology|Shift from baseline of blood chemistry|Dose limiting toxicity (DLT)|Absolute lymphocyte count (ALC)|RT-PCR for COVID-19|Assessment of clinical improvement by modified early warning score (MEWS)|Ordinal scale for clinical improvement (WHO) in each visit|The proportion of subjects who have progressed to death or a critical illness|Immune repertoire || Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses|Sars-Cov2 IgM|Sars-Cov2 IgG || Change in activated partial thromboplastin time (APTT) > 1.5|Viral load in nasal swab reverse transcription polymerase chain reaction (RT-PCR).|Number of participants needing supplemental oxygen therapy|Number of participants needing mechanical pulmonary ventilation|Number of hospitalization days|Number of participants that develop renal failure|Number of participants that develop major cardiovascular events|Number of participants transferred to the intensive care unit (ICU)|Number of participants presenting secondary pulmonary bacterial infections|Number of participants that develop deep vein thrombosis (DVT)|Number of participants that develop pancreatitis|Number of participants that need corticosteroid therapy|Number of deaths among participants|Number of participants with increased white blood cell count|Number of participants with increased C reactive protein test|Number of participants with deterioration of arterial blood gas paO2/pFiO2 ratio|Number of participants with altered sodium|Number of participants with altered potassium|Number of participants with increased pulmonary area compromised (%) || Identify post covid symptoms|prevalance of post covid syndrome among survivours || Time to normalize the oxygen requirement (oxygen dependence)|Need for Invasive Mechanical Ventilation (IMV) and / or Respiratory Distress Syndrome Acute (ARDS)|Development of Acute Respiratory Distress Syndrome (ARDS)|30-day mortality|Hypotension with vasopressor requirement|Mortality || Proportion of virologically cured (PCR-negative status) as assessed on day six|virologic cure on other study days|virologic semiquantitative analysis of changing viral load|proportion of initially symtomatic subjects with disappearance of clinical symptoms|proportion of initially asymtomatic subjects with appearance of new clinical symptoms|proportions of subjects with potentially medication- related adverse events || Time to recovery|All-cause mortality|Composite of time to recovery, free/not free of respiratory support and mortality|Time from randomization to recovery|Days alive outside short-term acute care hospital|Incidence of clinical organ failure|Composite of death, clinical organ failure or serious infections|Composite of cardiovascular events and thromboembolic events|Composite of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death|Incidence of infusion reactions|Percentage of participants for whom infusion was interrupted or stopped prior to completion for any reason|Percentage of participants for whom infusion was interrupted or stopped prior to completion due to adverse event|Composite of hospital readmissions or death|Incidence of no home use of supplemental oxygen above pre-morbid oxygen use|Time to hospital discharge from initial hospitalization|Composite of death or serious clinical COVID-19 related events|Pulmonary ordinal outcome|Pulmonary+ ordinal outcome|Composite of SAEs or death|Change in SARS-CoV-2 neutralizing antibody levels|Change in overall titers of antibodies|Change in neutralizing antibody levels|Incidence of home use of supplemental oxygen above pre-morbid oxygen use || Virologic clearance of throat swabs or lower respiratory tract secretions|COVID-19 symptoms development|Adverse effects|Worsened condition || The clinical efficacy of SCTA01 (Phase II and III)|Cumulative incidence of SAEs(Phase II, III)|Change from baseline in viral shedding as measured by RT-qPCR(Phase II and III)|area under the curve (AUC0-t)(Phase II)|AUC0-∞(Phase II)|Half-life time (t1/2)(Phase II)|Maximum concentration (Cmax)(Phase II)|Peak time (Tmax)(Phase II)|Clearance (CL)(Phase II)|Apparent volume of distribution (Vd)(Phase II)|Elimination rate constant (λz)(Phase II)|Immunogenicity as measured by anti-drug antibodies (ADA) (Phase II, III) || Frequency of all adverse events|Frequency of infusion related serious adverse events|Frequency of serious adverse events|Mortality|Ventilator Free Days|ICU Free Days|Total Hospital Days|Total ICU Days|Improvement in Oxygenation || Rate and severity of local and systemic solicited adverse events|Rate and severity of unsolicited adverse events|Rate and severity of medically attended adverse events|Rate of serious adverse events|Adverse events leading to discontinuation of study vaccination|Adverse events leading to study discontinuation|Rate and severity of laboratory abnormalities (hematology, biochemistry, urinalysis)|Geometric Mean Titer (GMT) and the geometric mean fold increase in serum virus-neutralizing activity in a subset of participants post-vaccination over baseline|GMT and the geometric mean fold increase in serum receptor binding domain (RBD) antibody titers measured by ELISA post-vaccination over baseline|GMT and the geometric mean fold increase in serum virus-neutralizing activity in a subset of participants post-vaccination over baseline|GMT and the geometric mean fold increase in serum RBD antibody titers measured by ELISA post-vaccination over baseline|GMT and the geometric mean fold increase in serum spike protein antibody binding titers measured by ELISA post-vaccination over baseline || Treatment emergent adverse events|Pharmacokinetic parameters of TB006: AUC(0-last)|Pharmacokinetic parameters of TB006: Cmax|Pharmacokinetic parameters of TB006: Tmax|Pharmacokinetic parameters of TB006: T1/2|Immunogenicity|Preliminary Efficacy: Viral shedding change|Preliminary Efficacy: Viral shedding change at each visit|Preliminary Efficacy: Time to viral shedding clearance|Preliminary Efficacy: Proportion of treated patients with ≥ 1 COVID-19 related medically-attended visit through Day 28|Preliminary Efficacy: Total number of COVID-19 related medically-attended visits|Preliminary Efficacy: Proportion of treated patients admitted to a hospital due to COVID-19|Preliminary Efficacy: Time to sustained clinical recovery from baseline|Preliminary Efficacy: Clinical improvement from baseline at each visit through Day 28 (in patients with or without underlying comorbidities || Need for hospital admission|Micronutrient basal status (Vitamin A, Vitamin B1, Vitamin B6, Vitamin B12, Vitamin C, 25-OH-Vitamin D,Vitamin E, Folic Acid, Iron, Zinc, Copper, Selenium )|Micronutrient status at hospital admission (Vitamin A, Vitamin B1, Vitamin B6, Vitamin B12, Vitamin C, 25-OH-Vitamin D,Vitamin E, Folic Acid, Iron, Zinc, Copper, Selenium)|Micronutrient status at end of study (Vitamin A, Vitamin B1, Vitamin B6, Vitamin B12, Vitamin C, 25-OH-Vitamin D,Vitamin E, Folic Acid, Iron, Zinc, Copper, Selenium)|Inflammatory parameters|Thromboembolic disease|Oxygen supplementation|High-Flow oxygen supplementation|Invasive mechanical ventilation|Tracheostomy|Renal replacement|Death|Intensive Care Unit Admission|Cumulative hospital admission|Hospitalization needs (days)|Survival|Adverse events|Serious Adverse Events || Changes in Patient-reported Quality of life recorded with the help of the European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l) questionnaire|Changes in Patient-reported Quality of life recorded with the help of the Short Form Health 36 (Sf36)|Changes in Patient-reported Quality of life recorded with the help of the Patient-Reported Outcomes Measurement Information System (PROMIS Profile)|Changes in Patient-reported Quality of life recorded with the help of the Neuropathy Questionnaire (Mnsi)|Changes in Patient-reported Quality of life recorded with the help of the Trauma Patient Health Questionnaire|Changes in Patient-reported Quality of life recorded with the help of the PTSD (Post-traumatic stress disorder) Checklist for Diagnostic and Statistical Manual of Mental Disorders 5 (PCL-5).|Changes in Patient-reported Quality of life recorded with the help of the National Eye Institute Visual Function Questionnaire (NEI-VFQ)|Changes in Patient-reported Quality of life recorded with the help of the St. George's Respiratory Questionnaire (SGRQ)|Changes in neruocognitive testing with Cambridge Neuropsychological Test Automated Battery (CANTAB)|Changes in neruocognitive testing with Montreal Cognitive Assessment Test (MOCA)|Changes in blood pressure measured during spiroergometry testing|Changes in sensomotory testing with the questionnaire for peripheral neuropathy (Michigan Neuropathy Screening Instrument, MNSI)|Changes in sensomotory testing with the questionnaire (painDETECT-questionnaire, pDQ)|Changes in Quantitative sensory testing (QST)|Changes in Point-of-care neurography|Changes in pulmonary function assessed by body plethysmography|Changes in pulmonary function assessed by single breath CO (carbon monoxide) diffusion capacity (DLCO)|Changes in heart rate measured with ECG (Electrocardiogram) during spiroergometry testing|Changes in the oxygen saturation of the blood measured during spiroergometry testing|Changes in the total concentration of carbon dioxide (ctCO2) of the blood measured during spiroergometry testing|Changes in the pH value of the blood measured during spiroergometry testing|Changes in the bicarbonate content of the blood measured during spiroergometry testing|Changes in the blood lactate levels during spiroergometry testing|Changes in the partial pressure of carbon dioxide (pCO2) of the blood measured during spiroergometry testing|Changes in heart rhythm type measured with ECG (Electrocardiogram) during spiroergometry testing|Changes in time intervals of PQ measured with ECG (Electrocardiogram) during spiroergometry testing|Changes in time intervals of QRS measured with ECG (Electrocardiogram) during spiroergometry testing|Changes in time intervals of QT measured with ECG (Electrocardiogram) during spiroergometry testing|Deviations in the ST segment depicted with the use of ECG (Electrocardiogram) during spiroergometry testing|Changes in body temperature|Changes in blood pressure|Changes in heart rate|Changes in breath frequency (respiratory rate)|Changes in peripheral oxygen saturation|Changes in the clinical score SOFA (sequential organ failure assessment)|Changes in the clinical score Berlin ARDS (acute respiratory distress syndrome) severity score (if provided)|Changes in the clinical score APACHE (Acute Physiology and Chronic Health Evaluation) Score|Changes in the clinical score NEWS (National Early Warning Score)|Changes in the clinical score qSOFA Score (quick sequential organ failure assessment)|Changes in the Barthel Index|Changes in the Frailty score|Changes in the clinical score Murray Score|Changes in the clinical score Glasgow Coma Scale (GCS)|Changes in the clinical score RASS (Richmond Agitation Sedation Scale)|Changes in the clinical score CAM-ICU (Score Confusion Assessment Method for Intensive Care Unit)|Changes in the clinical score SAPSII (Simplified acute physiology Score II)|Changes in the clinical score NRS (numeric rating scale) pain score|Changes in the clinical score BPS (behavioural pain scale) pain score|Changes in the clinical score CPOT (Critical Care Pain Observation tool)|Changes in the clinical score DDS (Delirium detection score)|Changes in the checked items on the ICDSC (Intensive Care Delirium Screening checklist)|Changes in the heart time volume|Changes in the cardiac index|Changes in EVLWI (Extravascular Lung Water Index)|Changes in Systemic Vascular Resistance Index (SVRI)|Changes in ITBVI (Intrathoracic Blood Volume Index)|Changes in the score WHO (World Health Organisation) clinical ordinal scale|Changes in the NYHA (New York Heart Association) score|Changes in the Post-COVID-19 Functional Status (PCFS) scale|Changes in the National Institutes of Health Stroke Scale (NIHSS)|Changes in the Katz Index|Changes in the Rose Dyspnea Scale || Change form baseline in Arterial oxygen saturation|Days to clinical improvement|Change Form Baseline in C reactive protein at 25 days|Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes|Change Form Baseline in pro-inflammatory cytokines: IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10|Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE. || Number of responder participants after 7 days of treatment|Change of pro-inflammatory markers (IL-6, IL-1 alpha, IL-1 beta, TNF-alpha, PCR, PCT, neopterin)|Change of anti-inflammatory markers (IL-4, IL-10)|Change of brain damage markers (S100b, ENS)|Change of coagulation indices (INR, fibrinogen, D-dimer)|Change of hematological parameters|Change of oxygenation indices (P/F ratio, lactates)|Number of participants who developed delirium|Number of participants who developed anxiety and/or depression || Determining the highest-tolerated & safety-tested AT-100 dose|Reduction in mechanical ventilation || For Clinical Domain: Time-to-sustained-resolution|For the Viral Domain: Change in Viral Shedding|Time to viral cessation|Time to first resolution|Time to full resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2 || Clinical improvement|Sequential organ failure assessment (SOFA) score change|PAI-1 Levels|Ventilator free days || Frequency|Reduction || Treatment-Emergent Adverse Events|COVID-19 Symptom Improvements|COVID-19 Symptom Resolution|Negative SARC-CoV-2 Testing|SARS-CoV-2 Viral Load Change|SpO2/FiO2 Ratio Change|Oxygen Support|Hospitalization|COVID-19 Related Death || Clinical improvement|Hospitalisation|NPS viral load|TS viral load|Inflammatory markers|Adverse events|Mortality || Measure frequency of acceptance of vaccination|Describe causes of refusal of vaccination || Frailty|Comorbidity || Change in oral SARS-CoV-2 load in oral cavity of COVID-19 patient using prophylactic mouth rinse || Intubation rate|WHO ordinal scale COVID19|Oxygenation || Percentage of participants who have recovered at Day 28|Number of participants reaching a score of ≥6 on the WHO (0-10) scale at Day 28|Time to recovery|Viral load|Number of participants with Adverse events (AEs), Serious adverse events (SAEs), Adverse events of special interest (AESIs) and Laboratory abnormalities as a measure of safety || Clinical Improvement by Day 14|*Title: Clinical Improvement at Day 7, 14 and 21|Glycaemic Control|Occurrence of Adverse Events|Occurrence of Serious Adverse Events|Duration of Hospitalisation|Time to Intubation/ Mechanical Intervention|Mortality Rate || Clinical radiologic changes|Percentage of RT-PCR test convertion|Adverse event|Hospital length of stay (LOS)|Case Fatality Rate (CFR) || Time from randomization to sustained recovery|All-cause mortality|Composite of time to sustained recovery and mortality|Days alive outside short-term acute care hospital|Pulmonary ordinal outcome|Pulmonary+ ordinal outcome|Incidence of clinical organ failure|Composite of death or serious clinical COVID-19 related events|Composite of cardiovascular events and thromboembolic events|Composite of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death|Incidence of infusion reactions|Composite of SAEs or death|Change in SARS-CoV-2 neutralizing antibody levels|Change in overall titers of antibodies|Change in neutralizing antibody levels|Incidence of home use of supplemental oxygen above pre-morbid oxygen use|Incidence of no home use of supplemental oxygen above pre-morbid oxygen use || Change in Glutathione concentrations|Change in Interleukein 6 concentrations|Change in Ordinal scale|Change in oxidative stress|Change in marker of damage due to oxidative stress|Change in inflammatory cytokines|Change in mitochondrial energetics|Change in immune function|Change in cognition|Change in function|Change in fatigue|Change in circulating marker of memory || Participants enrolled || Virological clearance of throat swabs or lower respiratory tract secretions|Adverse effects|Worsened conditions|COVID-19 symptoms || pneumonia severity.|Aorta diameter|Pulmonary artery diameter|Pulmonary artery diameter TO Aorta diameter ratio|Description of the lesions found in the CT scan || An indicator for discrepancy in interpretation of findings by participant versus by technician via photo (interrater reliability)|An indicator for whether the home saliva test is positive as determined by the patient (to assess sensitivity and specificity by the patient)|An indicator for ambiguous findings as measured by percent confidence (if < 80% confident) in interpretation of results by participant and by technician (ease of interpretation)|An indicator that the participant appropriately followed instructions for using the kit (≥ 80% confident) (ease of use)|An indicator for whether participant called technical support and by reason (e.g., processing was not possible due to broken part) (ease of use)|An indicator by participant that the sample was sufficient and reached the indicated line for sample integrity (sample integrity)|An indicator for whether the home saliva test is positive as determined by the technician (to assess sensitivity and specificity by the technician) || Change in distance walked on the six-minute walk test (6MWT)|Change in Modified Borg Dyspnoea Scale (mBDS) score|Quality of Life assessment as collected using the SF-36 || Evaluation of the rate of patients presenting an improvement in their anosmia|Evaluation of the time until recovery of at least 1point in 10 (Visual Analog Scale) from anosmia,|Assessment of the duration of anosmia|Evaluation of the recovery of at least one point in 10 (Visual Analog Scale) depending on the oils || Time to outcome measure of fever (<100.40F)and cough|Negative RT-PCR test on day 5 of treatment || All-cause mortality rate at D29|All-cause mortality rate at Day 60|Time to discontinue mechanical ventilation (MV) at Day 29|Time to improvement of two categories on WHO 10-Point Ordinal Scale from baseline at Day 29|Time to discontinue supplemental oxygen at Day 29|Time to hospital free at Day 29|Change from baseline in viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR)|SAE|Anti-drug antibody (ADA) || 6 minute walk test|Modified Borg Dyspnea Scale|SF-36 QUESTIONNAIRE || Resolution of symptoms|Progression of the disease || Rate of viral clearance Time to viral clearance|Time to clinical improvement || Mortality Rate|Length of Hospitalization|Side Effects || Dose finding|Absolute lymphocyte count (ALC)|Treatment related Adverse Events|Status of COVID-19 infection|To evaluate the efficacy of GX-I7 in patients with COVID-19|Improvement in clinical parameters|Assess in improvement in clinical parameters || Evaluate the impact of a short delay in delivering results in delocalized biology on the emergency medical care time, in comparison with the reference method by RT-PCR at the central laboratory of microbiology|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the final orientation of the patient|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the bed management|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the number of additional examinations carried out and their deadline|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the prescriptions and the timeframe for the implementation of specific therapies against Covid-19 in hospitalized patients|Evaluate the impact of the rapid result in DMBE in comparison with the reference method on the prescription of antibiotic treatments|Compare the primary endpoint for two subgroups of patients according to their treatment schedule|Evaluate the level of satisfaction and the feelings of the medical and paramedical teams of the Emergency Department regarding the DMBE Test ID Now ™ COVID-19 and its impact || Dose 1 Completion|Vaccine Completion || The association between changes in blood biomarkers for inflammation and the presence of neuroradiologically verified brain injury and neurocognitive disorder|The association between changes in blood biomarkers for nerve cell damage and the presence of neuroradiologically verified brain injury and neurocognitive disorder|The association between changes in blood biomarkers for neurodegeneration and the presence of neuroradiologically verified brain injury and neurocognitive disorder|The association between changes in coagulation factors and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder|The association between changes in coagulation ability (ROTEM analysis - rotational thromboelastometry) and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder|The association between changes in inflammatory biomarkers and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder|Blood biomarker changes of inflammation impact|Blood biomarker changes of neurological impact|Neuroradiological changes|Clinical course - Pulmonary gas exchange|Clinical course - Lung function recording|Patient characteristics || Inpatient all-cause mortality|Rates of major bleeding events|Rates of venous thromboses|Intensive care unit/Step down unit length of stay || hospitalization|length of hospital stay|in-hospital mortality|ICU admission || Microbiome composition|Intestinal barrier|sCD14|endotoxin|TNFalpha|Interleukin 1b|Interleukin 6|Interleukin 6 receptor|interleukin 8|interleukin 10|interleukin 17|interleukin 23|neutrophil function burst function|neutrophil function phagocytosis|neutrophil NET formation|neutrophil surface receptor expression|monocyte burst|monocyte phagocytosis|monocyte function surface receptor expression|T cell immunophenotyping|B cells immunophenotyping|Spirometry|Lung volume|Gas diffusion || PICU|Heart dysfunction|CAA|Hypotension || DEATH|Any POSTCOVID-19 symptom || Mortality|TEAE|SAEs|Safety laboratory|Blood pressure|fecal RNA virus clearance|Body temperature|Heart rate|SaO2|ECG || Time of clinical improvement|Time-to-death from all causes|Time free from mechanical ventilation|Viral load|Length of hospital stay || Frequency of symptoms related to post-traumatic stress in all staff who worked at the GHPSJ during the crisis (from March 15 to May 15, 2020).|Look for demographic and professional characteristics that may favor the onset of these symptoms|Evaluate the impact of frequentation of the staff bubble on the occurrence of anxiety / depressive disorders|Evaluate the impact of frequentation of the staff bubble on the occurrence of post-traumatic stress|Evaluate the impact of the psychological support unit on the occurrence of anxiety / depressive disorders|Evaluate the impact of the psychological support unit on the occurrence of post traumatic stress|Evaluate the benefit felt by staff from frequenting the staff bubble|Evaluate the benefit felt by the staff of the meeting with the psychological support unit || 1.Efficacy of wearable device to detect respiratory infection parameters: cough count|2.Monitoring of respiratory infection symptoms, WURSS-11 Survey || IL-6 Change|IL-1β|CRP|Change in time to recovery || Time to recovery (free of respiratory failure)|Lymphopenia|Survival|Hospital length of stay|Requirement for high flow oxygen supplementation|Duration of high flow oxygen supplementation|ICU admission|ICU length of stay|Mechanical ventilation|Duration of mechanical ventilation|Change in any existing comorbidities (e.g., worsening congestive heart failure) or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections (other respiratory, urinary tract, cellulitis, etc.)|AEs/SAEs|Changes to vital signs|Changes in laboratory parameters || Detection of Cellular-Mediated Immune Response|Detection of T cell subpopulation maturation || Need for oxygen supplement|Difference in the number of patients admitted to ICU|Difference in the number of patients requiring mechanical ventilation|Changes in the length of ICU stay|Changes in in-hospital mortality rate || The type, extent and intensity of physical activity || Radiological response|Remission of respiratory symptoms|SPO2 and PaO2/FiO2|Adverse events|Hospitalization|Overall survival|Ferritin value|blood cell count|C-reactive protein|D-dimer|LDH levels || Need for hospitalization|Time to recovery|Percentage of reduction in CRP|Percentage of reduction in LDH|Percentage of reduction in Ferritin|Time to recovery from leucopenia || prognostic value of the TREM-1 pathway activation on clinical worsening || Composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality as measured by hospital records.|The composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality as measured by hospital records.|New, symptomatic VTE (inclusive of DVT, PE, or other venous thrombosis) for up to 30 days after randomization as measured by hospital records.|New, symptomatic ATE (inclusive of ischemic stroke, MI, or peripheral arterial thromboembolism) for up to 30 days after randomization as measured by hospital records. || Mortality rate|Readmission rate || proportion of patients treated who achieve >50% of urine measurements above pH 7.0 over the duration of intervention || 6 minute walking test|FEV-1|FVC|FEV1/FVC|MVV|St. George's Respiratory Questionnaire || Spirometry-FVC and FEV1/FVC tests|6 Minute Walk Distance test (6MWD)|Distance-desaturation product from 6MWD|San Diego Shortness of Breath Questionnaire (SOBQ)|Short Form-36 (SF-36)|Modified Single Assessment Numeric Evaluation (SANE)|Medications|Incidence of adverse events|Incidence of surgical/other treatment interventions || incidence of autoimmune conditions || Acceptability of vaccine studies in the care home setting through feedback questionnaire with loose themes and no unique measurements.|Acceptability of vaccine studies in the care home setting through feedback interview with loose themes and no unique measurements|Acceptability of new ways of delivering research through explorative interview with loose themes and no unique measurements|Acceptability of new ways of delivering research through explorative questionnaire with loose themes and no unique measurements || Combined endpoint: all-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism|All-cause mortality|Mortality related to venous thromboembolism|Mortality related to arterial thromboembolism|Rate of venous and/ or arterial thromboembolism|Rate and length of mechanical ventilation|Length of initial stay at ICU after application of IMP|Rehospitalisation|Rate and length of renal replacement therapy|Cardiac arrest/ CPR || Clinical course || Death|Duration of ICU stay|Duration of mechanical ventilation|In-Hospital complications || Participant-reported overall health|Effect of COVID-19 on the health status of participants|Symptom Severity of common COVID-19 symptoms|Total symptom duration|Incidence of delayed return to usual health|Frequency of Hospitalizations|Hospital Length of Stay|All-cause mortality || Clinical symptoms alleviation|Hospitalisation|Time to negative viral load|Inflammatory changes|Mortality|Adverse events and serious adverse events || Oxygenation|Carbon dioxide|SpO2|Respiratory rate|Subjective dyspnoea|PaO2 || All cause Mortality|Duration of hospital stay|Time to first receiving ventilation|Time to admission to the intensive care unit || Change in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3.|Progression of pneumonia|PaO2/FiO2|cause mortality to 28 days after started treatment|Length of hospital stay|patients requiring Intensive Care Unit admission|evolution of inflammatory parameters IL12|evolution of inflammatory parameters IL-10, IL-1, IL-6, IL-17 and IFN-gamma|evolution of inflammatory parameters Procalcitonin (PCT),|evolution of inflammatory parameters C-reactive protein (PCR),|evolution of inflammatory parameters D-dimer|evolution of inflammatory parameters and ferritin|pharmacokinetics of tocilizumab Cmin|pharmacokinetics of tocilizumab Cmax|pharmacokinetics of tocilizumab Cmedia|pharmacokinetics of tocilizumab Tmax|pharmacokinetics of tocilizumab AUC|Adverse event|Adverse event to cause the treatment interruption.|Adverse event Abnormalities in laboratory || Days alive without respiratory support (any supplemental oxygen) after 15 days (DAFOR15)|SOFA - Sequential Organ Failure Assessment Score up to 15 days after randomization|Need for mechanical ventilation|Duration of mechanical ventilation || Mean PaO2/FiO2 ratio|Clinically Significant Bleeding|Incidence of venous thromboembolism || Health-related quality of life|Functional capacity|Independency || Reduction in the WHO ordinal scale of clinical status by at least two points|Time to discharge|Mortality || In-hospital mortality|C reactive protein (CRP) levels|IL-6 levels|D-dimer levels|Hospital stay|Duration of positive PCR swab || Swallowing safety|Swallowing efficiency|Time-to-Laryngeal-Vestibule-Closure|Laryngeal Vestibule Closure duration|Pharyngeal Constriction || Determination of antibody binding of patients diagnosed with COVID-19 to proteins of the SARS-CoV-2 virus|Determination of the presence of peptides of the SARS-CoV-2 virus in the plasma of patients diagnosed with COVID-19|Determination of the degree of oxidative damage to lipids (lipid peroxidation) in the blood plasma of patients infected with coronavirus|Revealing the degree of protein damage in the blood plasma of patients infected with coronavirus|Measurement of iron (Fe3+) content in blood plasma of patients infected with coronavirus|Metagenomic analysis of viral and bacterial respiratory flora of selected samples|Analysis of the genetic variability of the SARS-CoV-2 virus, including the heterogeneity of the viral population in one patient || NIAID 8-point ordinal scale || Number of participants with symptomatic laboratory confirmed COVID-19|Incidence of AEs, SAEs, MAAEs, and AESI|Incidence of local and systemic solicited AEs|Post-treatment GMTs in SARS-CoV2 S and/or RBD antibodies|Post-treatment GMFRs in SARS-CoV2 S and/or RBD antibodies|Proportion of participants with post-treatment seroresponse (> 4-fold rise in titers) to the S and/or RBD antigens of GRAd-COV2|Time to first SARS-CoV2 RT-PCR positive severe or critical symptomatic illness|Proportion of participants who have a post-treatment response for SARS-COV2 Nucleocapside antibodies|Time to first case of SARS-COV2 RT-PCR positive symptomatic illness using CDC criteria|Time to first COVID-19 related Emergency Department admission|Time to COVID-19 related death|Post-treatment GMTs in SARS-CoV-2 S and/or RBD antibodies|Post-treatment GMFRs in SARS-CoV-2 S and/or RBD antibodies|Proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) in S and/or RBD antigens of GRAd-COV2.|Post-treatment GMTs in SARS-CoV2 S neutralizing antibodies|Post-treatment GMFRs in SARS-CoV2 S neutralizing antibodies|Proportion of participants with post-treatment seroresponse (> 4-fold rise in titers) in SARS-COV2 neutralizing antibodies || Numbers and % of subjects who experience at least 1 treatment-emergent adverse event|Mortality rate|Adverse events of special interest|Effect of alvelestat on blood pharmacodynamic biomarkers of inflammation || Change from baseline to day 7 for cytokine IL-18|Percentage of subjects that do not require invasive mechanical ventilation|Mean number of days of invasive mechanical ventilation for those subjects requiring invasive mechanical ventilation|Mean number of days of non-invasive ventilation for those subjects requiring non-invasive ventilation|Mean number of days of supplemental oxygen|Percentage of subjects that deteriorate 1 or more points in the 7-point WHO Ordinal Scale from baseline to Day 14|Percentage of subjects that are not admitted to the Intensive Care Unit (ICU)|28-day mortality || parental compliance|parental anxiety || increase levels of IFNγ|registering adverse events || Change in D-dimer level from Baseline to Day 8, or day of discharge if prior to Day 8 (Phase 2b)|Number of major or non-major clinically relevant bleeding events within eight (8) days of randomization|Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)|Change in D-dimer level from baseline to 24 hours post-dose (Day 2) and Day 3 (Phase 2b)|Number of major or non-major clinically relevant bleeding events with rNAPc2 vs. heparin (Phase 2b and 3)|Number of bleeding events in subjects treated with higher vs. lower dose rNAPc2 through Day 30 (Phase 2b)|Time to first occurrence of a composite of thrombotic events and all-cause mortality within thirty (30) days of randomization (Phase 3 only)|Time to first occurrence of thrombotic events within thirty (30) days of randomization (Phase 3 only)|Time to all-cause mortality within thirty (30) days of randomization (Phase 3 only)|Change in Tissue Factor laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline through Day 8 (Phase 2b)|Change in interleukin-6 laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline through Day 8 (Phase 2b)|Change in high sensitivity C-reactive protein laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline through Day 8 (Phase 2b) || Incidence of Treatment-Emergent Adverse Events|Change of National Early Warning Score 2 units from baseline|Change in WHO-9 point ordinal scale || 21 Day Organ Support (respiratory or vasopressor) Free Days|Key Platform Secondary Thrombotic Endpoint|Other Platform Secondary Endpoints of Morbidity and Hospitalization|All cause mortality || Safety of Mesencure|Improvement in RA-O2 saturation|Elevation of lymphocytes level|Reduction of CRP|Improvement of health questionnaire|Reduced hospitalization duration|improvement in pulmonary infiltrates/ pulmonary congestion || Frequency of solicited symptoms of reactogenicity|Grade of solicited symptoms of reactogenicity|Frequency of unsolicited adverse events|Grade of unsolicited adverse events|Frequency of serious adverse events (SAEs)|Frequency of medically-attended adverse events (MAAEs)|SARS-CoV-2 specific IgG/IgA|Neutralizing antibody titers to SARS-CoV-2|Antigen-specific IgG/IgA antibody secreting (ASCs)|Th1/Th2 polarization || Change in Clinical status of subject on a 7-point ordinal scale|PCR test|Supplemental Oxygen|Mechanical Ventilation|Incidence of Treatment-Emergent Adverse Events|C-reactive protein (CRP)|Interleukin 6 (IL-6)|D-dimer|Interferon gamma|Ferritin|TNF alpha|Interleukin 1-β || Immediate AEs|Solicited local and systemic AEs|Unsolicited AEs|SAEs|AESIs || Proportion of cured patients in the interventional group versus the proportion of cured patients in the control group|Monitoring of adverse events. || Improvement in symptoms || Mortality|Predictive value || Primary Outcome Measure|Secondary Outcome Measure || Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.|mortality at day 28 and day 90.|Association between MR-ProADM and mortality at day 28.|Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28. || Safety - Adverse Events|Efficacy - PaO2 or SO2/FiO2 Ratio|Efficacy - SOFA score|Efficacy - mortality|Efficacy - organ function / support measurements || Incidence and severity of adverse events|Clinical status using 8-point ordinal scale || inflammation panel: interleukine 6 (IL-6)|inflammation panel: tumor necrosis factor alfa (TNFα)|inflammation panel: C-reactive Protein (CRP)|inflammation panel: Erythrocyte sedimentation rate (ESR)|coagulation panel: D-Dimer|coagulation panel: fibrinogen|coagulation panel: thrombin clotting time (TT)|coagulation panel: activated partial thromboplastin time (aPTT)|Dyspnoea Visual Analog Scale Score (VAS)|Oxygen saturation|Evaluation of Lungs conditions|The total hospital stay|Mean Corpuscular Hemoglobin (MCH)|Mean corpuscular volume (MCV)|mean corpuscular hemoglobin concentration (MCHC)|haemoglobin Hb|Red blood cells count|beta - hydroxybutyrate (BHB)|Alanine transaminase (ALT)|Aspartate transaminase (AST)|lactate dehydrogenase (LDH) || nose smell-print|stability of smell print || Functional capacity|dyspnea|Sleep quality|anxiety and depression || symptoms reduction time frame|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Fatigue|Symptom Resolution: Muscle/body aches|Symptom Resolution: Headache|Symptom Resolution: New loss of taste|Symptom Resolution: New loss of smell|Symptom Resolution: Congestion/ runny nose|Symptom Resolution: Nausea|Symptom Resolution: Vomiting|Symptom Resolution: Diarrhea|Day 5 Symptoms|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects || Medium-term evolution between 3 and 6 months|Cognitive impairment at M3|Cognitive impairment at M6|Memory Scores at M3|Memory Scores at M6 || Amount of SARS-CoV2 virus (COVID-19) collected|Clinical concordance rate|Patient comfort || Death or 30-day all cause mortality|Mechanical ventilation, intubation|Transfer to an ICU setting|New requirement for hemodialysis (HD) or continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO)|New thrombotic events|Major bleeding event|Time to recovery (defined as no limitation or minor limitation in activity level or hospitalized but require no oxygen) || Ventilation free days at D28 || Patient-rated device acceptability|Patient-rated device comfort|Patient-rated device ease of use|Expert-rated device data quality|Adverse events and adverse device events|Length of time spent with the device on the patient.|Length of time taken for the patient to apply the device|Time spent to train patients to use the device.|Pressure sore EPUAP grade || lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferons|All cause mortality rate|Serum level of viral RNA|Ventilation free days|ICU free days || MTD|Viral load|Time to clinical improvement || Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Rate of Hospitalization|Time to Symptom Resolution || Efficacy: Frequency of hospitalization or death|Safety: Changes in adverse events from baseline to end of study || Differences in the electrocardiographic QRS axis shift(°),|Differences in the electrocardiographic rotation|Differences in the CO-RADS5/CO-RADS1-4 ratio || Change in C-reactive protein (CRP) level || Immune system markers|Upper respiratory tract infection symptoms severity and progression || a composite of acute VTE, arterial thrombosis, treatment with ECMO, or all-cause mortality|Rate of all-cause mortality|Rate of objectively-confirmed VTE|Ventilator free days|Rate of major bleeding|Rate of clinically-relevant non-major bleeding|Rate of severe thrombocytopenia|Rate of rise in liver enzymes|Clinically-diagnosed myopathy|Objectively-confirmed arterial thrombosis || Rating of perceived exertion (Borg Scale)|Level of satisfaction and acceptability.|St. George's Respiratory Questionnaire, SGRQ|Age|Sex|Diagnosis of respiratory pathology || Change from baseline to the lowest S/F oxygen ratio|Change in S/F Ratio|Percentage change in S/F Ratio|Percentage of participants at each level on the WHO OSCI score|Percentage of participants with shifts from each level of the WHO OSCI score at baseline|Percentage of participants remaining at their baseline score on the WHO OSCI (or lower)|Percentage of participants reporting each level of the WHO OSCI score at their worst post-baseline day|The time in days spent at each participant's worst reported WHO OSCI score (excluding death).|Intubation and mechanical-ventilation free survival|Overall survival|Number of days requiring oxygen therapy|Number of days with pyrexia|Maximum daily temperature|SpO2 level|Time to discharge|Time to oxygen saturation (SpO2) ≥94%|Time to recovery|Number of participants experiencing AEs by seriousness and relationship to treatment|Incidence of clinically significant abnormal lab parameters || Efficacy in terms of viral load or surrogate || Prevention of very severe respiratory failure or mortality|Prevention of mortality|Prevention of very severe respiratory failure|Incidence of Adeverse Events|Incidence of bacterial/fungal infections|Reduction of the requirements of orotracheal intubation/ECMO|Evolution of the NEWS-2 score|Evolution of the MELD score|Velocity in clinical improvement|Velocity in discharge|Fever disappearance|Changes in periperal blood leukocyte number|Changes in periperal blood neutrophils counts|Changes in periperal blood lymphocytes|Changes in periperal blood platelets|Changes in blood hemoglobin levels|Changes in blood creatinine levels|Changes in blood albumin|Changes in blood bilirubin|Changes in blood LDH|Changes in blood AST|Changes in blood ALT|Changes in blood CK|Changes in blood C-reactive protein|Changes in blood IL-6|Changes in blood protrombine time (INR)|Changes in blood ferritin|Changes in blood troponin T|Changes in blood triglycerides|Changes in blood HDL-colesterol|Changes in blood total colesterol|Changes in blood D-Dimer|Changes in PaO2 at arterial gas analysis|Changes in PaO2/FiO2|Development of late complications || To evaluate safety and efficacy Nuvastatic™ (C5OSEW5050ESA)|IL-6 reduction|Serum c-reactive protein (CRP)|IgG|Hb|Total leucocyte count|F2-Isoprostane|Improvement in ARDS associated clinical symptoms cause || Time to clinical improvement|Rate of clinical improvement|Rate of clinical deterioration|Time to viral clearance|Rate of viral clearance|Change in viral load|Mortality rate|Duration of hospital stay|Time to resolution of symptoms|Requirement of supplemental oxygen|Requirement of mechanical ventilation|Rate of alive patients|Adverse events || SADR|Viral load|Trend viral load|Clinical resolution|Viral clearance|Virological clearance|hospitalization rate|Severity score || Incidence of MAAEs and SAEs|Incidence and severity of solicited local reactogenicity AEs|Incidence and severity of solicited systemic reactogenicity AEs|Incidence and severity of unsolicited AEs|Incidence of changes of laboratory safety examinations|Vital Sign - Temperature|Vital Sign - Heart rate|Vital Sign - Blood Pressure|Vital Sign - Respiratory Rate|GMFR in IgG titer|GMT of S-specific, RBD-specific, and N-specific antibodies|Percentage of participants who seroconverted|GMFR in neutralizing antibody|GMT of neutralizing antibody|Seroconversion rate of neutralizing antibody|New HIV infections in vaccine recipients || DEATH OR RECOVERY|NEED FOR MECHANICAL VENTILATION|TIME OF REMAINED INTUBATED|LENGTH OF STAY IN ICU|TIME OF STAY HOSPITALIZED|Occurrence of clinical complications. || Non-inferiority of self-swabbing compared to conventional swabbing concerning diagnosis sensitivity|Correlation between age, sex and swabbing-induced pain|Correlation between eye color and swabbing-induced pain|Correlation between eye color and swabbing-induced discomfort|Correlation between symptoms (fever, headache, asthenia, anosmia, agueusia, cough, dyspnea, muscle pain, sore throat, diarrhea) and swabbing-induced pain|Correlation between body mass index and swabbing-induced pain|Correlation between anticipated pain and actual pain|Correlation between anticipated discomfort and actual discomfort.|Richness assessment for respiratory cells|Non-inferiority of self-swabbing compared to conventional swabbing concerning pain|Non-inferiority of self-swabbing compared to conventional swabbing concerning pain discomfort|Non-inferiority of self-swabbing compared to conventional swabbing concerning acceptability || Intubation rate|Total hours of prone position at day|Total number of prone sessions at day|Hours of the longest prone session each day|Change in oxygenation 1-hour after first prone session|Change in the ROX-index 1-hour after first prone session|Total days of prone positioning therapy|Adverse effects of prone positioning therapy|Mechanical ventilation days|Intensive care unit length of stay|Hospital length of stay|Hospital mortality || Incidence of Serious Adverse Events|Average number of renal replacement therapy (RRT)-free days|Average number of mechanical ventilation-free days|Incidence of All-Cause Mortality|Proportion of participants who experienced deterioration from baseline || Serious Adverse Events|Change in oxygenation status|CoV Severity Category || [PaO2 / FiO2] ratio|ΔPeso measured using an esophageal balloon catheter|Concentration of CO2 at the end of expiration (EtCO2, mmHg)|Intensity of dyspnea|Tolerance of the technique|The occurrence of side effects due to PP || Sensitivity|Specificity || evaluate the combined effect of Sofosbuvir and Daclatasvir in treatment of patients with mild-moderate Covid-19. || Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol|Immunogenicity. Number of participants who seroconverted || GLASKOW COMA SCALE|mMRC dyspnea scale|SpO2|carbon dioxide (CO2)|cardiac output test || Reduction of P / F normalization times || Feasibility of wearing Fitbit device|Survey completion || PCR Sampling|Blood Tests|Radiological Imaging || Description of the methods of contamination of patients|Evaluation in time of the spread of the virus during the 2nd epidemic wave.|Evaluation in space of the spread of the virus during the 2nd epidemic wave. || Hierarchical composite endpoint|Number of days alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support in the 30 days following randomization|Seven-category ordinal scale || Neutrophil-lymphocyte ratio (NLR)|D-dimer|Fibrinogen || Incidence of contamination of any part of the base clothing or exposed skin of the upper body|1) Number of body areas contaminated|2) Number of discrete areas of contamination of <1 cm2 and >1 cm2|3) Visibility during the simulated procedure|4) Ease of intubation procedures when wearing PPE|5) Ease of breathing while wearing PPE|6) Thermal comfort while wearing the PPE|7) Incidence of breaching of doffing procedures || Number of participants with symptoms at presentation to the research clinic|Short Physical Performance Battery|Quadricep muscle strength|Chalder's Fatigue Score|Number of participants with rehabilitation needs at presentation to clinic|EQ-5D-5L|Montreal Cognitive Assessment|Anxiety and Depression|Pittsburgh Sleep Quality Index|Healthcare service needs following COVID-19 diagnosis|Biological markers of recovery from COVID-19|Fried Frailty Index|Body composition || Number of participants with solicited local and systemic adverse events for 7 days Following Each Dose|Incidence and severity of adverse events (AEs), including withdrawals due to safety or tolerability reasons|Humoral response to SARS-CoV-2 as measured by neutralizing antibodies using wild-type virus assay|Humoral response to SARS-CoV-2 as measured by serum IgG and IgA antibodies to the SARS-CoV-2 spike protein (ELISA)|Humoral response to SARS-CoV-2 as measured by mucosal IgA antibodies to the SARS-CoV-2 spike protein (ELISA) and total mucosal IgA|Measurement of cytokine-producing T cells specific for the SARS-CoV-2 spike protein (ELISpot)|Measurement of adenovirus 6 (Ad6) neutralizing antibodies (anti-drug antibodies (ADA)) || Evolution of viral load|Clinical remission|Clinical signs of toxicity || Proportion of patients with Treatment-Emergent Adverse Events (TEAEs)|Proportion of patients with Serious Adverse Events (SAEs)|Proportion of patients with Adverse Events of Special Interest (AESI)|Secondary efficacy endpoint: Proportion of patients with disease progression|Secondary efficacy endpoint: Time to negative RT-PCR for SARS-CoV-2|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of COR-101|Assessment of PK parameter: Time to Cmax (tmax) for COR-101|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for COR-101|Assessment of PK parameter: Clearance (CL) for COR-101|Assessment of PK parameter: Mean residence time (MRT) of COR-101|Secondary PD endpoint: Change of the viral load of SARS-CoV-2 from baseline, as measured from nasopharyngeal swab samples by qRT-PCR|Secondary immunogenicity endpoint: Percentage of patients with detectable neutralizing antibodies to COR-101 || Pharmacokinetic concentrations - (Maximum Plasma Concentration [Cmax])|Pharmacokinetic concentrations - (Time to Reach Cmax [Tmax])|Pharmacokinetic concentrations - (Trough Plasma Concentration [Ctrough])|Pharmacokinetic concentrations - (Area under the plasma concentration-time curve from zero to 24 hours [AUC0-24h])|Pharmacokinetic concentrations - (Area under the plasma concentration-time curve from zero to 48 hours [AUC0-48h])|Pharmacokinetic concentrations - (Average Plasma Concentration at steady state [Cavg ss])|Pharmacokinetic concentrations - (Apparent Terminal Half-Life [T1/2])|Safety and Tolerability - Number of participants with treatment emergent adverse events (TEAEs)|Safety and Tolerability - Number of participants with abnormal electrocardiograms (ECG)|Safety and Tolerability - Number of participants with abnormal clinical neurological exam, as assessed by the investigator|Safety and Tolerability - Number of participants with abnormal urine and/or blood test, as compared to reference laboratory values|Safety and Tolerability - Number of participants with abnormal physical exams, as assessed by the investigator || Superiority of the vaccine Ad5-nCoV to placebo by the level of seroconversion|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (titer of SARS-CoV-2 antibodies)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (level of seroconversion)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (rise of SARS-CoV-2 antibodies)|Immunogenicity of the vaccine Ad5-nCoV compared with placebo (T-cell response)|Frequency of confirmed COVID-19|Frequency of confirmed cases of COVID-19, requiring hospitalization|Frequency of cases with severe course of COVID-19|Frequency of death due to COVID-19.|Reactogenicity of the vaccine Ad5-nCoV compared with placebo|Frequency and character of adverse events and serious adverse events.|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (blood pressure)|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (heart rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on vital parameters (respiratory rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of physical examination|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of electrocardiography (Heart rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of electrocardiography|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry (enzymes)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of serum chemistry|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (hemoglobin)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (hematocrit)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (erythrocytes)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of complete blood count (erythrocyte sedimentation rate)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of coagulogram|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of coagulogram (fibrinogen)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (relative density)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (pH)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (protein)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of clinical urinalysis (glucose)|To evaluate safety of the vaccine Ad5-nCoV by its effect on results of determination of immunoglobulin E serum concentrations. || Number of participants experiencing Treatment Emergent Adverse Events (TEAEs)|Number of participants experiencing Serious Adverse Events (SAEs)|Maximum observed plasma concentration (Cmax) of BGB-DXP593|Area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUCt) of BGB-DXP593|AUC from time zero to infinity (AUCinf) of BGB-DXP593|AUC from time zero to Day 29 (AUC0-29) of BGB-DXP593|Time to maximum observed plasma concentration (tmax) of BGB-DXP593|Terminal half life (t1/2) of BGB-DXP593|Clearance (CL) of BGB-DXP593|Volume of distribution (Vz) of BGB-DXP593|Immunogenic response to BGB-DXP593 as assessed by the Detection of antidrug antibodies (ADA) || Work environment|Health|Economy || All cause mortality at 28 days|ICU admission|ICU length of stay|Hospital length of stay|Need for higher oxygen supplementation|Invasive mechanical ventilation|Duration of invasive mechanical ventilation|ECMO|Need for tracheostomy|Development of secondary bacterial or fungal infections|Development of clinically significant hyperglycemia|Oxygen supplementation upon discharge from the hospital|Subjective symptoms at 28 days|Disposition upon discharge || Treatment emergent number of Adverse Events || Duration of hospitalization|Duration of supplemental oxygen|Duration of mechanical ventilation|Number of deaths|Number of grade 3 and greater adverse events|Clinical severity of disease || Fit test|Colony count of microorganisms|Load of Tensile strength || Covid Case Rate|Population count|Facebook mobility rate|Knowledge of COVID-19 thanksgiving prevention message (recall of ad, intent to travel, mask wearing and beliefs about travel)|average number of tiles people occupy (Mobility measure)|percentage of eligible participants only observed in a single level-16 Bing tile (no change in movement) || Glaskow coma scale|APACHE II|mMRC Dyspnea Scale || Incidence of Treatment-Emergent Adverse Events || Feasibility of proteomic profile|Interest of proteomic profile|Stability of proteomic profile || Correlation of biomarkers with mortality and disease subgroups || Occupational Balance Questionnaire || Percentage increase in testing during the study compared to tests completed prior to study start || activated partial thromboplastin time (aPTT), acute phase|activated partial thromboplastin time (aPTT), chronic phase|platelet count, acute phase|platelet count, chronic phase|Number of incidents of epistaxis, acute phase|Number of incidents of epistaxis, chronic phase|Other adverse effects, acute phase|Other adverse effects, chronic phase || Number of normal and abnormal standard and telerobotic ultrasound examinations|Age of participants|Number of anomalies found|Parent satisfaction|Medical assistant satisfaction|Sonographer satisfaction || The primary endpoint is that participating staff rate Bubble PAPR to be more comfortable than current PPE.|Staff rate Bubble PAPR as safer than current PPE|Staff rate Bubble PAPR as easier to communicate with colleagues than existing PPE|Staff rate Bubble PAPR as easier to communicate with patients than existing PPE || Percentage of Successful Fits|Quality of Fit Score|Percentage of Participants that Fit in a Small Size Mask|Percentage of Participants that fit in a Medium Size Mask|Percentage of Participants that fit in a Large Size Mask|User Acceptance Percentage|Percentage of Impression Change || Proper face mask use up to 60 minutes|Descriptive analysis by demographics || Number of bacterial colony forming units (CFUs) .|Change in number of CFUs || Adverse Event|Serious Adverse Event || Demographic characteristics|Compliance to mask-wearing directives|Questionnaire subscale: Near vision|Questionnaire subscale: Distance vision|Questionnaire subscale: Ocular discomfort|Questionnaire subscale: Driving|Questionnaire subscale: Limitation|Questionnaire subscale: Collaboration|Questionnaire subscale: Need for help|Questionnaire subscale: Emotional impact|Assessment of the relationship between the compliance to mask-wearing directives and the use of spectacles|Assessment of the relationship between the compliance to mask-wearing directives and the other demographic characteristics|Assessment of the relationship between the compliance to mask-wearing directives and the questionnaire items|Assessment of the relationship between demographic characteristics and the 20 questionnaire items || Local tolerability|Pharmacokinetic parameter"
Covid19|SARS-CoV Infection,"Prevalence of COVID-19 infection among French military professional aircrew|Predictive factors of COVID-19 infection|Techniques used for COVID-19 screening|Reasons for COVID-19 screening|Experienced symptoms of COVID-19|Medical care of COVID-19|Social consequences of the COVID-19 pandemic|Factors associated with pejorative consequences of the COVID-19 pandemic || Development of database containing physiological, behavioral data in combination with SARS-CoV-2 infection|Correlation between SARS-CoV-2 infection and collected wearable data and self-reported data|Development of analytical models for real-time COVID-19 surveillance at the individual and population levels|Performance of the analytical models for real-time COVID-19 surveillance at the individual and population levels. || Prevalence of COVID-19|PCR Conversion in Exposed Individuals || [18F]F-AraG uptake in participants with convalescent COVID-19|[18F]F-AraG uptake in participants with convalescent COVID-19 over time|[18F]F-AraG uptake in participants with mild to severe COVID-19 symptoms|[18F]F-AraG uptake in female versus male participants || COVID-19-related emergency room visit or COVID-19- related hospitalization, or death (any cause)|Disease Progression based on NIAID Score|Time to Disease Progression based on NIAID Score|Change from Baseline in Symptom Scores|Adverse Events || Comparison of the percentage of clinically improved inpatients between D0 and D14 || SARS-CoV-2 glycoprotein-specific antibodies titer|Seroconversion rate|IFN-gamma antigen-specific release|CD4+/CD8+ proliferating cells|Virus-neutralizing antibodies titer|Incidence and severity of adverse events || Number of SARS-CoV-2 infections|Duration of symptoms|Maximum score on WHO Ordinal Scale|Time to onset of SARS-CoV-2 infection|Number of symptomatic SARS-CoV-2 infections|Number of asymptomatic SARS-CoV-2 infections|Peak score on modified Flu PRO || Change in COVID-19 Severity || Clinical characteristics|Biological characteristics|Radiological characteristics|Number of patient hospitalised for Covid-19|Overall Inpatient Mortality|Requirement for mechanical ventilation|ICU Length of Stay (LOS)|Evolution of patient general state during hospitalisation|Biological tests || First occurrence of Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19.|First occurence of Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19 based on the case definition for the secondary efficacy symptomatic endpoint.|Virologically confirmed (RT-PCR positive) severe cases of COVID-19|Virologically confirmed COVID-19 cases of any severity occurring among participants 18 through 59 years of age and ≥60 years of age.|Virologically confirmed COVID-19 asymptomatic and symptomatic cases occurring from two weeks after the second vaccination.|Reactogenicity and Safety|The occurrence of enhanced respiratory disease episodes.|Immunogenicity: Lot-to-Lot consistency of three consecutive GMP Lots|Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) || Reduction in SARS-CoV-2 Viral load|Reduction in Severity of COVID-19 Disease || Composite outcome|All-cause mortality|ICU admission|Intubation|Cardiovascular complications || Need in biological therapy or/and respiratory support|Number of days spent in hospital|All-cause death || All-cause mortality|Incidence and course of symptoms of COVID-19 infection|Hospitalizations|Oxygen supplementation|Use of invasive mechanical ventilation|Intensive care unit length of stay || Decreased oxygenation|Emergency Department Utilization|Maximum symptom severity|Clinical Progression Scale|Time to meaningful recovery|Laboratory Outcome Subsidy || Hospital length of stay|Human metabolome and proteome || Viral Load Change from baseline|4-day trend in viral load change|Levels of live virus (viral infectivity titer)|The tolerability of the intervention measured using the validated Sino-nasal outcome test (SNOT-22) scale.|Compliance as measured by percent of expected washes completed|Compliance as measured by percentage of randomized participants that withdrew consent and elected not to continue in the study.|Acceptability of the intervention as measured by 7 item questionnaire based an acceptability framework described by Sekhon (2017) || Rate of decline in viral load|Time to resolution of viral load|Comparison of proportion of subjects who are asymptomatic and symptomatic|Change in modified NEWS-2|Proportion of subjects with treatment emergent adverse events || Mortality|Hospital Mortality|ICU Admission|days alive and free of vasopressors, ventilation, and renal replacement therapy|SOFA score|Acute cardiac injury|Severe adverse events || Symptom Severity|Symptom progression || All-cause unplanned hospital admission for at least 24 hours or death|All-cause unplanned hospital admission for at least 24 hours|All-cause mortality|Time to recovery|Health status|Oxygen administration in the home setting|All-cause mortality at 1 year after randomization|Cardiovascular and thromboembolic complications|Symptom duration for each individual symptom|Duration of hospital admission for those admitted to hospital|Health services usage|Consumption of antibiotics|Participants' quality of life || Death or need for intubation"
Healthy,"COVID-19 Awareness Survey || Posttraumatic Stress Disorder (PTSD)|PTSD|Psychological Distress|Sleep Impairment|Workplace stress|Resilience|Burnout|Moral Distress || Knowledge of COVID|Fear of COVID-19 Scale|COVID-19 Anxiety Scale (CAS)|COVID Stress Scales|Burn-Out de Maslach Inventory|Steps per day|International physical activity questionnaire|Barriers to being active quiz|Questionnaire of the transtheoretical model of change of physical exercise|Hospital Anxiety and Depression Scale|Connor-Davidson Resilience Scale|COPE-28|Pittsburgh Sleep Quality Index|Morningness-eveningness questionnaire (MEQ)|Epworth sleepiness Scale|Insomnia severity index|EuroQoL-5D|Charlson Comorbidity Index || Change in self-reported symptom scores (Likert scale from 0-7) in the Electronic diary from well to sick in symptomatic SARS-CoV-2 positive participants.|Change in voice features; such as pitch, jitter, harmonicity, entropy, flatness, shimmer from the voice collection as captured by the Electronic diary from well to sick in symptomatic SARS-CoV-2 positive participants.|Percentage of total days of voice recordings entered in the Electronic diary.|Percentage of total days of symptoms entered in the Electronic diary.|Percentage of recordings with signal to noise ratio ≥ 20 dB that have duration ≥ 3 sec for phoneme and ≥ 10 sec for reading tasks.|Percentage of participants with SARS-CoV-2; and/or Influenza; and/or RSV RT-PCR based positivity in self-swabs.|Percentage of participants administering the self-swab at self-swab #1 and self-swab #2.|Percentage of participants reporting symptoms in the Electronic diary, who have a self-swab collected at or around symptom onset.|Percentage of self-swabs with valid (positive or negative) or invalid (non- reportable due to technical or self-collection failures) results. || Change in Emotional Problems || Missing Outcome Measures || Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination|Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination|Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination|Cohort 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 1 Year after the Second Vaccination|Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination|Cohorts 1, 2, and 3: Number of Participants With SARS-CoV-2 Neutralizing Antibody Titers as Assessed by Virus Neutralization Assay (VNA)|Cohorts 1, 2, and 3: Number of Participants with SARS-CoV-2 Binding Antibodies Assessed by ELISA|Cohorts 1, 2, and 3: Number of Participants with T-helper (Th)-1 and Th-2 Immune Responses as Assessed by Flow Cytometry || Number of Participants with Solicited Local Adverse Events (AEs) for 7 days after First Vaccination|Number of Participants with Solicited Local AEs for 7 days after Second Vaccination|Number of Participants with Solicited Systemic AEs for 7 days after First Vaccination|Number of Participants with Solicited Systemic AEs for 7 days after Second Vaccination|Number of Participants with Unsolicited AEs for 28 days after First Vaccination|Number of Participants with Unsolicited AEs for 28 days after Second Vaccination|Number of Participants with Serious Adverse Events (SAEs)|Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Neutralization as measured by Virus Neutralization Assay (VNA)|SARS-CoV-2-Binding Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) || Number of participants with treatment emergent serious adverse events (TESAEs)|Number of participants with treatment emergent adverse events (TEAE) of special interest|Number of participants with treatment-emergent adverse events (TEAE)|Maximum observed serum concentration (Cmax)|Minimum observed serum concentration (Cmin)|Time of maximum serum concentration (Tmax)|Area under the concentration vs. time curve (AUC0-last), AUC0-∞)|Terminal half-life (T1/2)|Systemic clearance (CL)|Steady-state volume of distribution (Vss)|Number of participants with treatment-emergent adverse events (TEAEs)|Number of participants with treatment-emergent serious adverse events (TESAEs)|Maximum observed serum HFB30132A concentration (Cmax) in nasal and oral secretions|Minimum observed serum HFB30132A concentration (Cmin) in nasal and oral secretions|Time of maximum serum HFB30132A concentration (Tmax) in nasal and oral secretions|Area under the concentration vs. time curve (AUC0-last), AUC0-∞) in nasal and oral secretions|Terminal half-life (T1/2) of HFB30132A in nasal and oral secretions|Systemic clearance (CL) of HFB30132A in nasal and oral secretions|Steady-state volume of distribution (Vss) of HFB30132A in nasal and oral secretions|HFB30132A Anti-drug antibodies || Incidence and Severity of Adverse event of ZYIL1 following a single oral dose in healthy subjects|Maximum plasma concentration (Cmax) || Number of Participants with Solicited Local Adverse Events (AEs)|Number of Participants with Solicited Systemic AEs|Number of Participants with Unsolicited AEs|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Medically-attended Adverse Events (MAAEs)|Number of Participants with MAAEs leading to Discontinuation|Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination|Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After First Vaccination|Serological Response to Vaccination as Measured by ELISA 28 Days After Second Vaccination|Number of Participants with Antibody GMC 28 Days After Second Vaccination|Number of Participants with Pregnancy Outcomes|Number of Participants with Pregnancy Related AEs|Number of Neonates and Infants with any Complications, Anomalies and Deaths|Number of Neonates and Infants with SAEs|Number of Neonates and Infants with MAAEs|Number of Neonates and Infants with MAAEs leading to Study Discontinuation|Serological Response to Vaccination as Measured by ELISA|Number of Neonates and Infants with Antibody GMC || To compare the emitted small particle fraction between various respiratory activities.|To assess the influence of different face masks on the emitted small particle fraction of various respiratory activities.|To assess the emitted particle size distribution of various respiratory activities.|To assess the reproducibility of exhaled particle quantification.|To assess the influence of different face masks on the emitted particle size distribution of various respiratory activities. || Incidence of Treatment-Emergent Adverse Events|pharmacokinetic changes of niclosamide from baseline in each dose group: Cmax|pharmacokinetic changes of niclosamide from baseline in each dose group: Tmax|pharmcodynamic analysis of niclosamide from baseline in each dose group and time point: CRP || Part 1: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)|Part 1: Cmax (maximum measured concentration of the analyte in plasma)|Part 2: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)|Part 2: Cmax (maximum measured concentration of the analyte in plasma)|Part 1: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)|Part 2: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) || Oxygen concentration while wearing purpose-designed mask|Oxygen concentration while wearing improvised snorkel-based mask|Carbon dioxide concentration while wearing purpose-designed mask|Carbon dioxide concentration while wearing improvised snorkel-based mask|Heart rate while wearing purpose-designed mask|Heart rate while wearing improvised snorkel-based mask|Respiratory rate while wearing purpose-designed mask|Respiratory rate while wearing improvised snorkel-based mask|Oxygen saturation while wearing purpose-designed mask|Oxygen saturation while wearing improvised snorkel-based mask || Change from baseline in positive affect at 1 week post-intervention|Change from baseline in optimism at 1 week post-intervention|Change from baseline in life satisfaction at 1 week post-intervention|Change from baseline in psychological well-being at 1 week post-intervention|Change from baseline in perceived stress at 1 week post-intervention|Change from baseline in perceived social support at 1 week post-intervention|Change from baseline in loneliness at 1 week post-intervention|Change from baseline in depressive symptoms at 1 week post-intervention|Change from baseline in anxiety symptoms at 1 week post-intervention|Change from baseline in light physical activity (in general) at 1 week post-intervention|Change from baseline in moderate physical activity (in general) at 1 week post-intervention|Change from baseline in sleep quality (in general) at 1 week post-intervention|Change from baseline in sleep quantity (in general) at 1 week post-intervention|Change from baseline in negative affect at 1 week post-intervention || Survey || Groups 1-6: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2|Groups 1-6: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After Vaccination 2|Groups 1-6: Virus Neutralization Assay Geometric Mean Titer (GMT) 28 Days After Vaccination 2|Groups 1-6: Enzyme-linked Immunosorbent Assay Geometric Mean Concentrations (GMCs) 28 Days After Vaccination 2|Groups 1-6: Serological Response to Vaccination as Measured by VNA Titers 28 Days After Vaccination 1|Groups 1-6: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay 28 Days After Vaccination 1|Groups 1-6: Virus Neutralization Assay Geometric Mean Titer 28 Days After Vaccination 1|Groups 1-6: Enzyme-Linked Immunosorbent Assay Geometric Mean Concentrations 28 Days After Vaccination 1|Groups 7-8: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2|Groups 7-8: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay 28 Days After Vaccination 2|Groups 7-8: Virus Neutralization Assay GMTs 28 Days After Vaccination 2|Groups 7-8: Enzyme-linked Immunosorbent Assay Geometric Mean Concentrations 28 Days After Vaccination 2|Groups 9-10: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2|Groups 9-10: Serological Response to Vaccination as Measured by ELISA 28 Days After Vaccination 2|Groups 9-10: Virus Neutralization Assay GMTs 28 Days After Vaccination 2|Groups 9-10: Enzyme-linked Immunosorbent Assay GMCs 28 Days After Vaccination 2|Groups 1-6: Number of Participants with Solicited Local AEs for 7 Days After Each Vaccination|Groups 7-8: Number of Participants with Solicited Local AEs for 7 Days After Each Vaccination|Groups 9-10: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination|Groups 1-6: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination|Groups 7-8: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination|Groups 9-10: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination|Groups 1-6: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination|Groups 7-8: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination|Groups 9-10: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination|Groups 1-10: Number of Participants with Serious Adverse Events (SAEs)|Groups A-F: Number of Participants with Solicited Local AEs for 7 Days After Each Vaccination|Groups A-F: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination|Groups A-F: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination|Groups A-F: Number of Participants with SAEs|Groups A-F: Serological Response to Vaccination as Measured by VNA Titers 28 Days After Vaccination 1|Groups A-F: Virus Neutralization Assay GMTs 28 Days After Vaccination 1 Assessed by Humoral Immune Response|Groups A-F: Serological Response to Vaccination as Measured by VNA Titers 28 Days After Vaccination 2|Groups A-F: Virus Neutralization Assay GMTs 28 Days After Vaccination 2 Assessed by Humoral Immune Response|Groups 1-6: Virus Neutralization Assay GMTs 28 Days After Vaccination 1 Assessed by Humoral Immune Response|Groups 7-8: Virus Neutralization Assay GMTs 28 Days After Vaccination 1 Assessed by Humoral Immune Response|Groups 9-10: Virus Neutralization Assay GMTs 28 Days After Vaccination 1 Assessed by Humoral Immune Response|Groups 1-6: Virus Neutralization Assay GMTs 28 Days After Vaccination 2 Assessed by Humoral Immune Response|Groups 7-8: Virus Neutralization Assay GMTs 28 Days After Vaccination 2 Assessed by Humoral Immune Response|Groups 9-10: Virus Neutralization Assay GMTs 28 Days After Vaccination 2 Assessed by Humoral Immune Response|Groups 1-5, 7 and 9: Serological Response to Vaccination as Measured by VNA Titers 7 Days After Antigen Presentation|Groups 1-5, 7 and 9: Serological Response to Vaccination as Measured by ELISA 7 Days After Antigen Presentation|Groups 1-5, 7 and 9: VNA GMT 7 Days After Antigen Presentation|Groups 1-5, 7 and 9: Enzyme-Linked Immunosorbent Assay Geometric Mean Concentrations 7 Days After Antigen Presentation|Groups 1-5, 7 and 9: Number of Participants with Solicited Local Adverse Events for 7 Days After Antigen Presentation|Groups 1-5, 7 and 9: Number of Participants with Solicited Systemic Adverse Events for 7 Days After Antigen Presentation|Groups 1-5, 7 and 9: Number of Participants with Unsolicited AEs for 28 Days After Antigen Presentation|Groups 1-5, 7 and 9: Number of Participants with Serious Adverse Events Throughout the Study|Groups 1-10: SARS-CoV-2 Neutralizing Antibody Titers as Assessed by VNA|Groups 1-10: SARS-CoV-2 Binding Antibodies Measured as Assessed by ELISA|Groups A-F: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 1 and 2|Groups A-F: Serological Response to Vaccination as Measured by ELISA 28 Days After Vaccination 1 and 2|Groups A-F: Enzyme-linked Immunosorbent Assay Geometric Mean Concentrations (GMCs) 28 Days After Vaccination 1 and 2|Groups A-F: Serological Response to Vaccination as Measured by VNA Titers 7 Days After the Booster Vaccination|Groups A-F: Serological Response to Vaccination as Measured by ELISA 7 Days After Booster Vaccination|Groups A-F: VNA GMT 7 Days After Booster Vaccination|Groups A-F: Enzyme-linked Immunosorbent Assay GMCs 7 Days After Booster Vaccination|Groups A-F: Number of Participants with Solicited Local AEs for 7 Days After Booster Vaccination|Groups A-F: Number of Participants with Solicited Systemic AEs for 7 Days After Booster Vaccination|Groups A-F: Number of Participants with Unsolicited AEs for 28 Days After Booster Vaccination|Groups A-F: Number of Participants with SAEs After Booster Vaccination|Groups A-F: SARS-CoV-2 Neutralizing Antibody Titers as Assessed by VNA|Groups A-F: SARS-CoV-2 Binding Antibodies Measured as Assessed by ELISA"
SARS-CoV 2,"Relationship between body mass index (BMI) and SARS-CoV-2|Associations between BMI and outcomes is independent of the known cardiometabolic risk factors|Investigate the modifying effects of age and sex on the associations between BMI and outcome: Invasive mechanical ventilation|Investigate the modifying effects of age and sex on the associations between BMI and outcome: mortality || Change of inflammatory cytokines concentration (mmol / L) in Covid19 + patients from Baseline at 6 months|Change of interrelationship between inflammation (cytokines levels) and ICU delirium in Covid19 + patient from Baseline at 6 months|Modification in inflammatory genes expressed (expressed / non expressed) in PBMC between Baseline and M6|Change in quantity of chromatine's openings (chromatin accessibility profiles) in ICU patient recovering from covid19 infection|Change in genes expression in Covid-19 patient with delirium in ICU between Day2 and Month6 || Isolation of recombinant monoclonal neutralizing antibodies directed against SARS-CoV-2, isolated from COVID19 hospitalized patients blood probes.|Description of biological biomarkers (cytokine, IL6) predictive of worsening|Description of biological biomarkers (cytokine, IL10) predictive of worsening|Description of biological biomarkers (Cellular immune responses, lymphocytes) predictive of worsening|Description of biological biomarkers (Cellular immune responses, monocytes) predictive of worsening|Description of biological biomarkers (complement system, CH50) predictive of worsening|Description of biological biomarkers (complement system, CH50a) predictive of worsening|Description of biological biomarkers (complement system, C3) predictive of worsening|Description of biological biomarkers (complement system, C4) predictive of worsening || SARS-CoV-2 infection || Cumulative incidence of hospitalization or death prior to hospitalization|Cumulative incidence of treatment-related serious adverse events|Cumulative incidence of treatment-related grade 3 or higher adverse events|Change in serum SARS-CoV-2 antibody titers|Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity || Development of a test based on the MALDI-TOF profiling method to detect individuals infected with SARS-CoV2 from saliva sample.|Rate of correct classification by the test (MALDI-TOF MS profiling) from saliva sample|Rate of correct classification by RT-PCR from saliva sample|Identification of proteins specific to the SARS-CoV2 infection|Presence of a positive anti-SARS-CoV2 antibody response by RT-PCR|Correlation between the identified protein markers and the clinical course of the participants. || IgG/IgM antibodies || Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization or an increase of 2 points or more from the basal level|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients requiring treatment.|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19. || The primary endpoint is the time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation|Time from investigational medication (or placebo) to at least one point worsening on clinical improvement scale for subjects requiring supplemental oxygen (score >= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline|Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline || Phase 1: Feasibility and safety of treating hospitalized patients with SARS-CoV-2 pneumonia with single or bilateral whole lung irradiation|Phase 2: Proportion with clinical improvement on a 7-point ordinal scale on day 4 after randomization|Improvement or worsening on the 7-point ordinal scale over additional intervals|Rate and duration of use of supplemental oxygen|Rate and duration of fever > 38ºC|Rate and duration of invasive mechanical ventilation|Duration of hospitalization|Proportion of participants with overall survival up to 30 days after randomization|Improvement in radiographic findings related to infection/inflammation; comparisons include on study versus baseline scans and irradiated vs. unirradiated lung in subjects randomized to receive single lung irradiation|Treatment-emergent adverse events || Immediate adverse event (AEs)|Solicited local and systemic adverse events (AEs)|Unsolicited adverse events (AEs)|Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths|Safety labs|Neutralizing antibody (Nab assay) response|Specific Th1 cell-mediated immunity (CMI) response|Specific Th2 cell-mediated immunity (CMI) response|Specific antibody response induced by the vaccine against the SARS-CoV-2 virus measured by total IgG and/or IgM levels|Neutralizing antibody (Nab assay) response induced by the treatment groups against the SARS-CoV-2 virus|Specific Th1 cell-mediated immunity (CMI) response induced by the vaccine against the SARS-CoV-2 virus|Specific Th2 cell-mediated immunity (CMI) response induced by the vaccine against the SARS-CoV-2 virus || Percentage of dysautonomia patients found within the first 24 hours of hospitalization (%)|Analyse the other mathematical indices measuring autonomic balance, obtained by Holter-ECG recording over the first 24 hours and throughout their hospitalisation, in search of possible dysautonomia|To investigate whether the autonomic balance of patients with CoV-2 SARS correlates with the severity of their clinical condition during their hospital stay.|To investigate whether the various autonomic parameters recorded are predictive of clinical worsening or improvement, by calculating a prediction threshold for each of the parameters. || Latency of electrophysiological response|Delay of Muscle contraction|Delay of silent period|Duration of silent period|Inhibition rate || Cumulative incidence of SARS-Cov2 infection in the general population.|Maintenance over time of the acquisition of anti-SARS-Cov2 antibodies|Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection|Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social determinants|Proportion of tests proposed, accepted, performed, based on social and demographic characteristics|Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence|Strengths of associations between socio-behavioral factors and level of seroprevalence || Survival rate in asymptomatic subjects at inclusion|Survival rate in symptomatic subjects at inclusion|Survival rate in overall subjects|Cumulative incidence of Covid-19 infection in asymptomatic subjects at inclusion || Cumulative incidence of ventilator-associated lower respiratory tract infection|Cumulative incidence of ventilator-associated tracheobronchitis|Cumulative incidence of ventilator-associated pneumonia|the cumulative incidence of ICU acquired bacteremia diagnosed|ICU mortality|Mortality|the duration of mechanical ventilation|Length of stay in Intensive Care Unit || Virologic Efficacy|Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach|Number of Participants With any Adverse Events (AEs), Grade 2 or higher as Assessed by Kaplan Meier Approach || Time to medical discharge|All-cause mortality|Hospital readmission || Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801|Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS|Number of Participants With any Adverse Events(AEs) as assessed by DAIDS || Loss of autonomy|Hospital readmission|Nursing home admission|All-cause mortality|change in self-rated health || Composite endpoint of alive and free of organ failure|Occurrence of serious adverse events following treatment|Alive at days 28 and 60|Alive and out of ICU|Alive and out of hospital"
SARS-CoV Infection,"Viral load of SARS-CoV-2|The temporal profile of viral load of SARS-CoV-2|The proportion of patients with virological clearance|SaO2|hospitalization stay|Intensive care|COVID-19 Severity Score|in-hospital mortality || Assessment of the effectiveness of citizens being vaccinated with one of the SARS-CoV-2 vaccines|Number of breakthrough infections in the 24 months period will be used to compare the effectiveness between the vaccines|Assessment of the safety of the vaccines will be compared between groups|Assessment of any Adverse Event from the vaccines will be compared between groups || Sensitivity of the antigen detection test used in the study of contacts of COVID-19 patients.|Specificity of the antigen detection test used in the study of contacts of COVID-19 patients.|Positive predictive value of the antigen detection test used in the study of contacts of COVID-19 patients.|Negative predictive value of the antigen detection test used in the study of contacts of COVID-19 patients.|Positive likelihood ratio of the antigen detection test used in the study of contacts of COVID-19 patients.|Negative likelihood ratio of the antigen detection test used in the study of contacts of COVID-19 patients.|Change in the pretest probability when the antigen detection test result is positive in a COVID-19 patient contact.|Change in the pretest probability when the antigen detection test result is negative in a COVID-19 patient contact.|Cut-off point of the cycle threshold of the polymerase chain reaction test that discriminates infectivity.|Risk of SARS-CoV2 infection in close contacts of COVID-19 patients with a positive polymerase chain reaction test depending on whether the antigen detection test is positive or negative.|To predict a positive result of the polymerase chain reaction test based on the appearance of symptoms during quarantine|The percentage of COVID-19 patient contacts with symptoms during the quarantine. || positive nasal swab and serological test|Relation of positive SARS-CoV2 tests to risky contact history || Clinical response after administration|Clinical response to treatment|Duration of hospitalization|Clinical outcome of the treatment|Supplemental Oxygen Requirement from Baseline || Clinical response after administration|Clinical response to treatment|Duration of hospitalization|Supplemental Oxygen Requirement from Baseline || Prevalence and persistence of the SARS-CoV-2 virus in the faeces, and change in associated health status|Viral strain-specific prevalence, associated with change in health status|Biogeographical viral strain identification, associated with change in health status|Create a SARS-CoV-2 biological sample repository || Incidence rate of COVID-19 on day 14 according to positive results of RT-PCR rate at day 14|Safety and adverse events (AEs) incidence rate at day 14|IgM antibodies positive rate for COVID-19 at day 28|Incidence rate of COVID-19 on day 28 according to positive results of RT-PCR rate at day 28|Safety and adverse events (AEs) incidence rate on day 28 || To Measure the efficacy of NONI compared to saline placebo control to shorten the duration of COVID-19 viral infectivity|To Measure the virucidal effect of NONI compared to placebo in the nasal cavity in subjects with mild COVID-19 infection|To Measure the efficacy of NONI in prevention of progression of COVID-19|To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life (QoL) in subjects with COVID-19|To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19|To measure the tolerance of NONI compared to saline placebo in participants with mild COVID-19 infection || Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development || Severity progression of COVID-19|Stay at ICU|Mortality ratio|Viral load|Lung abnormalities|Levels of immunoglobulins|Gastrointestinal manifestations, where 0 means good health status and 5 worse status|Fecal microbiome|Adverse events|Change on Serum Biomarkers|Duration of Individual Symptoms || clinical outcome after plasma therapy|Clinical response to treatment || Proportion of late hospitalizations, within 48 hours of first discharge from emergency department, and motivated by worsening symptoms secondary to SARS-Cov2 infection.|Proportion of immediate hospitalizations after the 1st admission at emergency department.|Proportion of adverse events related to SARS-Cov2 infection within 7 days of patient inclusion.|Establish the correlation between the number of chair rises performed on STST and the occurrence of an adverse event.|Correlation between SpO2 and the occurrence of an adverse event|Correlation between heart rate (HR) and the occurrence of an adverse event|Correlation between dyspnea score and the occurrence of an adverse event || Qualitative result of molecular tests for the SARS-CoV-2 virus. || Magnitude of the decrease in aerobic performance on return to work || SARS-CoV-2 susceptibility in healthcare workers and patients|SARS-CoV-2 transmission in healthcare workers and patients|SARS-CoV-2 severity in healthcare workers and patients || Phase 1: ECG characteristics in patients presenting with severe form of SARS-CoV-2 infection|Phase 2: Correlation between ECG signs and needs for invasive mechanical ventilation and/or mortality in the acute phase|Phase 3: Correlation between ECG signs and cardiac involvement and mortality in the chronic phase || Presence of SARS-CoV-2 infection in those with high clinical suspicion and/or a positive RT-PCR swab. || Change of lipid profile during exposure to SARS-Cov-2|HDL-cholesterol size|circulating plasma cytokine levels|ACE2 gene polymorphisms || Mechanical ventilation|ICU transfer|Oxygen therapy || Patients requiring admission to the hospital or experiencing death || To demonstrate the efficacy of VERU-111in the treatment of SARS-Cov-2 Infection|To determine the percentage of subjects that are alive without respiratory failure at various intervals. || Incidence of immediate adverse events.|The incidence of solicited local and systemic adverse events|The incidence of serious adverse events (SAEs)|The incidence of unsolicited adverse events|To evaluate the humoral immune responses of BBV154|To compare the humoral responses between single dose group and double dose group.|To evaluate the immune responses against spike protein of SARS-CoV-2 virus and Adenovirus vector|Vaccine induced cell mediated antigen specific T-cell responses across the three groups.|Vaccine induced cell mediated antigen specific cytokines across the three groups. To evaluate the vaccine induced Cell mediated immune response.|To evaluate the vaccine secretory IgA antibody response.|To evaluate the safety of the vaccine in terms of assessing adverse event of special interest (AESI) || oral manifestation || taste sensation survey"
SARS-CoV-2,"SARS-CoV-2 semen result || Follicular - Serum Anti COVID-19 antibody (Immunoglobulin G) ratio|Spermatic fluid- Serum Anti COVID-19 antibody (Immunoglobulin G) ratio|Follicular fluid Estradiol level (pmol/L)|Follicular fluid Progesterone level (nmol/L)|Follicular fluid Perlecan level (nmol/L) || Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire || Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice|Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|Information on the patterns of use of these drugs (dose, duration of treatment,|Adverse events|Time of hospital admission and/or stay in ICU and maximum severity reached.|Treatments for SARS-CoV-2 positive patients not described in the protocol|healthy survey for patients after their recovery/discharge from hospital. || Number of COVID-19 infections during the 12 weeks of intervention|Severity of the COVID-19 infection|Duration of symptoms of the COVID-19 infection|Frecuency of symptoms of the COVID-19 infection || Serum levels of cytokines and chemokines|Viral load|Immunophenotype of myeloid cells|RBD-SARS-CoV Protein S- antibodies|Analysis of cellular immune response|Hematopoietic stem cells and progenitor cells populations in peripheral blood|Questionnaire of Sociodemographic, labor, pathological and personal characteristics|SOFA (Secuential Organ Failure Assessment Score)|Fibrinogen|C-Reactive protein || questionnaire assessing the incidence of disturbance of COVID-19 pandemic on ophthalmology training programs among residents|questionnaire assessing the negative impact of COVID-19 pandemic on mental health among ophthalmology residents|questionnaire assessing the attitude on COVID-19 vaccination of ophthalmology residents || Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy || Prevalence of SARS-CoV-2 in the sampled tissue || Positive percent agreement (PPA) and negative percent agreement (NPA) between the COVIDSeq Test and a comparator EUA test for the detection of SARS-CoV-2 RNA || Clinical Presentation and Incidence of Covid-19 Infection in patients hospitalised in Strasbourg Hospital || Number of people with detectable antibodies to SARS-CoV-2|Number of people with detectable SARS-CoV-2 nucleic acid || presence of SARS-CoV-2 genome in tears|presence of systemic symptoms evaluated at the time of making an appointment by a systematic standardized interrogation|assessement of viral load levels || Clinical Presentation and Incidence of Covid-19 Infection in Different Cohorts of Solid Organ Transplant Patients || to establish the seroprevalence of SARS-CoV-2 || mean acute anti-SARS-CoV-2 antibody production on the day of the 1st vaccination|mean acute anti-SARS-CoV-2 antibody production 7 days after the 1st vaccination|mean acute anti-SARS-CoV-2 antibody production 14 days after the 1st vaccination|mean acute anti-SARS-CoV-2 antibody production on the day of the 2nd vaccination|mean acute anti-SARS-CoV-2 antibody production 7 days after the 2nd vaccination|mean acute anti-SARS-CoV-2 antibody production 14 days after the 2nd vaccination|plasma antibody levels against SARS-CoV-2|immune cell phenotyping (B cells, T cells) || Number of Subjects with Adverse Events (AEs) post-dosing|Number of Subjects with Adverse Events that Led to Discontinuation or Temporary Suspension of IV Infusion|Number of Subjects with AEs after a Single IV Infusion|Number of Subjects with SAEs after a Single IV Infusion|Number of Subjects with AEs after a Repeat IV Infusion|Number of Subjects with SAEs after a Repeat IV infusion|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of SARS-CoV-2 antibodies after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of SARS-CoV-2 antibodies plus the additional area extrapolated to infinity (AUC0-inf) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 14 days (AUC0-14d) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 28 days (AUC0-28d) after a single dose of COVID-HIGIV|Pharmacokinetics parameter of maximum observed concentration (Cmax) of SARS-CoV-2 antibodies observed after a single dose of COVID-HIGIV|Pharmacokinetics parameter of time at which Cmax occurs after a single dose of COVID-HIGIV|Pharmacokinetics parameter of trough concentration of SARS-CoV-2 antibodies observed 28 days after a single dose (Cmin28d) of COVID-HIGIV|Pharmacokinetics parameter of terminal elimination constant after a single dose of COVID-HIGIV|Pharmacokinetics parameter of apparent terminal elimination half-life after a single dose of COVID-HIGIV|Pharmacokinetics parameter of systemic clearance after a single dose of COVID-HIGIV|Pharmacokinetics parameter of volume of distribution after a single dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 14 days (AUC0-14d) after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 28 days (AUC0-28d) after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of maximum observed concentration (Cmax) of SARS-CoV-2 antibodies observed after initial dose and repeat dose of COVID-HIGIV.|Pharmacokinetics parameter of time at which Cmax occurs after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of trough concentration of SARS-CoV-2 antibodies observed 28 days after initial and repeat dose of COVID-HIGIV|Pharmacokinetics parameter of accumulation ratios after repeat dose over initial dose of COVID-HIGIV || Share of participants with SARS-CoV-2 detectable in PCR|Seroprevalence of SARS-CoV-2 antibodies|SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life || Identification of nucleic acid sequencing, antibodies and antigens to be used in detection methods or treatments and/or vaccines || COVID 19 Severity || Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination|Determination of neutralizing titer of antibodies raised to SARS-CoV-2 following vaccination with polio vaccine || Incidence of solicited adverse events|Incidence of unsolicited adverse events|Incidence of serious adverse events|Geometric mean titer (GMT) of antigen-specific binding antibody titers|Percentage of subjects who seroconverted after vaccination|Geometric mean titer (GMT) of neutralizing antibody level|Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers || Change in SARS-CoV-2 viral load in nasopharyngeal swabs|Viral Load Response Rate (VLRR)|Percentage of patients reporting each severity rating on an 8-point ordinal scale.|Change in National Early Warning Score scale|Changes in thoracic CT scan|Percentage of patients admitted to Intensive Care Unit (ICU)|Time to admission to Intensive Care Unit (ICU)|Percentage of patients requiring mechanical ventilation|Percentages of patients negative for SARS CoV 2 RNA in nasopharyngeal swabs|Time to negative viral load|Time to resolution of symptoms|Duration of need for supplemental oxygen|Duration of hospitalisation|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or ECMO use|Number of non-invasive ventilation/high flow oxygen free days|Number of oxygenation free days|Patient all-cause mortality|Cumulative incidence of any AE|Cumulative incidence of Grade 3 and 4 AEs|Cumulative incidence of SAEs || Incidence and prevalence of medical sequelae|Risk factors for medical sequelae|Quality of life and social impact|Incidence and prevalence of reinfection|Biorepository || World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events || Ordinal Scale for Clinical Improvement|Progression to pneumonia (hospital setting only)|Time to clinical improvement (hospital setting only)|National Early Warning Score 2 (NEWS2) assessment of acute-illness severity (hospital setting only)|Changes in daily breathlessness, cough and sputum scale (BCSS)|Safety and tolerability - blood pressure (hospital setting only)|Safety and tolerability - heart rate|Safety and tolerability - temperature|Safety and tolerability - respiratory rate (hospital setting only)|Safety and tolerability - oxygen saturation|Safety and tolerability - adverse events|Safety and tolerability - concomitant medications|Time to clinical improvement (home setting only)|Time to improvement of COVID-19 symptoms (home setting only).|Time to self-reported recovery (home setting only)|Self-reported daily rating of overall feeling of wellness (home setting only).|Quality of life measured using EQ-5D-5L (home setting only).|Virus clearance/load (if samples are available)|Blood and sputum biomarkers (if samples are available).|Contact with health services (home setting only)|Consumption of antibiotics (home setting only)|General Anxiety Disorder 7 (home setting only)|Patient Health Questionnaire - 9|FACIT Fatigue Scale|Nottingham Extended Activities of Daily Living Scale || Diagnostic assessment|Limit of detection determination. || Incidence of adverse events|Geometric mean titer (GMT) of antigen-specific binding antibody titers|Evaluation of positive response rate of T cell responses induced by GLS-5310 DNA vaccine|Geometric mean titer (GMT) of neutralizing antibody titers || Questionnaire to assess the psychological impacts of SARS-CoV-2 on health care workers || Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), or Adverse Events of Special Interest (AESI)|Number of Participants Who have Reached the Acceptable Threshold for the Serum Ab Level at Day 57|Comparison of the Geometric Mean of the Serum Neutralizing Antibody (nAb) level against the Geometric Mean of the Serum nAb level in Study mRNA-1273-P301 (NCT04470427)|Geometric Mean Value of SARS-CoV-2 Spike Protein (S2P)-specific binding antibody (bAb)|Geometric Mean Value of SARS-CoV-2-specific nAb|Number of Participants with a SARS-CoV-2 Infection Starting on Day 57|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo || SARS-CoV-2 serum neutralizing titers - Seroconversion rates (SCR)|The geometric mean titer (GMT) of SARS-CoV-2 serum neutralizing titers at 1 month after dose 2|SARS-CoV-2 serum neutralizing titers - SCR|SARS-CoV-2 serum neutralizing titers - GMT|SARS-CoV-2 anti-S1 immunoglobulin G (IgG) antibody level - SCR|SARS-CoV-2 anti-S1 IgG antibody level - GMT|SARS-CoV-2 serum neutralizing antibody level - Geometric mean fold rise (GMFR)|SARS-CoV-2 anti-S1 IgG antibody level - GMFR|Percentage of participants reporting local reactions|Percentage of participants reporting systemic events|Hematology laboratory assessments|Chemistry laboratory assessments|Adverse events (AEs)|Serious AEs (SAEs) || Efficacy: Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of mRNA-1273|Safety: Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal|Safety: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Safety: Number of Participants with Unsolicited AEs|Safety: Number of Participants with Serious AEs (SAEs)|Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of mRNA-1273 or Placebo|Number of Participants with a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection regardless of symptomatology or Severity Starting 14 Days after Second Dose of mRNA-1273 or Placebo|Number of Participants with a Secondary Case Definition of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of mRNA-1273 or Placebo|Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Regardless of Evidence of Prior SARS-CoV-2 Infection|Number of Participants with a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo|Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)|Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb|Quantified Levels or GMT of S Protein-Specific Binding Antibody (bAb)|GMFR of S Protein Specific bAb || Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Medically-Attended Adverse Events (MAAEs)|Number of Participants with Serious Adverse Events (SAEs)|Change from Baseline in the Measure of Clinical Safety Laboratory Values in Cohort 2|Number of Participants with Abnormalities in Blood Pressure, Temperature, HR, or Respiratory Rate|Number of Participants with Abnormalities in Physical Examinations|Level of SARS-CoV-2-Specific Binding Antibody (bAb) as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)|Titer of SARS-CoV-2-Specific Neutralizing Antibody (nAb)|Seroconversion as Measured by an Increase of SARS-CoV-2-Specific Neutralizing Antibody (nAb) Titer|Level of SARS CoV-2-Specific Serum Binding Antibody || Incidence of Solicited Adverse Events|Incidence of Unsolicited Adverse Events|Incidence of Serious Adverse Events|GMT and GMFR of Antigen-specific Binding Antibody Titers|Percentage of Subjects Who Seroconverted After Vaccination|GMT and GMFR of Neutralizing Antibody Level|GMSN and GMFR of Spot Forming Unit (SFU) detected by IFN-gamma ELISPOT assay || Specific detection of SARS-CoV-2 specific RNA|Analytical sensitivity of the LAMP test.|The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.|Evaluation of the use of saliva samples compared to nasopharyngeal samples || Efficacy: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2|Safety: Proportion of participants with grade 3 or more adverse events|Tolerability: Proportion of participants that discontinue prophylactic treatment due to grade 1 or 2 adverse events || Primary safety endpoint: Adverse events|Exploratory Endpoint: Alive at Day 5 without bronchospasms, unexpected infections, or clinical deterioration|Exploratory Endpoint: Proportion of patients with respiratory rate ≤ 23/min for 24 hours|Exploratory endpoint: Change in respiratory rate from baseline to Day 5|Exploratory endpoint: Proportion of patients with SpO2 saturation ≥94% for at least 24 hours|Exploratory endpoint: Change in SpO2 saturation from baseline to Day 5|Exploratory endpoint: Proportion of patients with no artificial ventilation after 5 days of treatment|Exploratory endpoint: Proportion of patients with a change in absolute lymphocyte count, sustained for ≥48 hours after 5 days of treatment|Exploratory endpoint: Change in the absolute lymphocyte count from baseline to Day 5|Exploratory endpoint: Change in neutrophil-to-lymphocyte ratio (NLR), sustained for ≥48 hours after 5 days of treatment|Exploratory endpoint: Change in neutrophil-to-lymphocyte ratio (NLR) from baseline to Day 5 || Number of participants with resolution of hypoxia|Number of adverse events.|Days with fever|Time to resolution of fever|Rate of progression to requiring critical care|Overall survival|Time to discharge || Evaluation of EPA-FFA efficacy compared to placebo|Time to and amount of clinical improvement|Change in recovery and survival rate|Reduction of CRP and IL-6|Increase in IFN-γ|Reduction in proinflammatory chemokines and cytokines. || Occurrence of solicited local reactions in the subjects (e.g., vaccination sites: pain/tenderness, erythema/redness, induration/swelling) during the 14-days after each dose of BNT162b1 or placebo.|Occurrence of solicited systematic reactions (e.g., nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) during 14-day after each dose of BNT162b1 or placebo.|Occurrence of adverse event (AE) associated with vaccination in subjects during the 21-day period after prime vaccination of BNT162b1 or placebo.|Occurrence of AE associated with vaccination in subjects during the 28-day period after boost dose of BNT162b1 or placebo.|The proportion of subjects experiencing serious adverse events (SAEs), occurring up to Day 21 after prime vaccination and Day 28 after boost vaccination, up to Month 3, 6 and 12.|The proportion of subjects experiencing AE associated with BNT162b1, occurring up to Month 3, 6 and 12.|The proportion of subjects experiencing abnormal markers of hematology, blood chemistry and urine analysis, occurring at Hour 24 and Day 7 after prime vaccination and Day 7 period after boost dose of BNT162b1 or placebo.|Geometric mean titer (GMT) of anti-S1 IgG antibody at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|GMT of anti-receptor binding domain (RBD) immunoglobulin G (IgG) antibody at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|GMT of SARS-CoV-2 neutralizing antibody (including true virus-based SARS-CoV-2 neutralizing test) at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|Fold increase in antibody anti-S1 IgG antibody titers, as compared to baseline, at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|Fold increase in antibody anti-RBD IgG antibody titers, as compared to baseline, at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|Fold increase in SARS-CoV-2 neutralizing antibody titers (virus neutralizing test), as compared to baseline, at Day 7, Day 21 after prime vaccination, at Day 7, Day 21 after boost vaccination, and at Month 3, 6 and 12.|Seroconversion rates (SCR) defined as a minimum of 4-fold increase of antibody titers, as compared to baseline, at Day 7, Day 21 after prime vaccination, and at Day 7, Day 21 after boost vaccination. || Toxicity|Medically Attended Adverse Events (MAAEs) || Safety and tolerability of two doses of HDT-1 vaccine|Immunogenicity of two doses of HDT-1 vaccine || Death || Treatment success|Time to mechanical ventilation|Change from baseline in Modified Early Warning system score|Change from baseline in resting peripheral capillary oxygen saturation (SpO2)|Change from baseline in partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2)|Change of pH in hemogasanalysis from baseline|Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline|Change of oxygen tension (pO2) in hemogasanalysis from baseline|Change of potassium in hemogasanalysis from baseline|Change of sodium in hemogasanalysis from baseline|Change of chloride in hemogasanalysis from baseline|Change of lactic acid in hemogasanalysis from baseline|Change of hemoglobin in hemogasanalysis from baseline|Change from baseline in oxygen supplementation|Change of findings of high-resolution computed tomography (CT) scan of the chest|Change from baseline in Ferritin|Change from baseline in lactate dehydrogenase (LDH)|Change from baseline in D-dimers|Change from baseline in White Blood Cells with differential counts|Change from baseline in Red Blood Counts|Change from baseline in Hemoglobin|Change from baseline in Platelet count|Change from baseline in Fibrinogen|Change from baseline in Complement factors C3/C4|Change from baseline in Prothrombin time|Change from baseline in Cardiac troponin|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in total bilirubin levels|Change from baseline in C-Reactive Protein|Change from baseline in Creatinine|Overall survival|Time to hospital discharge || Total amount of dummy-inhaled virus copies per 30 minutes sampling per size fraction (>10 µm, <10 µm)|Viability of dummy-inhaled viable virus per size fraction (>10 µm, and <10 µm)|Reduction of dummy-inhaled virus copies per 30 minutes sampling in a type II-masked setup, as compared to unmasked, per size fraction (>10 µm, <10 µm) || Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Medically-Attended AEs (MAAEs), AE of Special Interest (AESIs), and Serious Adverse Events (SAEs)|Geometric Mean (GM) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)|GM of SARS-CoV-2-Specific Binding Antibody (bAb)|Seroconversion as Measured by an Increase of SARS-CoV-2-Specific nAb Titer or bAb Titer || The number of participants with Serious Adverse Events following administration of ADM03820 to the final visit|The number of participants with AEs from administration of ADM03820 to the final visit|The assessment of Peak Plasma Concentration (Cmax) for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|The assessment of Tmax for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|The assessment of the Area under the plasma concentration (AUC(0-t)) for total antibodies of ADM03820 as measured by enzyme-linked immunosorbent assay (ELISA) methods designed for total monoclonal antibody in the Drug Product.|To assess the anti-drug antibody levels || Safety of a 2-dose regimen of VAX-001 when doses are given 14 days apart|Mean change from baseline in safety laboratory measures|Frequency of treatment-emergent Serious Adverse Events (SAE) throughout the study and up to 6 months post-second dose immunization (Day 196).|Percent seroconversion defined as a 4-fold or greater increase in IgG titers after one or two doses as measured by IgG ELISA|Geometric mean neutralizing antibody titers against pseudo-virion after one and two doses|Percent seroconversion defined as a 4-fold or greater increase in IgG titers after one or two doses as measured by pseudo-viral neutralization assay.|Persistence of IgG antibody titers as measured by ELISA and neutralizing antibody titers measured by pseudo-virion neutralization assay, six months after the second vaccine dose || Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Medically-Attended AEs (MAAEs)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Adverse Events of Special Interest (AESIs), including Multisystem Inflammatory Syndrome in Children (MIS-C)|Number of Participants with Serum Antibody (Ab) Levels that Meet or Exceed the Threshold of Protection from COVID-19|Geometric Mean (GM) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)|Seroresponse Rate of Vaccine Recipients|GM of SARS-CoV-2 S-Protein Specific Binding Antibody (bAb)|GM of SARS-CoV-2 Specific nAb|Number of Participants with SARS-CoV-2 Infections Regardless of Symptomatology Starting 14 Days After the Second Dose|Number of Participants with Asymptomatic SARS-CoV-2 Infections|Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose || Incidence, severity and dose-relationship of AEs|Geometric mean titre for SARS-CoV-2-specific serum neutralizing antibody|Mean titre for SARS-CoV-2-specific serum neutralizing antibody levels|Geometric mean fold rise in titre for SARS-CoV-2-spike protein specific neutralizing antibody levels || Percentages of participants reporting solicited local adverse events|Percentages of participants reporting solicited systemic adverse events|Percentages of participants reporting adverse events|Percentages of participants reporting serious adverse events|Percentages of participants reporting medically attended adverse events|Percentages of participants reporting new onset of chronic disease|Percentages of participants with abnormal safety laboratory test values|Percentages of participants with abnormal vital sign assessments|SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs|SARS-CoV-2 binding antibody levels, expressed as GMCs"
SARS-CoV-2 Infection,"Change on viral load results from baseline after using COVID19-0001-USR via nebulization || Phase 1 Unexpected serious adverse events|Phase 2 Patients turning COVID-19 negative (RT-PCR negative)|Phase 2 Patients turning COVID-19 negative (RT-PCR Negative)|Phase 1 Patients turning COVID-19 negative (RT-PCR Negative)|Phase 1 Exploratory outcome|Phase 1-Exploratory outcome|Phase 1- Exploratory outcome|Phase 2 Unexpected serious adverse events|Phase 2 Change in WHO clinical progression scale || Efficacy of Moderna COVID-19 Vaccine against SARS-CoV-2 infection|Effect of Moderna COVID-19 Vaccine on peak nasal viral load|Impact of Moderna COVID-19 Vaccine on secondary transmission of SARS-CoV-2 infection|Efficacy of Moderna COVID-19 Vaccine to prevent serologically confirmed SARS-CoV-2 infection|Efficacy of Moderna COVID-19 Vaccine against COVID-19 disease confirmed by PCR test and symptoms|Effect of Moderna COVID-19 Vaccine on magnitude of viral load over time|Efficacy of Moderna vaccine regardless of baseline serostatus (SARS-CoV-2 infection by PCR)|Effect of Moderna vaccine on viral load regardless of baseline serostatus (Viral load)|Effect of Moderna vaccine on secondary status regardless of baseline serostatus (Secondary transmission events)|Immunogenicity of Moderna COVID-19 vaccine|Immune responses as correlates of risk of SARS-CoV-2 acquisition, viral load, secondary infection, and COVID-19 disease|Efficacy of Moderna COVID-19 vaccine against asymptomatic SARS-CoV-2 infection|Efficacy of Moderna COVID-19 Vaccine against SARS-CoV-2 infection and COVID-19 disease|Effect of Moderna COVID-19 Vaccine on viral load|Effect of Moderna COVID-19 Vaccine on secondary transmission || Mean duration and severity of disease|Incidence/Safety of Adverse Events || Number of people with a positive SARS-CoV-2 PCR.|Incidence of people with a positive SARS-CoV-2 PCR.|Number of people with a positive total immunoglobulin titer and positive IgG for SARS-CoV-2.|Prevalence of people with a positive total immunoglobulin titer and positive IgG for SARS-CoV-2.|Number of people with a positive SARS-CoV-2 Ig total titer and a negative IgG. || Day 28 severity outcome|Proportion of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA|Duration of Need for Supplemental Oxygen|Duration of Hospitalization|In-hospital and 28-day mortality|Time-to-clinical improvement in-hospital|Host genetic differences at day 0|Host transcriptomic differences at days 0,7,14 || SARS-CoV-2 viral load|In Vitro Infectivity|Sensitivity and specificity of rapid SARS-CoV-2 antigen tests in saliva samples compared to RT-qPCR || Change in serial monthly log-transformed antibody titre levels as measured|Proportion of completely asymptomatic healthcare workers with evidence of SARS-CoV-2 antibodies|The attack rate of SARS-CoV-2 in healthcare workers who have antibodies compared to those who do not|The immune correlates of protection against future exposure to SARS-CoV-2 || Number of participants with past SARS-CoV-2 infection|Number of infections in health personnel who have taken voluntary hydroxychloroquine as a prevention strategy for COVID-19 infection|Number of infections in health personnel based on the degree of exposure to patients infected with COVID-19.|Number of infected participants who are active smokers and/or have chronic lung disease and/ or have history of hypertension.Relationship of degree of exposure to participants infected with SARS-CoV-2 admitted to the hospital.Professional category.|Number of participants infected with SARS-CoV-2 that presented symptoms and their grade. Number of participants infected with SARS-CoV-2 who required hospitalization. Number of participants infected with SARS-CoV-2 who received treatment.|Number of family members infected from each participant with SARS-CoV-2 infection || COVID-19 incidence|Adherence to closed face shields use|Percentage of participants with a positive serological test at baseline|Percentage of seroconversion in the experimental group and active control group || COVID-19 infection|Incidence of hospitalization for COVID-19|Incidence of ICU admission for COVID-19|Incidence of ARDS|Mechanical ventilation for COVID-19|Secondary infection in COVID-19|COVID-19-related Mortality|Incidence of DVT || correct classification of SARS-CoV-2 infected and not infected subjects || Nasopharyngeal SARS-CoV-2 Viral Load || To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events || National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival || Patient rate with a transition to category 3 or lower according to the WHO scale by Day 14 after the beginning of drug administration.|Time till clinical improvement, which is described by presence of all of the following factors during 48 hours in a row.|Patient rate with clinical improvement by day 2-28. Presence of all of the following factors during 48 hours in a row.|Patient rate with a negative test result for SARS-CoV-2 by Day 7±1, 15±1, 21 ±1 and 28 ± 1.|Duration of hospitalization.|Patient rate transferred to the intensive care unit (ICU) during hospitalization.|Duration of ICU stay.|Patient rate with ARDS during hospitalization.|Presence of a fatal outcome.|Patient rate requiring oxygen therapy by Day 2-28.|Patient rate requiring high-flow oxygen therapy by Day 2-28.|Patient rate requiring non-invasive ventilation by Day 2-28.|Patient rate requiring invasive ventilation by Day 2-28.|Patient rate requiring extracorporeal membrane oxygenation (EMO) by Day 2-28.|The total duration of oxygen therapy by the last day of hospitalization.|The total duration of high-flow oxygen therapy by the last day of hospitalization.|The total duration of non-invasive ventilation by the last day of hospitalization.|The total duration of invasive ventilation of lungs by the last day of hospitalization.|The total duration of EMO by the last day of hospitalization.|Patient rate with Sp02 > 95% by Day 2-28.|Average alteration of Sp02 by Day 2-28 from baseline.|Average time to reach SpO2 ≥ 95%.|Patient rate with RR < 22 / min by Day 2-28.|Average alteration in RR by Day 2-28 from baseline.|Average time to reach RR ≤ 22 / min.|Patient rate with body temperature < 37.5°C by Day 2-28.|Average alteration in body temperature by Day 2-28 from baseline.|Average time until the patient reaches a body temperature of ≤37.5°C.|Patient rate with CT-1 according to CT data by Day 2-28.|Average alteration in CT data by 1 point in terms of severity (CT-1, CT-2, CT-3, CT-4) by Day 7, 10, 15, 18, 21 and 28 compared to the baseline value.|Average time to reach CT-1 according to CT data.|Patient rate with a score < 2 according to the Daytime and Nighttime Cough Scale by Day 2-28.|Mean change in Daytime and Nighttime Cough scores by Day 2-28 from baseline.|Average time to reach < 2 points when assessed according to the Daytime and Nighttime Cough Scale.|Patient rate with a score < 1 for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28.|Average change in score for each symptom (general fatigue, chest congestion, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale by Day 2-28 from baseline.|Average time to reach a score of < 1 for each symptom (general fatigue, feeling of congestion in the chest, sore throat, decreased sense of smell and taste, nasal congestion) according to a 4-point scale.|Patient rate with a transition decrease to category 3 or lower according to the WHO scale by Day 2-13 and Day 15-28.|Mean WHO grade change by Day 2-28 from baseline.|Average time to reach the 3rd category or below according to the WHO scale.|Patient rate with a NEWS score < 2 by Day 2-28.|Average change in NEWS score by Day 2-28 from baseline.|Average time to reach a NEWS score ≤ 2. || To assess the safety and tolerability of REM use in Hungary in the conditionally approved indication (EMA)|The proportion of patients with at least 1 treatment-emergent adverse event|Proportion of patients with treatment-emergent clinical || Sars-CoV-2 Seropositivity || Specific immune responses || Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days) || Rate of Adverse Events after a single DZIF-10c infusion [Safety and Tolerability]|Pharmacokinetic profile of DZIF-10c|Development of anti-drug antibodies|Change in viral load in nasopharyngeal swabs after DZIF-10c administration || Number of participants with local and systemic reactions|Incidents of treatment-adverse events as assessed by FDA Toxicity grading scale.|Number of participants with humoral immune response at Study Day 43 (+/- 2).|Number of participants with binding antibody response rate|Number of participants with neutralizing antibody response rate|Number of participants with ACE-2 binding inhibition || The primary outcome is the rate of decline in viral load over the 10 days after randomization || Time to improvement in body temperature|Time to improvement in SpO2|Time to improvement in chest imaging findings|Time to improvement in negative SARS-CoV-2|(1) Changes in patient status on a 5-point scale|(2) Changes in the level of SARS-CoV-2 viral genome|(3) SARS-CoV-2 virus genome clearance rate|(4) Duration of pyrexia|(5) Changes in clinical symptoms|(6) Changes in NEWS (National Early Warning Score)|(7) Changes in chest imaging findings on Days 4,7,10,13,16,19,22,25,28.|(8) Percentage of patients requiring adjuvant oxygen therapy|(8) Adjuvant oxygen therapy average duration|(9) Percentage of patients requiring mechanical ventilation therapy|(9)Adjuvant oxygen therapy average durationduration || Rate of Adverse Events after a single DZIF-10c inhalation [Safety and Tolerability]|Rate of Adverse Events after a single combined DZIF-10c inhalation and infusion [Safety and Tolerability]|Pharmacokinetic parameter AUC0-672|Development of anti-drug antibodies|Change in viral load in nasopharyngeal swabs after DZIF-10c administration || Mucosal antibodies|Mucosal antibodies in all participants|SARS-CoV-2 infection|Serum antibodies|Functional antibody assays || Phase 2 portion: Immediate adverse event (AEs)|Phase 2 portion: Solicited local and systemic adverse events (AEs)|Phase 2 portion: Unsolicited adverse events (AEs)|Phase 2 portion: Number of subjects with normal and abnormal clinically significant urine values|Phase 2 portion: Number of subjects with normal and abnormal clinically significant haematological values|Phase 2 portion: Number of subjects with normal and abnormal clinically significant biochemical values|Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant urine values|Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant haematological values|Phase 2 portion: Percentage of subjects with normal and abnormal clinically biochemical values|Phase 2 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths|Phase 2 portion: Neutralizing antibody (Nab assay) response|Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response|Phase 3 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection|Phase 2 portion: Solicited local and systemic AEs|Phase 3 portion: Immediate adverse event (AEs)|Phase 3 portion: Solicited local and systemic AEs|Phase 3 portion: Unsolicited adverse events (AEs)|Phase 3 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths|Phase 2 portion: Neutralizing antibody Geometric mean tiers (GMT) response|Phase 2 portion: Specific antibody (IgG) response|Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers|Phase 2 portion: Specific Th1 cell-mediated immunity (CMI) response|Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response|Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response|Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response|Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response|Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT)|Phase 3 portion: Specific antibody (IgG) response|Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers|Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response|Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response|Phase 3 portion: Specific cell-mediated immunity (CMI) response|Phase 2 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection|Phase 2 portion: Severe COVID-19 disease|Phase 3 portion: Severe COVID-19 disease|Phase 3 portion: COVID-19-related symptoms|Phase 3 portion: Laboratory-confirmed asymptomatic SARS-CoV-2 infection|Phase 3 portion: Laboratory-confirmed symptomatic SARS-CoV-2 infection|Phase 3 portion: Viral shedding after SARS-CoV-2 infection || To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II)|To evaluate the therapeutic efficacy CT-P59 for Part 2 (Phase III)|To evaluate the overall efficacy of CT-P59 for Part 1 and 2|To evaluate the overall safety of CT-P59 for Part 1 and 2|To evaluate virology for part 1 and part 2 || To evaluate the preliminary safety and tolerability of CT-P59 up to Day 14 of the last enrolled subject|To evaluate the viral efficacy and characterization of SARS-CoV-2 viral isolates of CT-P59|To evaluate the efficacy of CT-P59|To evaluate the Pharmacokinetics of CT-P59 || Treatment emergent adverse events - Part 1|Treatment emergent adverse events - Part 2|Clinical status at Day 15 and Day 29 - Part 2|Maxiumum Serum Concentration [Cmax]|Mortality at Day 29|Duration of Supplemental Oxygen Requirement|Change in Hemolytic Assays (CH50 and AH50) from Baseline || Primary safety outcome|To evaluate the safety of CT-P59|To evaluate the Pharmacokinetic(PK) of CT-P59"
Sars-CoV2,"COVID-19 Test Conversion|Duration of Hospitalization|Rate of self-reported COVID-19 exposure|Rate of complications from COVID-19 || Number of patients in whom the prone position caused an increase in oxygenation|The feasibility of prone position || Covid19 infection clinical evolution|Risk factors for intra-hospital mortality|The impact of a fragility index (IF)|Prognostic score|The lung sequelae of SARS-COV-2 pneumonia|The accuracy of IF in elderly patients|Coagulation system anomalies|The impact of the prone position on the oxygenation || Induced SARS-CoV2 immunity|Long-term protection of induced SARS-CoV2 immunity at 6 months|Long-term protection of induced SARS-CoV2 immunity at 1 year|Anti-SARS-CoV2 antibodies kinetics in blood throughout the study|Anti-SARS-CoV2 antibodies kinetics in saliva throughout the study|Kinetics of serum neutralization in blood throughout the study|Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 0|Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 21 || Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.|Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.|Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.|Anti-SARS-Cov2 seroprevalence at Day 0.|Correlation between seroconversion and socio-demographic factors - sex|Correlation between seroconversion and socio-demographic factors - age|Correlation between seroconversion and professional factors - job type|Correlation between seroconversion and professional factors - personal protective equipment type|Correlation between seroconversion and non-professional factors - contact with infected individuals|Correlation between seroconversion and non-professional factors - wearing of professional equipment|Correlation between seroconversion and non-professional factors - respect of barrier gestures || Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team|Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission || Proportion anti-SARS-CoV2 seropositive|Proportion of asymptomatic anti-SARS-CoV2 seropositive participants|Agreement between the anti-SARS-CoV2 serological results obtained using two different techniques (detecting the presence of different antibodies)|Proportion of serum neutralization positive|Change of antibody level over time || SARS-CoV-2 positive test|Transformation|Predictors (asymptomatic)|Predictors (symptomatic)|Percentage from different departments || Analysis of the effect of prone position in patients with covid-19 in intensive care || Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff || the prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection|immunologic status of health Care Worker|inflammatory biomarkers status of Health Care Worker || Sensitivity of the method by SARS-CoV2 ELISA compared|Detectability of the antibodies IgA type against SARS-CoV2 virus || the incidence of SARS- Cov2 infection Heath Care Worker diagnosed by the positivity of SARS-Cov2 RT-PCT and serological testing|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection || Proportion of participants with no evidence of SARS-CoV-2 infection|Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples || Analysis of risk factors for intubation tube obstruction || Number of patients ""confirmed cases"" of SARS-CoV-2 infection who died at D28 of inclusion|Correlation between Infection characteristics of patients at inclusion and all predictors for Covid-19|Correlation between evolution infection characteristics of patients during stay of hospitalisation and all predictors for Covid-19|Positivity for Covid-19 patients performed and all predictors for Covid-19|Correlation between hospitalisation and all predictors for Covid-19|Correlation between risk factors measured at D0 for severe CoV-2 SARS infection and all predictors for Covid-19|Correlation between overall survival at Day 28 and all predictors for Covid-19|Cumulative incidence of at least one complication related to COVID 19|Cumulative incidence of the thrombosis complication related to COVID 19|All type of co-infections|Alteration of microbiota|Biobanking for further analyses such as SARS-CoV2 studies || Pharmacokinetics of hydroxychloroquine (HCQ)|Correlation between hydroxychloroquine (HCQ) concentration and cardiac toxicity (QT interval)|Correlation between Pharmacokinetic (concentration) and pharmacodynamic (viral load) of hydroxychloroquine (HCQ)|Pharmacokinetic model || Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|"" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome "" || Seroprevalence|seroconversions|Incidence of definite cases|Incidence of probable cases|Antibody kinetics|Potential work-related risk factors|Proportion of asymptomatic seroconversions|Concerns for safety for infection with COVID-19 || Mechanical Ventilation|Oxygen Therapy|Length of Stay || Composition of the fecal bacterial and fungal microbiota|Analysis of the faecal microbiota from rectal swab|Analysis of the respiratory microbiota from the bronchoalveolar lavage liquid|Serum inflammatory markers changes|Inflammatory markers changes|Mortality|mechanical ventilation free days || Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19 || Development or worsening of a ventilatory disorder and/or chronic respiratory failure assessed by spirometry|Assessment of dyspnea|Description of pulmonary lesions as assessed by lung CT scan|Development of pulmonary fibrosis as assessed by lung CT scan|Incidence or worsening of cardiovascular diseases|Incidence or worsening of renal disease|Incidence or worsening of liver disease|Incidence or worsening of psychological pathology : anxiety|Incidence or worsening of psychological pathology: depression|Incidence or worsening of psychological pathology: post-traumatic stress|Incidence or worsening of psychological pathology: insomnia|Assessment of the health-related quality of life|Assessment of the fatigue|Assessment of the socioeconomic deprivation|development or worsening of metabolic disorders: diabetes, thyroid diseases, dyslipidemia, adrenal disorders, malnutrition|Development of auto-immune disorders|Assessment of the evolution of the humoral anti-SARS-CoV-2 immunization profile|Patients' self-reported level of physical activity|Determination of risk factors associated with sequelae or comorbidities || Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate || Efficacy: Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis|Safety and Tolerability: Proportion of subjects with serious adverse events (SAEs)|Efficacy: Daily change in the WHO 9-point severity score|Efficacy: All cause mortality rate at Days 28 and 90|Efficacy: Proportion of subjects alive without the ongoing use of vasopressors, ongoing intubation/mechanical ventilation, ongoing residence in an intensive care unit (ICU), new ongoing need for dialysis/renal replacement therapy|Efficacy: Proportion of subjects discharged to home or immediate prior residence|Efficacy: Length of stay (LOS) of surviving subjects in the hospital and in ICU|Efficacy: Proportion of subjects readmitted to the hospital|Safety and Tolerability: Proportion of subjects with adverse events (AEs)|Safety and Tolerability: Proportion of subjects with new or worsening clinically significant laboratory abnormalities|Immunogenicity: Proportion of subjects with rhu-pGSN antibodies|Pharmacokinetics: Maximum concentration (C max) of added rhu-pGSN|Pharmacokinetics: Time to maximum concentration (T max) of added rhu-pGSN|Pharmacokinetics: Half-life (T 1/2) of added rhu-pGSN|Pharmacokinetics: Area under the curve from time 0 to 8 hours (AUC 0-8) of added rhu-pGSN|Pharmacokinetics: Area under the curve from time 0 to infinity (AUC 0-inf) of added rhu-pGSN || proportion of patients with an alteration of the capillary alveolus barrier at 12 months of follow-up, characterized by a decreased of the diffusing capacity for carbon monoxide (DLCO) below the lower limit of normal || Hematic biometry|Blood chemistry|Blood gas|blood gas|thorax radiography || Vrological profile of newborns.|Immunological profile of newborns. || death|clinical worsening (composite criteria)|Assisted-ventilation and/or hospitalization (composite criteria)|National Early Warning Score (NEWS)|cumulative incidence of hospitalizations|cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)|Mortality|cumulative incidence of viral shedding on SARS-CoV-2 rt-PCR on nasopharyngeal swab;|adverse drug reactions || Clinical deterioration rate|Mortality and cause of death|Incidence and type of Adverse Events (EAs)|Incidence and type of Serious Adverse Events (SAE)|Discontinuation rate or temporary suspension of treatment|Descriptive radiologic changes on chest CT scans || Understanding the dissemination of SARS Cov2 in hospital|Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2 || Mortality|Total number of days of full hospitalization|Duration of oxygen therapy|Ferritin level in the blood|CRP level in the blood|LDH level in the blood|Lymphocyte level in the blood|PNN level in the blood|platelet level in the blood|WHO performance index|WHOQOL-OLD questionnaire|Lung function by pulmonary computed tomography|Lung function by EFR|Readmission Rates || Measure of anti-Xa activity|Analysis of hemorrhagic risk|Venous thromboembolic events|Analysis individual patient characteristics by the biomarker of Kidney function|Analysis individual patient characteristics by the biomarker of inflammation|Analysis individual patient characteristics by the biomarker of coagulation|Demographic characteristics"
